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A B S T R A C T
Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with
ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first
successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage
attempts with radiotherapy. This led to the empiric delineation of a window for conservative management
subject to a “state of metastatic grace” never to be violated.
Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of
improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic
chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10
years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely
intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, de-
finitive eradication of radiotherapy and reduction of systemic chemotherapy.
Here we intend to review the relevant knowledge susceptible to improve the conservative management of retino-
blastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging
modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns,
and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a
classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced
complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.
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Retinoblastoma is the archetype of developmental tumors and is
responsible for 17% of neonatal (Halperin, 2000), 13% of infantile
(Vasilatou-Kosmidis, 2003), 6% and 3% of all pediatric cancers under
age 5 and 15 years, respectively (Broaddus et al., 2009; Group et al.,
2013). Left untreated, this malignancy is rapidly recognizable as a
protruding mass. Within the limitations of retrospective diagnosis
(Kivela and Polkunen, 2003), it is thus not surprising to find retino-
blastoma already mentioned in the medical literature at the turn of the
XVIth and XVIIth centuries by Pawius in the Netherlands (Pawius, 1657)
and Hildanus in Switzerland (Hildanus, 1682) respectively. According
to the Hippocratic theory of four humors still in use at that time, ocular
tumors were thought to result from a causal chain, of which the pa-
tient's constitution and hygiene was the first link (causa primitiva),
triggering black bile overflow (causa antecedens) pouring into the eye
after its transfer to the brain (causa coniuncta) (Koelbing, 1954). The
advocated treatment was a combination of poultice, leech and purge to
eliminate the flood of melancholic humor. This approach was sup-
planted by enucleation, made possible by the advent of anesthesia in
the middle of the XIXth century, leading to the first success in terms of
patient survival. This surgical period lasted more than 50 years, until
the radiosensitivity of retinoblastoma was discovered by Hilgartner in
1903 (Hilgartner, 1903), allowing for the first time a conservative
(globe-preserving) management of the disease. Since then, and for the
next 90 years, external beam irradiation became the first line treatment,
complemented by focal therapeutic modalities such as cryotherapy,
xenon photocoagulation and brachytherapy for less advanced diseased
eyes. In 1996, following the recognition of a radio-induced neoplasm
predisposition in germline carriers, chemoreduction replaced radio-
therapy, which use was relegated to treat chemo-resistant disease in
only eyes as an alternative to enucleation. The introduction of this
whole-body therapy failed, however, to improve eye preservation in
advanced disease, while exposing children to systemic toxicity. This
was explained by the pharmacokinetics of the perfused drugs not
reaching tumoricidal concentrations in the various intraocular seeding
compartments. To overcome these limitations, the concept of targeted
chemotherapy using intra-arterial and intravitreal drug delivery was
pioneered in Japan by Akihiro Kaneko already 30 years ago (Kaneko
and Takayama, 1990; Yamane et al., 2004). In 2008, the technique of
intra-arterial chemotherapy, revisited by Abramson (Abramson et al.,
2008), became rapidly adopted and proved its efficacy to control retinal
and subretinal tumors, but not vitreous seeds. The latter fully surren-
dered only to intravitreal chemotherapy, which became available in
2012 following the description of a safety-enhanced injection technique
(Munier et al., 2012a). Aqueous seeding, the very last intra-ocular
sanctuary to resist virtually all available treatment modalities, became
manageable only since 2015 with the description of a technique
adapted to safely inject into the anterior and posterior chambers
(Munier et al., 2015), now successfully implemented in the current
management of aqueous disease (Munier et al., 2017a, 2018). To date,
the appropriate combination of all these modalities has enabled un-
precedented eye survival rates, even for advanced retinoblastoma,
contributing at the same time to the eradication of external beam ir-
radiation in the treatment of intraocular retinoblastoma without jeo-
pardizing patient survival.
2. Epidemiology
Retinoblastoma is a cancer of early childhood, habitually described
as a rare tumor. Statistical evidence, however, suggests that it is likely
the most common eye cancer worldwide (Kivela, 2009). As a devel-
opmental cancer, its incidence is highly dependent on age (Table 1),
and therefore difficult to establish. To date, the most stable estimates
are derived by assigning incident retinoblastomas to the year the pa-
tient was born, a method known as birth cohort analysis (Li et al., 2016;
Park et al., 2014; Seregard et al., 2004).
2.1. Incidence
The incidence of retinoblastoma depends on the size of the popu-
lation and the birth rate (Kivela, 2009). Around 7980 retinoblastomas
are predicted to have been diagnosed in 2015 (Table 2). Predictions for
Africa, representing 16% of the world population, are 2,293, or 29% of
Table 1
Incidence rates of retinoblastoma in various age groups reported in the literature during the last 15 years.
Age Group Source Region Incidence/million
(95% Confidence Interval)
Birth cohort Li et al. (2016) Taiwan 58
Park et al. (2014) Korea 53 (48–57)
Seregard et al. (2004) Sweden and Finland 60 (54–66)
Live births Park et al. (2014) Korea 59 (54–64)
Seregard et al. (2004) Sweden and Finland 65 (60–71)
0–1 year MacCarthy et al. (2006) Europe, ACCIS 20.4
0–4 years Fernandes et al. (2018) United States, SEER 12.1 (11.3–13.0)
Park et al. (2014) Korea 11.2 (10.2–12.2)
Rangamani et al. (2015) India, 5 registries 9.6
MacCarthy et al. (2009) Great Britain 10.0
Seregard et al. (2004) Sweden and Finland 11.6 (10.7–12.5)
Khandekar et al. (2004) Oman 8.3
1–4 years MacCarthy et al. (2006) Europe, ACCIS 7.5
0–5 years Jaradat et al. (2011) Jordan 9.3
0–6 years Azar et al. (2006) Australia, NSW 8
0–9 years Park et al. (2014) Korea 5.3 (4.8–5.8)
5–9 years Fernandes et al. (2018) United States, SEER 0.5 (0.4–0.6)
Rangamani et al. (2015) India, 5 registries 2.0
MacCarthy et al. (2009) Great Britain 0.4
MacCarthy et al. (2006) Europe, ACCIS 0.5
0–14 years Rangamani et al. (2015) India, 5 registries 3.5
Moreno et al. (2014) Argentina 5.0 (3.5–6.4)
Gatta et al. (2012) Europe, 64 registries 3.0 (2.7–3.3)
Khandekar et al. (2004) Oman 4.0
10–14 years MacCarthy et al. (2006) Europe, ACCIS 0.1
ACCIS=Automated Childhood Cancer Information System; NSW = New South Wales; SEER = Surveillance, Epidemiology, and End Results program.
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the total. Almost double the number, 4258 or 53%, is predicted for Asia,
with 60% of the world population. Latin America, North America, and
Europe with 8%, 3% and 6% of retinoblastomas also have fewer in-
cident cases relative to their percentage of the world population of 9%,
5% and 10%, respectively. These discrepancies stem from differences in
birth rates that range from 33.6 per 1000 population in Africa to 10.5 in
Europe (Table 2).
Comprehensive registration of retinoblastoma has succeeded mainly
in North America, Europe, and Japan, all of which have low birth rates
and easy access to health care. For the rest of the world, registration has
been incomplete. Mathematical estimates based on birth rates and po-
pulation size remain more accurate than published incidences, which
are derived from regional rather than national registers and subject to
cultural, economic and logistic factors. Published incidence rates have
at best approached, and more often fallen short of, those derived
mathematically (Li et al., 2016; Usmanov and Kivela, 2014). Registra-
tion of childhood cancers in general is incomplete, although coverage
increases with advances in diagnosis and treatment (Kroll et al., 2012).
Mathematical estimates are important in order to study and predict
trends in incidence of retinoblastoma across countries and regions.
Calculations based on World Population Prospects (United Nations,
2017) suggest that the world incidence of retinoblastoma will peak at
8300 cases in 2045 and then level off (Fig. 1). In Asia, Europe, and Latin
America, the incidence has been declining, although recent waves of
refugees from regions in which birth rates are higher may slow down
the decline in Europe. The incidence increases in North America and
especially in Africa where the annual incidence of retinoblastoma is still
predicted to rise by 1300 cases, approaching that of Asia by 2060. Such
long-term predictions might be affected by shifts in birth control po-
licies and natural or other disasters such as famine and war, both di-
rectly and through refugees and other migrants.
Despite annual variation in crude incidences, especially in small
populations and over short observation periods, the incidence of re-
tinoblastoma has remained stable over the last fifty years wherever
reliable records exist (Broaddus et al., 2009; Gatta et al., 2012;
Gregersen et al., 2016; Li et al., 2016; MacCarthy et al., 2009; Moreno
et al., 2014), especially when the analysis is based on birth cohorts
rather than on live births or on children of specified age in a given year
(Park et al., 2014; Seregard et al., 2004).
Unilateral retinoblastoma represents 61–75% of all cases, with 25–39%
bilateral according to recent population-based series (Andreoli et al., 2017;
Azar et al., 2006; Gregersen et al., 2016; Khandekar et al., 2004; MacCarthy
et al., 2009; Moreno et al., 2014). Part of this variation is explained by the
fact that some initially unilateral hereditary retinoblastomas will progress to
bilateral disease (Moreno et al., 2014), while the contribution from familial
cases also varies between countries (Usmanov and Kivela, 2014). The in-
cidence of trilateral tumors is estimated to be 3.5% in patients with her-
editary disease (de Jong et al., 2015b).
2.2. Prevalence
Data on survivors of retinoblastoma are not readily available (Gatta
et al., 2012). In the absence of a national registry, a crude prevalence
estimate can be derived as follows: for every child born with retino-
blastoma, the number of survivors will be roughly the number corre-
sponding to the average life expectancy in that country or region, de-
ducted by the average retinoblastoma mortality, then multiplied by the
average number of retinoblastoma cases per year. To give an example,
for a country with a mean life expectancy at birth of 73 years between
1950 and 2015 (from the World Population Prospects), a mean mor-
tality from retinoblastoma of 3%, and 4 new patients per year, the es-
timate would be (73-(0.03x73))x4 or 283 survivors.
2.3. Predisposing factors for sporadic retinoblastoma
Age. Seven to 10% of retinoblastomas are neonatal (Kivela and
Hadjistilianou, 2017), being diagnosed during the first month of life
and occasionally at birth. In general, retinoblastoma is diagnosed in
children under 3 years of age, is rare after 8 years of age and typically
not found after the age of 15 (Gatta et al., 2012; Park et al., 2014;
Rangamani et al., 2015). It is virtually unknown in adults (Kaliki et al.,
2015a; Sengupta et al., 2016), accounting for less than 0.1% of all re-
tinoblastomas.
Sex. In two large population-based registries of 1601 and 1452 pa-
tients, the ratio was 1.07 and 1.09 respectively (Andreoli et al., 2017;
MacCarthy et al., 2009), while others report a preponderance of boys
over girls with a ratio of 1.12–1.64 (Li et al., 2016; Moreno et al., 2014;
Park et al., 2014; Rangamani et al., 2015), which is higher than the
world statistic of 1.06 at birth (United Nations, 2017) (Andreoli et al.,
2017; MacCarthy et al., 2009). The reasons for this discrepancy are not
known, but it might be that in some cultures boys are preferentially
brought to treatment (Li et al., 2016).
Ethnicity and latitude. No consistent difference in the incidence of
retinoblastoma by ethnicity or latitude has been reported. However,
racial and ethnic disparities in the incidence of retinoblastoma were
recently reported in the United States (Friedrich et al., 2017; Steliarova-
Foucher et al., 2017), with a significantly higher incidence of bilateral
retinoblastoma in the Hispanic population, which remains as yet un-
explained.
Parental influence. The risk of sporadic retinoblastoma increases
with parental and especially maternal age (Moll et al., 1996; Saremi
et al., 2014; Yip et al., 2006), although not consistently (Heck et al.,
2012), and with maternal active smoking during pregnancy (Azary
et al., 2016).
Precursor lesions. Retinoma has emerged as a frequent intermediary
in the genesis of both hereditary and nonhereditary retinoblastoma. In
one study, 20% of enucleated eyes with retinoblastoma had a retinoma
component in the tumor, generally located towards the tumor base
(Eagle, 2009). Like retinoblastomas, retinomas carry two mutated RB1
alleles, but they will remain quiescent unless additional hits drive them
into retinoblastoma (Dimaras et al., 2008). The apparent high pro-
pensity of retinomas to degenerate into retinoblastoma likely explains
their rarity as a true benign counterpart of retinoblastoma. It is widely
presumed that transformation of long-standing retinomas is responsible
for the exceptional adult retinoblastoma (Sengupta et al., 2016).
3. Diagnosis
3.1. Presenting features
Retinoblastoma is the only pediatric cancer presenting with re-
cognizable signs, allowing awareness campaigns to be credited with
significant shortening of the time to diagnosis as shown in Switzerland
(Wallach et al., 2006). Similarly, the implementation of a national
Table 2
Estimated incidence of retinoblastoma in 2015 by world regiona.
Population Birth Estimated Annual Incidence
at Risk Rate/1000 Median 95% Confidence Interval
Africa 1,194 million 33.6 2,293 2,060−2,526
Asia 4,420 million 16.5 4,258 3,824−4,691
Europe 741 million 10.5 464 417–511
Latin America 632 million 16.4 615 552–677
North America 356 million 12.4 264 238–292
World 7,383 million 18.6 7,983 7,170−8,795
a Based on total population, crude birth rate, and infant mortality rate as
reported in the World Population Prospects: The 2017 Revision (United
Nations, 2017), and the reported retinoblastoma incidence of 1 in 16,642 live
births (95% confidence interval 15,105−18,528) by birth cohort analysis
(Seregard et al., 2004), as described (Usmanov and Kivela, 2014).
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Fig. 1. Incidence and predicted incidence of retinoblastoma from 1960 to 2060. A. In the world and by region (B) Africa, (C) Asia, (D) Europe, (E) Latin
America, and (F) North America. The population, birth rate and infant mortality are taken from the World Population Prospects, 2017 Revision (United Nations,
2017), and the number of retinoblastomas per live born children from a North European birth cohort estimates (Seregard et al., 2004). Vertical lines indicate 2015.
Undulations and peaks in the graphs are primarily explained by changes in birth rates.
Fig. 2. Gaze-dependent leukocoria as presenting sign of a retinoblastoma in the left eye of a 14-month-old boy not visible on straight gaze but only from the
temporal side (A) due to the nasal location of the tumor (B).
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educational program in Honduras allowed to significantly reduce the
proportion of patients with extraocular spread at diagnosis within less
than a decade (Leander et al., 2007). This unique feature of retino-
blastoma has the potential to improve patient and ocular survival by
earlier detection, not only in developing countries where more than
90% of retinoblastoma patients reside (see 2), but also in high-income
countries where there is still room for increased sensitization.
In high-income countries, it is estimated that less than 3% of re-
tinoblastoma patients are diagnosed with extra-ocular disease at the
time of presentation (Chantada et al., 2011). Leukocoria, a white pu-
pillary reflex, is the inaugural sign in 60% of the cases (Abramson et al.,
1998). According to the size and location of the tumor(s) (Fig. 2), this
sign can be initially intermittent, with detection also influenced by the
pupil diameter, and frequently misinterpreted as an optical illusion by
the parents or health care providers until the growing tumor elicits a
permanent leukocoria. It is not rare to identify leukocoria with flash
photography (photoleukocoria), which can precede the diagnosis by
several months, especially when the anti-red eye reflex mode of the
camera is inactivated, preventing pupil constriction from the pre-pho-
tograph flash.
Strabismus occurs when central vision is lost secondary to macular
tumoral involvement. It is the second most frequent presenting sign,
found in 20% of the cases, manifesting earlier and associated with less
advanced disease and better ocular survival than leukocoria (Abramson
et al., 1998, 2003; Shields et al., 2004a; Wallach et al., 2006).
Atypical signs in the remaining 20% of cases usually manifest in
older children, where they can masquerade other conditions such as
uveitis, glaucoma, cataract, and presumed trauma with intra-ocular
hemorrhage. These manifestations in a patient with unsuspected re-
tinoblastoma often lead to invasive diagnostic or curative procedures
and are associated with iatrogenic risk of tumor spread. Finally, mid-
facial dysmorphic features suggestive of a syndromic form of retino-
blastoma with developmental delay and birth defects due to a deletion
of the long arm of chromosome 13, can prompt screening of the fundus
in otherwise asymptomatic patients (see 5.1.2.2).
In developing countries, the diagnosis can be significantly delayed,
with extra-ocular disease present at diagnosis, occurring in less than
10% of cases in middle-income countries (Chantada et al., 2004, 2011;
Kaliki et al., 2019) and up to 45% in low-income countries (Bowman
et al., 2008; Waddell et al., 2015). In this context, late presenting signs
such as buphthalmic eyes with neovascular glaucoma, hyphema, non-
infective orbital cellulitis and proptosis predominate.
3.2. Clinical examination and ancillary testing
Retinoblastoma is the only pediatric cancer not requiring pathology
to confirm the diagnosis, due to its pathognomonic funduscopic fea-
tures. Indirect ophthalmoscopy with scleral depression under an-
esthesia is the gold standard for detection of retinoblastoma and is
usually sufficient to establish the diagnosis and grouping of eye disease.
Fundus photography provides the necessary documentation for mon-
itoring conservative therapy as well as for telemedicine purposes.
Ancillary investigations, such as ultrasonography and MRI, are instru-
mental for the differential diagnosis in eyes with opaque media and for
staging purposes, by revealing possible extraocular extension of the
disease. During conservative management, the therapeutic strategy is
continuously challenged by tumor's response and treatment-related
complications. The fine tuning in decision making increasingly relies on
ancillary imaging techniques such as fluorescein angiography (FA),
optical coherence tomography (OCT) and ultrasonic biomicroscopy
(UBM). These imaging modalities have become pivotal in the sub-
clinical detection and monitoring of tumoral and non-tumoral events,
and thus have a profound impact on both the treatment strategy and the
final clinical outcome. As such, these diagnostic tools should be part of
the equipment of any tertiary referral center for retinoblastoma.
3.2.1. Fundus documentation and fluorescein angiography
Iconographic documentation of the fundus is mandatory at pre-
sentation and at each new exam, to provide precise and detailed doc-
umentation of each tumor comprising location, size and aspect, to-
gether with their relation to the optic nerve, macula or ora serrata.
Rupture of the internal limiting membrane on the tumor apex, presence
of vitreous seeding, retinal detachment (past or present) or subretinal
dissemination are signs of more extensive disease and thus higher risk
of recurrence and therapeutic failure. All of these clinical details must
be documented accurately to better anticipate the disease course and to
adapt the treatment strategy accordingly.
Fundus drawing is the simplest and also the most instructive method
of documentation for the examiner, requiring a rigorous sense of ob-
servation and faithful interpretation. It is, however, time consuming
and examiner-dependent. The schematic representation according to a
conventional code may easily fail to depict small changes of the tumor,
or slow progression of growth. In addition, exchange with other experts
or physicians with this kind of support can be problematic. For these
reasons, fundus photography has taken on an important role in the
documentation of retinoblastoma, providing objective representation
and easier comparison of images. Several models of hand-held digital
cameras with corneal contact lenses (30–130°) are commercialized for
use in the operating theater, namely the RetCam™ (Clarity Medical
Systems, Inc., Pleasanton, CA, USA), the PanoCam™ Pro (Visunex
Medical Systems, Fremont, CA, USA), and ICON™ (Phoenix Technology
Group, Pleasanton, CA, USA). FA modules are available on all 3 devices.
For children over 4 years of age and examined without anesthesia,
Optos™ (Marlborough, MA, USA) is an ultrawide-angle imaging system
providing a 200° retinal field view in one non-contact capture, even
with a pupil diameter as small as 1mm.
FA of both the anterior and posterior segment plays an essential role
in the evaluation of retinoblastoma patients, especially in the context of
intra-arterial chemotherapy, by providing undeniable information re-
garding tumor activity or vascular complications under the following
circumstances:
(i) At presentation, to detect subclinical iris neovascularization (Kim
et al., 2014) and assess the tumoral and retinal vascularization status
(Ohnishi et al., 1982).
(ii) After each intra-arterial course, to detect vascular complications
such as ischemic retinopathy, associated or not with retinal and/or iris
neovascularization (see 7.3.4).
(iii) At completion of first line and consolidation therapy, to provide
a baseline angiogram to be used for future comparison (Shields et al.,
1982).
(iv) In case of suspicion of relapse, especially in the context of type
II and III regression patterns, by revealing tumor neovascularization
(Ohnishi et al., 1982; Shields et al., 1982).
(v) In case of new retinal detachment, neovascularization and/or
intraocular hemorrhage during conservative treatment, to assess the
intraocular vascularization status (Stathopoulos et al., 2018a).
(vi) To monitor treatment response to intraocular vascular compli-
cations such as focal treatment of ischemic retina, retinal detachment
repair and/or anti-Vascular Endothelial Growth Factor (VEGF) therapy
(Stathopoulos et al., 2018a).
3.2.2. Ultrasonic biomicroscopy (UBM)
UBM yields high resolution images of the anterior segment and
structures of the posterior chamber that are hidden from direct visua-
lization, such as the ciliary body, zonules or anterior hyaloid. Over the
last decade, UBM has proved to be instrumental in evaluating any
anterior extension of retinoblastoma (Moulin et al., 2012; Vasquez
et al., 2011). Using a 35MHz transducer with an acoustic 68 μm axial
resolution (OTI Scan 2000; Ophthalmic Technologies, North York,
Ontario, Canada), we have shown that tumoral invasion of the posterior
chamber can be detected with high sensitivity (81%) and specificity
(100%), even in the absence of anterior chamber involvement (Moulin
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
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et al., 2012). It is now possible to obtain scans of 12mm at 50MHz
(Aviso™, Quantel Medical, Clermont-Ferrand, France) with a 35 μm
axial resolution, providing unprecedented details of the micro-anatomy
of the anterior segment (Fig. 3) and improvement in terms of tumor
detection sensitivity
In clinical practice, UBM has become a fundamental tool for:
(i) Assessing the anterior extent of retinoblastoma at diagnosis or at
relapse with respect to the integrity of the anterior hyaloid and the
anterior uvea (ciliary body and iris) (see 6.2.4).
(ii) Exploring the extreme periphery and posterior chamber in diffuse
anterior retinoblastoma for the identification of the primary tumor,
which can be located in the retinal rim under the vitreous base or
anterior to the ora serrata (see 6.1.2.3).
(iii) Identifying a safe pars plana meridian, devoid of parietal tumor
growth, as entry site for intravitreal chemotherapy, especially
when pupil dilation is compromised or in the presence of opaque
media (see 7.3.2).
3.2.3. Optic coherence tomography (OCT)
Commercialization of hand-held spectral-domain OCT apparatus (HH-
SD OCT), (Bioptigen™, Durham, North Carolina, USA or Optovue iVue,
Fremont, CA, USA) specifically adapted for pediatric use, has enabled OCT
imaging in children lying in the supine position. The integration of HH-SD
OCT in the management of retinoblastoma is attested by an increasing
number of publications allowing better understanding and evaluation of
both tumoral and non-tumoral abnormalities.
In practice, OCT provides an invaluable tool to improve retino-
blastoma care in the following situations:
(i) Early detection of tumors or tumor growth allowing prompt ther-
apeutic response, particularly beneficial in case of juxta-papillary
or juxta-foveal lesions. Specific cases include the following pre-
sentations:
a. Cryptic retinal tumors (Berry et al., 2016a; Rootman et al.,
2013; Seider et al., 2016; Soliman et al., 2017), appearing as
round hyperreflective lesions located in the inner or outer retina
(Fig. 4A and B). Such subclinical findings challenge the classi-
fication if present at diagnosis, possibly changing unilateral to
bilateral involvement and/or grouping (see 3.3.1).
b. Cryptic incipient retinal recurrences (Gaillard et al., 2018)
(Fig. 4C).
c. Epipapillary lesions at a pre-invasive stage (Fabian et al.,
2017b) (Fig. 4D and E).
d. Choroidal invasion (Stathopoulos et al., 2018b) (Fig. 4I).
e. Precise delineation of the invisible front line of tumor growth in
diffuse infiltrating retinoblastoma (Stathopoulos et al., 2019)
(Fig. 9G–I).
f. Cluster of cells (anterior chamber seeding) in the irido-corneal
angle and/or placoid growth on the corneal endothelium that
could otherwise go unnoticed (anterior chamber OCT) (Fig. 13 E).
(ii) Monitoring of the treatment response in the vitreous (Fig. 4G and
H) or retina (Fig. 4J and K). In the specific case of cryptic type 0
regressed tumors (Saktanasate et al., 2015), OCT enables doc-
umentation of a residual hyperreflective lesion that should either
receive focal therapy to result in a type 4 regression, or be carefully
monitored to prove its inactivity (absence of growth) (Fig. 4J and
K).
(iii) Evaluation of the retinal and optic nerve status behind dense ret-
rohyaloid or epiretinal seeding (Hasanreisoglu et al., 2015) (Fig. 4
F).
(iv) Assessment of the foveal integrity to evaluate visual potential. In
the specific case of retinal detachment, OCT can be used to monitor
foveal detachment while awaiting complete spontaneous or
Fig. 3. Fundus extremicus. A-B. Schematic representation of the normal microanatomy of the retinal extreme periphery. A. En face view (dash line= longitudinal
section) and (B) longitudinal section C. Photograph of peripheral infero-nasal retinal indentation showing retinal oral teeth (13) and an isolated ciliary retinal island
(12). D. Longitudinal UBM (ultrasonographic biomicroscopy) of the periphery (50MHz). 1. Choroid 2. Retina 3. Internal limiting membrane 4. Posterior hyaloid. 5.
Peripheral retina posterior to the vitreous base 6. Posterior limit of the vitreous base 7. Retinal vitreous base with fenestrated inner limiting membrane and devoid of
overlying hyaloid 8. Ora serrata and posterior insertion of the anterior hyaloid 9. Cone-enriched rim 10. Anterior hyaloid 11. Pars plana. 12. Isolated ciliary retinal
island (ectopic retina) devoid of inner limiting membrane 13. Retinal oral tooth devoid of inner limiting membrane 14. Pars plicata. 15. Posterior chamber 16.
Anterior chamber 17. Hannover's canal 18. Petit's canal 19. Vitreous.
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surgical reapplication before intensifying amblyopia treatment
(see 7.3.1).
(v) Documentation of non-tumoral treatment-related alterations such
as choroidal thinning post intra-arterial chemotherapy (Maidana
et al., 2014) or radio-induced macular edema (Miller et al., 2005).
(vi) Differential diagnosis of other retinal tumors (Fig. 4L–N).
3.2.4. Magnetic resonance imaging (MRI)
High-resolution contrast-enhanced MRI is currently considered to
be the most sensitive technique to evaluate any extraocular extension of
retinoblastoma. In middle and high-income countries, it has now
completely supplanted computer tomography (CT) imaging, which
carries an increased risk of radiation–induced oncogenesis without
(caption on next page)
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adding any diagnostic value. The success of MRI in the context of re-
tinoblastoma relies, however, on specific requirements which differ
from those used for routine brain and orbit examinations. A consensual
standardized protocol for the evaluation of retinoblastoma at diagnosis
has recently been proposed by members of the European
Retinoblastoma Imaging Collaboration (ERIC) (de Graaf et al., 2012). In
order to achieve high resolution imaging, two techniques using 1.5 or
3 T scanners can be employed. With the 1.5 T scan, the use of a surface
coil to increase the signal-to-noise ratio is necessary. Surface coils have,
however, the disadvantage of requiring more time for accurate posi-
tioning, allow the examination of only one orbit at a time, and are less
precise in imaging the posterior part of the orbit due to rapid signal
loss. Surface coils are not needed with a 3 T scanner equipped with a
32-channel coil (de Jong et al., 2015a).
MRI plays a critical role in assessing the following:
(i) Detection of tumor calcifications, which is important in the dif-
ferential diagnosis especially in cases where the fundus view is
obscured. Calcifications can be observed with high sensitivity and
specificity on T2 images without the help of CT, as proved by an ex
vivo MRI study (Rodjan et al., 2015).
(ii) Patient staging by enabling detection of extra-ocular invasion at
Fig. 4. Role of optical coherence tomography (OCT) in the management of retinoblastoma. A. Detection of an invisible parapapillary tumor in the left eye of a
2-month-old girl referred for a familial retinoblastoma (scT1bN0M0), (B) which regressed to a hyperreflective scar on OCT after Argon laser treatment. C. Early
diagnosis of a recurrence over a parapapillary scar. D. Diagnosis of an invisible epipapillary vitreous seed. Note the intact demarcation line between the seed and the
papilla, supporting the absence of prelaminar invasion, before (D) and after (E) treatment with intravitreal melphalan. F. Documentation of an intact fovea behind
dense epiretinal seeding predictive of a good visual prognosis. G. Assessment of the treatment response of prehyaloidal vitreous seeds (spheres) before (G) and after
(H) intravitreal melphalan. The appearance of hyperreflective dots in spheres indicates complete response implying treatment completion. I. Early diagnosis of a
secondary choroidal invasion. J. Posterior pole retinoblastoma (arrow heads) at diagnosis and (K) after 6 cycles of systemic chemotherapy in the context of bilateral
disease, showing regression type 0 on indirect ophthalmoscopy, but persistent lesion on OCT necessitating appropriate follow-up. L-N. Two-week-old girl with
leukocoria, neovascular glaucoma and total exudative retinal detachment in the right eye (L) referred for suspicion of retinoblastoma. M, N. Left eye examination
revealed multiple small retinal lesions involving the nerve fiber layer on OCT, corresponding to retinal astrocytic hamartomas. Tuberous sclerosis was confirmed on
magnetic resonance imaging one week later, and by the presence of a germline TSC2 mutation. Pathology of the enucleated right eye revealed a giant cell astro-
cytoma. NB: Lines on fundus photography correspond to the adjacent optical coherence tomography scan.
Fig. 5. Magnetic Resonance Imaging of the pineal
gland. A. Pineal trilateral retinoblastoma: T1 sagittal
image after injection of gadolinium in a 19-month-
old girl with bilateral retinoblastoma B. Suprasellar
trilateral retinoblastoma: T1 sagittal image after in-
jection of gadolinium in a 14-month-old boy,
showing a cystic and nodular pineal gland and a
large tumor in the pituitary sella. C. T1 sagittal
image after injection of gadolinium showing a pineal
nodule in the posterior wall of a cystic gland in a 45-
month-old boy, growing to pinealoblastoma three
months later (D). E-F. T2 sagittal TSE (Turbo spin
echo) image in a 4 months old patient with bilateral
retinoblastoma showing the growth of a pineal 2a
cyst over 15 months, followed by a gradual regres-
sion over 4 years (G).
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the level of the:
a. Optic nerve. In the presence of a normal-sized optic nerve
sheath, the diagnosis of retrolaminar invasion relies on contrast
enhancement after gadolinium injection in T1. However, high
resolution-MRI shows limited sensitivity in depicting early-stage
optic nerve invasion and therefore cannot substitute for patho-
logical analysis. These limitations are highlighted in a 1.5 T
surface coil study with histological verification, which proved to
be disappointing in terms of sensitivity, although high specifi-
city (range 0.64–1) and high negative predictive values (range
0.81–0.97) could be confirmed (Brisse et al., 2015). In the case
of massive optic nerve invasion, an intra-cranial mass can form
and cerebrospinal fluid invasion leading to leptomemingeal
enhancement can be visualized.
b. Choroid. The normal choroid enhances after gadolinium injec-
tion, whereas disruption of the choroid blush is a sign leading to
the suspicion of choroidal invasion (de Graaf et al., 2012).
c. Sclera. The sclera does not enhance and is seen as a hypointense
line on T2 images. Disruption of this line and the deformation of
the globe are signs of scleral invasion.
(iii) Screening for trilateral retinoblastoma (see 3.6) (Fig. 5).
(iv) Diagnosis of second primary neoplasms, especially in hereditary
retinoblastoma survivors treated by external beam irradiation (see
3.8).
3.3. Classifications
Classification schemes in cancer aim to provide a universal language
for the evaluation of the disease extent, which is necessary to determine
and compare different treatment strategies and to enable prognostica-
tion. Unlike cancers affecting other organs, where tumor excision or
biopsy is usually performed for diagnosis confirmation and histo-
pathologic grading, the diagnosis of retinoblastoma is clinical.
Classifying retinoblastoma poses, however, a particular challenge as
both intraocular and extraocular tumor extension need to be assessed in
order to predict not only the likelihood of eye preservation, but also the
Table 3
TNMH classification (8th Edition).
Clinical Definitions (cTNM)
Category Subcategory Description
cTX Unknown evidence of intraocular tumor
cT0 No evidence of intraocular tumor
cT1 Intra-retinal tumor(s) with subretinal fluid≤5mm from base of any tumor
cT1a Tumors≤3mm and further than 1.5mm from disc and fovea
cT1b Tumors > 3mm or closer than 1.5 mm from disc or fovea
cT2 Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding
cT2a Subretinal fluid > 5mm from the base of any tumor
cT2b Vitreous seeding and/or subretinal seeding
cT3 Advanced intraocular tumor(s)
cT3a Phthisis or pre-phthisis bulbi
cT3b Tumor invasion of choroid, pars plana, ciliary body, lens, zonules, iris, or anterior chamber
cT3c Raised intraocular pressure with neovascularization and/or buphthalmos
cT3d Hyphema and/or massive vitreous hemorrhage
cT3e Aseptic orbital cellulitis
cT4 Extraocular tumor(s) involving orbit, including optic nerve
cT4a Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve
cT4b Extraocular tumor clinically evident with proptosis and/or an orbital mass
cNX Regional lymph nodes cannot be assessed
cN0 No regional lymph node involvement
cN1 Evidence of preauricular, submandibular, and cervical lymph node involvement
cM1 Distant metastasis without microscopic confirmation
cM1a Tumor(s) involving any distant site (e.g, bone marrow, liver) on clinical or radiologic tests
cM1b Tumor involving the CNS on radiologic imaging (not including trilateral retinoblastoma)
pM1 Distant metastasis with microscopic confirmation
pM1a Pathological evidence of tumor at any distant site (e.g. bone marrow, liver, or other)
pM1b Pathological evidence of tumor in the cerebrospinal fluid or CNS parenchyma
H Hereditary Trait
HX Unknown or insufficient evidence of a constitutional RB1 gene mutation
H0 Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays
H1 Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family
history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation
Pathological Definitions (pTNM)
pTX Unknown evidence of intraocular tumor
pT0 No evidence of intraocular tumor
pT1 Intraocular tumor(s) without any local invasion, or with focal choroidal invasion, or pre- or intralaminar involvement of the optic nerve
pT2 Intraocular tumor(s) with local invasion
pT2a Concomitant focal choroidal invasion and pre- or intralaminar involvement of the optic nerve head
pT2b Tumor invasion of stroma of iris and/or trabecular meshwork and/or Schlemm's canal
pT3 Intraocular tumor(s) with significant local invasion
pT3a Massive choroidal invasion (> 3mm in largest diameter, or multiple foci of focal choroidal involvement totalling > 3mm, or any full-thickness
choroidal involvement)
pT3b Retrolaminar invasion of the optic nerve head, not involving the transected end of the optic nerve
pT3c Any partial-thickness involvement of the sclera within the inner two thirds
pT3d Full-thickness invasion into outer third of the sclera and/or invasion into or around emissary channels
pT4 Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal spaces around the optic nerve, full thickness
invasion of the sclera with invasion of the episclera, adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids
Mallipatna, A.C et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK et al., editors. AJCC Cancer Staging Manual, 8th ed.
New York: Springer; 2017.0.819–31.
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risk of dissemination, which in turn correlates with patient survival.
Historically, the classification of retinoblastoma was divided into
multiple intraocular retinoblastoma eye grouping (see 3.3.1) and pa-
tient staging (see 3.3.2) systems, still variously used and therefore
making comparison between studies difficult. The 8th edition of the
American Joint Committee on Cancer “Tumor, Node, Metastasis and
Heritability” (TNMH) classification has recently been proposed to more
accurately predict the salvage of the eye(s), metastasis and patient
survival and holds the promise to provide a single universal classifi-
cation (Mallipatna et al., 2017) (Table 3).
Surprisingly, despite the broad use of OCT in retinoblastoma pa-
tients (see 3.2.3), none of the existing classification systems have been
adapted to consider possible subclinical findings at diagnosis.
Moreover, although heavily-pretreated eyes are being increasingly of-
fered salvage therapies, a classification of intraocular retinoblastoma at
relapse is still missing and precludes the possibility to compare study
outcomes of salvage treatments. This prompted us to add subclinical
features at diagnosis in the TNMH classification system (see 3.3.1) as
well as to propose a classification at relapse (see 3.3.3).
3.3.1. Grouping of the eye at presentation (RE, IIRC, ICRB, COG, TNMH)
A system to evaluate the intraocular extent of the disease was first
introduced in the 1960s by Reese and Ellsworth, who stratified in-
traocular retinoblastoma into five groups (RE I to V), predicting eye
survival in response to external beam radiotherapy (Reese and
Ellsworth, 1963). The therapeutic shift from external beam radio-
therapy to chemoreduction motivated the introduction by Linn Mur-
phree, in 2005, of a novel International Intraocular Retinoblastoma
Classification (IIRC), recapitulating the natural history of retino-
blastoma into five groups (A to E) (Table 4) (Linn Murphree, 2005),
with the presence of group E features being an absolute indication for
enucleation. In 2006, this classification was revisited with some mod-
ifications by the group of Philadelphia (Shields et al., 2006a), followed
in 2011 by the Children's Oncology Group (COG) giving rise to the
International Classification of Retinoblastoma (IRCB) and the COG,
respectively. At the present time, the parallel use of 3 coexisting A to E
classifications confuses the literature, especially regarding advanced
eyes and impairs comparison of different clinical reports (Scelfo et al.,
2017). For example, in a study of more than 2000 eyes (Kaliki et al.,
2019), up to 56% of IRCB group E eyes would have been classified IIRC
group D eyes, since IIRC group D eyes with tumor occupying 2/3 of the
eye volume are reclassified ICRB group E eyes.
Although the TNMH classification includes the use of radiologic
imaging to assess any optic nerve involvement (Mallipatna et al., 2017)
(Table 3), it fails, like the previous ones, to allow grouping of invisible
tumors only detected by OCT, as may be the case in the context of
screening RB1 mutant carriers with a positive family history. We
therefore propose to revise the TNMH classification by adding cate-
gories scT1a and b for subclinical staging: scT1a in case of subclinical
tumor(s) at least further than 1.5mm from the optic nerve head or
3mm from fovea, and scT1b if closer (Fig. 4A).
3.3.2. Patient staging at presentation (IRSS, TNMH)
The first classification system for retinoblastoma aiming to cover the
whole spectrum of the disease (IRSS) was introduced in 2006 by a
multidisciplinary team of physicians from different countries and based
on clinical evaluation, imaging and histopathology (Chantada et al.,
2006a) (Table 5). Two years later, the same group standardized the
processing of the enucleated eyes in order to obtain reliable histo-
pathologic results and fresh tumor for molecular testing to define pa-
thological risk factors for extraocular relapse (Sastre et al., 2009). The
recently introduced TNMH classification considers not only intraocular,
extraocular and pathological disease but also, for the first time, the
hereditary status and aims to become the gold standard reference in the
future (Mallipatna et al., 2017).
The recommended procedures for assessing extraocular dissemina-
tion in retinoblastoma include contrast-enhanced MRI of the brain and
orbits (de Graaf et al., 2012) as well as bone marrow and cerebrospinal
fluid cytopathologic evaluation, with or without PCR-based detection of
specific molecular biomarkers (Laurent et al., 2016) (see 3.7.1).
Staging investigations, such as lumbar puncture and bone marrow
aspiration/biopsy are relatively invasive and require general an-
esthesia. They are not commonly performed in early stages (IRSS stage
0 or 1) where the risk of harboring disseminated disease is considered
minimal. These investigations, as well as skeletal scintigraphy are,
however, indicated in case of symptoms (pain, neurologic manifesta-
tions), exteriorization of the disease or high-risk pathology features
reported after enucleation (Azar et al., 2003; Barai et al., 2004;
Karcioglu et al., 1997; Moscinski et al., 1996; Pratt et al., 1989). If
conservative treatment is attempted, some groups advocate cytological
evaluation of the cerebrospinal fluid in cases where the optic nerve
cannot be visualized (Mallipatna et al., 2017). At the present time,
however, a universal consensus especially for the metastatic work-up
concerning conservatively-treated advanced intraocular disease is still
missing. The development of more precise or less invasive techniques,
such as molecular biomarkers in cerebrospinal fluid and bone marrow
(Torbidoni et al., 2015), or functional imaging, would be ideal for di-
agnosis and follow-up of disseminated disease (Kohe et al., 2015).
3.3.3. Classification of retinoblastoma at relapse (RSU classification)
Similar to the classification of retinoblastoma at presentation, the
classification of retinoblastoma at relapse aims to standardize appro-
priate treatment for relapse, achieve a better comprehension of treat-
ment outcomes, predict prognosis for ocular salvage and define en-
ucleation criteria for secondary enucleation. However, because
recurrences do not necessarily involve the retina (R), but can be ex-
clusively extraretinal with isolated seeding (S) or uveal involvement
(U), it is not possible to classify them by applying one of the grouping
Table 4
International intraocular retinoblastoma classification (IIRC).
Group A Small tumors (≤3mm) confined to the retina (no seeding), at least 3mm from the fovea and 1.5 mm from optic nerve.
Group B Tumors (> 3mm) confined to the retina in any location, with clear subretinal fluid≤ 5mm from the tumor margin
Group C Localized vitreous and/or subretinal seeding (< 5mm in total from tumor margin). If there is more than 1 site of subretinal/vitreous seeding, then the total of these
sites must be < 6mm. Up to 1 quadrant subretinal seeding may be present.
Group D Diffuse vitreous and/or subretinal seeding (≥5mm in total from tumor margin). Seeding more extensive than Group C. Retinal detachment > 1 quadrant
Group E Massive retinoblastoma with anatomic or functional destruction of the eye with one or more of the following
- Neovascular glaucoma
- Massive intravitreal hemorrhage
- Aseptic orbital cellulitis
- Tumor anterior to anterior vitreous face
- Tumor touching the lens
- Diffuse infiltrating tumor
- Phthisis or pre-phthisis
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005; 18(1):41–54, viii
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systems used at diagnosis. Therefore, we propose a specific classifica-
tion for relapsing retinoblastoma based on its localization which is
detailed in Table 6. In this classification, the recognition of tumor re-
lapse does not only rely on clinical observation but also on imaging
devices such as UBM (Chhablani et al., 2010; Stathopoulos et al.,
2018b) or SD-OCT (Fabian et al., 2017b; Gaillard et al., 2018). The
definition of relapse or recurrence refers to any tumor regrowth or new
growth occurring after a minimum of 2 months progression-free and
treatment-free follow-up at a monthly examination. In contrast, per-
sistent, due to absence of response, or progressive disease despite on-
going treatments, as well as new primary retinal tumors, have to be
distinguished from recurrence, and as such are not concerned by the
proposed RSU-classification. Moreover, caution should be taken not to
label as relapse, active disease diagnosed without an intermediate
progression-free follow-up interval of at least two months since the last
treatment, as in such cases disease persistance/progression cannot be
excluded.
Prompt secondary enucleation is mandatory for relapse in the pre-
sence of persisting vitreous hemorrhage obscuring the fundus, neovas-
cular glaucoma, phthisis bulbi or suspicion of extra-ocular extension.
3.4. Differential diagnosis
The list of conditions simulating retinoblastoma includes a broad
spectrum of both acquired and congenital diseases (Balmer and Munier,
2007; Shields et al., 2013) (Table 7). In children seen in non-ocular
oncology specialized centers, leukocoria, the main presenting sign of
retinoblastoma, was due to congenital cataract in 25–65% of the cases
and retinoblastoma in only 6–18% (Haider et al., 2008; Meier et al.,
2006). In a retrospective review of nearly 2800 cases specifically
Table 5
International retinoblastoma staging system (IRSS).
Stage 0 Stage I Stage II Stage III: Regional extension Stage IV: Metastatic disease






A: overt orbital disease










NB: In cases of bilateral disease, the staging depends on the eye with more advanced disease. Abbreviation: CNS= central nervous system.
Chantada, G et al. A proposal for an international retinoblastoma staging system. Pediatric blood & cancer. 2006; 47(6):801–5.
Table 6
Retinoblastoma classification at relapse (RSU-Classification).
Category Subcategory Description
RX Retinal relapse not assessable due to opaque media
R0 No retinal relapse
R1 Intra-retinal relapse
R1a Localized (accessible to focal therapy including brachytherapy) retinal relapse at least > 3mm from the foveola and 1.5 mm from the optic nerve head
R1b Diffuse retinal relapse (any retinal relapse which is not localized) or any retinal relapse contiguous to the foveola (≤3mm) or the optic nerve head
(≤1.5mm)
SX Seeding not assessable due to opaque media
S0 No seeding relapse
S1 Subretinal seeding relapse
S1x Subretinal seeding not assessable due to opaque media
S1a Localized subretinal seeding (≤1 quadrant), at least > 3mm from the foveola and 1.5 mm from the optic nerve head
S1b Diffuse (> 1 quadrant) subretinal seeding or any subretinal seeding contiguous to the foveola (≤3mm) and/or the optic nerve head (≤1.5mm)
S2 Intravitreal seeding relapse
S2x Intravitreal seeding not assessable due to opaque media
S2a Localized vitreous and/or retrohyaloid seeding (≤3mm from retinal tumor)
S2b Diffuse vitreous and/or retrohyaloid seeding (any vitreous and/or retrohyaloid seeding which is not localized)
S3 Aqueous seeding relapse
UX Uveal relapse not assessable due to opaque media and no UBM/MRI evaluation
U0 No uveal relapse
U1 Choroidal relapse
U1a Focal choroidal relapse (≤3mm in largest diameter)
U1b Massive choroidal relapse (> 3mm in largest diameter)
U2(x) Intraciliary relapse (x= number of clock hours involved)
U3 Iris relapse
Table 7
Pseudoretinoblastoma: acquired and congenital diseases mimicking retino-
blastoma.
A. Developmental abnormalities
- Persistent hyperplastic primary vitreous
(PHPV), persistent fetal vasculature
syndrome
- Posterior coloboma
- Congenital retinal folds
- Myelinated nerve fibers






- Congenital retinal fold
C. Vascular abnormalities
- Coats' disease








- Retinal capillary hemangioma
- Combined retinal hamartoma
- Acute leukemia
- Juvenile xanthogranuloma
- Amelanic choroidal melanoma
- Heterotopic brain
tissue= retinal choristoma
- Choroidal osteoma= choroidal
choristoma
B. Inflammatory & infectious disorders
- Ocular toxocariasis
- Congenital toxoplasmosis
- Congenital cytomegalovirus retinitis
- Herpes simplex retinitis











- Congenital corneal opacity
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referred for suspected retinoblastoma in a tertiary center in the United
States of America, 78% had a confirmed retinoblastoma whereas 22%
suffered a different disease, dominated by Coats' disease (Shields et al.,
2013). The latter has notably the particularity of mimicking retino-
blastoma at different stages, including endophytic macular retino-
blastoma group B in Coats' disease stage 2B2, characterized by the
presence of a subfoveal pseudo-tumor measuring up to 2.5mm and
sometimes associated with pseudo-feeding vessels (Daruich et al.,
2017), or exophytic retinoblastoma group D and E in Coats’ disease
stages 3B and 4, respectively (Gaillard et al., 2014). In the majority of
cases, a comprehensive history with thorough clinical examination and
appropriate ancillary tests is usually sufficient to avoid misdiagnosis
and undesirable treatments (Shields et al., 2013). The indication for
fine needle biopsy should be limited to extraordinarily unusual cir-
cumstances (Karcioglu, 2002).
3.5. Prenatal diagnosis of retinoblastoma
Early screening for retinoblastoma is advised for children with a
positive family history of the disease. Intra-uterine and early postnatal
retinoblastoma lesions are predominantly located in the posterior pole,
where they are more likely to compromise vision (Kivela and
Hadjistilianou, 2017; Soliman et al., 2016) and known for their rapid
growth with an estimated doubling time of 2 weeks (Shah et al., 2010).
Before genetic testing and the use of modern imaging techniques
(high frequency ultrasound probes and MRI), diagnostic screening for
retinoblastoma was performed postnatally with indirect ophthalmo-
scopy (Abramson et al., 2002). With the introduction of RB1mutational
testing, offspring of parents with a known mutation can now be
screened during pregnancy. Currently, DNA extraction for mutational
analysis can be proposed either by chorionic villus sampling at the end
of the first trimester (11 weeks of gestation) or by amniocentesis during
the second trimester (16 weeks of gestation). Parents should be in-
formed of a procedure-related potential miscarriage risk of 0.22% and
0.11% after chorionic villus sampling and amniocentesis, respectively
(Akolekar et al., 2015). Confirmation of a fetal RB1 mutation allows
parents to make an informed decision as to whether or not to proceed
with the pregnancy. Standards for the follow-up of a fetus with high-
risk to develop the disease do not currently exist. In Lausanne, for
parents who decide to proceed with the pregnancy despite confirmation
of a fetal RB1 mutation, or for those who refused amniocentesis, fetal
ultrasonography is performed at 26 weeks of gestation and repeated
every 3 weeks until 32 weeks, and then every 2 weeks until 36 weeks of
gestation. The ultrasonography includes standard 2D and 3D images of
fetal anatomy acquired through a magnified axial view of both eyes
(Fig. 6). The 3D acquisition of volume is an integral part of our eva-
luation as it allows systematic analysis of the posterior wall of the eye.
An alternative imaging detection method is fetal MRI, which, compared
to ultrasonography, has a higher contrast resolution but is more af-
fected by fetal motion (Staffieri et al., 2015). In case of tumor detection,
a consultation with an ocular oncologist, perinatologist and neonatol-
ogist is needed to balance the burden of an early term delivery, pre-
ceded or not by pulmonary maturation therapy, against the oncologic
risks of management of a full-term delivery.
In practice, only few cases of fetal retinoblastoma have been pub-
lished. Two were very large lesions that deformed not only the globe
but also the face (Maat-Kievit et al., 1993; Salim et al., 1998). Five
occurrences of small intraocular retinoblastomas were reported either
by ultrasonography (Paquette et al., 2012; Soliman et al., 2016;
Stathopoulos et al., 2018c; Toi et al., 2003) or by MRI (Staffieri et al.,
2015). Ultrasonography is not sensitive enough to detect tumors mea-
suring less than 2mm in thickness. In a fetus carrying a RB1 mutation,
two lesions of 1.2 and 1.9 mm, respectively, were detected at the pos-
terior pole in each eye by MRI performed at 35 weeks of gestation
(Staffieri et al., 2015). In a prospective study of the use of both ultra-
sonography and MRI in 6 high risk fetuses, fetal MRI did not detect any
tumors, whereas one could be seen on ultrasonography, possibly be-
cause of the limitation of slice thickness (Paquette et al., 2012).
A recent retrospective observational study suggested that induced
early delivery (by 37 weeks of gestation), which remains a controversial
procedure (Gombos, 2012), might benefit the child carrying a mutated
RB1 in terms of treatment-related morbidity and ultimate salvage of
vision (Soliman et al., 2016). Noteworthy, when retinoblastoma is di-
agnosed during the neonatal period, at least half of the children initially
have a unilateral rather than bilateral tumor, typically group B, but
almost all germline mutation carriers later progress to bilateral in-
volvement (Kivela and Hadjistilianou, 2017; Soliman et al., 2016). On
the other hand, all infants with neonatal retinoblastoma have at least
one eye with a tumor close to the foveola, whereas the macula of the
fellow eye is often spared and loss of reading vision from both eyes is
consequently infrequent (Imhof et al., 2006; Kivela and Hadjistilianou,
2017; Soliman et al., 2016).
Fig. 6. A. Prenatal detection of a macular tumor in
the left eye by transabdominal ultrasonography
(5MHz) at 33 weeks of gestation. B. Postnatal ul-
trasonography (10MHz) obtained after provocation
at 36 weeks of gestation showing the left macular
tumor on ultrasonography and (C) fundus photo-
graphy. D-F. Corresponding imaging of the right eye
showing a tiny posterior pole lesion sparing the fovea
detectable only post-natally on both ultrasound and
fundus photography (infero-temporal to the fovea).
(Images courtesy of: Dr. Ants Toi, Medical Imaging,
Mt. Sinai Hospital and Dr. Brenda Gallie,
Ophthalmology and Vision Sciences. Hospital for
Sick Children. University of Toronto. Canada).
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3.6. Trilateral retinoblastoma
Approximately 3.5% of patients with hereditary retinoblastoma will
develop an intracranial tumor, located most often in the pineal gland
and less frequently in the supra- or parasellar region (de Jong et al.,
2014a) (Fig. 5A and B). Such a primitive neuroectodermal tumor as-
sociated with hereditary retinoblastoma was first described in 1977
(Jakobiec et al., 1977) and in 1982, named trilateral retinoblastoma
(Bader et al., 1982). Originally considered to have a dismal prognosis
(Kivela, 1999; Paulino, 1999), sophisticated imaging allowing earlier
detection and improved chemotherapy regimens have, since 1995,
significantly increased 5-year survival rates from 6 to 44% for pineal
tumors and from 0 to 57% for non-pineal tumors (de Jong et al.,
2014a). On the other hand, understanding that children frequently have
a cystic, non-neoplastic pineal gland with radiological features that
differ from pineoblastoma, has helped to avoid over-diagnosis of tri-
lateral retinoblastomas (Barboriak et al., 2001; Beck Popovic et al.,
2006).
3.6.1. Incidence, early detection and screening
The risk period of developing trilateral retinoblastoma extends from
birth to 7 years of age (de Jong et al., 2014a; Kivela, 1999), with 95% of
the cases diagnosed before the age of 5 (de Jong et al., 2015b). Patients
with hereditary retinoblastoma have a higher risk of developing tri-
lateral disease compared to those with non-hereditary disease, the latter
carrying the same risk as the normal population. A recent meta-analysis
restricted to cohorts with at least 100 retinoblastoma patients estimated
the risk of developing trilateral disease to be 3.8% in bilateral disease
(2.9% for pineal tumors) and 3.5% (3.2% for pineal tumors) when
considering all hereditary retinoblastoma, including unilateral cases
with a positive family history (de Jong et al., 2015b). This naturally
leads to the question of the need and the frequency at which one should
screen for trilateral retinoblastoma with MRI.
Trilateral retinoblastomas detected synchronously with intraocular
retinoblastoma are usually smaller in size, asymptomatic and have a
better prognosis compared to those detected metachronously (de Jong
et al., 2014a; Kivela, 1999). Five-year survival is also more favorable if
the trilateral tumor is pineal and less than 15mm in size (de Jong et al.,
2014a). Baseline screening is therefore currently considered justified by
most authors (De Ioris et al., 2014; de Jong et al., 2014a; Rodjan et al.,
2012), but cost-effectiveness of subsequent imaging remains con-
troversial (Moll et al., 2002).
3.6.2. Influence of the retinoblastoma treatment on the incidence of
trilateral retinoblastoma
Previous radiotherapy for retinoblastoma, especially before the age
of 12 months, has been associated with a potentially higher incidence of
pineal trilateral retinoblastoma in patients with hereditary retino-
blastoma, even though the pineal gland is usually not (directly) within
the field of radiation (Moll et al., 2002). The question of whether pre-
vious systemic chemotherapy is protective of developing trilateral re-
tinoblastoma is still debated with reports that favor (Shields et al.,
2001) or challenge such a preventive effect (Chantada et al., 2014). In
the current era of intra-arterial and intravitreal chemotherapy, the
likelihood to develop trilateral retinoblastoma does not seem to have
increased, with a reported incidence of 2.7% at 5 years follow-up
(Habib et al., 2018).
3.6.3. Improved treatment of trilateral retinoblastoma: high-dose
chemotherapy
Trilateral retinoblastoma used to be treated with surgery, che-
motherapy, and radiotherapy (Blach et al., 1994; Jubran et al., 2004).
In 2010, a multimodality approach to metastatic retinoblastoma with
intensive induction of chemotherapy, high-dose chemotherapy and
stem cell reinfusion was reported to provide a 5-year survival of 67% in
a small series of patients with non-central nervous system (CNS)
metastases (Dunkel et al., 2010c) and a cure for only 1 out of 6 patients
with CNS dissemination from trilateral retinoblastoma (Dunkel et al.,
2010b). This led to a collaborative, prospective clinical trial for meta-
static or trilateral retinoblastoma by the Children's Oncology Group
(COG) and Grupo de America Latina de Oncologia Pediatrica (GALOP).
The treatment consisted of four courses of intensive chemotherapy and,
according to response, a three-drug high-dose chemotherapy regimen
with stem cell reinfusion, with or without radiotherapy. The results
recently confirmed a 3-year event-free survival of 79% after non-CNS
metastases, whereas the survival rate remained at an unsatisfactory 8%
after CNS metastases or trilateral retinoblastoma (Dunkel et al., 2017).
3.6.4. Differential diagnosis: pineal cysts
Technological progress in imaging has contributed to an increased
observation of pineal cysts, a benign finding reported in more than half
of the pediatric population using 3 T MRI (Whitehead et al., 2013).
These lesions must be distinguished from trilateral retinoblastomas in
order to avoid the administration of unnecessary chemotherapy. On 3 T
MRI, typical benign cysts are characterized by an enlarged pineal gland
with a hypointense central region on T1-weighted images, isointense on
T2-weighted images with a thin wall that enhances after gadolinium
injection, and no nodular structures (Barboriak et al., 2001; Whitehead
et al., 2013). They can increase in size during the first year of ob-
servation as the child grows, and then stabilize or decrease in size
(Fig. 5E–G) until the age of 4–5 years (Sirin et al., 2016). Pineal cysts in
retinoblastoma patients have a reported incidence ranging between 5
and 37%, with some authors indicating an association with hereditary
disease (Beck Popovic et al., 2006; Ruiz Del Rio et al., 2014), whereas
others do not (Ramasubramanian et al., 2013). They are comparable in
size with cysts in age-matched healthy controls (Pham et al., 2015), and
do not progress to a tumor (Barboriak et al., 2001; Beck Popovic et al.,
2006; Karatza et al., 2006; Ramasubramanian et al., 2013).
Contrary to typical pineal cysts, nodular pineal cysts can transform
to pineoblastoma (de Jong et al., 2014b) (Fig. 5 C, D). Moreover, in
some instances pineoblastomas can also show a cystic part. Any unusual
feature in a pineal cyst calls therefore for close follow-up (Rodjan et al.,
2012). A retrospective analysis (de Graaf et al., 2012) by the European
Retinoblastoma Imaging Collaboration (ERIC) recently resulted in a
description, terminology and classification that allows clinicians to
distinguish benign pineal cysts from those that need to be followed
because of risk of transformation to pineoblastoma (Sirin et al., 2016).
3.7. Metastatic retinoblastoma
Metastatic retinoblastoma at presentation is rare in high-income
countries, but represents the most frequent cause of death for this
tumor worldwide (Canturk et al., 2010). In high-income countries, the
few cases seen are those developing metastasis after initial treatment
with enucleation or conservative therapy. The median time between
diagnosis of intraocular retinoblastoma primarily enucleated with high
pathologic risk factors and first evidence of metastases is 10 months
(range: 2–24 months) in patients receiving adjuvant chemotherapy, but
appears to occur earlier at 5 months in untreated ones (Antoneli et al.,
2003; Chantada et al., 2010; Cozza et al., 2009; Lu et al., 2018; MacKay
et al., 1984; Rodriguez-Galindo et al., 2003). In low-income countries,
metastatic dissemination is generally already observed at diagnosis in
older children who present with extensive orbital masses or after par-
ents declined enucleation of an eye with intraocular disease (Canturk
et al., 2010), and is attributed to delayed diagnosis/treatment rather
than a difference in tumor biology (Chawla et al., 2016; Leal-Leal et al.,
2006).
3.7.1. Diagnosis of metastatic retinoblastoma
Retinoblastoma may metastasize to the CNS, bone, bone marrow or
lymph nodes and, rarely, to other sites such as the liver. The diagnosis
of metastatic disease can occur in asymptomatic patients during a work-
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up motivated by clinical features at presentation, presence of classic
high-risk pathologic findings (Sastre et al., 2009), or possibly by the
degree of anaplasia (Mendoza et al., 2015) after enucleation, or in
symptomatic patients during/after conservative treatment. In most
cases of metastatic disease at diagnosis, massive orbital extension oc-
curs along with distant metastatic dissemination (Kaliki et al., 2017).
The detection of minimally disseminated disease in bone marrow and
cerebro-spinal fluid at diagnosis and follow-up can be now evaluated by
means of quantitative polymerase chain reaction of cone-rod homeobox
(CRX) transcription factor messenger RNA (Laurent et al., 2016).
CNS metastasis. CNS involvement occurs mainly by direct extension
of the tumor via the optic nerve or the sub-arachnoidal space (lepto-
meningeal dissemination), but can also be parenchymal or paraspinal
through hematogenous dissemination, and rarely as a direct CNS ex-
tension through a facial bone. In the case of trilateral retinoblastoma,
the tumor may also disseminate to the cerebrospinal fluid from a
midline mass (Popovic et al., 2007), typically resulting in a leptome-
ningeal dissemination (Laurent et al., 2013). Interestingly, molecular
studies using polymerase chain reaction for detecting minimally dis-
seminated disease showed that cerebrospinal fluid relapses occurred
more commonly as an isolated event with negative bone marrow,
suggesting that the route of dissemination to the cerebrospinal fluid in
retinoblastoma is mainly through the optic nerve and independent of
systemic dissemination (Torbidoni et al., 2015) or due to trilateral
seeding (Torbidoni et al., 2018). However, seeding by subclones arising
from the systemic circulation at diagnosis, which persists during
therapy, cannot be ruled out. Affected subjects may show increased
intracranial pressure resulting in headache, irritability, vomiting, vision
loss, and less commonly, focal neurological signs. Clinical examination
includes evaluation of the orbit and facial bones as well as evaluation of
the whole neuroaxis. CNS dissemination is investigated by both cere-
brospinal fluid cytology (Bakhshi et al., 2011) and imaging, with the
latter being performed prior to diagnostic lumbar puncture in order to
exclude intracranial hypertension. A cytospin of cerebrospinal fluid
cytology typically shows retinoblastoma cells in clusters. If isolated,
these cells can, however, be missed or confused with normal lympho-
cytes in young children. For this reason, the cytospin should always be
examined microscopically, and malignant cells confirmed with im-
munocytology for GD2 or CRX. If this procedure is not available, flow
cytometry examination, usually available in centers that also treat pe-
diatric leukemia, can be useful to depict the non-hematopoietic origin
of the cells by showing the lack of expression of molecules such as CD45
antigen with positivity for CD56 (Shen et al., 2013).
Bone and bone marrow metastasis. Bone metastasis may present as a
painful and palpable mass in the long bones, but facial bones may also
be affected, as well as the diploe of the neurocranium. Bone marrow
invasion may occasionally be suspected by detecting abnormal blood
counts, especially thrombocytopenia, but is more commonly detected in
asymptomatic patients by bone marrow biopsy or on imaging such as
MRI or positron-emission tomography (Chantada et al., 2006b). Bone
marrow evaluation needs at least 2 aspirates and 2 biopsies and, if
available, immunocytology using markers like GD2 (Chantada et al.,
2006b) or reverse transcriptase quantitative PCR for CRX mRNA should
be performed (Torbidoni et al., 2015).
3.7.2. Treatment of metastatic retinoblastoma
Although retinoblastoma is a chemosensitive tumor, metastatic
disease is not curable with conventional treatment and is therefore
considered to have a poor prognosis, especially in cases of CNS in-
volvement (Kaliki et al., 2017; Pant et al., 2017). High dose che-
motherapy, followed by autologous stem cell rescue with radiation to
the sites of bulky disease, has been the only treatment reported to date
to potentially cure these patients (Dunkel et al., 2010c; Palma et al.,
2012), allowing remission in close to 70% of children in a series of 15
patients with metastatic retinoblastoma not involving the CNS (Dunkel
et al., 2010c), whereas those with CNS involvement have only
anecdotally benefitted from it (Dunkel et al., 2010a). Focusing on in-
trathecal chemotherapy either with topotecan (Laurie et al., 2005) or
radio-immunotherapy with radiolabeled anti-GD2 antibody (Kramer
et al., 2010) may improve the currently dismal outcome.
3.7.3. Influence of conservative retinoblastoma treatment in the occurrence
of metastasis
While reducing the enucleation rate, the transition from one ther-
apeutic era to the next also brought great concerns regarding a potential
negative impact on the “state of metastatic grace”, an empiric window
for globe preserving therapies, where the risk for metastasis is not
higher than the risk encountered following enucleation with adjuvant
therapy in case of histopathologic high risk factors. Fear of in-
appropriate management of secondary enucleated eyes due to down-
staging after chemotherapy on the one hand (Zhao et al., 2011), and of
the possible consequences of lower systemic chemotherapy exposure in
patients treated with intra-arterial chemotherapy alone on the other
hand (Yousef et al., 2016), is nourished by the lack of well-designed
studies aimed at capturing metastatic events and related deaths.
Among the few studies which have addressed this crucial issue, two
compared the incidence of metastatic disease and orbital recurrence in
advanced retinoblastoma group D/E treated with either systemic or
intra-arterial chemotherapy versus primary enucleation and concluded
to the absence of variation by treatment modality (Berry et al., 2017b;
Yannuzzi et al., 2015). In another paper comparing patients primarily
treated by external beam radiotherapy versus first line chemotherapy
(Chantada et al., 2014), the authors failed to detect a change in the
probability of extraocular relapse, despite the prediction of a putative
positive effect of chemoreduction in preventing systemic metastasis in
children with microscopically disseminated disease. The controversy
regarding the rate of metastases following first line intra-arterial versus
intravenous chemotherapy for advanced disease clashes with biases
linked to the fact that these two administration routes influence the
ratio of CNS versus non-CNS dissemination (Brennan et al., 2015).
Neoadjuvant systemic chemotherapy may offer a less favorable cov-
erage in patients with high risk for CNS involvement when compared to
the unmatched chemotherapeutic optic nerve concentration achieved
by intra-arterial drug delivery (Taich et al., 2016), while intravenous
chemotherapy may be more efficient against distant minimally dis-
seminated disease. Although the end result in terms of survival remains
unknown to date, patient survival following the introduction of first
line intra-arterial chemotherapy appears, however, unimpaired com-
pared to previous treatment regimens, with no increase in the metas-
tasis rate, ranging between 2 and 2.5% (Funes et al., 2018) and death
rate from metastatic disease around 1% (Abramson et al., 2017b).
Noteworthy, in all cases, the cause of metastases resulting in death was
parental refusal of enucleation of a single remaining eye (Abramson
et al., 2017b).
3.8. Second primary neoplasms
Retinoblastoma patients with a germline RB1 mutation are at life-
time risk to develop various types of second primary (Abramson et al.,
1979; Eng et al., 1993; Wong et al., 1997) and even third, fourth and
fifth malignancies (Abramson et al., 2001; Marees et al., 2010) (see
3.8.1). This risk is further increased after external beam irradiation and,
to a lesser extent, chemotherapy (see 3.8.3.2). In middle and high-in-
come countries where the majority of patients survive retinoblastoma,
second primary tumors represent the leading cause of death in patients
with hereditary retinoblastoma (Kleinerman et al., 2005; Marees et al.,
2009; Moll et al., 1997, 2001). Despite various follow-up strategies for
retinoblastoma survivors (Baker et al., 2016), specific screening pro-
tocols are still missing (see 3.8.4).
3.8.1. Incidence and mortality of second primary neoplasms
According to long-term retinoblastoma survivor cohort studies from
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around the world (Marees et al., 2010), the risk of second primary
neoplasms is much higher for hereditary than for non-hereditary re-
tinoblastoma survivors, for whom the standardized incidence ratio is
comparable to that of the general population (Table 8). This risk also
increases significantly with a longer follow-up, in particular for epi-
thelial cancers such as lung, bladder or breast carcinomas. Thus, ac-
cording to a Dutch study, the 40-year absolute excess risk of second
primary neoplasms in hereditary retinoblastoma survivors was 261
excess cases per 10,000 survivors per year with a cumulative incidence
of 28% (95% confidence interval=CI (21.0–35.0%) (Marees et al.,
2008).
The cumulative mortality from second primary malignancies 50
years after retinoblastoma diagnosis was 25.5% (95% CI (21–30%)) in
hereditary versus 1% (95% CI (0.2–1.8%)) in non-hereditary retino-
blastoma survivors (Marees et al., 2009; Yu et al., 2009).
3.8.2. Characteristics of secondary primary neoplasms
Second primary tumors can develop in diverse anatomic locations,
including the skull, bones, soft tissues, nasal cavity, skin, orbit, brain,
breast, bladder and lung. In a review of 676 secondary primary ma-
lignancies in 602 retinoblastoma survivors, the most prevalent neo-
plasms were sarcoma (68%), carcinoma (14%), melanoma (8%), leu-
kemia and lymphoma (4%) (Woo and Harbour, 2010). The latency to
develop a second tumor depends on the secondary primary tumor type
and previous treatment. The median age at diagnosis was 13 years for
sarcoma, 27 years for melanoma and 29 years for carcinomas (Woo and
Harbour, 2010). In a cohort of German pediatric retinoblastoma sur-
vivors, the most prominent second primary neoplasms were sarcoma
and leukemia with a standardized incidence ratio of 148 (95%CI
(39.81–378.87)) and 41 (95%CI (11.13–105.95)) respectively
(Temming et al., 2015). In this study, a different latency in the diag-
nosis was observed for solid versus non-solid second primary neo-
plasms, diagnosed in children older or younger than 5 years of age,
respectively (Temming et al., 2015). However, in this cohort, the in-
creased risk of leukemia could be due to the adjunct of systemic alky-
lating agents in the German protocol (Kunkele et al., 2015).
The diagnosis of a second primary neoplasm needs to be confirmed
by cytopathologic analysis of a tumor biopsy. Small round blue cell
tumors such as lymphoma, rhabdomyosarcoma or nephroblastoma,
however, can be hard to distinguish from metastatic retinoblastoma. In
such cases, the presence or absence of previously identified somatic RB1
mutations and/or retinoblastoma-specific somatic copy number
changes can help differentiate second cancers from metastatic disease
(Racher et al., 2016).
3.8.3. Factors influencing the risk of secondary primary neoplasms
3.8.3.1. Genetic predisposition. Retinoblastoma survivors carrying a
germline mutation, treated with enucleation or focal treatment with
no additional radiation or chemotherapy, are clearly at increased risk to
develop second primary tumors (Abramson et al., 1979; Eng et al.,
1993; Wong et al., 1997).
In a study investigating variations in second cancer risk by family
history of retinoblastoma among long-term survivors, the authors
concluded that carriers of an inherited germline mutation are at slightly
higher risk compared with those with a de novo germline mutation
(Kleinerman et al., 2012), which may be partially attributed to
mosaicism or reduced penetrance (Moll et al., 2012). Preliminary re-
search also suggested an increased second primary malignancy risk in a
group with a nonsense RB1 mutation (hazard ratio or HR=3.53 (95%
CI (1.82–6.84)) compared to bearers of a low penetrance RB1 mutation
(HR=0.19 (95% CI (0.05–0.81)) (Dommering et al., 2012). However,
this observation was recently challenged, at least in irradiated heredi-
tary patients, suggesting no protective effect in low penetrant RB1
mutation carriers (Chaussade et al., 2019).
3.8.3.2. Influence of therapy
3.8.3.2.1. Radiotherapy. External beam irradiation increases the
risk of developing second primary malignancies in patients with
hereditary retinoblastoma threefold (Kleinerman et al., 2005; Marees
et al., 2008; Temming et al., 2017), especially bone cancers and soft
tissue sarcomas in a dose-dependent manner (Fletcher et al., 2004;
Wong et al., 1997), or if given before the age of one year (Abramson
and Frank, 1998; Moll et al., 2001). More recent radiotherapeutic
modalities with proton radiotherapy and/or stereotactic conformal
radiotherapy are expected to induce fewer second primary neoplasms
in hereditary retinoblastoma survivors compared to conventional
radiotherapy (Munier et al., 2008; Pica et al., 2011; Sethi et al., 2014).
3.8.3.2.2. Chemotherapy. There is still little long-term information
about the contribution of chemotherapy alone on the risk of second
primary malignancies in hereditary retinoblastoma patients. The
cumulative incidence ratio in hereditary retinoblastoma treated with
chemotherapy alone (3.0, CI 0.3–10.8) appears, however, to be
comparable to patients treated with enucleation or focal treatment
alone and 3 times lower compared to patients receiving external beam
irradiation (Temming et al., 2017). Some have reported a potential
acute risk to develop at an early time point acute myelogenous
leukemia after systemic chemotherapy (Chantada et al., 2014;
Gombos et al., 2007; Temming et al., 2015), while this was not
confirmed by others for chemoreduction with vincristine, etoposide
and carboplatin (Turaka et al., 2012). However etoposide-related
secondary leukemias with 11q23 involvement have been reported in
the literature even in patients who received what are considered safe
cumulative dosages for other pediatric tumors (Chantada et al., 2014;
Gombos et al., 2007).
Targeted chemotherapy (periocular, intra-arterial and intravitreal)
does not seem to increase the rate of secondary primary malignancies
(Ishida et al., 2016; Suzuki et al., 2011), although follow-up time is too
short to draw definite conclusions. Recently, a review of 214 patients
with hereditary retinoblastoma treated by intra-arterial chemotherapy
over a 10-year period revealed a comparable rate of second primary
neoplasm to previously published ones (Habib et al., 2018).
3.8.4. Long-term follow-up in heritable retinoblastoma survivors
While some institutions routinely perform annual MRI of the head or
total body MRI screening (Friedman et al., 2014), others perform com-
plementary exams only when indicated. In general, retinoblastoma sur-
vivors undergo as many, but not more, cancer screening tests compared to
the general population (Sheen et al., 2008). Regular skin examination for
melanoma is important, especially for patients with impaired vision.
Overall, the most important aspect of screening starts by educating the
patient, family and (primary) doctors on the increased risk and on
common signs of second primary tumors (Dimaras et al., 2015).
Table 8
Incidence of second primary neoplasms in different countries.
Standardized incidence ratio (95% Confidence interval) Absolute excess risk of second primary tumors
per 10,000 survivors per year
Hereditary retinoblastoma survivors Non-hereditary retinoblastoma survivors
MacCarthy et al. (2013) Great Britain 13.7 (11.3–16.5) 1.5 (0.9–2.3) 58
Kleinerman et al. (2005) USA 19 (16–21) 1.2 (0.7–2.0) 97
Marees et al. (2008) Holland 20.4 (15.6–26.1) 1.85 (0.96–3.24) 68
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4. Retinoblastoma genesis
Like any cancer, the biological and clinical behavior of retino-
blastoma is dictated by the unique features of the cancer cells and their
interactions with the host. In turn, the cancer cell features are largely
determined by the intrinsic gene expression program of the retino-
blastoma cell-of-origin in combination with changes to the cell-of-origin
signaling circuitry that are induced by oncogenic mutations. However,
in contrast to most cancers, the genetic changes that initiate retino-
blastoma are well defined, and the mechanisms through which the
retinal cell-of-origin transforms into a cancer are coming into focus.
This chapter describes how our understanding of retinoblastoma gen-
esis has come about, including the identification of the RB1 gene,
genomic alterations beyond RB1 mutations, the origin of retino-
blastoma from cone photoreceptor precursors, and collaboration of RB1
mutations with the underlying cone precursor circuitry.
4.1. Mutational inactivation of the RB1 gene initiates retinoblastoma
tumorigenesis
Based on a statistical study of the distribution of the number of
tumors and age at diagnosis in 48 patients with retinoblastoma, Alfred
Knudson hypothesized that retinoblastoma is caused by two mutational
events (Knudson, 1971). It was not part of Knudson's original hypoth-
esis that these alterations target two alleles of an autosomal gene locus.
However, analysis of genotype changes at genetic polymorphisms in
tumors, specifically the pattern of loss of constitutional heterozygosity
(LOH), indicated that two mutational events target a gene on chro-
mosome 13q (Cavenee et al., 1983).
In 1986, fifteen years after Knudson's initial paper, RB1 was iden-
tified as the gene that is the target of two-step mutational inactivation
in retinoblastoma (Friend et al., 1986; Fung et al., 1987; Lee et al.,
1987). Fulfilling the predictions of Knudson's hypothesis, heritable and
non-heritable retinoblastoma are distinct with respect to the timing of
the two mutational events that are required to alter both RB1 alleles
(see 5.1).
In more recent years, comprehensive genomic analysis has con-
firmed that, as far as genetic alterations are concerned, bi-allelic in-
activation of RB1 may be sufficient for retinoblastoma genesis (Grobner
et al., 2018; Zhang et al., 2012). Indeed, somatic chromosomal copy
number alterations are absent in most retinoblastomas from children
who are diagnosed at an early age (Herzog et al., 2001), and exome
sequencing analyses revealed that some early tumors lack gene muta-
tions other than RB1 as well as chromosomal copy number alterations
(Kooi et al., 2016a). However, the question of whether this implies that
all retinoblastomas initially form without further genomic alterations
remains open.
4.2. Most retinoblastomas show more than two-hits
Although early tumors may develop with biallelic RB1 loss as the
sole genomic alteration, cytogenetic meta-analyses of several hundred
retinoblastomas have shown recurrent chromosome 1q, 2p, and 6p
gains and 16q losses (Corson and Gallie, 2007; Kooi et al., 2016b).
Genomic gains on the short arm of chromosome 2 appear to target the
MYCN locus. The targets of genomic gains at 1q and 6p are not well-
defined, but initial candidates included MDM4, KIF14 on 1q and DEK
and E2F3 on 6p (Corson and Gallie, 2007). A meta-analysis identified
other genes in the peak gain regions with significant gene-dosage ef-
fects, including ZBTB41, CRB1 and NEK7 on 1q and SOX4 on 6p (Kooi
et al., 2016b). Numerous genes have been proposed to underlie the
frequent 16q loss such as CDH11, encoding a cadherin possibly in-
volved in cell-cell attachments and RB1-like 2 (RBL2) encoding the pRB-
related p130 protein, which have decreased expression in tumors with
16q loss (Kooi et al., 2016b). These chromosome 16q changes appear to
be associated with vitreous seeding, yet a causal link has not been
established (Gratias et al., 2007). Exome analyses also revealed re-
current focal deletion or mutational inactivation of BCOR, a gene on the
X chromosome that encodes a non-canonical polycomb repressor
complex 1 component in about 10% of retinoblastomas and a recurrent
mutation of CREBBP at even lower frequency (Kooi et al., 2016a; Zhang
et al., 2012).
At present, it is unclear whether the recurrent genomic changes (1q,
2p, and 6p gains, 16q losses, and BCOR and CREBBP inactivation) are
required for the initial development of the retinoblastomas in which
they are found, or if they are selected after the initial appearance of a
tumor in order to mediate more rapid growth. Motivated by the ob-
servation that genomic gains and LOH are often present in addition to
bi-allelic RB1 gene inactivation, a multistep model of development of
retinoblastoma was suggested (Corson and Gallie, 2007; Gallie et al.,
1999). Further support for such a model was drawn from the ob-
servation that samples from tumor areas that were classified as re-
tinomas based on histomorphologic findings, showed bi-allelic RB1
inactivation and relatively few chromosomal copy number changes,
whereas adjacent areas with histomorphologic features of retino-
blastoma had more chromosomal gains and losses (Dimaras et al., 2008;
Sampieri et al., 2009). Likewise, the larger tumors typical of later di-
agnosis have more chromosomal alterations as well as decreased dif-
ferentiation-related gene expression, suggesting that retinoblastomas
progress via sequential acquisition of chromosomal and gene expression
changes (Cobrinik, 2015; Kooi et al., 2015). However, subsequent
analyses indicated that chromosomal change did not appear in a par-
ticular order (Kooi et al., 2016b). Thus, the multistep evolution of re-
tinoblastoma may differ from the prototypical adenoma-carcinoma se-
quence in colon cancer in which chromosomal alterations appear in a
specific sequence (Vogelstein et al., 1988).
A better understanding of retinoblastoma progression may come
from studies of retinoblastoma tumor DNA obtained via paracentesis of
aqueous humor. Recently, it was shown that DNA in the aqueous humor
resembles that of enucleated tumors and can change over time (Berry
et al., 2017c). In one case, a recurrent chromosomal change (6p+) was
not detected in the earliest sample but appeared in subsequent aqueous
humor taps, suggesting that this change was selected during tumor
evolution, albeit under chemotherapy selection. Further analyses of
copy number alterations in multiple aqueous humor samples beginning
at the time of diagnosis, may reveal the order(s) in which they occur
during conservative treatment (see 8.4).
4.3. RB1 mutations initiate tumorigenesis in the retinoblastoma cell-of-
origin – the cone photoreceptor precursor
The malignant behavior of retinoblastoma depends on the effects of
RB1 loss and other genomic alterations superimposed on the cell sig-
naling circuitry of the retinoblastoma cell-of-origin. Here, we recount
efforts to identify the cell-of-origin, the evidence favoring or disfavoring
a cone photoreceptor origin, and the potential contributions of the cell-
of-origin circuitry for retinoblastoma initiation and clinical behavior.
4.3.1. First hints pointing towards a photoreceptor cell-of-origin
The identity of the retinoblastoma cell-of-origin has long been de-
bated, in part because early inferences were based on analyses of tumor
cells that were far removed from tumor initiation events. Briefly, the
tumors were initially referred to as “glioma of the retina” based on use of
imperfect stains that suggested a glial composition. In the 1890s,
Flexner and Wintersteiner independently recognized that a subset of the
tumors had symmetrically arranged structures – later termed “Flexner-
Wintersteiner rosettes” – that appeared to be composed of photo-
receptor-like cells and were suggestive of a rod or cone origin (Flexner,
1891; Wintersteiner, 1897). However, most tumors lacked Flexner-
Wintersteiner rosettes while others had “Homer Wright rosettes” that
are also seen in diverse non-retinal tumors (Albert, 1987), which argued
against a photoreceptor origin. Eventually, the term “retinoblastoma”
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was adopted based on the perceived similarity of the tumor cells to
embryonic retinal progenitor cells (Albert, 1987; Verhoeff and Jackson,
1926), yet this hardly settled the cell-of-origin question.
Decades later, a growing body of evidence emerged suggesting a
predominant cone photoreceptor phenotype in retinoblastoma.
Specifically, researchers detected an intact cone but not rod photo-
transduction cascade as well as high-level expression of RNAs and
proteins mediating cone phototransduction in both differentiated and
undifferentiated tumors (Bogenmann et al., 1988; Hurwitz et al., 1990;
Rodrigues et al., 1992). However, the cone phenotype remained argu-
able, with evidence that retinoblastoma cells might simultaneously
express non-cone markers and recognition that some retinoblastoma
cell phenotypes could be adopted after transformation of an unrelated
retinal cell type. Further evidence of a cone origin came from the
finding that retinoblastoma foci are distributed over the retinal surface
in a pattern similar to that of L/M cones (Curcio et al., 1990; Munier
et al., 1994), although the cone-like distribution could also have other
explanations (King et al., 2015).
4.3.2. Efforts to identify the retinoblastoma origin using genetically
engineered mice
The lack of progress in identifying the cell-of-origin based on
characteristics of retinoblastoma tumors prompted the adoption of
mouse modeling approaches that held potential to reveal inaugural
steps in retinoblastoma initiation. However, this approach also ran into
difficulties, as no retinal tumors formed in Rb1 ± mice (Clarke et al.,
1992; Jacks et al., 1992; Lee et al., 1992). Furthermore, mice with re-
tina-targeted mutation of Rb1 and constitutive germline mutation of the
Rb1-related p107 or p130 formed retinal tumors with a predominant
amacrine or horizontal cell phenotype, rather than the cone photo-
receptor phenotypes that seemed to predominate in human retino-
blastoma (Cobrinik, 2013; Macpherson, 2008). Perhaps, the different
human vs. mouse phenotypes could have been reconciled if tumors in
both species derived from retinal progenitor cells yet took on different
retinal cell-type-specific features. However, the data showed that ret-
inal progenitor cells in Rb1−/− as well as in Rb1−/−;p107−/−
retinae were largely unaffected, whereas diverse post-mitotic retinal
neurons re-entered the cell cycle, proliferated, and underwent apoptosis
to varying extents (Chen et al., 2004). Concordantly, mice with retina-
specific inactivation of Rb1 in a p130−/−;p107 ± background ap-
peared to initiate tumorigenesis in horizontal cell interneurons only
after terminal differentiation and synaptogenesis had begun (Ajioka
and Dyer, 2008). Thus, models with combined Rb1 family mutations
revealed that retinal tumors can develop from post-mitotic interneurons
that aberrantly re-enter the cell cycle, rather than from retinal pro-
genitor cells that fail to exit the cell cycle. Moreover, the resulting
mouse tumors retained features of their interneuron cell-of-origin, at
odds with the notion that retinal tumors dramatically alter their phe-
notype during tumorigenesis.
4.3.3. Circumstantial and direct evidence for a cone precursor cell-of-origin
The disparate retinal phenotypes that had been observed in re-
tinoblastoma tumors prompted a re-examination of the retinal cell-type-
specific protein expression (Xu et al., 2009). The studies focused on
retinal cell-type-specific transcription factors and distinguished neo-
plastic retinoblastoma cells, which are deficient in the RB1-encoded
pRB protein, from pRB + non-neoplastic cell infiltrates. Analyses of 40
retinoblastomas revealed that the vast majority of pRB– tumor cells
expressed the cone-specific cell lineage factors TRβ2 and RXRγ, the
cone + rod + bipolar cell-specific CRX transcription factor, and the
cone-specific phototransduction proteins cone arrestin and L/M-opsin.
Rare pRB– cells co-expressed S-opsin and L/M-opsin, consistent with
the occasional S- and L/M-opsin co-expression in developing L/M cones
(Cornish et al., 2004). All of these proteins were expressed at levels
comparable to the cone precursors in developing retina. In contrast,
only rare and non-neoplastic pRB + cells in rare tumors expressed
markers of rods, retinal ganglion cells, amacrine or horizontal cells, or
retinal progenitor cells at levels comparable to the developing retina
(including NRL, rhodopsin, Brn3b, syntaxin, Prox1, Chx10, and Pax6).
Moreover, combined immunostaining and in situ hybridization revealed
that rare cells that lacked pRB and cone marker expression retained two
RB1 alleles, implying that only cone-marker + cells had biallelic RB1
loss (Xu et al., 2009). These findings indicated that pRB-deficient and
RB1-mutant retinoblastoma cells express numerous proteins that are
characteristic of L/M-cones but not markers specific to other retinal cell
types.
In keeping with the predominant cone protein expression profile of
the pRB– cells, the Muller cell and astrocyte markers Nestin and GFAP
were consistently detected only in non-neoplastic pRB + cells (Xu
et al., 2009). The Nestin+ and GFAP + cells also expressed PAX2,
indicative of derivation from non-neoplastic retinal astrocytes, and
expressed the astrocyte and neural stem cell determinant SOX2 (Xu
et al., 2010), consistent with the detection of other neural stem cell
markers in a subset of cells in retinoblastoma tumors (Seigel et al.,
2007). Importantly, SOX2 was only detected in cells expressing pRB
protein and/or retaining RB1 alleles, establishing the lack of this stem
cell marker in neoplastic retinoblastoma cells (Xu et al., 2010).
The neoplastic retinoblastoma cells' cone protein expression profile
provided one of several lines of circumstantial support for a cone pre-
cursor cell-of-origin. For example, a cone origin was also consistent
with the high-level pRB expression observed in maturing human cone
precursors (Lee et al., 2006) but not in maturing mouse cone precursors
(Spencer et al., 2005; Xu et al., 2009). Moreover, maturing human but
not mouse cone precursors prominently expressed the proto-oncopro-
teins MDM2 and MYCN (Xu et al., 2009). As most tumors require the
inactivation of the p53 pathway as well as the RB pathway (Sherr and
McCormick, 2002), the cone precursors' high-level MDM2 expression
provided a way to suppress p53 function without mutation of the TP53
gene or MDM2 amplification. However, the cone precursor's expression
of these oncoproteins provided only circumstantial evidence of a cone
origin, as their expression could have been acquired during the devel-
opment of retinoblastoma from an alternative cell type.
More recent studies provided direct evidence for the cone precursor
cell-of-origin. Specifically, pRB knockdown elicited cell cycle entry and
proliferation of human cone precursors but not other retinal cell types
(Xu et al., 2014). The cone precursor response to pRB knockdown was
evident in dissociated retinal cultures, in prospectively isolated cone
precursors, and in non-dissociated retinal tissue. Moreover, cell cycle
entry depended on the cone cell lineage factors TRβ2 and RXRγ and on
the cone-precursor-expressed MYCN, whereas the survival of the
aberrantly proliferating cells depended on the endogenous MDM2.
Notably, co-depletion of 130 along with pRB enhanced proliferation,
consistent with evidence that the RBL2/p130 gene on 16q is often lost
in retinoblastoma. Finally, pRB-depleted and pRB/p130-depleted cone
precursors formed retinoblastoma-like tumors in orthotopic xenografts,
documenting the cone precursors’ capacity to serve as a retinoblastoma
cell-of-origin.
4.3.4. Reconciling the cone precursor cell-of-origin with apparently
contradictory observations
Despite the direct evidence of the cone precursors ability to form
retinoblastoma-like tumors (Xu et al., 2014), the cone origin theory - if
true – must be reconciled with all relevant biologic and clinical ob-
servations. In this regard, two observations that initially seemed to
contradict the cone cell-of-origin theory are addressed here.
First, the earliest lesion detected in retinoblastoma patients via OCT
appear to be centered in the inner retina, either in the inner nuclear
layer or in the outer plexiform layer, rather than in the outer aspect of
the outer nuclear layer where cones reside (Berry et al., 2016a;
Rootman et al., 2013). This location suggested that the tumors either
derive from a non-cone cell in the inner nuclear layer (which might
subsequently adopt a cone phenotype) or derive from cones that are
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displaced towards the inner nuclear layer, perhaps through a rare but
normal phenomenon (Semo et al., 2007) or in response to pRB loss.
Recently, the movement of pRB-depleted cone precursors from the
outer edge of the outer nuclear layer to the outer plexiform layer were
detected via live imaging of intact cultured retinae, in support of the
cone precursor cell-of-origin concept (Singh et al., 2018a).
A second concern was that retinoblastoma tumor cells express RNAs
that encode proteins that are characteristic of diverse retinal cell types
(McEvoy et al., 2011). The expression of non-cone-related RNAs ap-
peared to conflict with evidence that retinoblastoma cells mainly ex-
press cone-related proteins (Xu et al., 2009) and suggested that the
retinoblastoma cell-of-origin might have adopted a hybrid gene ex-
pression program, with expression of cone as well as non-cone genes,
after the transformation of non-cone cell type. However, the data is also
consistent with the expression of a hybrid program after transformation
of cone precursors in combination with preferential translation of cone-
related RNAs. More studies are needed to resolve the discrepance in the
expression of non-cone RNAs with the predominant cone-related pro-
tein profile in retinoblastoma cells.
Finally, if cone precursors represent the cell-of-origin, pRB deple-
tion may be expected to induce not only cone precursor proliferation
but also the different tumorigenesis stages that have been inferred from
clinical observations. With regard to this hypothesis, non-proliferative
RB1−/− retinoma lesions were found to be present at the base of
some, and perhaps most, retinoblastoma tumors (Dimaras et al., 2008),
suggesting that small retinoma-like lesions might be present but im-
perceptible at birth and later reactivate to form retinoblastoma tumors.
Thus, if cone precursors do represent the cell-of-origin, pRB depletion
would be expected to induce not only cone precursor proliferation but
also a proliferative arrest with retinoma-like features, followed by re-
tinoblastoma-like tumors. Indeed, pRB depletion was found to enable
cone precursor proliferation, a retinoma-like arrest, and the emergence
of retinoblastoma-like masses in long-term human retina cultures
(Singh et al., 2018b). The retinoblastoma-like masses emerged with
timing that was similar to that of retinoblastomas in babies, consistent
with them representing an authentic retinoblastomagenesis process
(Fig. 7).
4.4. Collaboration between RB1 inactivation and the cell-of-origin circuitry
The evidence of the cone precursor origin of retinoblastoma in-
evitably provokes the question of why the tumors derive from this cell
type. More specifically, why is RB1 loss sufficient to initiate retino-
blastoma with exceptionally high penetrance in cones but not in all
other retinal cell types? While the answers are still emerging, it appears
likely that cone precursor circuitry is oncogenic in-and-of-itself, and
collaborates with RB1 loss to mediate cell cycle re-entry. As mentioned
above, the cone precursors have high-levels MDM2 and MYCN, which
may subvert p53-mediated tumor suppression and promote prolifera-
tion, respectively (Fig. 7). Moreover, MDM2 and MYCN may be part of
a wider cone precursor proliferation-related program (Singh et al.,
2016) that is ultimately linked to the transcriptional programming of
the cells. For example, Xu et al. found that the human MDM2 gene is
regulated by the cone-specific transcription factor RXRγ (Fig. 7) and
suggested that the nearly perfect RXRγ consensus binding site in the
human MDM2 promoter underlies high-level MDM2 expression (Xu
et al., 2009). More recent studies suggest that the wider cone precursor
proliferation-related program is limited to a single cone maturation
stage (Singh et al., 2018b). The manifestation of this cone precursor
state in humans, but not other species, appears to confer the uniquely
human susceptibility to retinoblastoma as well as the unique char-
acteristics of retinoblastoma tumors.
5. Retinoblastoma genetics and genetic counseling
In this part are described the different variants of heritable (50%)
and non-heritable (50%) (MacCarthy et al., 2009) presentations of re-
tinoblastoma, as well as their implications for the patient's family
members, based on family history, laterality at presentation, and cur-
rent genetic tests.
5.1. Genetic presentations of retinoblastoma
Retinoblastoma can be classified into four distinct genetic pre-
sentations according to the timing of the first RB1 mutation:
1. Familial, or inherited heritable form, in which the retinoblastoma
Fig. 7. Origin of retinoblastoma from maturing L/
M cone precursors. The scheme depicts the gen-
eration of L/M cone precursors from a retinal pro-
genitor cell, the increased expression of prolifera-
tion-related proteins during cone precursor
maturation, the terminal differentiation of L/M cone
photoreceptor, and the proposed stages of pRB-defi-
cient cone precursor tumorigenesis. Recent studies
indicate 1) that L/M-cone precursor maturation is
associated with increased expression of pRB, MDM2,
MYCN, and additional cell cycle proteins, 2) that
pRB-deficient cone precursors that have reached
maturation stage marked by cone arrestin (ARR3)
expression proliferate and avoid apoptosis under the
influence of intrinsically highly expressed MYCN and
MDM2, 3) that the majority of the initially pro-
liferating pRB-deficient cone precursors enter a se-
nescence-like retinoma state that rare cells escape or
bypass to form retinoblastoma tumors. The maturing
human cone precursor circuitry is thought to drive
the expression of oncoproteins that sensitize to pRB
loss, such as by RXRγ-dependent expression of
MDM2 and MDM2-dependent expression of MYCN,
which have so far been characterized in retino-
blastoma cells (arrows). The model is based on data
of Lee et al. (2006); Dimaras et al, 2008; Xu et al.
(2009), 2014; Qi and Cobrinik (2017); and Singh
et al., (2016) and Singh et al. (2018b).
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patient has inherited a predisposition to retinoblastoma from an
affected parent;
2. Isolated (or sporadic) heritable form, in which retinoblastoma is ty-
pically bilateral with no family history resulting from a de novo pre-
zygotic germline mutation;
3. Mosaic form, in which retinoblastoma is usually unilateral, caused
by a post-zygotic mutation, and heritable only if the germline is also
involved;
4. Non-heritable forms, in which retinoblastoma is always unilateral,
unifocal and sporadic, resulting from a somatic mutation.
The heritable form of retinoblastoma – either familial or isolated – is
caused by germline genetic alterations that disable the RB1 gene
functions, also referred to as oncogenic variants or alleles. Individuals
with familial or isolated heritable retinoblastoma are heterozygous for
an oncogenic RB1 allele (the “first mutation”) throughout their body
(Fig. 8A). Each individual retinoblastoma focus that develops in such
individuals is initiated by an additional genetic alteration targeting the
other RB1 allele (the “second mutation”) during retinal development.
Thus, expressivity varies according to the number of independent
second mutations that give rise to tumor foci. In addition, expressivity
can also vary according to the nature of the first mutation, which de-
termines the complete or incomplete penetrance of the inherited or de
novo predisposition, as described below.
5.1.1. Inherited heritable retinoblastoma (familial retinoblastoma)
Familial occurrence of retinoblastoma is a form of heritable re-
tinoblastoma in which predisposition to this tumor is transmitted as an
autosomal dominant trait. In the familial setting, retinoblastoma
screening may be initiated pre- or perinatally and therefore usually
associated with a presymptomatic diagnosis (see 3.5). In high-income
countries, the fraction of familial cases among heritable retinoblastoma
is estimated around 25%, but is rapidly rising due to improved life
prognosis.
5.1.1.1. Familial retinoblastoma with complete retinoblastoma. In most
pedigrees with familial retinoblastoma, all family members who are
heterozygous for an oncogenic RB1 allele develop at least one
retinoblastoma focus (complete penetrance, Fig 8Ba). Typically,
patients develop several tumors and, consequently, bilateral
retinoblastoma is prominent in most families. As a rule, a high
probability of tumor development is caused by genetic alterations
that result in complete or almost complete loss of pRB protein
function, which are most often nonsense alterations, frameshift-indels,
and alterations at canonical splice signals that result in frameshift exon
skipping. In these pedigrees, the mean number of tumors per patient is
around 6 (Abramson and Gombos, 1996; Munier et al., 1994).
5.1.1.2. Familial retinoblastoma with incomplete penetrance. In some
pedigrees, heritable retinoblastoma shows incomplete penetrance
with some family members free of any tumor, despite being
heterozygous carriers of an oncogenic RB1 allele (Fig. 8 Bb).
Incomplete penetrance is a consequence of lower probability of tumor
development and those patients typically develop fewer retinoblastoma
foci compared to those with complete penetrance, associated with
genetic alterations that retain some of the pRB protein functions or
affect regulation of transcription of this gene (reviewed in Lohmann and
Gallie, 2004). Consequently, patients in families with incomplete
penetrance also tend to show only unilateral retinoblastoma. Most of
the difference in penetrance of heritable retinoblastoma can be
explained by differences in the functional consequences of oncogenic
RB1 alterations. The most prominent examples of variant RB1 alleles
associated with a low penetrance phenotype are certain missense
variants (e.g. LRG_517p1:p.R661W), in-frame indels, alterations at
remote splice signals, specific variants in exon 1, and alterations of
transcription-factor binding sites in the RB1 promoter.
Fig. 8. A. Schematic timing of the first mutation in retinoblastoma. a.
Inherited heritable b. Isolated heritable. c. Mosaic d. Non-heritable. The timing
of the first mutation determines both the presence of a constitutional tumor
predisposition and the risk of transmission to offspring. In familial retino-
blastoma (a) an oncogenic variant allele (rb) is inherited from a parent. The
individual is heterozygous (RB rb) and half of the individual's gametes will
carry the variant allele. Inactivation of the other allele in the retinoblast by a
second mutation (red arrow) will trigger the development of retinoblastoma. In
isolated heritable retinoblastoma (b) the first mutation has occurred de novo
prior to conception (pre-zygotic mutation). As the individual is heterozygous
(RB rb) the situation regarding tumor predisposition and transmission to off-
spring is as in familial disease. A first post-zygotic mutation may result in so-
matic mosaicism (c). The extension of the mutant sector and the risk of
transmission to offspring depend on the timing and targeted cell type of this
mutation. Risk of retinoblastoma oncogenesis is proportional to the extent of
mutated retina. Likewise, the proportion of gametes carrying the mutant allele
is determined by the contribution of the mutant sector to the individual's
germline. A somatic first mutation in a retinoblast (d) is expected to predispose
to one single tumor focus with no possible transmission to offspring (isolated
non-heritable retinoblastoma). B. Pedigrees/modes of presentation of re-
tinoblastoma. a. Multigenerational, complete penetrance (bilateral retino-
blastoma) b. Multigenerational, incomplete penetrance (uni/bilateral and un-
affected) c. Two-generational, founder unilateral d. Isolated bilateral e. Isolated
unilateral.
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Families with lower probability of tumor development provide a
good opportunity to identify factors in trans to the RB1 locus that may
affect intra-familial variation of phenotypic expression. The minor al-
lele of rs2279744 (NM_001145337.2:c.-291T > G), a single-nucleotide
polymorphism in the MDM2 promoter known to be linked to enhanced
MDM2 expression, has been reported to act as a modifier of phenotypic
expression in heritable retinoblastoma (Castera et al., 2010). Parent-of-
origin effects have been identified as another source of intra-familial
variation of phenotypic expression (Klutz et al., 2002), found later to be
related to human RB1 gene imprinting (Eloy et al., 2016; Kanber et al.,
2009).
Identification of the mechanisms underlying phenotypic expression,
namely low-penetrance RB1 alleles, trans-acting modifiers, and epige-
netic factors, is not an end in itself. It can be anticipated that some of
the mechanisms mediating milder phenotypic expression will be used to
reduce the number of tumor foci, in family members at risk.
5.1.2. Isolated heritable retinoblastoma
In this presentation, retinoblastoma occurs in a child of unaffected
parents. Isolated heritable retinoblastoma results from a de novo pre-
zygotic mutation in the gametes of one of the healthy parents.
According to the nature of the first mutation, expressivity – defined as
the number of primary tumor foci – may be attenuated or not.
5.1.2.1. Isolated bilateral retinoblastoma (full expressivity). Most patients
with newly diagnosed bilateral retinoblastoma have no relatives with
retinoblastoma and are referred to as having isolated or sporadic
bilateral disease (Fig. 8 Bd). Most patients (95%) with isolated
bilateral disease are heterozygous for an oncogenic RB1 allele
(Lohmann and Gallie, 2004) and, consequently, also have heritable
disease, but occasionally (5%) may be mosaic (see 5.1.3). Typically,
oncogenic alleles identified are the result of de novo mutations (Fig. 8
Ab). They are usually indistinguishable from RB1 alleles underlying
familial retinoblastoma with complete penetrance, and result in
complete or almost complete loss of pRB protein functions (see 5.1.1.1).
Due to the non-familial occurrence, patients with isolated bilateral
retinoblastoma will not have been formally screened for retinoblastoma
during infancy, and the age at diagnosis reflects the mean time to elicit
symptoms, which is usually around 9 months (Goddard et al., 1999). In
this population, the mean number of tumors per patient is 6, which is
no different from that observed in familial retinoblastoma patients with
complete penetrance (personal observation).
5.1.2.2. Isolated retinoblastoma with genomic 13q14 deletion (reduced
expressivity). Some patients with germline deletions include RB1 as
well as neighboring genes on chromosome 13q. Those have a lower
probability of tumor development and thus show an excess of unilateral
presentations (40%) (Munier et al., 1989) compared to patients
carrying other types of loss of function alleles. The mean age at
diagnosis in this population is around 17 months (Baud et al., 1999;
Munier et al., 1989), which is intermediate between isolated heritable
and non-heritable RB1-related retinoblastoma. It appears that the risk
to develop retinoblastoma in carriers of deletions larger than 1Mb
containing the MED4 gene is reduced compared to non-chromosomal
mutation carriers (Mitter et al., 2011) with a mean number of tumors
per patient of 2.5 (FLM personal observation) versus 6.3 (Munier et al.,
1994) respectively. The observed 61% reduction of tumor number in
13q-patients actually closely corresponds to the 63% predicted
tumorigenic event due to loss-of-heterozygosity (Zhu et al., 1992),
those turning lethal by nullisomy of housekeeping genes in
retinoblastoma 13q-precursor cells. Individuals with large interstitial
13q deletions show a developmental syndrome resulting from the
haplo-insufficient loss of the affected 13q genes and display a
recognizable midfacial dysmorphic phenotype (Motegi et al., 1983;
Munier et al., 1989; Bojinova et al., 2001).
5.1.3. Mosaic retinoblastoma
In familial retinoblastoma with complete penetrance it is not unusual
to find that the first affected family member (i.e. the founder on the
phenotype level), presents with unilateral retinoblastoma while affected
family members in subsequent generations show bilateral disease (Fig. 8
Bc). Genetic analysis has shown that some of these founders are somatic
mosaics for an oncogenic RB1 allele (Sippel et al., 1998). In these in-
dividuals, the first mutation that led to the oncogenic RB1 allele was not
received via the germline but occurred somatically after conception,
giving rise to a mutant sector of variable extent according to the timing of
the event. A mutational event that occurs during early stages of in-
trauterine development may result in a mutant sector in the individual.
The number of tumor foci in those patients is expected to be lower because
the probability of initiation of retinoblastoma development in an in-
dividual with somatic mosaicism is reduced inasmuch as the mutant sector
contributes only partially to the developing retina.
Mosaicism for an oncogenic RB1 allele is estimated to account for
5% of patients with isolated bilateral disease (Fig. 8 Ac) and 20% of the
cases with isolated unilateral retinoblastoma (Lohmann D personal
communication). If the proportion of the mutant allele present in DNA
from peripheral leucocytes is low, this may result in false negative
findings in genetic testing. The absence of detectable mosaicism,
however, does not rule out somatic mosaicism, since the cells carrying
the mutant RB1 allele might not be detected in the sampled cells (blood,
buccal etc), but might be present in other tissues such as the retina or
germ cells. Thus, there is no test that excludes risk of retinoblastoma in
the unaffected eye or, if the mutant sector includes germline cells, in
offspring of the patient. However, risk estimates are lower in unilateral
retinoblastoma patients who test negative for constitutional RB1 mu-
tation compared to the pretest state of knowledge.
5.1.4. Non-heritable retinoblastoma
5.1.4.1. Isolated unilateral retinoblastoma with somatic biallelic RB1
mutation. In about half of newly diagnosed retinoblastoma patients
only one eye is affected and family history is negative (isolated
unilateral disease, Fig. 8 Be). In nearly 90% of these patients, genetic
analysis of DNA from retinoblastoma shows genetic or epigenetic
alterations of both RB1 alleles that, upon targeted genetic testing, are
not detected in DNA from blood (Schuler et al., 2005). This shows that
both alterations are the result of mutation events that occurred in
somatic cells but does not rule out somatic mosaicism instigated by the
first mutation. In the remaining 10% of isolated unilateral
retinoblastoma a de novo germline mutation can be identified.
In non-heritable retinoblastoma, there is only one tumor in the af-
fected eye (i.e., there is a unilateral unifocal phenotype). The mean age
at diagnosis in this population is 24 months (Goddard et al., 1999),
although an earlier age at presentation is not necessarily suggestive of a
germline or mosaic RB1 mutation carrier (Schuler et al., 2005).
5.1.4.2. Retinoblastoma without alterations of the RB1 gene. In less than
3% of patients with isolated unilateral retinoblastoma, analysis of DNA
from the tumor shows no alteration at the RB1 locus. However, nearly
half of these tumors (1.4%) show high amplification levels of a genomic
region on the short arm of chromosome 2 that includes the MYCN gene
(Rushlow et al., 2013). Although some retinoblastomas with RB1 gene
inactivation also show increased MYCN copy numbers, tumors without
RB1 mutations have gained a far higher number of MYCN copies. The
distinct genetic makeup of MYCN-amplified tumors is reflected by a
clinical phenotype marked by very early age at diagnosis of less than 6
months and histopathologic features reminiscent of neuroblastoma.
Thus, it might be appropriate to regard this genetic variant as a distinct
entity, possibly linked to a distinct genesis. However, a recent report
suggests that tumors from MYCN transduced retinal cells not only
appear earlier than those with RB-depletion, coinciding with earlier age
at diagnosis in MYCN-induced retinoblastoma patients, but also derive
from a cone precursor cell of origin (Singh et al., 2019).
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5.2. Genetic counseling and testing
Initial counseling and the testing approach for each individual pa-
tient depends on the clinical presentation, including familial versus
isolated background and bilateral versus unilateral appearance. The
three presentations do not necessarily reflect the genetic types of re-
tinoblastoma described in 5.1, as sporadic bilateral or unilateral re-
tinoblastoma can result from several genetic mechanisms.
5.2.1. Familial retinoblastoma
For pre-test genetic counseling and recurrence risk prediction in
typical situations of familial bilateral retinoblastoma it is reasonable to
assume a probability of transmission of 50% (autosomal dominant in-
heritance) and a probability of tumor development of 100% (complete
penetrance in heterozygous individuals). Consequently, the estimated
pretest recurrence risk of heritable retinoblastoma in offspring of a fa-
mily member with bilateral retinoblastoma is 50% at birth. Although
indirect genetic testing by linkage analysis of marker alleles linked to
the RB1 gene may be available, most laboratories prefer direct genetic
testing by determining the presence or absence of the oncogenic heri-
table predisposition in a given family.
A wide spectrum of genetic alterations can result in oncogenic RB1
alleles (allelic heterogeneity) (Valverde et al., 2005). Various methods
are required to cover the relevant genomic regions and the different
types of potential oncogenic alterations (small mutations, copy number
changes, rearrangements).
In almost all pedigrees with apparent complete penetrance and bi-
lateral retinoblastoma, current routine methods will identify a patho-
genic allele (> 95%), provided that the mutation screening analysis is
performed on a sample from an affected family member who has in-
herited the retinoblastoma predisposition.
In rare pedigrees with complete penetrance retinoblastoma, no on-
cogenic RB1 allele is identified, due to inactivating alterations not
covered by current routine technology (e.g. in frame copy number,
neutral inversions), but destined to be diagnosed in the near future with
diagnostic sensitivity improvement, especially with the implementation
of genomic sequencing technology for routine testing.
In pedigrees where incomplete penetrance is obvious, diagnostic
sensitivity of genetic testing is somewhat lower compared to families
with complete penetrance. This is because there are fewer constraints
regarding the spectrum of alterations that result in only partial in-
activation of pRB protein functions compared to alterations that result
in full inactivation. As current routine methods used for mutation
screening do not cover all regions that may be affected by oncogenic
alterations with incomplete penetrance (e.g. deep intronic variants,
regulatory variants outside of known transcription factor binding sites),
some oncogenic alterations are missed.
Another point that contributes to reduced diagnostic sensitivity of
genetic testing in familial retinoblastoma with incomplete penetrance is
the uncertainty regarding the pathogenetic role of variants of unknown
significance, even if cosegregating with the heritable predisposition.
Although there is no valid report of familial retinoblastoma not
genetically linked to the RB1 locus, locus heterogeneity cannot be
formally ruled out. What has been reported, however, are observations
of fortuitous co-occurrence of retinoblastoma in relatives (Dryja et al.,
1993; Munier et al., 1993).
5.2.2. Isolated bilateral retinoblastoma
The empirical recurrence risk for siblings of a sporadic bilaterally-
affected patient is 2% (Draper et al., 1992) and this figure reflects both
the low frequency of germinal mosaicism in one of the parents and the
lower than 50% probability of transmission of a mutant allele in these
situations. It is rare to find an unaffected parent heterozygous for a
variant that confers high probability to tumor formation. Consequently,
recurrence risk in more remote family members (e.g. cousins) is low.
Pretest recurrence risk in offspring of a patient with isolated bilateral
retinoblastoma is expected to be 50% at the time of birth, assuming a
50% probability of transmission of 100% probability of tumor devel-
opment. However, as some patients with isolated bilateral retino-
blastoma have somatic mutational mosaicism, the overall probability of
transmission is less than 50%.
In principle, the strategies of genetic testing are analogous to those
in familial retinoblastoma. With current routine methods, an oncogenic
variant is identified in DNA from blood of almost 95% of patients with
isolated bilateral retinoblastoma, which is lower compared to familial
retinoblastoma, due to somatic mosaics with low proportions of mu-
tation-carrying leukocytes. Although this limitation can be overcome by
deep sequencing technology, at least for some types of alterations such
as single nucleotide variants, robust strategies for technical validation
of low-level findings remains to be established. In most patients, the
signal ratio of wild type and variant alleles in DNA from blood suggests
a heterozygous genotype. However, checking a second source of con-
stitutional DNA (e.g. DNA from buccal swabs or finger nails) is a
worthwhile adjunct analysis as it may detect possible somatic mosai-
cism. If informed consent is granted, parents should be tested for the
presence of the variant allele. Most loss of function-type alleles appear
to have occurred de novo, and are preferentially found on the allele of
paternal origin (Hagstrom and Dryja, 1999; Zhu et al., 1989).
In some patients, the signal ratio of wild type and variant alleles in
DNA from blood is imbalanced. Such a finding may be due to somatic
mosaicism, but further genetic testing is required to validate this in-
terpretation. However, if somatic mosaicism is confirmed this excludes
an increased risk in siblings and relatives of the patient's parents.
Therefore, the additional efforts required to confirm somatic mosaicism
in a patient with isolated bilateral retinoblastoma are often justified.
Another option to overcome the limitations of diagnostic sensitivity
due to somatic mosaicism is to include analysis of tumoral DNA.
Analytically, the most reliable source of tumor DNA is a fresh frozen
sample obtained at the time of enucleation. If the tumor mutations are
not identified, constitutionally heterozygous intragenic polymorphic
RB1 markers can be used looking for a loss of heterozygosity (LOH) in
the tumor, as seen in 63–70% of the cases (Cavenee et al., 1983; Zhu
et al., 1992). Whenever LOH is present, the recurrence risk is linked to
the transmission of the allele retained in the tumor. If tumor DNA
markers are not informative, or in the absence of enucleation, the
known paternal preferential origin of de novo germline RB1 mutants,
seen in 90% of the cases, can be used to modulate the recurrence risk,
which is maximized if the paternal or grand-paternal allele is passed to
a sib of an offspring respectively (Tran et al., 2012).
If the oncogenic RB1 variant responsible for the heritable predis-
position is known in the index patient, genetic counseling in relatives is
as straightforward as in familial retinoblastoma (see above), with two
notable exceptions: i) If testing of DNA from blood of parents did not
show the variant allele identified in the child, this will reduce but not
exclude increased risk in siblings. The remaining risk is due to germline
mosaicism, i.e. the presence of cells with the mutant allele in germline
cells of a parent. Unfortunately, empirical data required to quantify the
risk due to germline mosaicism are still missing. ii) The second caveat
relates to the origin of chromosomal aberrations such as genomic de-
letions at 13q14 (see 5.1.2.2). If a chromosomal alteration identified in
a child is not present in either parent, this does not exclude the presence
of aberrations causing unbalanced ones. Chromosome analysis in par-
ents can detect such aberrations in some families.
5.2.3. Isolated unilateral retinoblastoma
Pretest genetic counseling has to take into account that various
genetic mechanisms may result in isolated unilateral retinoblastoma.
The empirical recurrence risk figures provided by Draper, which in-
tegrate all alternative causes, are still valid for risk estimation in sib-
lings and offspring of patients with isolated unilateral retinoblastoma
(Draper et al., 1992). The low empirical recurrence risk for siblings (1%
at time of birth) reflects that heterozygosity with incomplete
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penetrance or germline mosaicism for an oncogenic allele in a parent is
rare. Moreover, although the probability of transmission of an onco-
genic allele from a rare heterozygous parent is 50%, recurrence risk is
further reduced because of the lower probability of tumor development
caused by alleles associated with incomplete penetrance. Risk for the
patient's first child is higher (6% at time of birth) and, in most cases, is
due to somatic mosaicism in the unilaterally affected parent. Because of
somatic mosaicism, probability of transmission is reduced (overall<
50%). However, the oncogenic alleles transmitted by such parents are
typically associated with high probability of tumor development. This
explains why tumors in children of patients with isolated unilateral
retinoblastoma typically show bilateral disease.
The results of genetic testing can help to identify which of the
alternative genetic mechanisms has resulted in isolated unilateral dis-
ease in a given patient. In fewer than 15% of patients, constitutional
heterozygosity for an oncogenic RB1 allele is detected. Genetic coun-
seling of these families must take into account estimates of disease
penetrance as indicated by the functional type of mutation. The most
frequent genetic mechanism (in over 80% of isolated unilateral pa-
tients) is somatic inactivation of both alleles of the RB1 gene. This di-
agnosis excludes an increased recurrence risk in siblings. If testing
shows no evidence of somatic mosaicism then pretest risk in offspring is
reduced (possibly less than 1%), with the option to exclude an increased
risk after predictive genetic testing for heritable oncogenic alterations
that had been identified in the parent's tumor. Of note, although some
somatic alterations that cause RB1 inactivation in retinoblastoma are
Fig. 9. Retinoblastoma growth patterns. A.
Endophytic retinoblastoma with class 1 (dust) and 2
(spheres) vitreous seeding. B. Exophytic retino-
blastoma with peritumoral retinal detachment C.
Exophytic growth with total retinal detachment
causing complete spontaneous vitrectomy (kissing
retinal bubbles). D. Mixed, predominantly exophytic
growth with extended class 2 subretinal seeding and
class 3 (cloud) vitreous seeding. E. Cavitary retino-
blastoma with exophytic growth and coexisting en-
dophytic retinoma before (E) and after (F) intra-ar-
terial chemotherapy. G. Diffuse infiltrating
retinoblastoma in a 14-year-old boy. White arrow-
heads delineating the posterior front line of the
tumor as documented by OCT before (H, H′) and 3
weeks after (I, I′) the first course of systemic che-
motherapy. The white asterisk in H shows the pos-
terior limit of the tumor front line. NB: Lines on
fundus photograph correspond to the adjacent ul-
trasonography image or optical coherence tomo-
graphy scan.
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not heritable (e.g. chromothripsis (McEvoy et al., 2014)) and epigenetic
silencing (Greger et al., 1994), it is still possible that the propensity to
acquire such alterations is influenced by heritable genetic variation.
In rare cases, genetic analysis of the patient's retinoblastoma shows
no alteration at the RB1 locus but high-level amplification of the MYCN
gene. Current data and models strongly suggest that these tumors are
distinct entities without recurrence risk for the unaffected eye of the
patient, nor for his or her relatives. However, to date, the genetic di-
agnosis of MYCN-retinoblastoma has not been validated medically.
Moreover, prior to utilizing the results for predictive testing, it would
be reassuring to have results from longitudinal observations of patients
and their families. Recognition of this specific entity is likely to be
possible even in conservatively-treated eyes based on liquid biopsy, by
paracentesis of aqueous humor as shown for copy number variations
(Berry et al., 2018b).
6. Clinical growth and seeding patterns
The retinoblast undergoing malignant transformation initiates a
primary intraretinal tumor, which has not only the capacity to metas-
tasize but also, unlike other cancers, to generate secondary tumors by
seeding. Clinical features of retinoblastoma retinal growth and seeding
patterns are reviewed below.
6.1. Retinoblastoma growth patterns
Primary tumors generated by retinal oncogenesis are characterized
clinically by 6 distinct growth patterns, namely endophytic, exophytic,
cavitary, diffuse infiltrating, anterior diffuse and spontaneously re-
gressed retinoblastoma. Note that on top of this phenotypic retinal re-
pertoire, retinoblastoma can also result from extra-retinal oncogenesis
leading to ectopic growth in the pineal gland and supra/parasellar re-
gion (trilateral retinoblastoma) (see 3.6).
6.1.1. Classic growth patterns of primary retinoblastoma: endophytic,
exophytic, mixed growth
Incipient retinoblastoma can be traced by OCT to the inner nuclear
layer or in the outer plexiform layer (see 4.3.4). By definition, tumor
progression towards the inner or outer retina is associated with en-
dophytic or exophytic retinoblastoma respectively (Fig. 9 A, B), but the
link with the OCT variants remains unknown.
Endophytic retinoblastoma presents as a whitish mass rapidly in-
terrupting the retinal vasculature and protruding into the vitreous
cavity secondary to alterations of the vitreo-retinal interface by two
distinct mechanisms (Fig. 9 A):
(i) At the tumor apex, by tumoral infiltration of the internal limiting
membrane and hyaloid, leading to vitreous seeding (see 6.2.1).
(ii) At the tumor base, by tractional detachment of the hyaloid, creating
a new ocular compartment for retrohyaloid seeding (see 6.2.2).
Finally, note that in case of endophytic growth, the retina con-
tiguous to the tumor base can also undergo a localized circumferential
tractional detachment with well-demarcated boundaries.
Exophytic retinoblastoma presents as a mass beneath the retina,
sparing the retinal surface, which retains unaltered retinal vasculature
(Fig. 9 B). This growth variant impacts the retinal pigment epithelium-
photoreceptor complex by causing an exudative retinal detachment,
under which subretinal seeding can occur. The detachment, initially
intermittent, position-dependent, and leaving poorly defined de-
marcation lines on the retina, can become total and bullous with further
tumor growth, inducing complete spontaneous vitrectomy when the
retina enters in contact with the lens (Fig. 9 C).
Mixed endophytic and exophytic growth is a feature of more ad-
vanced retinoblastoma (Fig. 9 D), often associated histopathologically
with choroidal infiltration across the RPE and Bruch's membrane. This
uveal invasion tends to occur more often with exophytic than en-
dophytic retinoblastoma (Nawaiseh et al., 2015; Palazzi et al., 1990;
Shields et al., 1993a). Endophytic and exophytic retinoblastoma can
also coexist in the same eye.
6.1.2. Rare variants of retinoblastoma
In addition to the common endophytic and exophytic growth pat-
terns, 3 other variants of retinoblastoma can be encountered, ac-
counting for about 5% of the cases at presentation, namely cavitary
(2.7–4%) (see 6.1.2.1), diffuse infiltrating (1–2%) (see 6.1.2.2), and
diffuse anterior retinoblastoma (< 1%) (see 6.1.2.3). All these subtypes
are characterized by an atypical presentation, often causing a delayed
diagnosis or even life-threatening invasive investigations or therapeutic
procedures. Awareness of characteristic features described below help
the early recognition, crucial to provide appropriate management.
6.1.2.1. Cavitary retinoblastoma. Cavitary retinoblastoma is a rare low-
grade endophytic growth variant with intratumoral pseudo-cysts visible
as grey lucent cavities at the tumor surface on ophthalmoscopy,
appearing hypofluorescent on fluorescein angiography, and as empty
spaces on ultrasonography (Palamar et al., 2008) (Fig. 9 E, F). Cavitary
retinoblastoma typically displays a mean number of 2–3 cavitations of
an average diameter of 3mm (Chaudhry et al., 2018; Rojanaporn et al.,
2012). Diagnosis is made at a mean age of about 15 months and
predominates in bilaterally affected patients in approximately 2/3 of
the cases (Chaudhry et al., 2018; Rojanaporn et al., 2012). These
tumors may co-exist with non-cavitary retinoblastoma tumor foci in the
same or fellow eye. Secondary intracavitary seeding has been observed
in 10% (n=2/20) of the cases followed in Lausanne (unpublished
data) (see 6.2). Noteworthy, cavitary retinoblastoma may develop new
cavities during treatment, and secondary cavities may become visible in
an initially non-cavitary tumor after an average of two courses of
chemotherapy (Chaudhry et al., 2018). On the other hand, cavities can
collapse under treatment as seen in 44% of the eyes after a mean follow-
up of 18 months (Chaudhry et al., 2018).
In contrast to non-cavitary retinoblastoma where systemic or intra-
arterial chemotherapy induces a mean tumor reduction of approxi-
mately 30–35% in basal diameter and 50–56% in thickness (Shields
et al., 1996, 2011), cavitary tumors typically show shrinking only by
half these values as a mean (Rojanaporn et al., 2012), and sometimes
not at all (Fig. 9E and F). In addition, relapse of cavitary retinoblastoma
appears to be exceptional, occurring in none of 18 eyes (0%) after a
mean follow-up of 40 months in a series from London (Chaudhry et al.,
2018), and in only one of 26 eyes (4%) in the series from Philadelphia
after a mean follow-up of 4 years (Rojanaporn et al., 2012), again very
different from the relapse rate of 20–28% characterizing non-cavitary
retinoblastoma (Gombos et al., 2002; Shields et al., 2004b, 2011).
In general, despite apparent resistance, cavitary retinoblastoma
does not require aggressive or prolonged treatment. However, con-
sidering a recurrence risk estimate of about 4%, similar to that of re-
tinoma, life-long follow-up is advised (Abouzeid et al., 2012; Balmer
et al., 1991; Singh et al., 2000) (see 6.3).
6.1.2.2. Diffuse infiltrating retinoblastoma. Diffuse infiltrating
retinoblastoma is another rare variant found in 1–2% of the cases,
characterized by a planar horizontal growth rather than the vertical
growth seen in endophytic and exophytic retinoblastoma (Fig. 9 G).
Typically, the tumor infiltrates the retina which appears thickened on
B-scan, UBM or MRT, without visible mass or calcifications.
Histopathologic reports have shown diffuse tumoral invasion of the
ganglion cell layers (Fernandez et al., 2017), appearing as a hyper-
reflective homogenous thickening on OCT (Stathopoulos et al., 2019)
(Fig. 9 H, I). This OCT signature was shared in all four diffuse
infiltrating tumors investigated so far in Lausanne (Stathopoulos
et al., 2019; FLM unpublished data). Interestingly, a type 0 regression
with complete restoration of the retinal microanatomy was observed on
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OCT after intra-arterial and intravenous chemotherapy (Stathopoulos
et al., 2019) (Fig. 9 H′, I’).
Compared to classic retinoblastoma, the diagnosis of diffuse in-
filtrating retinoblastoma is usually made in older children (mean age
5.7 years) following atypical presenting symptoms such as vision loss,
ocular redness or pain, in the context of misleading signs most fre-
quently masquerading inflammation or pointing to other diagnoses,
including neovascular glaucoma and cataract (Traine et al., 2016). In
addition to frequent diagnostic delay, slow tumor growth could explain
the older age at presentation (Bhatnagar and Vine, 1991; Traine et al.,
2016). Most cases (> 90%) are unilateral and sporadic. Diffuse in-
filtrating retinoblastoma and typical retinoblastoma have, however,
been observed in the same patient (FLM personal observation) or within
family members carrying the same mutation (Kao, 2000; Schedler et al.,
2016), raising the question of a possibly distinct genesis in this atypical
disease subtype. As retinal specific micro-environmental features are
known to contribute to retinoblastoma tumorigenesis (Xu et al., 2010),
a specific tropism of infiltrating retinoblastoma tumor cells for the
ganglion cells favoring this atypical growth over the inner plexiform
layer can be hypothesized.
Until recently, all cases have been managed with primary enuclea-
tion (Bhatnagar and Vine, 1991; Fernandez et al., 2017; Foster and
Mukai, 1996; Shields et al., 2008). Last year, for the first time, one
successful case of eye salvage with vision preservation was reported
after focal treatment and intra-arterial chemotherapy at an updated 38-
month follow-up (Stathopoulos et al., 2019). Optical coherence tomo-
graphy provides instrumental information to monitor the tumor front
line following treatment in such cases.
6.1.2.3. Diffuse anterior retinoblastoma. The term diffuse anterior
retinoblastoma was first proposed in 1998 to describe an exceedingly
rare variant of the disease (Grossniklaus et al., 1998), totalizing only 13
published cases up to now (Jijelava and Grossniklaus, 2013; Kelly et al.,
2016; Munier et al., 2017a; Shields et al., 2016c). Diagnosis occurs
usually later than the other forms (mean age 6.4 years). Half of the
cases present with a cellular infiltration of the anterior chamber
without retinal or vitreous involvement, while in the other half, a
small retinal lesion is found at the ora serrata, typically with
concomitant vitreous seeding (Jijelava and Grossniklaus, 2013; Kelly
et al., 2016; Munier et al., 2017a; Semb et al., 1961; Shields et al.,
2016c).
Diffuse anterior retinoblastoma has been considered a variant of
diffuse infiltrating retinoblastoma, originating either from a very small
focus close to the ora serrata (Jijelava and Grossniklaus, 2013) or di-
rectly from the anterior segment (Shields et al., 2016c). In our opinion,
however, this subtype of retinoblastoma constitutes a unique, separate
entity, originating from two distinct sources found at the extreme
fundus periphery (Fig. 10), explaining the two different clinico-patho-
logic manifestations observed in this subtype of retinoblastoma, namely
without or with minimal peripheral retinal involvement. Hence, in the
case of diffuse anterior retinoblastoma without retinal tumor, we think
that the tumor arises from ectopic retina found anteriorly to the ora
serrata, corresponding either to retinal islands embedded in the pars
plana (Eisner, 1973) or to cristae retinae (Fig. 10). As both structures
lack the internal limiting membrane (Daicker, 1972), a tumor origi-
nating from this ectopic retina is expected to seed immediately into the
posterior chamber without growing a mass (Fig. 10A–C). Conversely, in
the case of anterior diffuse retinoblastoma with a minimal peripheral
retinal involvement, we believe that the tumor originates from the
retinal rim found under the vitreous base (Fig. 10), where L/M cones
are known to out-number rods (Ahnelt, 1998; Williams, 1991). Since
the retinal rim under the vitreous base is devoid of hyaloid and has a
thin fenestrated inner limiting membrane (Le Goff and Bishop, 2008), a
tumor arising from this location will initially grow as an endophytic
mass which can rapidly invade both posterior chamber and vitreous
cavity (Le Goff and Bishop, 2008) (Fig. 10D–F).
6.2. Intra-ocular seeding
Seeding of tumor cells is a characteristic feature of retinoblastoma.
It can, however, be observed in other primary intra-ocular tumoral
conditions such as melanocytoma of the optic nerve (Shields et al.,
2006c), ciliary body medulloepithelioma (Kaliki et al., 2013a), retinal
astrocytoma (Cohen et al., 2008), and uveal melanoma (Metz et al.,
2016).
Seeding of the primary tumor engenders no less than 12 recogniz-
able phenotypes, comprising all possible combinations of the 3 known
classes of seeds, i.e. dust, spheres and clouds, across the 4 intraocular
seeding compartments, i.e. the vitreous, aqueous, as well as the sub-
retinal and retrohyaloid spaces (Francis et al., 2015a; Munier, 2014).
Fig. 10. Primary aqueous humor invasion mechanisms in anterior diffuse retinoblastoma. A-B. Schematic illustration of anterior diffuse growth. In this case,
the tumor presumably arises from the peripheral retina where it can grow both trans-orally directly into the posterior chamber (Petit's canal) and/or into the vitreous
through the fenestrated limiting membrane, as illustrated in (C) by fundus photography and UBM (50MHz) of a primary oral tumor in an 11-year-old patient. D-F.
Anterior diffuse growth with aqueous seeding (no retinal tumor) arising from ectopic ciliary retina (E) or from an oral retinal tooth (F). NB: For the microanatomy of
the schematic en-face view and longitudinal sections of the fundus extremus please refer to the legends given in Fig. 3. Tumor and tumor spread into the different
compartments are characterized by the yellow mass and yellow arrows respectively. Invaded aqueous and vitreous compartments are indicated in light yellow.
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6.2.1. Vitreous seeding
Vitreous seeding occurs following the disruption of the inner lim-
iting membrane of the retina and hyaloid either by spontaneous or by
iatrogenic mechanisms. Interestingly, transmission electron microscopy
measurements showed that the thickness of the internal limiting
membrane is characterized by huge topographic variations ranging
from 20 nm at the foveola to 2500 nm in the macular region and de-
creasing progressively with greater eccentricity down to 50 nm at the
vitreous base (Foos, 1972), where the inner limiting membrane is
perforated (Le Goff and Bishop, 2008). The inner limiting membrane
opposes therefore less resistance to seeding in the periphery, accounting
for the preferential anterior location of class 3 seeds as recently re-
ported (Francis et al., 2016). Schematic representation and peripheral
clinical limits of intravitreal seeding in endophytic retinoblastoma
growth pattern is shown in Fig. 11 A-C.
Spontaneous vitreous seeding can be present at diagnosis (primary
seeding) as a pathognomonic feature of endophytic retinoblastoma, or
complicate the disease course at tumor relapse (secondary seeding)
independently of the initial growth pattern (Munier, 2014). In the first
scenario, by far the most frequent, the passage of tumor cells into the
vitreous is part of an active infiltration at tumor apex, discharging in-
dividual cells (class 1 seeds). The ability of these cells to survive and
grow under the hypoxic vitreous conditions will depend on metabolic
reprogramming and/or resistance to anoikis. In other words, only a
fraction of these cells will acquire the clonal capability to form spheres
(class 2 seeds). According to their adhesion-independent or dependent
properties, they will give rise to free floating spheres or hemispheres
anchored to the inner face of the hyaloid. In the second scenario, the
passage into the vitreous follows a passive mechanism by mechanical or
necrotic disruption of the tumor apex, leading to the formation of a
cloud (class 3 seeds). The translocation of the tumor content by gravity
into the vitreous body is sometimes endowed of gravitational motility,
thus masking or unmasking the retina depending on the head position
(Fig. 12A-C). Here again the translocated tumor mass is mostly com-
posed of dead cells (Amram et al., 2017) and only a minority will
survive to produce spheres (class 2 seeds).
Iatrogenic (secondary) vitreous seeding is a well-known complica-
tion of inappropriate energy transfer by photocoagulation or diode-
mediated hyperthermia (Gombos et al., 2006), followed by dispersion
of tumor cells (class 1 seeds) into the vitreous. It can also occur in the
context of intravenous (Parness-Yossifon et al., 2009) or intra-arterial
chemotherapy (De Francesco et al., 2014), with the sudden formation of
class 3 seeds consecutive to internal limiting membrane disruption
following rapid tumor regression. Finally, indentation during ophthal-
moscopic examination of endophytic tumors at diagnosis, or during
positioning of a plaque, may also be at the origin of iatrogenic tumor
dispersion.
6.2.2. Retrohyaloid seeding
Retrohyaloid seeding is underdiagnosed and often confounded with
vitreous seeding. The retrohyaloid space is generated secondary to
rapid endophytic growth and formation of a tractional hyaloid de-
tachment, or to the inability of the contracted vitreous to re-expand and
compensate the collapsed tumor volume after treatment. The extent of
the retrohyaloid volume can be evaluated by ultrasonography, occu-
pying up to half of the vitreous volume. The recognition of a hyaloid
detachment is crucial in order to avoid grade 4 or 5 melphalan-induced
retinopathy linked to inadvertent retrohyaloid injection of intravitreal
chemotherapy (see 7.3.5.1.2.2).
The retrohyaloid seeds can float freely (Fig. 12D-F), or attach to the
inner limiting membrane of the retina and/or the outer hyaloid face.
Class 3 retrohyaloid seeding typically appears as a circular position-
Fig. 11. Schematic representation and peripheral clinical limits of intravitreal, retrohyaloid and subretinal seeding in endophytic and exophytic re-
tinoblastoma growth patterns. A-C. Vitreous seeding from endophytic growing peripheral retinal tumor secondary to the rupture of the internal limiting membrane
and hyaloid. C. Fundus picture and UBM (35MHz) showing vitreous seeding respecting the anterior hyaloid with a tumor-free posterior chamber. D-F. Retrohyaloid
class 3 seeding from an endophytic growing tumor, secondary to internal limiting membrane rupture but with an intact hyaloid (D, E). In this context. (F), anterior
seeding extension is limited by the vitreous base, posteriorly to the ora serrata (F). G-H. Subretinal seeding from an exophytic growing tumor. (I) Fundus photo-
graphy showing subretinal seeding reaching the ora serrata by gravity. NB: For the microanatomy of the schematic en-face view and longitudinal sections please refer
to the legends given in Fig. 3. Tumor and tumor spread into the different compartments are characterized by the yellow mass and arrows respectively.
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dependent cloud, masking the optic nerve and fovea only in dorsal
decubitus (Munier, 2014) (Fig. 12G-K). Schematic representation and
peripheral clinical limits of retrohyaloid seeding in endophytic retino-
blastoma growth pattern is shown in Fig. 11 D-F.
6.2.3. Subretinal seeding
Subretinal seeding is the hallmark of exophytic retinoblastoma. Two
distinct presentations of class 2 subretinal seeding can be distinguished,
i.e. spheres usually anchored to the detached outer retina, or flat pla-
coid lesions with a tendency to confluence in a shallow subretinal space
(Fig. 11G–I). The area of initial retinal detachment remains at risk for
persistent or recurrent subretinal seeding following first line treatment.
It is important to keep in mind the full extent of the detached retinal
territory, sometimes difficult to identify due to the on/off phenomenon
seen in exudative retinal detachment, in order to distinguish new per-
ipheral tumors from recurrent subretinal seeds.
By gravity, class 2 seeds tend to accumulate inferiorly just posterior
to the ora serrata (Fig. 11G–I). In the case of bullous retinal detach-
ment, the seeds attach to the outer retina and can project anterior to the
ora serrata. When the retina is folded over the pars plana, UBM is the
only way to differentiate these subretinal ante-oral tumors from an
invasion of the posterior chamber.
6.2.4. Aqueous seeding
Aqueous seeding refers not only to the presence of retinoblastoma
tumor cells in the anterior chamber on biomicroscopy (Fig. 13), but also
to its invisible posterior chamber counterpart. Chronologically, inva-
sion of the posterior chamber typically occurs first, leaving the anterior
Fig. 12. Head-position-dependent seeding location in supine position. A-C. Free moving class 3 vitreous seeding (cloud) revealing intact optic nerve head and
macula. D-F. Displacement of class 2 retro-hyaloid pavimentous seeding from temporal to nasal side of the retina by tilting the head from right (J) to left (K). G-K.
Free moving class 3 retro-hyaloid seeding (cloud) over the posterior pole (F) in primary position and with the head tilted to the right (G,H) and left (J,K). L-K.
Displacement (L, M) of class 2 intra-cavitary seed with optical coherence tomography localization (N). L.K. Intra-cavitary class 2 seed displacement, with (N) optical
coherence tomography confirming the intra-cavitary localization of the moving seed.
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chamber in a transient cryptic seeding state before converting to an
overt involvement. In case of infiltration of the iris root by (choroido)-
ciliary or supraciliary mass, however, the passage of retinoblastoma
cells to the anterior chamber can bypass the posterior chamber (see
6.2.4.3).
Ultrasonographic biomicroscopy is instrumental to document ante-
rior segment tumor involvement, enabling in particular to determine
whether the aqueous seeding is isolated or associated with an anterior
uveal infiltration of the ciliary body and/or iris (Fig. 14).
6.2.4.1. Prevalence of anterior chamber seeding. Anterior chamber
seeding at diagnosis is rarely seen in high-income countries, being
present in approximately 1% of the cases (Haik et al., 1987), except in
two rare subtypes of retinoblastoma, namely diffuse infiltrating (Shields
et al., 2008) and anterior diffuse retinoblastoma (Jijelava and
Grossniklaus, 2013), where it is found in 65% and 100% of the cases,
respectively. The presence of anterior chamber seeding automatically
grades disease as group E according to the International Intraocular
Retinoblastoma Classification (IIRC), with primary enucleation
recommended (Linn Murphree, 2005).
Secondary anterior chamber seeding appears at a mean interval of
28 months (range 3–99) after diagnosis (Munier et al., 2018), and was
found in 6% of secondary enucleated eyes with advanced retino-
blastoma treated with chemoreduction (Shields et al., 2009), and 23.5%
(Kiratli et al., 2017) to 50% (Pavlidou et al., 2015) of those treated with
intra-arterial chemotherapy.
Until recently (see 7.2.4), secondary anterior chamber seeding has
always been managed by enucleation (De Francesco et al., 2014;
Parness-Yossifon et al., 2009).
6.2.4.2. Prevalence of anterior uvea invasion. Anterior uvea (iris and
ciliary body) invasion, isolated or combined with aqueous seeding is
reported in 2–7% of primary enucleated eyes in developed countries
(Brennan et al., 2015; Kaliki et al., 2013b; Uusitalo et al., 2001), versus
8–12% of primary enucleated eyes in developing countries (Kaliki et al.,
2015b). In a recent series directly comparing primary and secondary
enucleations, the authors described a significantly higher incidence of
anterior segment involvement (17% vs 0%, p < 0.05) following
Fig. 13. Aqueous seeding. (A) Class 1, (B, C) 2 and (D) 3 seeding. E. Anterior segment optical coherence tomography showing presence of hyper-reflective material
over the corneal endothelium, iris and angle.
Fig. 14. Invasion of the anterior uvea and aqueous seeding class 3. A, B.
Iris and intra-ciliary body invasion documented by slit lamp photography and
both longitudinal and transverse ultrasound biomicroscopy (35MHz) in a 26-
month-old boy with previous enucleation of the contralateral eye, before (A)
and after (B) successful treatment. C. Fundus of the same patient at 18-month
event-free follow-up (Snellen visual acuity 0.5).
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secondary enucleation (Fabian et al., 2017c). Others reported similar
findings with a higher frequency of ciliary body invasion in secondary
enucleated eyes having received neoadjuvant chemotherapy (13%)
compared to primary enucleation (7%), and hypothesized that this
increase in anterior histopathologic features may reflect a differential
targeting of chemotherapy against ciliary body compared to posterior
uvea, due its poorer vascular supply (2 long posterior vs 20 short
posterior ciliary arteries) (Brennan et al., 2015).
6.2.4.3. Invasion mechanisms of the aqueous humor. Aqueous humor
invasion can occur via five different pathways, as documented on
clinical, ultrasonographic (UBM) and histopathologic observations
(Fig. 15):
(i) Trans-hyaloid invasion from tumor cells originating from vitreous
seeds anchored to the anterior hyaloid, or from peripheral parietal
tumors growing over the pars plana (Fig. 15E–H).
(ii) Trans-ciliary invasion via growth of a ciliary/choroido-ciliary tumor
directly into the posterior or anterior chamber and/or by infiltra-
tion of the iris root (Fig. 15 A, B).
(iii) Iatrogenic invasion by tumor cells freely invading the posterior
chamber from the posterior segment after mechanical disruption of
the anterior hyaloid, e.g. post pars plana vitrectomy, endocapsular
lensectomy or posterior capsulorhexis.
(iv) Epiciliary invasion by tumor cells originating from an oral or ectopic
retinal source, as seen in diffuse anterior retinoblastoma (see
6.1.2.3) (Fig. 10).
(v) Supra-ciliary invasion by anterior chamber angle infiltration of a
supra-ciliary mass (Fig. 15 C, D).
In a consecutive series of 33 eyes with anterior segment involve-
ment followed in Lausanne, the most frequently observed invasion
mechanism was transhyaloid, seen in 67% (n= 22/33), followed by
trans-ciliary (12%, n=4/33) and iatrogenic routes (12%, n= 4/33).
The epiciliary and the supraciliary invasion were observed only in 6%
(n= 2/33) and 3% (n=1/33), respectively (unpublished data).
Recognition of the invasion mechanism underlying aqueous humor
invasion is determinant for the adequate treatment strategy, as the
seeding source must be sterilized concomitantly to the aqueous seeding,
which became treatable only recently with intracameral chemotherapy
(see 7.2.6) (Fig. 16). Whereas iris invasion can be controlled by intra-
arterial melphalan (Munier et al., 2018), ciliary body involvement
needs to be treated by brachytherapy alone (Chhablani et al., 2010) if
isolated, or by combining brachytherapy and intracameral che-
motherapy if associated with aqueous seeding (Munier et al., 2018).
Fig. 15. Secondary aqueous humor invasion me-
chanisms: schematic representation (left column)
and histopathologic correlation (right column).
(NB the trans-oral or epiciliary pathway is illustrated
in Fig. 10A–C). A-B. Trans-ciliary pathway. Aqueous
humor invasion secondary to choroido-ciliary growth
into (A) the posterior chamber across the bi-layered
ciliary epithelium and/or into the anterior chamber
through the iris root. (B) Histopathology (HE 13x)
showing invasion of the corpus ciliaris and infiltra-
tion of the iris root (inferior inset HE 63x) with dis-
ruption (asterix) of the ciliary epithelium (superior
inset HE 126x). C-D. Supra-ciliary pathway. Aqueous
invasion secondary to choroidal growth (C)
spreading through the supra-ciliary space with in-
filtration of the iris root. (D) Histopathology (HE
24x) showing massive supra-ciliary tumor invasion
with anterior displacement of the ciliary body. E-H
Trans-hyaloid pathway (E) Vitreous seeds anchored
on the anterior hyaloid with trans-hyaloid passage.
(F) Histopathology (HE 24x) with retro-hyaloid
seeding crossing into the posterior chamber (Inset HE
252x). (G) Parietal tumor growing over the pars
plana infiltrating the anterior hyaloid. (H) Histo-
pathology (HE 13x) with infiltrated retina up to the
ora and passage into the posterior chamber through
the hyaloid.
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6.3. Retinoma/retinocytoma and phthisis bulbi
Retinoma, also called retinocytoma, retinoblastoma group 0, and
spontaneously arrested or regressed retinoblastoma, is used to desig-
nate a benign phenotypic counterpart of retinoblastoma. The pathologic
nature of these lesions was described in 1983 as benign photoreceptor
proliferations with numerous fleurettes and absence of necrosis or mi-
totic activity (Margo et al., 1983). More recently, review of histo-
pathologic sections of enucleated eyes showed areas with features of
retinoma in 15–20% of them, suggesting evolution from retinoma to
retinoblastoma (Dimaras et al., 2008; Eagle, 2009).
6.3.1. Prevalence and relationship with retinoblastoma
The exact frequency of retinoma in the population is not known.
Half of the reported cases are diagnosed by routine examination of first
degree relatives of retinoblastoma probands, especially in familial cases
(Abouzeid et al., 2012; Gallie et al., 1982). In a series of 171 sporadic
retinoblastomas, retinoma was diagnosed in only 2 asymptomatic
progenitors (FLM personal observation). The reported proportion of
retinoma among the population with retinoblastoma varies from 1.8%
(17/920) to 3.2% (16/505) (Abouzeid et al., 2012; Singh et al., 2000).
Retinoma can also be suspected retrospectively in late-onset diagnosed
retinoblastoma in older children or adults (Eagle et al., 1989; Mataftsi
Fig. 16. Retinoblastoma invasion of the posterior
chamber before (left column) and after (right
column) successful treatment, documented by
photography and longitudinal and transverse UBM
(ultrasound biomicroscopy) (35MHz). A, B. Invasion
of Hannover's canal with class 2 seeds, treated with
intracameral chemotherapy and anterior segment
protontherapy. C, D. Invasion of Petit's canal, treated
with intracameral chemotherapy. E, F. Involvement
of the pars plicata, treated by intracameral che-
motherapy and brachytherapy G, H. Involvement of
the pars plicata and ciliary body, treated by in-
tracameral chemotherapy and brachytherapy.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
29
et al., 2012), or in tumors with no or minimal initial response to che-
moreduction and absence of growth after discontinuation of all treat-
ments (Chung et al., 2010; Shields et al., 2002).
Like retinoblastoma, retinoma can be present in one or both eyes.
The lesion can also co-exist with retinoblastoma in the same or fellow
eye. In retinoma germline carriers, the underlying disease-predisposing
RB1 mutations are indistinguishable from those found in retino-
blastoma patients (Abouzeid et al., 2009), indirectly confirming that
RB1 double hits are necessary but not sufficient to cause retinoblastoma
(Dimaras et al., 2008).
6.3.2. Clinical features and risk of malignant transformation
The majority of the lesions correspond to spontaneously arrested
and/or regressed proliferations, appearing typically as a translucent
retinal mass with or without calcifications and/or retinal pigment
epithelial alterations (Gallie et al., 1982). In a report on 86 retinoma
foci in 49 eyes, 40% of the retinoma foci showed regression patterns
types I and IV, and 60% types II and III, including 5 tumors with
pseudo-cyst, among which 2 displayed benign cavitary enlargement
over time (Abouzeid et al., 2012).
Phenotypic variability also includes spontaneously regressed vitr-
eous seeds (Abouzeid et al., 2012; Hadjistilianou et al., 2006; Lueder
et al., 1995; Shah et al., 2011), regressed subretinal seeds, clinical signs
of past retinal detachment and histopathologic evidence of full thick-
ness choroidal and prelaminar optic nerve head invasion (Abouzeid
et al., 2012) (Fig. 17 A, B). Such findings suggest the existence of a more
aggressive retinoma subtype prior regression than typical ones. Finally,
phthisis bulbi has been reported in 6.6–8.3% in the two largest series of
patients with spontaneously regressed retinoblastoma (Abouzeid et al.,
2012; Gallie et al., 1982).
The mechanisms underlying regression/growth arrest of retinoma
remain to be determined. Considering the occasional multifocal and/or
bilateral disease, however, such a coordinated growth stop of millions
of cells across different ocular compartments is more likely to be caused
by a still unknown humoral or circulating factor, than explained by a
cell-intrinsic mechanism or vascular collapse.
As retinoma can undergo secondary malignant transformation with
an estimated lifelong risk of about 5%, regular control of the lesions are
needed (Abouzeid et al., 2012; Singh et al., 2000) (Fig. 17C–E).
7. Conservative management of intraocular retinoblastoma
With the emergence of new therapies over the last 20 years, the
management of retinoblastoma has also become more complex. The
first rule remains the defense of life, which presupposes a permanent
arbitration between pursuit of conservative therapy and secondary
enucleation. This being said, one of the most important keys to success
is continuous adaptation of the therapeutic strategy to the different eye
compartments involved. The right decision-making implies a solid
knowledge of the strengths and limits of the different modalities that
have come to enrich the therapeutic armamentarium of retinoblastoma,
but also the awareness of their potential complications. Efforts to im-
plement eye-conservative strategies in less developed countries should
consider local socio-economic and cultural factors as well as availability
of resources for treatment and patient support. In many of these set-
tings, compliance with follow-up visits and timely acceptance of en-
ucleation when conservative therapies have failed may not be com-
parable to higher income countries, causing an increased risk for
disease progression and death. In addition, even mild chemotherapy
regimens may be associated to increased risk of toxic death in these
settings (Chantada et al., 2013).
This part deals first with an overview of the pharmacokinetics of the
most commonly used chemotherapeutic drugs in retinoblastoma treat-
ment according to the different routes of delivery (see 7.1), illustrating
why the development of targeted routes of chemotherapy administra-
tion directly into the eye was essential to achieve control of tumor
seeding. We then review the different available therapeutic modalities
and their contribution in reducing the enucleation rate and eradicating
the need for external beam radiotherapy (see 7.2). Furthermore, major
disease- and treatment-related intraocular complications encountered
during conservative retinoblastoma management are highlighted to
bring into perspective one of the biggest remaining challenges of dis-
ease management, namely vision preservation (see 7.3). Finally, this
section ends with a review on the quality of life (see 7.4).
7.1. Pharmocokinetics
To achieve the intended goal, chemotherapeutic drugs must become
available in a sufficient concentration of their active form at the in-
tended tumor site. In parallel, for retinoblastoma patients, it is also
Fig. 17. Pre- and post-regression growth patterns
of retinoma. A. Endophytic sporadic unilateral re-
tinoma displaying a type III regression pattern with
inactive spontaneously regressed past vitreous
seeding (insert: OCT showing hyperreflective class 2
vitreous seeds) in a 45-year-old asymptomatic man.
B. Exophytic familial unilateral retinoma displaying
a type III regression pattern with spontaneously re-
gressed subretinal seeding and well demarcated past
exudative retinal detachment in a 31-years-old
asymptomatic woman. C-E. Fundus photograph,
fluorescein and indocyanin green angiography in a
case of spontaneous malignant transformation of a
sporadic unilateral retinoma in a 34-year-old
woman.
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important to take into account the amount of drug in the bloodstream
to counterbalance efficacy with systemic toxicity. The vitreous-to-
plasma and the retina-to-plasma drug exposure ratios are important
concepts to define the most selective route for ocular drug delivery and
to avoid exposure of normal tissues to antineoplastic agents.
Despite the use of chemotherapy in the conservative treatment of
retinoblastoma for more than 20 years, knowledge about the in-
traocular bioavailability of the different drugs remains incomplete.
Moreover, information, mainly based for ethical reasons on animal
studies, is often characterized by discrepancies with the clinical ob-
servations secondary not only to differences in the anatomy between
animal and human eyes, but probably also between non-tumor bearing
and tumor-bearing-eyes, whose integrity of the blood-ocular barrier is
compromised.
The following overviews the main pharmacokinetic studies with
emphasis on the different possible administration routes of the che-
motherapeutic drugs used against retinoblastoma. A schematic re-
presentation of previously published data of chemotherapy ocular ex-
posure in different animal models after several local and systemic
routes of drug delivery is presented in Fig. 18.
7.1.1. Intravenous drug delivery
To penetrate the different ocular compartments after intravenous
delivery, the drugs have first to make it through the first-pass meta-
bolism and, once in the choroidal and retinal vessel, to overcome the
blood-ocular barrier. The latter consists posteriorly of the tight junc-
tions of the retinal pigment epithelium and the retinal endothelial cells
and, anteriorly, of the inner non-pigmented ciliary epithelium, the
posterior iris epithelium, and the endothelium of the iris and ciliary
body vessels. High doses of chemotherapy are consequently required
intravenously to attain pharmacologically active concentrations in the
ocular tissues, carrying simultaneously the risk of severe systemic ad-
verse events (Del Amo et al., 2017; Edelhauser et al., 2010).
Systemic chemotherapy as conservative retinoblastoma treatment
(typically with carboplatin, etoposide, and vincristine) was introduced
in the 1990s, without preclinical studies on intraocular pharmacoki-
netics and remains the most frequently used treatment worldwide even
though only a small fraction of the administered drugs is thought to
make its way through the first-pass metabolism and the blood-ocular
barrier.
Specifically, studies in tumor-bearing juvenile rats showed that in-
travenous carboplatin, a cell-phase nonspecific alkylating agent,
achieved an intravitreal exposure of 60% of the systemic area under the
curve (AUC) (Laurie et al., 2005), whereas in a non-human primate
model, the maximum achieved concentration in the vitreous (Cmax) was
only 1% of the plasma Cmax but, surprisingly, the aqueous humor Cmax
was 20% of the systemic level (Mendelsohn et al., 1998). Interestingly,
the concentration of carboplatin in the vitreous in enucleated eyes from
retinoblastoma patients was 13-fold higher than that attained after the
same dosage in non-human primates (Abramson et al., 1999a), but si-
milar to the levels obtained by others in rabbits subjected to cryo-
therapy (Wilson et al., 1996).
Pharmacokinetic studies with intravenous etoposide, a topoisome-
rase II inhibitor, performed in rats and non-human primate models have
shown a very low to undetectable vitreous exposure compared to the
systemic exposure (Laurie et al., 2005; Mendelsohn et al., 1998).
Intravenous vincristine, a cell-mitosis inhibitor from the vinca al-
kaloid family, exhibited good retinal and vitreous exposure in rats, al-
most equal to plasma exposure, but the assays performed were not able
to distinguish between a degraded or protein-bound form of the mo-
lecule (Laurie et al., 2005).
The low selectivity of the intravenous route for chemotherapy de-
livery into the vitreous was also reported for topotecan, a topoisome-
rase type I inhibitor, in non-tumor-bearing rats and rabbits with a
vitreous-to-plasma exposure ratio of less than 0.4 (Carcaboso et al.,
2007; Laurie et al., 2005). Nonetheless, intravenous topotecan is still
used in the clinics for retinoblastoma treatment (Brennan et al., 2017).
From the above, it appears that other administration routes had to
be explored to improve tumor control, especially in advanced disease
with seeding into the different ocular compartments.
7.1.2. Intra-arterial drug delivery
The technique of the super-selective catheterization of the oph-
thalmic artery was developed to allow the injection of high drug con-
centration directly into the artery that irrigates the ocular tissues, thus
avoiding the first-pass elimination and reducing at the same time sys-
temic exposure to the cytotoxic drug. The hypothesis of an increased
bioavailability in the ocular tissues with greater selectivity compared to
systemic exposure was confirmed four years after the initial publication
on 9 cases treated this way (Abramson et al., 2008), in pharmacokinetic
animal studies using non-tumor bearing pigs (Schaiquevich et al.,
2012a, 2012b).
The most frequently injected drug in the ophthalmic artery is mel-
phalan, a nitrogen mustard agent found to be the most efficient drug
among the 12 tested against retinoblastoma cells in vitro (Inomata and
Kaneko, 1987). Its cytotoxic activity is mediated by alkylating nucleic
Fig. 18. Schematic representation of chemotherapy exposure in aqueous and vitreous humor and plasma after different routes of drug delivery in several
animal models. Abbreviations: IV, intravenous infusion; IVi, intravitreal injection; IAC, intra-arterial chemotherapy; PO, periocular injection; Cmax, maximum
concentration; AUC, area under the concentration versus time profile; vit, vitreous humor; pl, plasma; aq, aqueous humor. aDose:0.1mg (Nemeth et al., 2011);
bDose:70mg/kg (Laurie et al., 2005); cDose:2.4mg (Simpson et al., 2002); dDose:18.7mg/kg (Hayden et al., 2004); eDose: 10mg (Mendelsohn et al., 1998); fDose:
18.7mg/kg (Mendelsohn et al., 1998); gDose:10 μg (Nemeth et al., 2011); hDose: 2mg/kg (Laurie et al., 2005); iDose: 1mg (Schaiquevich et al., 2012a); jDose: 4mg
(Taich et al., 2016); kDose: 1mg (Schaiquevich et al., 2014); lDose: 1mg (Carcaboso et al., 2007); mDose: 1mg (Carcaboso et al., 2007); nDose: 5 μg (Buitrago et al.,
2010); oDose:7mg (Schaiquevich et al., 2012b); pDose: 15 μg (Buitrago et al., 2016); qDose: 0.4mg/kg (Daniels et al., 2018).
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acids and proteins, which alters DNA function and ultimately leads to
cell death. Rapid spontaneous hydrolysis of the reconstituted drug from
its commercial vial implies infusion within 1.5 h in order to avoid the
loss of the active moiety.
Another frequently injected drug is topotecan as its active moiety of
lactone operating during the S phase of the cell cycle, is commonly used
in combination with melphalan to take advantage of synergistic effects
(Kaufmann et al., 1996; Schaiquevich et al., 2012b).
7.1.2.1. Intraocular distribution of intra-arterial melphalan and
topotecan. Pharmacokinetics studies after intra-arterial melphalan in
non-tumor bearing pigs, found that attained vitreous Cmax barely
reached the concentration that inhibits 50% of the retinoblastoma
cell growth in vitro (IC50), whereas the vitreous AUC was 3-fold higher
than the plasma AUC (Schaiquevich et al., 2012b) (Fig. 19). The
relatively low intravitreal levels were thought to be related to a poor
affinity of the melphalan to the L-amino acid transporter 1 (LAT1), the
mediator of its transport through the blood-retina barrier (Hosoya et al.,
2008). Comparatively, intravitreal concentrations of topotecan after
intra-arterial injection using the same animal model were above IC50
for at least 4 h (Schaiquevich et al., 2012a) (Fig. 20) and the AUC in the
vitreous was 29-fold higher than that in the bloodstream of the study
pigs (Schaiquevich et al., 2012a). Another study also performed in pigs
showed 143- and 246-fold higher retina and vitreous levels respectively
after intra-arterial topotecan than after intravenous infusion of the
same dose (Taich et al., 2016), with comparable systemic exposure. In
the same study, topotecan exposure in the optic nerve was 80-fold
higher after intra-arterial injection than after intravenous infusion at
the same dose of 4mg.
Despite the melphalan vitreous-to-plasma ratio of almost 10-fold
less than the ratio obtained for topotecan in non-tumor pigs studies
(Schaiquevich et al., 2012a, 2012b), it was clear from clinical experi-
ence that melphalan alone was efficient to treat retinal and subretinal
tumors, whereas this was not the case with intra-arterial topotecan as
monotherapy. On the other hand, intra-arterial melphalan, alone or in
combination with topotecan, was insufficient to manage all cases with
vitreous disease.
Of note, melphalan was detected in the RPE-choroid in almost all
the eyes of the pigs after intra-arterial chemotherapy but barely quan-
tified in the retina, showing the selective accumulation of the drug in
the RPE-choroid tissue.
7.1.2.2. Systemic adverse effects of intra-arterial delivered
drugs. Although intra-arterial chemotherapy is a local route for ocular
drug delivery, a fraction of the administered drug becomes systemically
available. This implies that there is a limitation to the maximum dose
that can be given in order to avoid systemic adverse effects, and
supplementary caution should be made in cases of tandem therapy.
Normalizing the dose based on body weight was found to minimize
inter-patient variability in melphalan pharmacokinetics. Thus, patients
exceeding the threshold dosage of 0.48mg/kg showed a 50% chance of
presenting severe neutropenia compared to less than 1% in children
receiving lower dosages (Dunkel et al., 2014; Schaiquevich et al.,
2012b).
Finally, a clinical pharmacokinetic study on intra-arterial che-
motherapy with combined melphalan (0.48mg/kg) and topotecan
(0.5–1mg) in patients with retinoblastoma, failed to show severe he-
matologic toxicity secondary to a potential drug-drug interaction (Taich
et al., 2014). Total topotecan systemic exposure after intra-arterial
chemotherapy was 95 ng*h/ml per mg of topotecan with about one-
third of this exposure corresponding to the active lactone moiety (Taich
et al., 2014), which is way below the threshold for severe neutropenia
after intravenous delivery (Brennan et al., 2017).
7.1.3. Intravitreal drug delivery
Compared to all the other administration routes, drug injection
directly into the vitreous bypasses the ocular barriers and the first-pass
elimination, and provides therefore the highest intraocular exposure in
the vitreous humor, ideal for the management of vitreous disease. After
the intravitreal injection, elimination takes place anteriorly by drug
flow from the vitreous into the aqueous humor and thereafter
Schlemm's canal and posteriorly through the components of the blood-
retinal barriers to the choroidal blood flow and the systemic circulation.
Similar to intra-arterial chemotherapy, the most commonly injected
drugs are melphalan and topotecan. Other drugs, such as carboplatin
and etoposide phosphate, are under investigation in preclinical studies
with rabbits as a potential alternative to melphalan, but will not be
discussed here as they are not currently used clinically (Mohney et al.,
2017).
7.1.3.1. Intraocular distribution of intravitreal melphalan. Intravitreal
melphalan (15 μg-dose) in rabbits resulted in vitreous concentrations
above the IC50 for up to 5 h, while undetectable in plasma throughout
the 12-h period of the study (Buitrago et al., 2016) (Fig. 19). The high
selectivity for the vitreous and the low systemic exposure of melphalan
after intravitreal injection in the animal study are in agreement with the
notable efficacy for vitreous seeds control and the lack of hematologic
toxicity reported in patients treated this way (see 7.2.5.4). On the other
hand, the drug aqueous humor exposure was less than 1% of that in the
vitreous, making it inadequate for targeting anterior chamber seeding
(Munier et al., 2017a).
Although data are limited, binding of drugs to vitreous proteins as
well as drug interaction with melanin has been hypothesized to lead to
prolonged residence time in the vitreous humor and pigmented tissues
(iris, ciliary body, retinal pigment epithelium, choroid) respectively,
resulting in prolonged pharmacological toxicity (Rimpela et al., 2018).
This may explain, at least in part, the retinal and iris toxicity reported
after intravitreal melphalan in patients or in a preclinical rabbit model,
as well as the greater reduction in electroretinogram (ERG) components
observed in more pigmented human eyes (Francis et al., 2014, 2015b,
2017b).
7.1.3.2. Intraocular distribution of intravitreal topotecan. In rabbits, the
intravitreal administration of only 5 μg of topotecan led to vitreous
concentrations above the IC50 for up to 16 h after the injection
(Buitrago et al., 2010), with no retinal toxicity (Buitrago et al.,
Fig. 19. Melphalan concentration versus time profile in (●, green) vitreous
humor after 15 μg IVi (intravitreal) to rabbits, (■, blue) aqueous humor after
15 μg IVi to rabbits, (♦, black) retina concentrations after 15 μg IVi to rabbits,
and (▲, red) vitreous humor after IAC (intra-arterial chemotherapy) of 7mg to
pigs. Dotted line represents the IC50 (concentration of chemotherapy that re-
duces 50% the cell viability) determined in a commercial cell line of retino-
blastoma (Schaiquevich et al., 2012b; Winter et al., 2016). (Data corresponds to
results published in Schaiquevich et al., 2012b; Buitrago et al., 2016).
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2013). These pharmacologically active concentrations after such low
doses have never been attained with other routes of ocular delivery. In
addition, the selectivity of this route was demonstrated by a vitreous-to-
plasma ratio of 57 (Fig. 20). After intravitreal injection, topotecan
exposure in the aqueous humor was, however, only 5% of that in the
vitreous and that only in its carboxylate form, considered to be
pharmacologically inactive, whereas the active lactone form was
undetectable (Buitrago et al., 2010). Like intravitreal melphalan, this
makes it inappropriate to treat aqueous seeding.
7.1.4. Intracameral drug delivery
Intracameral injections were specifically developed to target the
anterior and posterior chambers as aqueous seeding had remained
untreatable with other delivery routes. Thus, despite drug penetration
to the anterior chamber after intravenous (see 7.1.1) or periocular de-
livery (see 7.1.5) achieving an even higher aqueous Cmax concentration
compared to the intravitreal one in both human and animal eyes (see
7.1.3), the obtained doses were not high enough to reach tumoricidal
levels. On the other hand, neither intravitreal melphalan (Buitrago
et al., 2016) nor topotecan (Buitrago et al., 2010) achieved pharma-
cologically active levels in the aqueous humor (see 7.1.3) in a non-
tumor bearing rabbit model. Finally, although preclinical studies have
not been designed to study aqueous concentrations after intra-arterial
chemotherapy, the latter has never been reported to be successful in the
management of aqueous seeding (see 7.2.4).
To date, very limited data are available on the drug pharmacoki-
netics after intracameral injections, but clinical evidence showed them
to be successful in treating aqueous seeding, although insufficient to
control intravitreous disease (Munier et al., 2015, 2017a).
7.1.5. Periocular drug delivery
Periocular delivery was developed before the use of intra-arterial
and intravitreal chemotherapy in an attempt to increase the intraocular
bioavailability of the chemotherapeutic drugs. After periocular injec-
tion, the intraocular bioavailability is limited by the sclera, choroidal
and outer blood-retinal barrier, as well as by the orbital and choroidal
clearance (Del Amo et al., 2017; Edelhauser et al., 2010). The diffusion
of periocular injected drugs can be stimulated by transcleral ionto-
phoresis, as shown for low-molecular-weight charged molecules, such
as carboplatin (Hayden et al., 2006).
Preclinical studies in rabbits showed a 6-fold increase in vitreous-to-
plasma AUC after periocular carboplatin compared to the same ratio
after intravenous infusion (Hayden et al., 2004; Simpson et al., 2002)
and, in the non-human primate, the vitreous and aqueous humor Cmax
was over 2-fold the levels attained in plasma (Mendelsohn et al., 1998).
Similar studies with periocular topotecan showed vitreous drug
exposure of only 30% of the systemic AUC after periocular injection in
rabbits (Carcaboso et al., 2007) (Fig. 19), whereas in non-tumor-
bearing rats and pigs, topotecan vitreous AUC was 2- and 3-fold the
systemic exposure, respectively (Nemeth et al., 2011; Schaiquevich
et al., 2012a), possibly due to inter-species differences in the orbital and
ocular vasculature. Lastly, pharmacokinetic data on topotecan after
periocular delivery in humans obtained from a Phase I study in re-
tinoblastoma patients, revealed a non-toxic systemic exposure to lac-
tone topotecan below 55 ng/ml/h (Chantada et al., 2009).
7.1.6. Suprachoroidal drug delivery
Despite not being explored for targeting retinal diseases, su-
prachoroidal administration may provide an alternative route for drug
delivery to the posterior segment. The drug is placed in the space be-
tween the sclera and choroid and could be used to localize drug delivery
to the choroid, retinal pigment epithelium and, to a lesser extent, the
retina (Patel et al., 2011). A rapid diffusion of the injected solution
around the eye has been shown in animal models (Chiang et al., 2018).
An interesting aspect is the use of microneedles for performing the in-
jection that allows minimal damage of the sclera and avoids penetration
into the choroid and retina (Hartman and Kompella, 2018; Patel et al.,
2011).
Although suprachoroidal drug delivery may be advantageous for
targeting the choroid and retinal pigment epithelium, less evidence is
available to demonstrate adequate and prolonged exposure in the retina
(Chiang et al., 2018; Del Amo et al., 2017).
7.2. Treatment modalities
Retinoblastoma has always been credited with the highest 5-year
disease-free survival rate among pediatric cancers, presently reaching
97–99% in high-income countries (Fernandes et al., 2018; Group et al.,
2013; Jenkinson, 2015). Until the recent introduction of new targeted
treatment modalities, namely intra-arterial and intravitreal che-
motherapy, survival was often only achieved using mutilating and
disabling therapies. During the irradiation era, 96% of bilaterally af-
fected children had their worst eye enucleated at diagnosis, with pri-
mary enucleation of both eyes necessary in 3% and secondary en-
ucleation of an only remaining eye due to treatment failure leading to
total blindness in 25–29% (Abramson et al., 2004; Epstein et al., 2003).
Despite the advent of systemic chemotherapy as first line treatment,
64–66% of children with bilateral disease still underwent primary en-
ucleation of the more advanced eye and 2–6% required initial bilateral
enucleation (Epstein et al., 2003; Kim et al., 2008), while advanced
diseased eyes frequently needed external irradiation and/or secondary
enucleation. The recent advances in targeted chemotherapy modalities
allowed treatment of advanced disease and salvage of heavily pre-
treated eyes, resulting in a further decline of the primary enucleation
rate to less than 8% and virtually no more bilateral ocular losses
(Francis et al., 2018b). A similar preference for primary conservative
treatment can be observed in unilateral disease with a continuing de-
crease of primary enucleation, from 95% of the cases during the late
20th century, to 56% in the early 21st century and to only 5–7% cur-
rently (Abramson et al., 2015a; Munier et al., 2017b). This marked
improvement in globe salvage, without the need of external beam ir-
radiation, undeniably contributes not only to a better quality of life, but
Fig. 20. Total topotecan concentration versus time profile in (●, green) vitr-
eous humor after 5 μg IVi (intravitreal) to rabbits, (▼, red) aqueous humor
after 5 μg IVi to rabbits, (■, blue) vitreous humor after 1mg IAC (intra-arterial)
to pigs, (♦, yellow) vitreous humor after 1mg PO (periocular) to rabbits, (▲,
violet) vitreous humor after 1 mg IV (intravenous) to rabbits, (♦, black) retina
concentration after 4mg IAC to pigs, and (●) optic nerve concentrations after
4 mg IAC to pigs. Dotted line represents the IC50 (concentration of che-
motherapy that reduces 50% the cell viability) determined in a commercial cell
line of retinoblastoma (Laurie et al., 2005; Schaiquevich et al., 2012a; Winter
et al., 2016). (Data corresponds to results published in Carcaboso et al., 2007;
Schaiquevich et al., 2012a; Buitrago et al., 2010).
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is also expected to reduce the incidence of binocular visual impairment
and blindness in this population (Stacey et al., 2019).
In Lausanne, the simultaneous availability since 2008 of both intra-
arterial and intravitreal chemotherapy as additional options to the tradi-
tional chemoreduction and focal treatment, contributed to achieve 5-year
ocular survival estimates of almost 100% for treatment-naïve IIRC group
A-C (98%, 99% CI 86.7%–99.7%) (Fig. 21), and significantly improved the
ocular survival of treatment-naïve IIRC group D and selected E eyes, with
Kaplan-Meier estimates of 85.7% (95%CI 75.7%–91.8%) at 2-years and
79.4% (95% CI 67.0%–87.6%) at 5-years (very similar to the 80.2% for
COG group D and E after Abramson (Abramson et al., 2017a)), with no
metastasis in the cohort of naïve cases. This compares favorably to the era
prior to 2008, where ocular survival estimates were 55.0%, (95% CI
38.7%–68.7%) at 2- and 49.2% (95% CI 33.0–63.6%) at 5-years
(p=0.0007) (Fig. 22, data shown for group D only).
7.2.1. Intravenous chemotherapy
The indications for intravenous chemotherapy in the treatment of
retinoblastoma have progressively changed over the years. During the
era of external beam radiotherapy (Ellsworth, 1969), systemic che-
motherapy was limited to extraocular (Doz et al., 1995; Pratt et al.,
1985) or metastatic disease (Saleh et al., 1988). In the 1990s, its role
extended to first line treatment with the concept of chemoreduction,
aiming to render the tumor volume amenable to focal treatment
(Greenwald and Strauss, 1996; Kingston et al., 1996; Murphree et al.,
1996; Shields et al., 1996). Systemic chemotherapy contributed to in-
crease globe salvage rate, significantly reducing the need for external
beam radiotherapy and the incidence of secondary primary malig-
nancies. To date, systemic chemotherapy has been supplanted in part
by the introduction of intra-arterial (see 7.2.4) and intravitreal (see
7.2.5) chemotherapy (Abramson et al., 2015b).
7.2.1.1. Drug regimen and number of cycles. Initiation of systemic
chemotherapy usually takes place within 24–48 h after the first
ophthalmological examination to take advantage of the focal
cryorupture performed to improve drug penetration into the vitreous
and/or subretinal fluid (Wilson et al., 1996). Before each new
chemotherapy cycle, the child undergoes an examination under
anesthesia in order to evaluate the tumor response. After completion
of the second course of chemotherapy, sequential intensive focal
treatment is applied for every lesion that is not flat or calcified
(Murphree et al., 1996) (see 7.2.8).
The decision regarding the drug combination and number of courses
needed has remained highly variable across different referral centers.
The majority of studies report the use of 6 courses of a 3-drug regimen
(carboplatin-etoposide-vincristine) combined with focal treatments
(Table 9). Different observations corroborate the approach, however,
that a 2-drug regimen (etoposide-carboplatin) with a limited number of
courses (2–3) could be considered as the standard of intravenous che-
motherapy for intraocular retinoblastoma, whereas other therapeutic
options have to be employed depending on disease evolution, as no
long-term benefit of prolonged systemic chemotherapy is obtained.
Indeed, systemic chemotherapy alone (without consolidation) has been
reported to reduce tumor volume by approximately 35% diameter and
50% thickness already after the two first cycles (Shields et al., 1996).
Absence of further reduction of tumor thickness with additional course
of intravenous chemotherapy is further demonstrated by the data pre-
sented in Fig. 23 (Lausanne, unpublished data). In addition, compared
to groups giving 6 or more cycles of a 3-drug regimen, equivalent tumor
control was achieved with a mean of 3 cycles of a 2-drug regimen
(etoposide-carboplatin) (Beck et al., 2000), even for group D eyes
(Munier et al., 2017b). Finally, in another study evaluating the efficacy
of 3 versus 6 cycles of carboplatin, etoposide, vincristine for group B
eyes with dose escalation and additional cycles in the short course
chemoreduction group if needed, no difference in the globe salvage rate
was found between the two groups at 5-year follow-up, sparing 63% of
the patients treated with the short course approach the extra 3 cycles of
systemic chemotherapy (Zhu et al., 2015).
7.2.1.2. Indications
7.2.1.2.1. Current indications. In the era of intra-arterial
chemotherapy, systemic chemotherapy remains the treatment of
choice for all tumors not accessible to focal treatments in children
younger than 3 months of age and/or weighing less than 5 kg, until
there is sufficient vascular maturation to proceed safely with the
catheterization of the ophthalmic artery (so-called bridge therapy)
(Gobin et al., 2012). Systemic chemotherapy can also be used in the
rare cases of technical failure to catheterize the ophthalmic artery, or as
salvage treatment with a 2 or 3-drug regimen for recurrent disease
resistant to intra-arterial chemotherapy.
Advanced bilateral cases are treated with systemic chemotherapy in
some centers, while others perform tandem intra-arterial chemotherapy
(Abramson et al., 2015b). The indications for asymmetric bilateral cases
with one eye accessible to focal treatment and unilateral cases, in-
cluding advanced group IIRC D and selected E eyes, have been now
replaced by intra-arterial, combined or not with intravitreal che-
motherapy (Abramson et al., 2015b).
7.2.1.2.2. Potential future indications. One case of choroidal relapse
that regressed totally to a flat scar already three weeks after the first
cycle of high-dose chemotherapy given for concomitant trilateral
Fig. 21. Five-year Kaplan-Meier survival curves for retinoblastoma IIRC group A-C eyes initially treated in Lausanne before and after 2008.
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disease has been recently reported (Stathopoulos et al., 2018b). The
long-term efficacy of systemic chemotherapy in such a situation
remains however unknown, as the child died of intravascular
disseminated coagulation-like disease after the 5th systemic
chemotherapy in her country of origin.
Unlike chemoreduction, intra-arterial chemotherapy appears to be
associated with a significant risk of rhegmatogenous detachment af-
fecting specifically endophytic eyes in 1/4 (Shields et al., 2017) to 1/3
of the cases (FLM unpublished data) (see 7.3.3.1). This complication
may be explained by the faster tumor shrinkage observed with intra-
arterial chemotherapy, inducing sudden shearing forces and con-
secutive dehiscence at the retino-tumoral junction. A single course of
chemoreduction given prior further intra-arterial chemotherapy may be
beneficial to reduce the incidence of rhegmatogenous retinal detach-
ment in advanced endophytic retinoblastoma.
7.2.2. Treatment outcomes
7.2.2.1. Relapse rate and role of consolidation by focal treatments. Since
its introduction in the conservative treatment of retinoblastoma,
systemic chemotherapy was commonly used in combination with
focal treatment by most groups (see Table 9). The role of
consolidation was specifically pointed out in a study which
demonstrated that chemotherapy alone (without consolidation) failed
complete inactivation of the disease in 92% of treated eyes, even after
completion of 6 cycles (Wilson et al., 2001). When retinal tumors were
treated by combined chemoreduction and focal therapy, disease control
was shown to improve substantially (p=0.05), with a 2.5 reduction of
the relapse risk (Shields et al., 2004b). In addition, focal treatment
given following chemoreduction as prophylactic consolidation (Wilson
et al., 2005) rather than deferred until documented disease progression
(Rodriguez-Galindo et al., 2003) was credited to decrease the need for
external beam radiotherapy for salvage after chemoreduction from 44
to 25–30% (Wilson et al., 2005).
7.2.2.2. Eye preservation without external beam radiotherapy. Despite the
concomitant use of diverse grouping classifications, and the variety of
protocols in terms of chemotherapy regimen and number of cycles
making comparison between studies difficult, major studies with at
least 2-year mean follow-up claim an overall tumor control of 70–100%
for RE I to III or IIRC group A to C and 23–64% for RE IV/V or IIRC
group D/E (Table 9). Despite an unsatisfactory outcome in advanced
eyes, intravenous chemotherapy contributed, however, overall to a
significant decrease in the use of irradiation and consequently the
incidence of secondary radiation-induced tumors (see 3.8).
7.2.3. Chemotherapy-related toxicity
Chemotherapy-related toxicity is one of the major concerns in the
treatment of pediatric cancers. Even if common and relatively easily
managed in centers of high-income countries, chemotherapy-related
adverse effects may sometimes result in fatal toxicities in less developed
countries (Luna-Fineman et al., 2019).
7.2.3.1. Expected toxicities. Systemic chemoreduction with standard
carboplatin-etoposide ± vincristine regimens usually causes mild
acute toxicity, mostly involving alopecia, nausea/vomiting, and
moderate myelotoxicity, occasionally requiring hospitalization for
fever, neutropenia or blood product transfusions. The use of more
intense regimens is predictably associated with higher myelotoxicity.
Febrile neutropenia requiring hospitalization has been variably
reported in 12.7–38% of the patients, depending on the specific
chemotherapeutic regimen (Bartuma et al., 2014; Berry et al., 2013;
Chung et al., 2008; Kunkele et al., 2013). The need for transfusion of
blood products is also inconsistently reported, ranging from 0% (Berry
et al., 2015) to 78% (Brennan et al., 2017) of the patients depending on
the intensity of treatment. Support with Granulocyte-colony stimulating
factor was used by some groups for 100% of the patients (Brennan
et al., 2017), whereas others completely avoided its use (Chantada
et al., 2014).
7.2.3.2. Long-term toxicities. As previously discussed (see 3.8.3.2.2),
intravenous etoposide may induce secondary leukemias, even in
patients who received what are considered safe cumulative dosages
(Chantada et al., 2014; Gombos et al., 2007). Permanent ototoxicity is
an important late effect of carboplatin-based chemoreduction regimens
reported in up to 5–25% of the cases, especially if given at a younger
age and with prolonged exposure (Jehanne et al., 2009; Qaddoumi
et al., 2012; Soliman et al., 2018).
7.2.4. Intra-arterial chemotherapy
The success of intra-arterial chemotherapy lies in the selective de-
livery of high dose drug(s) to the eye with minimal systemic absorption.
The modern technique of drug injection directly into the ophthalmic
artery through a trans-femoral microcatheter placed just beyond its
ostium, also called super-selective intra-arterial chemotherapy or oph-
thalmic artery chemosurgery, was introduced in 2008 by Abramson
et al. (2008), inspired by previous work by Kaneko et al. (Kaneko and
Takayama, 1990) and Yamane et al. (2004).
In the hands of well-trained interventional neuro-radiologists, the
procedure is safe and reaches a technical success rate of around 96–99%
(Francis et al., 2018a; Munier et al., 2011; Suzuki et al., 2011),
Fig. 22. Five-year Kaplan-Meier survival curve for retinoblastoma IIRC group D eyes initially treated in Lausanne before and after 2008.
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provided that it is performed in children with sufficient vascular ma-
turation (children older than 3 months and with a body weight of over
5 kg) (Gobin et al., 2012). Anatomic variants such as departure of the
ophthalmic artery from the meningeal artery, or unfavorable angle with
the internal carotid artery compromising direct access to the oph-
thalmic artery for the delivery of the chemotherapy (around 16% of the
procedures) (Abramson et al., 2012a), can usually be overcome with
the use of alternative non-ophthalmic routes and/or of a temporary
balloon-occlusion of the internal carotid (Klufas et al., 2012). When
assessing treatment response one should be aware that anastomoses
between the external and internal carotid or stenosis of its ostium, as a
consequence of a vasospasm or micro-dissection from a previous pro-
cedure, may alter the local hemodynamic flow of the ophthalmic artery,
and lead to insufficient drug perfusions (Francis et al., 2018a).
7.2.4.1. Drug regimen and number of cycles. There is no consensus to
date either on the minimal drug dose required, or on any advantage to
start the treatment with a single versus a combination of drugs. The
drug most commonly used is melphalan. Topotecan and/or carboplatin
can be used in combination with melphalan (2 or 3-drug regimen) to
capitalize on their synergistic effects. One to 3 cycles of melphalan are
generally given on a 3–4-week basis in intra-arterial chemotherapy-
naïve eyes, and a combination of drugs (usually melphalan and
topotecan) for tumor relapse or poor response following previous
treatment with melphalan only.
Carboplatin is usually given to minimize systemic side-effects in the
less advanced eye when combined (or so-called tandem) intra-arterial
chemotherapy is performed. When doing so, the more advanced eye is
usually treated with melphalan (with or without topotecan). Drugs
between the eyes are then switched during the second or third session
(Abramson et al., 2010, 2016b).
7.2.4.2. Indications
7.2.4.2.1. Current indications. Initially used as salvage treatment for
eyes that did not resolve with systemic chemotherapy and/or
radiotherapy, indications for intra-arterial chemotherapy extended to
first line treatment for naïve unilateral eyes (group B with macula and/
or papilla involvement, and group C and D). Other indications include
the more affected eye in bilateral cases with asymmetric presentation,
provided that the fellow eye is accessible to focal therapy. Simultaneous
tandem therapy is performed by some groups for bilateral cases with
any combination of group B with macula/papilla involvement, C, D or
selected E eyes, namely those characterized by tumor touching the lens
with or without total retinal detachment (Abramson et al., 2015b;
Rowlands et al., 2018) (Table 10), whereas some centers prefer to start
with chemoreduction, followed by intra-arterial chemotherapy if
needed for salvage treatment (Abramson et al., 2015b).
Group E eyes with neovascular glaucoma, buphthalmos, orbital
cellulitis, anterior chamber invasion or phthisis undergo enucleation. In
cases where enucleation cannot be performed safely, neoadjuvant sys-
temic chemotherapy can be advised prior to surgery, especially in eyes
with buphthalmos and/or radiological evidence of optic nerve invasion
(Bellaton et al., 2003).
7.2.4.2.2. Potential future indications. Intra-arterial chemotherapy
with combined melphalan and topotecan was reported to successfully
treat one case of a choroidal relapse that showed complete regression
on UBM three weeks after the first injection. The child received two
more intra-arterial injections and has since then remained metastasis-
and recurrence-free at an updated follow-up of more than 4 years
(Stathopoulos et al., 2018b). In another recent report, two courses of
intra-arterial melphalan enabled to control iris invasion in a
monophthalmic patient, but not a concomitant intra-ciliary
involvement responding only to brachytherapy with an updated
disease-free follow-up of more than 20 months (Munier et al., 2018).
The differential efficacy of intra-arterial chemotherapy on iris and
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of the latter consisting of 2 long posterior ciliary arteries vs 7 anterior
and 20 short posterior ciliary arteries vascularizing iris and choroid
respectively.
7.2.4.3. Treatment outcomes. Treatment outcomes of the major studies
obtained with first-line and salvage intra-arterial chemotherapy are
summarized in Table 11.
7.2.4.3.1. Recurrence rate and salvage therapy. Intra-arterial
chemotherapy appears to be associated with an increased risk of
recurrence if administered more than 4 weeks apart (p < 0.05) and
if more than 50% of the injections are delivered via a non-ophthalmic
route of delivery (p < 0.001) (Francis et al., 2018a). The role of focal
consolidation remains to be determined. Recurrences after first line or
salvage intra-arterial chemotherapy have been observed within the first
year following treatment completion in 24–25% of the cases receiving
also focal consolidation (Francis et al., 2018a; Munier et al., 2017b),
and in 29% of those without consolidation (Tuncer et al., 2016).
Relapse after intra-arterial chemotherapy can be successfully man-
aged with focal treatments, including intravitreal chemotherapy in
more than half of the cases (Francis et al., 2018a; Munier et al., 2017b).
A second course of intra-arterial chemotherapy can, however also be
given if needed, after first-line or salvage intra-arterial chemotherapy,
with a reported globe salvage rate of about 76% (Francis et al., 2015a;
Shields et al., 2015).
7.2.4.3.2. Eye preservation without external beam
radiotherapy. Comparison of the studies on globe salvage rate with
intra-arterial chemotherapy is not only challenged by the lack of
randomized clinical trials and the use of different versions of the
retinoblastoma classification (see 3.3.1), but also by the availability of
intravitreal chemotherapy at the time of the treatment. A survey of the
literature during the four years where only intra-arterial was available,
i.e. before the 2012 publication of the safety enhanced technique for
intravitreal chemotherapy, reveals that intra-arterial chemotherapy as
first line treatment achieved globe salvage without the need of external
beam irradiation in 96% group B and C eyes at a median follow-up of 16
months (Abramson et al., 2012a), 81% at 2 years of group D (Reese-
Ellsworth V) (Gobin et al., 2011), but only 64% at 2 years for those with
vitreous seeding (including group C, D and E) (Abramson et al., 2012c).
After 2012, first line intra-arterial chemotherapy associated with
intravitreal chemotherapy as necessary, achieved globe salvage without
the need of external beam irradiation in 100% ICRB/IIRC group B and C
at a mean follow-up of 19 months (Shields et al., 2014), a 5 year-ocular
survival of 85–100% COG/IIRC group D (Abramson et al., 2017a;
Munier et al., 2017b), and 36% in ICRB group E at a mean follow-up of
19 months (Shields et al., 2014).
7.2.4.4. Adverse effects. Intra-arterial chemotherapy is safe, with no
reported fatal complications and fewer systemic adverse effects
compared to intravenous chemotherapy and external beam
irradiation. Only one case of delayed neurological complication that
spontaneously resolved has been described to date (De la Huerta et al.,
2016). An intra-operative autonomous reflex characterized by hypoxia,
reduced lung compliance, systemic hypotension and bradycardia, that
can be easily managed by an experienced anesthesiologist, develops in
Fig. 23. Changes in tumor thickness following
systemic chemotherapy. Box and whisker plot
shows the percentage change in tumor thickness
following each systemic chemotherapy course (1, 2,
3, 4 and 5). The median change is given by the thick
horizontal line that bisects each box. The waist of the
box represents the interquartile range and the ends
of the whiskers the 5 and 95 centiles. The number of
eyes that underwent each course of chemotherapy is
given in the corresponding upper part of the graphic.
The repeatability limit of the ultrasound used
(10MHz detector) is approximately 0.3mm. In this
cohort, 90% of the tumors were greater than>3
mm, and the repeatability limit corresponds to less
than 10% of tumor thickness, as shown by the hor-
izontal dotted line.
Table 10
First-line retinoblastoma management in bilateral cases depending on the IIRC Classification.
Disease in first eye Treatment Disease in second eye Treatment
Group A and B macula/papilla spared Laser photocoagulation
Cryocoagulation
Plaque
Group A and B macula/papilla spared Laser photocoagulation
Cryocoagulation
Plaque
Group A and B macula/papilla spared Laser photocoagulation
Cryocoagulation
Plaque
Group B macula/papilla involved
Group C, D and selected E
IAC ± IViC
Groups B macula/papilla involved
Group C, D and selected E
IAC ± IViC or IVC Group B macula/papilla involved
Group C, D and selected E
IAC ± IViC or IVC
Legends: IIRC=International Classification System, Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North
Am. 2005; 18(1):41–54, viii; IAC= intra-arterial chemotherapy; IViC= intravitreal chemotherapy; IVC= intravenous chemotherapy.
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about 24% of the internal carotid catheterization procedures (Phillips
et al., 2013). In the post-operative period, some degree of neutropenia
(grade 1 or 2) is the most frequently reported systemic side effect after
intra-arterial melphalan (about 12% of the cases), but usually remains
subclinical if the melphalan dose does not exceed 0.4–0.5mg/kg
(Dunkel et al., 2014). In the context of tandem injections, however,
the occurrence of clinically significant fever/neutropenia was described
in 1% (2/209) of the procedures and transfusion of blood product was
limited to 4 transfusions in three patients (1.9% of the events)
(Abramson et al., 2016b). Evaluation of the immune function in
retinoblastoma patients treated with intra-arterial chemotherapy
failed to detect the presence of a clinically significant immune
suppression, justifying pneumocystis pneumonia prophylaxis (Fischer
et al., 2017).
Locally, adverse effects consist of redness (29%), transient eyelid
edema (5%), loss of eyelashes (5%), blepharoptosis (5%), forehead
hyperemia (2%), and rarely third or sixth nerve palsy, each of them
resolving within 2–3 months (Wyse et al., 2016). Intraocular vascular
complications, such as ophthalmic artery obstruction (2%), vitreous
hemorrhage (2%), choroidal occlusive vasculopathy (7%), are of
greater concern (see 7.3.5.2), especially in eyes with visual potential, as
they can irreversibly compromise vision (Dalvin et al., 2018; Shields
et al., 2014).
7.2.5. Intravitreal chemotherapy
The concept of intravitreal chemotherapy was confined for decades
to isolated heroic attempts with thiotepa in desperate cases (Ericson
and Rosengren, 1961; Seregard et al., 1995), due to the risk of extra-
ocular tumor spread. In 1994, Akihiro Kaneko started using this route of
drug delivery, injecting 8 μg of melphalan combined with whole-eye
hyperthermia for vitreous disease and reported a 51.3% eye survival
rate at more than 50 months follow-up (Kaneko and Suzuki, 2003),
comparable to the results achieved with external beam radiotherapy
(Abramson and Schefler, 2004b) and chemoreduction (47%) (Shields
et al., 2002). After the introduction of intra-arterial chemotherapy in
2008, the probability of globe preservation in eyes with vitreous
seeding increased to 64% in treatment-naïve eyes at 2 years follow-up,
but enucleation was still necessary in about 30% of the eyes due to
uncontrollable vitreous disease (Abramson et al., 2012c). Similarly, in
2011, Shields et al. published a 67% control of the vitreous disease at
approximately one year follow-up (Shields et al., 2011).
In 2012, the development of a safety-enhanced technique for in-
travitreal injection through a tumor-free pars plana site using anti-re-
flux measures and needle tract sterilization (Munier et al., 2012b) en-
abled vitreous disease to be specifically addressed and became rapidly
adopted worldwide, leading not only to the reduction of the enucleation
rate, but also definitively eradicating the need for external beam irra-
diation. Since then, long-term studies have confirmed safety and effi-
cacy for both primary and recurrent vitreous seeding, approaching
100% of vitreous disease control (see 7.2.5.3). On the other hand,
clinical observations and a better knowledge of the cellular composition
of the seeding allowed us to re-evaluate the treatment response and
redefine the treatment intensity according to the seed classification.
Finally, increased efforts have been made to understand and minimize
intravitreal melphalan-related toxicity (see 7.3.5.1.2).
7.2.5.1. Drug regimen and number of injections. As for intra-arterial
chemotherapy, the most commonly used drug for intravitreal
injections is melphalan. Preclinical studies have established that
melphalan of at least 4 μg/ml is required to fully suppress
retinoblastoma cells in vitro (Inomata and Kaneko, 1987), and that at
a vitreous concentration of 5.9 μg/ml is functionally and structurally
non-toxic to the retina of albino rabbits (Ueda et al., 1995). To date,
there is no international consensus regarding the starting dose, but we
recommend 20–30 μg depending on eye size and tumor volume (see














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
44
whereas a higher dose (50 μg) was associated with phthisis bulbi
(Ghassemi and Shields, 2012).
The second most frequently injected drug is topotecan, usually
combined with melphalan in case of failure of tumor control, poten-
tially due to melphalan resistance, or recurrences. Noteworthy, in the
10-year experience with intravitreal melphalan in Lausanne (more than
160 eyes and 750 injections), there was only a single case of true re-
sistance to melphalan requiring topotecan to control the recurrent
vitreous disease (personal observation). Compared to melphalan, to-
potecan has a longer intra-ocular half-life, with low ocular toxicity and
also the advantage of a lower cost (Schaiquevich et al., 2017).
Intravitreal chemotherapy is carried out every 7–10 days. At each
visit, the residual vitreous tumor burden is reassessed and usually an
additional injection for consolidation is given once complete regression
is observed. Complete response is established if the seeds either com-
pletely disappear (vitreous seeding regression type 0) or convert into
refringent and/or calcified residues (vitreous seeding regression type I),
amorphous often non-spherical inactive residues (vitreous seeding re-
gression type II), or a combination of the latter two (vitreous seeding
regression type III) (Munier, 2014). Another useful criterion of com-
plete response is the presence of hyper-reflective dots within class 2
seeds as shown by OCT (see 3.2.3) (Munier, 2014). The timing to
complete regression is a matter of weeks, months and up to one year for
class 1, 2 and 3 seeds respectively (Table 12). Since the initial re-
commendations (Francis et al., 2015a), the number of injections ne-
cessary to achieve tumor control for the various classes of vitreous seeds
can be reduced, namely two for class 1, three for class 2, and four for
class 3.
7.2.5.2. Safety. Since the adoption of the safety-enhanced technique of
injection in 2012, there has been no report, to our knowledge, of any
tumor exteriorization as documented by a meta-analysis of the
published literature (Smith and Smith, 2013) or by retrospective
analysis of more than 3500 injections performed in 10 North and
South American, European, Israeli, and Chinese centers (Francis et al.,
2017a). More recently, the safety of intravitreal chemotherapy was
further confirmed when assessing the expression of the cone-rod
homeobox gene (CRX) by real-time quantitative polymerase chain
reaction as a surrogate of retinoblastoma RNA, failed to detect any
CRX-positive cycle from the entry site or from the cryoprobe tip (Winter
et al., 2018).
7.2.5.3. Treatment outcomes. Intravitreal melphalan is efficient with a
reported vitreous seeding control in 69–100% of the cases (Table 13).
Two single-institution studies have compared the outcomes in the eras
before and after the introduction of intravitreal chemotherapy. In the
first, complete abandon of external beam radiotherapy was effective
only after the introduction of intravitreal chemotherapy (Francis et al.,
2018a), while the second documented a significant improvement of
ocular survival from 77 to 87%, and from 25 to 73% in ICRB group D
and E eyes respectively (p < 0.04) (Shields et al., 2016a), as well as a
threefold decrease in the enucleation rate during the pre-intravitreal
(44%) vs intravitreal (15%) era (p= 0.012). In a study comparing the
outcome of eyes with class 3 seeding (cloud) treated with intra-arterial
and intravitreal chemotherapy versus intra-arterial alone, the authors
demonstrated a significantly shorter time to regression (5.7 months vs
14.6 months, p < 0.001) as well as significantly fewer recurrences and
fewer enucleations with the concomitant use of intravitreal
chemotherapy (Francis et al., 2017c). The same group also reported
on their 4-year experience with intravitreal chemotherapy in 130 eyes
with a 2-year Kaplan-Meier estimate for ocular survival of 94.2% (CI
89.2–99.4%), and an estimate for disease-free survival of 86.2%
(Francis et al., 2017b). According to the literature, there also seems
to be no significant difference between eyes with persistent versus
recurrent vitreous seeding regarding time to regression, number of
injections needed, or cumulative dose of melphalan (Berry et al., 2017a;
Ji et al., 2016; Kaneko and Suzuki, 2003; Munier et al., 2012a).
Until now, additional topotecan was usually considered in the case
of resistant vitreous seeding and injected with concomitant melphalan
(Francis et al., 2017b; Ghassemi et al., 2014; Shields et al., 2016b). In a
recent paper, control of vitreous disease was achieved with intravitreal
topotecan alone in 100% of the case (n= 17) at a median follow-up of
24 months with no clinical ocular toxicity (Rao et al., 2018b).
Finally, although intravitreal chemotherapy is not primarily di-
rected against retinal or subretinal tumors, partial or complete regres-
sion of subretinal seeds after intravitreal melphalan has been docu-
mented in isolated cases (Francis et al., 2015c; Munier, 2014; Shields
et al., 2016b). The efficacy of intravitreal chemotherapy for indications
other than active vitreous disease remains, however, to be established
(Abramson et al., 2018, 2019).
7.2.5.4. Adverse effects. Intravitreal injections of melphalan have
proved to have fewer adverse effects and no systemic toxicity
compared to intra-arterial chemotherapy (Francis et al., 2014). The
most common side effect after standard doses of intravitreal melphalan
is localized salt-and-pepper retinopathy at the site of injection, reported
in 0.8–43% of the cases (Smith et al., 2014), which significantly
correlates with reduction in ERG amplitudes with an estimated 5.3 μV
decrease for every intravitreal melphalan injection of 25–30 μg (Francis
et al., 2017b) (see 7.3.6.1). Other rare side effects include sub-
conjunctival hemorrhage, mild vitreous hemorrhage, cataract,
transient hypotony and retinal detachment (Smith et al., 2014). Iris
depigmentation, iris recession with retinal necrosis and focal
scleromalacia with localized pigmentation have been reported in
isolated cases (Francis et al., 2015c).
7.2.6. Intracameral chemotherapy
Aqueous seeding (see 6.2.4.1) with or without concomitant anterior
uveal involvement was until recently considered an intractable form of
retinoblastoma. The prognostic value of aqueous seeding and/or ante-
rior uveal invasion such as iris or corpus ciliaris is controversial, but is
no longer considered to be high risk for metastasis and, consequently,
does not represent an automatic indication for adjuvant chemotherapy
(Baroni et al., 2014; Sreelakshmi et al., 2017; Suryawanshi et al., 2011).
Along the same lines as for intravitreal injections, a safety-enhanced
technique was developed for intracameral injections and used for the
first time in 2011 to successfully treat aqueous seeding in a patient with
diffuse anterior retinoblastoma (Munier et al., 2015, 2017a). Unlike
vitreous volume, the exact value of aqueous volume according to age is
not known, which precludes the precise determination of the aqueous
drug concentration following the injection of a given dose. In order to
obtain in all injected eyes the same final aqueous concentration of
melphalan irrespective to age, athalamia is first created by a para-
centesis emptying both anterior and posterior chambers, followed by
the reconstitution of the cameral volume by injecting a solution at the
desired final melphalan concentration (15–20 μg/ml) (Munier et al.,
2017a).
Alternatively, it is also possible to inject very small volumes of
highly concentrated drug without prior anterior chamber tap, i.e.
0.015ml at 500 μg/ml (7.5 μg) of topotecan (Paez-Escamilla et al.,
2017), or 0.05ml at 30 μg/ml (15 μg) of melphalan (Cassoux et al.,
2017). This technique, however, is suboptimal regarding the drug
concentration achieved in the aqueous humor, with a risk of under-
exposure at the level of the posterior chamber.
7.2.6.1. Treatment outcomes. Following the first case report on
intracameral chemotherapy (Munier et al., 2017a), a series of 11 eyes
with secondary aqueous seeding treated with this new technique was
published (Munier et al., 2018). In this study, intracameral melphalan
injection contributed to a globe preservation of 55% of the treated eyes
at a mean updated event-free follow-up of 29 months (range 16–48),
including 5 only eyes. Despite initial complete regression of the
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aqueous seeds, as assessed by cytopathology and cell culture (Munier
et al., 2018), five cases were nevertheless enucleated. Overall, the eye
retention rate appeared to be less favorable in eyes with iatrogenic
disrupted anterior hyaloid (25% or 1/4, salvaged), compared to eyes
with intact anterior hyaloid (71% or 5/7 salvaged). Since this
publication, three additional patients with anterior chamber seeding
benefited from intracameral chemotherapy in Lausanne, with a
recurrence-free follow-up of 3, 6, and 14 months respectively
(personal observation).
7.2.6.2. Treatment-related adverse effects. All 15 patients treated in the
Lausanne cohort are alive with no extraocular tumor spread or
metastasis at a mean follow-up of 18 months (range 3–84 months)
after a mean of 6.5 injections (range 3–14). Most frequently observed
ocular side effects were cataract in 6 eyes (40%), among which 5 eyes
had received concomitant brachytherapy for a retinal or ciliary body
relapses, and hypochromic heterochromia in 3 (20%). Noteworthy, no
potential cytotoxic effect was detected in the three patients old enough
to undergo endothelial cell count (personal observation). The technique
of intracameral injection having been only recently developed further
studies with more cases and longer follow-up will be needed to
conclude on long-term adverse effects.
7.2.6.3. Potential alternatives to intracameral chemotherapy for aqueous
seeding. Aqueous seeding control was also reported in isolated or
limited case series by means of intravenous chemotherapy combined
with intravitreal and periocular topotecan (Rao et al., 2018a) or
brachytherapy (Shields et al., 2016c). In the case from India, it is not
possible to determine how tumoricidal concentration was achieved to
control aqueous disease and which of the 3 routes of delivery and 4
injected drugs or combinations of drugs contributed to the result (see
Fig. 20). In the series from Philadelphia, 3 eyes with anterior diffuse
retinoblastoma devoid of any retinal or vitreous involvement, achieved
complete remission at a mean follow-up of 35 months by means of
iodine plaque therapy delivered to the entire anterior segment. All eyes
needed cataract surgery within a mean interval of 16 months. With such
an approach, other delayed, potentially sight-threatening complications
are to be feared, such as radio-induced damage to the trabeculum and/
or corneal limbal stem cells.
7.2.7. Periocular chemotherapy
Periocular chemotherapy with carboplatin or topotecan was in-
troduced in the 1990s, generally as an adjunct to systemic che-
motherapy or cryotherapy in order to increase the intraocular drug
concentration (see 7.1.5). The periocular delivery can be obtained using
subconjunctival (Abramson et al., 1999b) or sub-Tenonian (Francis
et al., 2015) injections with or without echographic localization
(Cebulla et al., 2009). Different drug vehicles have been tested, in-
cluding fibrin sealant (Mallipatna et al., 2011) or nanoparticles (Kalita
et al., 2014).
In a long-term study on periocular carboplatin (20mg in 2ml) (Marr
et al., 2012), only 2/13 eyes (15%) showed long-term complete re-
sponse to periocular carboplatin alone, indicating inefficiency if used as
monotherapy. Reported adverse local effects could also be quite severe,
including ocular motility restriction (Mulvihill et al., 2003), orbital fat
atrophy and fibrosis (Kim et al., 2010b) as well as optic nerve atrophy
and subsequent blindness (Schmack et al., 2006), relegating periocular
carboplatin to a marginal role, if any, in the conservative management
of retinoblastoma.
A phase I study on periocular topotecan showed that 2mg of the
drug diluted in 2ml normal saline could be administered without sig-
nificant toxicity (Chantada et al., 2009). A retrospective study on
periocular topotecan at a median dose of 0.18mg/kg (range
0.5–2.8 mg) in 10 eyes, reported efficacy restricted to tumor reduction
for group A and B eyes, which still required, however, complementary
focal treatments to be controlled. Periocular topotecan combined with
systemic chemotherapy was also found to be significantly inferior to
intra-arterial melphalan for salvage treatment of relapsed retino-
blastoma (Schaiquevich et al., 2013).
Since the availability of intra-arterial and intravitreal che-
motherapy, indications for periocular chemotherapy are limited to
consolidation therapy of recurrent resistant tumors at the posterior pole
in combination with other focal therapies. The recent description of
long-acting episcleral chemotherapy implant (chemo-plaque) could
revive the periocular route of drug delivery in advanced retinoblastoma
(Carcaboso et al., 2010; Pontes de Carvalho et al., 2006). Two pro-
spective studies are currently open in the United States using a device
for sustained controlled-release of topotecan for primary unilateral
group D and for eyes that have failed standard available therapy
(http://grantome.com/grant/NIH/RC3-CA150730-01).
7.2.8. Focal treatments modalities
Focal treatments, including cryotherapy, hyperthermia, photo-
coagulation and brachytherapy, are aimed at destroying small in-
traocular tumors confined to the retina without the need of treating the
whole eye. Because of their efficacy with few adverse effects, they re-
present important modalities in the therapeutic arsenal against retino-
blastoma. Current indications of focal therapies include first line use in
group A, macula/or papilla-sparing group B tumors, second line or
consolidation after chemoreduction/chemothermotherapy, and salvage
treatment of accessible recurrent retinal tumors. There is presently no
consensus regarding the need of consolidation focal treatments fol-
lowing intra-arterial chemotherapy and their potential role in pre-
venting recurrence as observed post chemoreduction (Table 11). Fi-
nally, although successful treatment of localized intravitreal seeding
has been occasionally reported with brachytherapy (Abouzeid et al.,
2008; Francis et al., 2013b) or cryotherapy (Abramson and Schefler,
2004a), these treatment modalities are not, however, primarily aimed
at the control of vitreous disease.
All focal treatments have in common to be performed under general
anesthesia. The choice of the treatment modality depends mainly on the
tumor size and location. The number of sessions is adapted to the tumor
response to treatment, with regression to a flat scar or totally calcified
tumor being the ideal endpoint of treatment. If needed, they can be
repeated (usually every 2–4 weeks) or used in combination. Presence of
fish-flesh tissue is associated with a higher recurrence rate compared to
calcified tissue, but corresponds to a complete response if stable over
the follow-up (Ghassemi et al., 2013; Schueler et al., 2006).
7.2.8.1. Cryotherapy. Cryotherapy destroys small tumors (usually up to
2mm high and less than 3mm diameter) by freezing them at −80 °C,
resulting in intracellular ice formation and plasmic membrane rupture
of tumor and endothelial cells, visualized by the presence of petechias
at the time of recirculation. The treatment is performed with a
cryoprobe directly applied to the outer surface adjacent to the tumor
with a triple freeze-thaw technique allowing the iceball to completely
cover the tumor. Cryotherapy is ideally used to treat pre-equatorial
tumors, but lesions located more posteriorly may be reached by placing
the cryoprobe in the sub-Tenon space after opening the conjunctival
cul-de-sac. The treatment leaves a chorioretinal scar and has been
reported to eradicate up to 90% of the treated lesions (Abramson and
Schefler, 2004b). The most frequently observed complication is
transient conjunctival chemosis, whereas retinal tears and
detachments, vitreous hemorrhage and transient subretinal fluid have
been infrequently reported (Anagnoste et al., 2000; Hamel et al., 2000;
Shields et al., 1993b).
7.2.8.2. Hyperthermia. Hyperthemia induces a cytotoxic effect on the
tumors by heating them up to sub-coagulation temperatures of
45 °C–60 °C. It is applied using an 810-nm infrared diode laser
applied transpupillary on a continuous mode, either by indirect
ophthalmoscopy and a 20 Diopter magnifying lens or with an adaptor
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coupled to an operating microscope through a three-mirror lens
contact. Compared to the indirect ophthalmoscopy where the spot
size is variable, the microscope adaptor allows to set the spot size
between 0.3 and 2.0mm as well as to achieve uniform delivery of the
laser on the lesion. In the absence of temperature monitoring during
treatment, the laser power setting is entirely empirical and varies from
100 to 1200mW adapted to the tumor size, location and underlying
level of pigmentation. The duration of treatment depends on the
observed clinical response (good signs being whitening of the treated
lesion and micro-hemorrhage on its surface) and usually varies from 5
to 30min. Small naïve tumors usually respond quickly, whereas white
avascular or calcified tumors show no changes due to limited energy
transfer. The problems regarding the setting of energy and duration
could be overcome in the future by the implementation of real-time
temperature determination using opto-acoustic technology (Brinkmann
et al., 2012). Ideal for posterior pole tumors, hyperthermia can also be
used for peripheral tumors after appropriate indentation of the lesion.
Hyperthermia resolves over 90% of small tumors (≤1.5mm in base
diameter) without the need of any other treatment (Abramson and
Schefler, 2004a). Indocyanine green (Grobner et al.), which has an
absorption peak similar to the emission of the diode laser and thought
to promote a potentiated laser response in ICG retaining tissue, has
been reported to be successful for tumors refractory to thermotherapy
after intravenous or intra-arterial chemotherapy (so called ICG-en-
hanced thermotherapy) (Francis et al., 2013a). Hyperthermia can also
be delivered 1–2 h after intravenous carboplatin, so-called che-
mothermotherapy, to potentiate its cytotoxic effect by virtue of a sy-
nergetic effect between heat and drug at the time of its plasmatic peak
(Murphree et al., 1996; Lumbroso et al., 2002). With the advent of
intra-arterial chemotherapy, chemothermotherapy is less frequently
used.
Complications of transpupillary thermotherapy include iris atrophy
with or without concomitant focal lens opacities, tumor seeding by
rupture of the internal limiting membrane, retinal fibrosis, rhegmato-
genous retinal detachment and vascular occlusion (Gombos et al., 2006;
Shields et al., 1999; Tawansy et al., 2006).
7.2.8.3. Photocoagulation. Photocoagulation can be done with a green
(532-nm) laser, continuous wave Nd:YAG (1064-nm) or infra-red
(810 nm) transpupillary laser (Hamel et al., 2000) and enables tumor
destruction indirectly by occluding tumor vessels (532-nm) or directly
by generating heat with protein-denaturing temperature in excess of
65 °C (coagulation) within the treatment spot. Complications include
retinal fibrosis, traction, and vitreous seeding secondary to rupture of
the internal limiting membrane (Gombos et al., 2006).
Transscleral diode laser (810 nm) can be used to destroy small
peripheral tumors with a power setting varying between 1000 and
2000mW and duration of 1–2 s, applied until a whitening of the tumor
is observed by indirect ophthalmoscopy. The laser probe has a focus of
1–2mm of penetration into the eye and is thus only suitable to treat
small peripheral tumors up to one disc diameter, but with the ad-
vantage to induce a much smaller chorioretinal scar than cryotherapy.
7.2.8.4. Brachytherapy. Brachytherapy is used for solitary, medium-
sized tumors (up to 10mm in diameter and 6mm in height) and located
more than 3mm from the optic disc or fovea. Most commonly employed
isotopes are iodine 125 (I125) or ruthenium 106 (Ru106) and
calculations are made for a delivered dose of 40 Gy to the apex of the
tumor. Both types of plaque allow a similar tumor control rate of up to
95% of the treated cases at a 5-year follow-up (Schueler et al., 2006;
Shields et al., 2001). However, radiation-related complications,
including proliferative and non-proliferative retinopathy, radiation-
induced maculopathy/papillopathy, subcapsular cataract and
neovascular glaucoma are less frequent with the beta-emitting Ru106
because of its limited axial and lateral dosimetry compared to the
gamma-emitting I125 (Fluhs et al., 2004).
7.3. Disease and treatment-related complications
The conservative treatment of retinoblastoma can be complicated
by various conditions, such as cataract, rhegmatogenous/tractional
retinal detachment or secondary neovascularization which, left un-
treated, may compromise the active tumor-related management or the
vision/globe preservation of eyes considered in remission. In the era of
intra-arterial and intravitreal chemotherapy, such complications are
actually representing up to 50% of the indications to secondary en-
ucleation (Eagle et al., 2011; Pavlidou et al., 2015) compared to less
than 5% in the era of systemic chemotherapy (Balaguer et al., 2009;
Chantada et al., 2007), and this rate is expected to increase in the future
as more eyes with very advanced disease are now offered salvage
treatments.
This section deals with the most frequently encountered complica-
tions during conservative management of retinoblastoma. Whereas
some of them (amblyopia, cataract, retinal detachment and secondary
neovascularization) can be offered specific treatments, others, related
to drug toxicity and/or drug delivery procedure (chorioretinal com-
plications after intravitreal or intra-arterial chemotherapy) are irre-
versible, and efforts should be made to prevent them until less toxic
therapies become available.
Among the treatable conditions, early amblyopia management is
without doubt one of the most important active measures to achieve
vision preservation. As there is now sufficient evidence that useful vi-
sion can be obtained in the majority of affected eyes, including those
with macular involvement, each time visual potential is not given a
chance to be realized can be considered a partial treatment failure (see
7.3.1).
Other conditions, such as cataract (see 7.3.2) or retinal detachment
(see 7.3.3) may require invasive procedures, considered hazardous in
the context of retinoblastoma. However, the introduction of safety-en-
hanced interventions can overcome the fear of potential tumor spread
and should enable intraocular surgery to be considered in selected
cases. As a rule, the decision to proceed with surgery should be based
on the status of the contralateral eye, the estimated visual potential
expected to be achieved after the intervention and, of course, full
parental informed consent on the risk and benefits of the procedure.
7.3.1. Amblyopia
The raising concern in preservation of visual function while mana-
ging ocular salvage has become noticeable in the increasing number of
recent publications in which visual acuity is considered as one of the
success criteria of surviving eyes after treatment (Chan et al., 2009;
Demirci et al., 2005; Hall et al., 1999; Kim et al., 2010a; Manjandavida
et al., 2014; Narang et al., 2012; Schefler et al., 2007; Suzuki et al.,
2011; Tsimpida et al., 2013; Weiss et al., 1994). Few authors, however,
have addressed the importance of active visual reeducation in retino-
blastoma eyes (Greenwald and Strauss, 1996; Watts et al., 2002). At
Jules-Gonin Eye Hospital, a retrospective study was conducted to
compare the visual outcome in 3 groups of children with a minimum of
4 years of age at last visit, all having fovea-involving tumors. The first
group (n=32) included patients with bilateral disease having under-
gone enucleation of one eye, these considered to be undergoing per-
manent occlusion. The second group (n= 27) included only unilateral
retinoblastoma patients undergoing active patching of the unaffected
eye. The third group (n=13) included patients with unilateral re-
tinoblastoma that failed to comply with amblyopia treatment. The
median best corrected visual acuity was 0.7logMAR, 1.1logMAR and
1.7logMAR for groups 1, 2 and 3 respectively. There was a highly sig-
nificant difference of visual acuity between the monophthalmic group 1
and the treated group 2 (p=0.001), and also between group 2 and the
untreated group 3 (p=0.016), demonstrating the benefit of active vi-
sual reeducation in all cases with foveal involvement. In addition, the
significant statistical difference between groups 1 and 2 suggests that a
more aggressive amblyopia treatment regimen could even increase the
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visual gain (Fig. 24).
The visual deprivation resulting from disease or treatment-related
foveal damage or obscuration following hemorrhage, seeding or cat-
aract, can cause not only amblyopia but also strabismus and possibly
nystagmus, these in turn having a potential negative impact on quality
of life. In a report on the visual outcome in patients with macular in-
volvement treated by chemoreduction and focal therapy, strabismus,
mostly exotropia, was noted in 16% of the patients (Schefler et al.,
2007). More recently, in a study on the long-term functional results in
patients with group D eyes, 22% had nystagmus, and 60% of bilaterally
salvaged patients had strabismus with exotropia being the most
common type (Fabian et al., 2017a). By univariate analysis, strabismus
and foveal tumor at presentation were found to be significantly asso-
ciated with strabismus at final follow-up (p=0.043), while only foveal
involvement was found to be significant (p < 0.001) on multivariate
analysis (Fabian et al., 2018). It should be stressed that conservation of
a misaligned eye can cause as much embarrassment as an artificial eye,
especially in teenagers. Strabismus surgery can be envisaged once
growth is completed. Similarly, an abnormal head posture due to nys-
tagmus can also benefit from muscle translocation in order to redress
the neutralized zone as close as possible to the primary position. Both
procedures have been successfully performed in Lausanne (unpublished
data).
7.3.2. Cataract
7.3.2.1. Incidence. During the irradiation era, cataract was a frequent
treatment-induced complication, developing usually within two years
following the treatment in up to 87% of the eyes treated with external
beam irradiation (Blach et al., 1996; Fontanesi et al., 1996) and up to
37% of those treated with lens sparing technique or stereotactic
conformal radiotherapy (Pica et al., 2011; Sahgal et al., 2006; Scott
et al., 1999). Since retinoblastoma is now managed without external
irradiation, cataract has become a less frequently encountered problem,
but can still complicate brachytherapy (Abouzeid et al., 2008;
Murakami et al., 2012; Schueler et al., 2006; Shields et al., 2006b),
transpupillary thermotherapy (Shields et al., 1996), intravitreal
(Francis et al., 2014; Ji et al., 2016; Munier et al., 2012a; Shields
et al., 2016b) and/or intracameral chemotherapy (Munier et al., 2018).
Radiation exposure during intra-arterial chemotherapy (from 5.55 to
191mGy per eye) is below the reported doses for cataract formation
(500mGy) (Thampi et al., 2013).
7.3.2.2. Cataract surgery. The risk of tumor spread in eyes with active
retinoblastoma undergoing cataract surgery has since long been
recognized (Brooks et al., 1990; Honavar et al., 2001) and requires
specific security guidelines. A minimum of 6–12 months disease-free
interval before surgery is recommended (Brooks et al., 1990; Honavar
et al., 2001; Miller et al., 2005; Osman et al., 2011), whereas eyes
where fundus view is lost sooner are usually treated with enucleation
(Berry et al., 2018a; Brennan et al., 2015). Providing that specific
additional precautions are followed, however, such eyes, in selected
cases, can still be managed conservatively.
General recommendations include performing clear cornea small
incisions rather than pars plana or scleral tunnel to avoid any sub-
Tenonian or sub-conjunctival contamination. The incisions should be
secured with sutures at the end of the intervention and intraocular
fluids sent for cytopathologic analysis to exclude retinoblastoma cells.
Posterior capsulorhexis associated with anterior vitrectomy remains
subject of controversy, since it can cause iatrogenic aqueous con-
tamination (Munier et al., 2018). The dilemma of whether to leave the
posterior capsule intact or not is particularly crucial in children younger
than 5 years of age in whom it is difficult to perform YAG laser cap-
sulotomy, but who at the same time are more likely to present a shorter
time interval for treatment-free follow-up and relapses.
Specific recommendations prior surgery for eyes with a disease-free
interval of less than 6 months should include an MRI to exclude ex-
traocular disease extension, as well as two intravitreal chemotherapy
injections one week apart in order to optimize safety prior the surgery.
Cytology-negative results of the paracentesis performed at the time of
the intravitreal injection should be confirmed before proceeding with
the cataract surgery. Finally, in case of suspicion of active disease,
posterior capsulotomy should only be done if the whole procedure is
performed under infusion of melphalan at the concentration of 5 μg/ml.
Following the above-mentioned recommendations, cataract surgery has
been performed in 24 retinoblastoma eyes at Jules-Gonin Eye Hospital
over the last 10 years, among which 9 had a disease-free follow-up of
less than 6 months. No metastasis nor deaths were observed at a mean
follow-up of 4.9 years (range 0.8–8.1 years) (unpublished data).
7.3.3. Rhegmatogenous retinal detachment
Retinal detachment, constitutive of exophytic growing tumor(s), is a
frequently observed feature of retinoblastoma at presentation. Such
detachments are purely exudative in nature and in the majority of cases
Fig. 24. Influence of amblyopia treatment in
fovea-involving retinoblastoma. Box and whisker
plot shows the distribution of final visual acuity in
three treatment groups. Group 1: only eye patients
(permanent occlusion) Group 2: unilateral disease
with active patching of unaffected eye. Group 3:
unilateral disease with no patching. The median vi-
sual acuity of each group is denoted with a thick
horizontal line that bisects the corresponding box-
plot. The interquartile range is shown by the waist of
the boxplot, when the waists of two boxplots do not
overlap, this represents a significant difference,
which is denoted with an asterisk (*p < 0.05,
***p < 0.001). The number of patient in each group
is given on the top of the graphic.
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complete resolution is achieved, regardless of the first line therapy
administered (Berry et al., 2016b; Rowlands et al., 2018; Shields et al.,
1997, 2012). Rhegmatogenous retinal detachments, however, can ap-
pear as a treatment-related complication and require appropriate
management to allow further tumor control and/or eye preservation.
7.3.3.1. Incidence. Little is known about the rate of rhegmatogenous
retinal detachment occurring during the conservative treatment of
retinoblastoma. It was found to complicate 6% (5/83) to 11% (5/45)
of the eyes treated conservatively during the external beam irradiation
era (Bovey et al., 1999; Lim and Robertson, 2000). All those eyes except
one treated with plaque brachytherapy only had received EBRT
(n=9), with additional treatment including focal treatment (n= 7)
and intravenous chemotherapy (n=3). In the only report detailing the
treatment of the eyes, those treated with external beam radiotherapy
alone (0/16, 0%) or focal treatments alone (0/21, 0%) did not develop
a retinal detachment (Bovey et al., 1999).
According to the single study focusing on vitreoretinal complica-
tions after systemic chemotherapy (Tawansy et al., 2006), the incidence
of rhegmatogenous and/or tractional retinal detachment was limited to
1.2% (n= 5/404) and the role of concomitant focal therapy in the
context of chemotherapy-related impaired wound healing pointed out
(Anagnoste et al., 2000; Tawansy et al., 2006).
More recently, in a series of 75 eyes (68 ICRB group D/E) treated
with first line intra-arterial chemotherapy without concomitant focal
treatments between 2008 and 2015 (Shields et al., 2017), 6 eyes (8%)
developed rhegmatogenous retinal detachment. Extensive endophytic
pattern was associated with a significantly higher risk for rhegmato-
genous retinal detachment (5/22, 23%) (p=0.0073), while only 4%
(1/24) of the eyes with mixed tumor growth and none of 29 eyes with
exophytic tumor growth developed a rhegmatogenous retinal detach-
ment. Similarly, in a series of 74 eyes (69 IIRC group D/E) receiving
first line intra-arterial chemotherapy without concomitant focal treat-
ments between 2008 and 2018 in Lausanne (unpublished data), 12
cases (16%) of rhegmatogenous retinal detachment were observed. The
incidence of the complication was also found to be significantly higher
in endophytic eyes (9/32, 28%) (p=0.015), compared to eyes with
mixed growth (3/24, 12%) or those with exophytic tumors (0/18, 0%).
In both series, most cases (80%) of retinal detachment occurred within
one month following the first intra-arterial chemotherapy, supporting
the hypothesis that the complication develops from atrophic (often
invisible) holes due to abrupt tearing forces caused by rapid necrotic
tumor regression. Although specific data are missing, the lower fre-
quency of rhegmatogenous retinal detachment observed after in-
travenous chemotherapy, suggests a more gradual tumor regression
compared to intra-arterial chemotherapy. If true, advanced endophytic
tumors may benefit of an initial course of systemic chemotherapy, as
done in bridge therapy, before intra-arterial chemotherapy to initiate a
less aggressive regression and prevent this complication (see 7.2.1.2.2).
Finally, rhegmatogenous retinal detachment, known to occur in
around 0.01% of intravitreal injections in adult eyes (mostly myopic)
(Meyer et al., 2011), was only reported following intravitreal che-
motherapy in one single case (Smith et al., 2014; Suzuki et al., 2015).
7.3.3.2. Surgical repair. The violation of the state of metastatic grace by
invasive surgical procedures, such as vitrectomy, in eyes previously
treated for retinoblastoma (Honavar et al., 2001) or with unsuspected
retinoblastoma (Kaliki et al., 2018; Shields et al., 2000; Spaulding and
Fuhs, 1968) remains a major concern. With this in mind, most authors
prefer minimally invasive methods for repair, including non-drainage
scleral buckling with retinopexy (Bovey et al., 1999; Mullaney et al.,
1997; Yousef et al., 2016) or with post-operative laser photocoagulation
of a visible retinal break (Buerk et al., 2006). To avoid high intraocular
pressure due to tightening of the band potentially resulting in central
retinal artery occlusion, different strategies have been proposed,
including intravenous mannitol infusion 1 h before surgery, post-
operative acetazolamide (Yousef et al., 2016), or per-operative
anterior chamber paracentesis (Mullaney et al., 1997). Some authors
recommend at least a 6- to 12-month disease-free interval before
considering scleral buckling with external drainage or vitrectomy
with cytopathologic evaluation of the intraocular fluids (Baumal
et al., 1998; Lim and Robertson, 2000; Madreperla et al., 2000;
Tawansy et al., 2006). In Lausanne, in the absence of signs of
spontaneous retinal reapplication, an early ab externo approach with
scleral buckling with no subretinal drainage is preferred, especially if
the detachment occurs in a child's eye with visual potential, as a
prolonged observation interval may compromise the functional
outcome. An intra-operative anterior chamber paracentesis is
performed systematically to allow sufficient tightening of the band. In
case of inadvertent scleral perforation, aspiration and cytopathologic
analysis of the fluid should be done and the operation field
prophylactically immerged with 2mg of topotecan (1mg/ml).
Following this strategy, complete retinal application was successfully
achieved in 92% of the 12 (n=11/12) above-mentioned eyes (see
7.3.3.1) and partially but with an applicated fovea in 1 eye at a mean
follow-up of 4.4 years (range 0.5–9.0). All patients are alive with no
metastases (unpublished data).
If an intraocular procedure is preferred, tumor reactivation should
be ruled out as the cause of the detachment. Pars plana vitrectomy (23
or 25G) with melphalan irrigation (5 μg/ml) with or without silicone oil
tamponade is possible (Yarovoy et al., 2015). In the case of retinal
detachment occurring concomitantly to proliferative vitreoretinopathy,
with or without retinal dehiscence, an intravitreal anti-VEGF injection
can be successfully given one week prior to vitrectomy under mel-
phalan infusion combined with retinotomy (Stathopoulos et al., 2018a).
7.3.4. Secondary neovascularization
Secondary neovascularization can develop during the conservative
management of retinoblastoma and affect both posterior and anterior
segments of the eye. Its occurrence has been associated with retinal
ischemia secondary to chronic retinal detachment (Stathopoulos et al.,
2018a; Tawansy et al., 2006), focal treatments (Ghassemi and Amoli,
2014; Kase et al., 2008; Schefler et al., 2007), external irradiation
(Archer et al., 1993; Hwang et al., 2017), plaque radiotherapy
(Abouzeid et al., 2008; Albert, 1987; Francis et al., 2013b; Murakami
et al., 2012), intra-arterial chemotherapy (Bianciotto et al., 2012;
Stathopoulos et al., 2018a) as well as active tumor progression
(Stathopoulos et al., 2018a) or recurrence (Kiratli et al., 2017;
Stathopoulos et al., 2018a).
The exact incidence of secondary neovascularization prior the era of
intra-arterial chemotherapy is unknown. In a retrospective study in-
cluding all eyes treated with primary or salvage intra-arterial che-
motherapy over a 10-year period in Lausanne, 20% (n=37/182) of the
eyes, among which 30% (n= 11/37) had active tumor, developed
secondary neovascularization, at a mean interval of 9.6 months since
the first injection and after a mean of 3 injections. In that study, the
incidence of secondary neovascularization was higher but not sig-
nificantly after salvage compared to first-line intra-arterial che-
motherapy (22%, 25/114 versus 18%, 12/68) (unpublished data),
which is similar to the rates of 20% (17/85) after primary and 16%
after salvage intra-arterial chemotherapy found by others over the same
period of time (Ancona-Lezama et al., 2018). If heavily pre-treated eyes,
particularly after external irradiation, are at higher risk to develop
neovascular complications after intra-arterial chemotherapy remains to
be established.
Neovascular complications in retinoblastoma, especially if con-
comitant with elevated intraocular pressure or intraocular hemorrhage,
are usually followed by enucleation. Anecdotally, cases with no active
tumor developing proliferative vitreoretinopathy associated with
chronic retinal detachment have been treated with pars plana vi-
trectomy and membrane peeling (Tawansy et al., 2006; Warden and
Mukai, 2006) and choroidoretinal neovascularization with Argon laser
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(Archer et al., 1993). The use of intravitreal anti-VEGF in the treatment
of 35 eyes with secondary retinal and/or iris neovascularization was
recently reported (Stathopoulos et al., 2018a). In this study, intravitreal
anti-VEGF provided the conditions for further conservative manage-
ment allowing an overall globe preservation rate of 51% (n=18/35) at
a mean follow-up of 2.4 years. Eyes with no concomitant active tumor
had a better globe salvage rate than eyes with active tumor (65% vs
25%) (Stathopoulos et al., 2018a).
7.3.5. Chorioretinal complications
Chorioretinal complications are the most frequently reported in-
traocular complications of both intravitreal and intra-arterial che-
motherapy, leading to the so-called intravitreal melphalan-induced
chorioretinopathy and choroidal occlusive vasculopathy respectively.
Both are irreversible and can cause permanent visual loss if the macula
is involved. Clinical features and risk factors of these adverse effects are
discussed below. In addition, measures to reduce/prevent the in-
travitreal melphalan-induced retinal toxicity after intravitreal mel-
phalan are proposed (see 7.3.5.1.2). Finally, a classification system to
grade the as yet poorly described choroidal occlusive vasculopathy
according to its extent is presented, in order to facilitate comparisons
between studies reporting adverse effects and functional outcomes after
intra-arterial chemotherapy in the future (see 7.3.5.2.1).
7.3.5.1. Intravitreal melphalan-induced chorioretinopathy
7.3.5.1.1. Clinical presentation, classification system and
incidence. Intravitreal melphalan-induced retinopathy, also referred to
as salt and pepper retinopathy, presents as an abrupt, irreversible,
chorioretinopathy usually confined to the meridian of the needle entry
site. The first visible signs are vascular in nature, resulting in an area of
intra-retinal hemorrhages occurring within 2 days of the injection and
evolving within one month to a well demarcated retinal atrophy with
pigmented changes, associated with choriocapillary atrophy of various
extents appearing progressively. A classification system of the
intravitreal melphalan-induced chorioretinopathy was proposed to
grade the retinal toxicity according to the location and extent of the
retinal damage (Munier, 2014), with grade 1–3 referring to a pre- and
retro-equatorial involvement sparing the macula, and grade 4 and 5 to a
Fig. 25. Intravitreal melphalan-induced chorior-
etinopathy. A, B. Grade 2 chorioretinopathy invol-
ving ante-equatorial retina over two clock hours
shown on fundus photography and fluorescein an-
giography. C-E. Fundus of a premature child born at
37 weeks of gestation by Caesarean section. C. Two
weeks after birth, diagnosis of a small juxtapapillary
group B familial retinoblastoma (white arrows) in
the papillo-macular bundle of the left eye. D. Grade 4
retinopathy involving macular and peripapillary re-
tina detected 1 week after the 3rd intravitreal mel-
phalan injection of 14 μg performed elsewhere (axial
length, 17mm) induced by an unfortunate in-
travitreal injection in the still open Cloquet's canal
(see F). E. At the age of 2 years 10 months, complete
peripapillary and macular atrophy surrounded by a
zone of partial atrophy (vision 20/400 with para-
central fixation at 6 years of age). F. Schematic re-
presentation of the intravitreal spaces and their re-
lationship to the retina with retina in blue, internal
limiting membrane in red and hyaloid in green: 1)
bursa pre-macularis or posterior precortical vitreous
pocket (virtual in the neonate). 2) Fovea. 3) Area of
Martegiani. 4) Optic nerve head. 5) Connecting
channel. 6) Cloquet's canal. 7) Ergellet's space. 8)
Berger's space. 9) Ligament of Wieger. 10) Anterior
hyaloid. 11) Posterior limit of the vitreous base. 12)
Vitreous base with fenestrated internal limiting
membrane. G. Grade 5 retinopathy with maculo-
pathy and neuropathy after retro-hyaloid intravitreal
injection performed elsewhere (Image courtesy of Dr
Youssef) under a detached posterior hyaloid pro-
jecting anteriorly performed elsewhere as shown by
the vertical axial ultrasonography (12MHz) (H). I.
Schematic representation of H.
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maculopathy and optic neuropathy respectively (Fig. 25).
Overall, the melphalan-induced chorioretinopathy has been var-
iously reported to occur in 0.8–43% of the cases (Smith et al., 2014). In
a retrospective review of all eyes (n=90) receiving a first intravitreal
treatment with melphalan at Jules-Gonin Eye Hospital over the last 10
years, 41% developed the complication, which was classified as grade 1
or 2 in over 90% of the cases. Complications grade 4 and 5 were never
observed in the Lausanne cohort (unpublished data) (Table 14).
7.3.5.1.2. Risk factors associated with intravitreal melphalan-induced
chorioretinopathy. There are several potential risk factors for
retinopathy following intravitreal melphalan, namely vitreous drug
concentration, eye pigmentation and localization of drug delivery.
These aspects are discussed in detail below.
7.3.5.1.2.1. Intravitreal concentration
The intraocular toxicity of intravitreal melphalan was initially in-
vestigated in preclinical studies on the rabbit showing that a vitreous
concentration of 5.9 μg/ml, corresponding to a human injected dose of
24 μg, was not causing any electroretinographic (ERG) perturbation
(Ueda et al., 1995). This was further confirmed in a study describing the
innocuity of melphalan at a vitreous concentration of 5 μg/mL, but a
52% decrease of both a- and b-wave amplitudes at a concentration of
10 μg/mL, with necrosis of the inner nuclear layer and thinning of the
outer nuclear layer (Shimoda et al., 2008). In humans, an immediate
and permanent 5.8 mV decrease in ERG amplitude per injection of 30 μg
was reported (Francis et al., 2014).
According to the above, it became accepted that it was efficient to
inject a dose of 20–30 μg melphalan (Munier et al., 2012a). As pre-
viously discussed, intravitreal injection of 8 μg melphalan has been
reported to be ineffective, whereas 50 μg has been associated with
phthisis bulbi (Ghassemi and Shields, 2012). Potential risk factors for
the severity of the melphalan-induced chorioretinopathy (grade 3
versus grade 1 and 2) were studied in a series of 90 eyes treated for the
first time with intravitreal melphalan in Lausanne (see 7.3.5.1.1), in-
cluding time to develop the complication since the first injection, total
intravitreal injected dose, and mean intravitreal drug concentration
reached until the occurrence of the complication. Only intravitreal drug
concentration integrating both age-related vitreous volume (Fledelius
and Christensen, 1996; Teichmann, 2002) (Fig. 26) and tumor volume
(effective intravitreal drug concentration) was found to be significantly
correlated with the severity of the melphalan-induced chorioretino-
pathy (p=0.04) (Table 14). To determine the effective intravitreal
melphalan concentration, the formula below was used, in which the
vitreous was estimated to occupy 80% of the eye volume and the tu-
mors to be ellipsoids:
=
=e
Effective intravitreal drug concentration
Dose







For this calculation, the axial lengths (AL, in mm) were estimated
according to age or the corrected age in case of prematurity. Height (h),
longitudinal (r1) and transverse (r2) radii (in millimeters) of each
tumor (n) were measured with ultrasonography (12MHz). The volume
occupied by each tumor was summed up and subtracted from the es-
timated vitreous volume.
These observations imply that tumor volume and not only age-
matched vitreous volume is an important factor to consider when
choosing the dose to be injected. Recommended melphalan doses for
intravitreal chemotherapy according to age and percentage of the
vitreous volume occupied by the tumor(s) are presented in Table 15.
7.3.5.1.2.2. Para-vitreal injections
Para-vitreal injections can lead to a toxic exposition of the retina,
despite adequate intraocular melphalan dose. Thus, in eyes with an
extensive posterior hyaloid detachment, injection into the retro-hyaloid
space may induce a grade 4 or 5 retinopathy (Aziz et al., 2017)
(Fig. 25). Similarly, injection into an open Cloquet's canal with sub-
sequent filling of the virtual bursa premacularis may induce a grade 5
retinopathy (Fig. 25).
To avoid paravitreal injections, ultrasonography should always be
performed prior to the procedure, to inject preferentially in a tumor free
quadrant where the posterior hyaloid is not detached. On the other
hand, the correct positioning of the needle centrally behind the lens
should be done under the operating microscope view, which also allows
the visualization of a retro-lental bubble after initial injection of a small
volume, indicating a smooth diffusion of the drug into the vitreous
cavity. If no bubble can be seen, mis-injection into Cloquet's canal
should be feared, requiring a reposition of the needle elsewhere where a
bubble can be observed.
7.3.5.1.2.3. Intraocular pigmentation
Since melphalan has a tropism for the melanin of the retinal pig-
ment epithelium (Süsskind et al., 2016), it would be reasonable to ex-
pect that more pigmented eyes may be at greater risk of having the
complication. Some authors showed a significant reduction in ERG
findings in eyes with brown iris and pigmented fundus compared to
those with blue iris and blond fundus (Francis et al., 2017b). In the
retrospective analysis of the above-mentioned cohort of patients treated
in Lausanne (see 7.3.5.1.1) considering the presence or absence of the
toxic retinopathy according to the iris color, the opposite was, however,
observed, with patients having blue or green irides (n=28) presenting
significantly more often the retinal complication than patients with
brown irides (n= 61) (16/28 57% vs 21/61 34%, p= 0.04). In the
eyes presenting intravitral injection-induced chorioretinopathy, the
total dose up to the complication was similar between the light- and
dark iris groups (57 μg vs 53 μg), and average effective intravitreal drug
concentration was within safety limits in both groups (7.9 μg/ml vs
6.6 μg/ml).
7.3.5.1.2.4. Concomitant drug interactions
It has also been suggested that concomitant intravitreal and intra-
arterial melphalan may increase the number of adverse effects (Francis
et al., 2017b). In the Lausanne cohort however (unpublished data),
there were fewer cases developing melphalan-induced
Table 14
Intravitreal melphalan-induced retinopathy. Results of a retrospective review including 90 consecutive eyes receiving their primary treatment for vitreous disease
in Jules-Gonin Eye Hospital with intravitreal melphalan between 2008 and 2017. There were no significant differences between eyes suffering Grade 1 or 2 versus
Grade 3 melphalan-induced retinopathy regarding the mean time to develop the complication, the total injected dosis until the first clinical signs of the retinopathy,
or the injected concentration when the latter was evaluated taking into account the age-related vitreous volume only. On the contrary, when tumor volume was
substracted from the age-related vitreous volume, the toxic retinopathy was significantly related to the intravitreal drug concentration (p=0.04).
Classification Number of
eyes
Mean time to retinopathy from
the 1st injection (months)
Total intravitreal melphalan dosis
received at time of retinopathy (μg)
Mean intravitreal melphalan concentration (μg/ml)




Grade 0 53 – – 6.0 6.6
Grade 1 15 0.65 44.4 5.6 6.3
Grade 2 19 0.63 59.4 6.6 7.4
Grade 3 3 0.53 30.0 7.5 10.6
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chorioretinopathy in the eyes which received intra-arterial melphalan
two days apart from the intravitreal injection compared to those who
were treated with intravitreal melphalan alone (19/52 (37%) vs 18/38
(47%), p=0.39, Fisher test)). Moreover, the eyes receiving combined
treatment had also fewer cases with grade 2 and 3 intravitreal mel-
phalan-induced chorioretinopathy (10/19 (52%) vs (12/18) 67%,
p=0.51, Fisher test) and a longer time to retinopathy development
(3.1 vs 2.1 weeks, p= 0.08, Mann-Whitney U test).
7.3.5.2. Choroidal occlusive vasculopathy. The occurrence of intraocular
adverse effects after intra-arterial chemotherapy was first reported in
2011, (Munier et al., 2011), with choroidal occlusive vasculopathy
being the most frequently observed (Bianciotto et al., 2012; Bracco
et al., 2013; Eagle et al., 2011; Muen et al., 2012; Munier et al., 2011).
7.3.5.2.1. Clinical presentation, classification system and
incidence. Clinically, choroidal occlusive vasculopathy, also referred
to as choroidal atrophy, choroidal ischemia or choroidal infarction, is
an irreversible adverse effect of intra-arterial chemotherapy first
recognizable by sectorial or diffuse retinal pigment epithelial
alterations evolving towards partial or complete choriocapillary and
retinal pigment epithelial atrophy. Like intravitreal melphalan-induced
chorioretinopathy, the severity of the choroidal vasculopathy can be
graded according to its extent and impact on the visual outcome. A
classification based on clinical observations is proposed in Table 16 in
the hope that it will help assessing the frequency and severity of this
complication across groups (Fig. 27).
Its incidence varies substantially in the literature ranging from 7%
(Dalvin et al., 2018) (Bianciotto et al., 2012) to 47% (Muen et al.,
2012). This variability may be explained at least in part by a learning
curve (Dalvin et al., 2018; Reddy et al., 2017), and/or by the fact that
not all grades of the complication are necessarily reported (see
Table 16). According to the Lausanne data collected over the last 10
years, this complication was observed in 21 of 560 injection procedures
(3.8%) administered to 213 eyes (9.8%), and typically occurred after a
mean number of 2.4 injections (range 1–5), distributed in 10% grade 1,
52% grade 3, 10% grade 4, and 28% grade 5.
7.3.5.2.2. Factors associated with choroidal occlusive
vasculopathy. Different hypotheses have been proposed to account for
the occurrence of choroidal occlusive vasculopathy, including the
injection mode and technique of cannulation of the ophthalmic
artery, the injected drug toxicity as well as intrinsic predisposing
factors. In the literature, there is a decline in the reported vascular
events over time, most likely due to a learning curve enabling
complications of ophthalmic artery catheterization to be avoided,
with the complication occurring in about 7–10% of the injected eyes
(Dalvin et al., 2018; FLM unpublished data). However, when isolated
choroidal atrophy (i.e. not associated with ophthalmic artery occlusion)
and choroidal atrophy resulting from ophthalmic artery occlusion are
cumulated, the overall choroidal vasculopathy incidence is between 10
and 15% of injected eyes (Ancona-Lezama et al., 2018; Dalvin et al.,
2018).
Intra-arterial chemotherapy with melphalan or carboplatin has been
shown in vivo to trigger vascular toxicity through endothelial cell in-
flammation and leukostasis, in a study without sham injection of saline
to test the effect of the ophthalmic catheterization per se (Steinle et al.,
2012). This was later tested in another animal model, demonstrating no
vascular damage following saline injection (Daniels et al., 2018). The
role of the micro-catheter positioning at the ostium versus occlusive
engagement into the ophthalmic artery, as well as the continuous
versus pulsatile injection mode, have also been debated. The issue of
Fig. 26. Intravitreal drug concentration with respect to axial length and injection dose of melphalan as calculated for an eye with completely regressed retinal tumor
(s) (regression type IV), or 0% of vitreous volume occupied by tumor(s).
Table 15
Estimated intravitreal concentration of melphalan with respect to eye size
(age) and tumor volume. Concentrations falling within the recommended
safety limits are in green, those in blue are too low to reach efficacy, and those
in red are outside the predetermined safety limits, exposing the patient to a high
risk of retinal damage.
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occlusive vs non-occlusive technique of injection appears not to be
primarily responsible for the choroidal occlusive complications, at least
in the rabbit model (Daniels et al., 2019).
A dose-related ocular toxicity of melphalan was hypothesized by the
London group (Reddy et al., 2017), who reported that visual compli-
cations may be minimized with age-adjusted melphalan dosages.
However, such a dosage effect, at least within the published dose range,
could not be demonstrated in a subsequent study from Philadelphia
(Dalvin et al., 2018).
The relative insolubility of melphalan is another potential source of
toxicity linked to the embolization of micro-crystals up to 20 μm in
diameter if not vigorously shaken (Tse et al., 2013). Filtration of mel-
phalan after reconstitution using a 0.22 μm filter has been advised but
its use is not widely reported in the intra-arterial chemotherapy lit-
erature.
Finally, genetic predispositions to thromboembolism have been re-
ported in association with choroidal occlusive vasculopathy, including
sickle cell trait, prothrombin mutation, plasminogen activator inhibitor-
1 polymorphism (Abramson et al., 2012b; Francis et al., 2012), as well
as methylenetetrahydrofolate reductase (MTHFR) polymorphic alleles
(Bohm et al., 2018). In the latter case, 4 patients were recently reported
who inhaled nitrous oxide pre-intra-arterial chemotherapy resulting in
an increase of homocysteine in the blood (Bohm et al., 2018). The exact
role of these inherited thrombophilic traits among the patients with
choroidal occlusive vasculopathy is still unknown.
7.4. Evaluation of quality of life
This review is sub-titled: “Alive, with good vision and no co-mor-
bidity”. Even fully achieved, this medical goal needs to be confronted
with patients' everyday life. How survivors themselves, as well as those
around them, cope with the disease seems especially important
(Hamama-Raz et al., 2012; van Dijk et al., 2009). To date, however, this
issue has been only poorly addressed (Moll et al., 2013). Even if most of
long-term retinoblastoma survivors and their parents report an overall
good quality of life and limited psychosocial problems in comparison to
peers (van Dijk et al., 2007a, 2007b; Weintraub et al., 2011; Sheppard
et al., 2005), confrontation with the consequences of the disease still
last for their entire lives. The perception of the disease as well as the
psychosocial functioning and development of an affected child is in-
fluenced by the parents’ ability to cope with the stress associated with
diagnosis and treatment (Hamama-Raz et al., 2012; van Dijk et al.,
2007a, 2007b; Weintraub et al., 2011). In addition, patients not only
have to withstand a delay in visuo-motor integration in comparison
with their healthy peers (Ross et al., 2001), but also a life-long fear of
developing recurrences, second primary malignancies, further loss of
vision and passing on the disease to their offspring (van Dijk et al.,
2010). When parents had to compare the quality of life of their affected
children with healthy siblings, their report was significantly worse re-
garding the former (Batra et al., 2016a). A study comparing self (child)-
versus parental evaluation of health-related quality of life showed that
parents reported worse on emotional domains (Batra et al., 2016b).
Over the last few decades, a substantial number of patients, mostly
those having received irradiation or experienced restrictions in daily
life and bullying at school, needed special educational services and
psychological guidance or treatment (Sheppard et al., 2005; van Dijk
et al., 2010). Finally, fewer marriages and more divorces have been
reported in retinoblastoma survivors treated by enucleation and/or
external beam radiotherapy (Byrne et al., 1995).
A multi-disciplinary retinoblastoma team should ideally include a
dedicated and fully integrated psychological and spiritual accom-
panying person. Such a presence benefits all families, regardless of re-
ligious confession, from diagnosis to final follow-up and, most im-
portantly, during the delicate therapeutic phases, not only to facilitate
communication between the patients’ family and the medical and
nursing staff, but also to provide support for both parents and staff
when confronted with enucleation, relapse or even death. The quality
of attention paid to emotional, psychological and spiritual aspects of
patient care has proved to be of inestimable importance to the quality of
life (Lima et al., 2013).
8. Future directions and conclusion
Historically, therapeutic innovation in the conservative manage-
ment of retinoblastoma was driven independently of randomized clin-
ical trials, often in the absence of preclinical studies, mostly due to the
orphan nature of the disease. Over the last decade, virtually all steps
forward were taken by challenging orthodoxy with new administration
routes of known drugs subsequently evaluated in non-randomized ret-
rospective studies. In the future, therapeutic breakthroughs should
benefit from an increasing contribution of translational research and
initiatives supporting rare disease consortium such as the European
Retinoblastoma Group (EuRbG), favoring prospective multicentric
clinical trials. In addition, the availability of new animal models for
preclinical studies is expected to potentially improve treatment options
(see 8.1). On the other hand, the advent of “omics” technology
Table 16
Clinical classification of the choroidal occlusive vasculopathy after intra-arterial chemotherapy.
Description
Grade 1 Any sectorial incomplete choroidopathy
a. Sparing the fovea
b. Not sparing the fovea
c. Involvement of the fovea not assessable (due to tumor location or media opacities)
Grade 2 Any sectorial complete choroidopathy
a. Sparing the fovea
b. Not sparing the fovea
c. Involvement of the fovea not assessable (due to tumor location or media opacities)
Grade 3 Any diffuse (= involving the whole fundus) choroidopathy with complete choroidal atrophy involving less than 50% of the fundus
a. Sparing the fovea
b. Not sparing the fovea
c. Involvement of the fovea not assessable (due to tumor location or media opacities
Grade 4 Mixed diffuse choroidopathy: fundus with 50% complete and 50% incomplete choroidal atrophy
a. Complete atrophy sparing the fovea
b. Complete atrophy not sparing the fovea
c. Involvement of the fovea not assessable (due to tumor location or media opacities)
Grade 5 Any diffuse choroidopathy with complete choroidal atrophy involving more than 50% of the fundus
a. Complete atrophy sparing the fovea
b. Complete atrophy not sparing the fovea
c. Involvement of the fovea not assessable (due to tumor location or media opacities)
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(Golabchi et al., 2018; Hudson et al., 2018; Kapatai et al., 2013; Kooi
et al., 2016b; Naru et al., 2017) is expected to allow not only a better
understanding of the mechanisms underlying tumor biology (MYCN vs
non-MYCN) and progression (somatic chromosomal copy-number al-
terations, epigenetic changes) including seeding, metastasis and re-
lapse, but also novel diagnostic and therapeutic applications. Last but
not least, this section also proposes to unveil some new potential
therapeutic avenues, including gene therapy (see 8.2), cell-of-origin
targeted therapy (see 8.3), personalized management (see 8.4) as well
as new drugs (see 8.5) or new Galenic formulation of known drugs (see
8.6).
8.1. Animal models
There is a surprising paradoxic discrepancy between the evolu-
tionary conserved RB-E2F pathway in most eukaryotes lineage species,
including animals and plants (Cao et al., 2010) and the fact that RB1
loss of function causes preferential retinal oncogenesis as a human-
specific condition, with no proven equivalent in the animal kingdom
other than anecdotal cases of sporadic unilateral retinoblastoma-like
tumors (RB1 status not investigated) in the dog and lama (Syed et al.,
1997; Fugaro et al., 2005; Regan et al., 2013). This has imposed al-
ternative models based in xenografts or genetically engineered mouse
models (GEMMs) to conduct translational research in the field. Methods
to monitor tumor growth and allow accurate evaluation of new treat-
ments evaluation such as small animal imaging systems and diagnostic
equipment adapted to the preclinical setting have been developed in
parallel (Nemeth et al., 2011).
Intraocular xenografts using Y79 and WERI-Rb1 cell lines estab-
lished more than 40 years ago from enucleated eyes of patients who
received no previous treatment have been widely employed in im-
munodeficient mice where they can reproduce the inactivation of RB1
and metastasize (Y79) to the central nervous system (CNS) (Chevez-
Barrios et al., 2000; Lee et al., 1988; McFall et al., 1977; Reid et al.,
1974). Over the last years, the orthotopic transplantation of fresh tumor
samples or early stage primary cultures to mice has been prioritized,
producing very relevant xenografts with striking anatomic and genetic
resemblance to the patient disease (Pascual-Pasto et al., 2016; Xu et al.,
2009; Zhang et al., 2012). A few institutions have developed programs
to systematize the sampling of viable tumor fragments or vitreous
seeding from enucleated eyes at the pathology laboratory (Benavente
and Dyer, 2015; Sastre et al., 2009). Serum-free, growth factor-sup-
plemented culture medium is used to expand the small tumor fragments
obtained from the enucleated eyes and maintain retinoblastoma cells in
culture. This method selects stem-like cells that grow as floating tumor
spheres resembling tumor seeding, as opposed to culture medium with
bovine serum that promotes cell differentiation (Bond et al., 2013; Ma
et al., 2011; Pascual-Pasto et al., 2016).
Alternatively, different genetically engineered mouse models
(GEMMs) have been developed through manipulation of the genes in
the Rb pathway (Benavente and Dyer, 2015). Inactivation of the Rb
gene alone, however, is not sufficient to develop retinoblastoma in mice
(Jacks et al., 1992), which need therefore concurrent inactivation of
Rb-related genes. For instance, conditional deletion of Rb and p130,
through the Pax6a promoter, induces bilateral intraocular tumors with
100% penetrance by one month postnatal, subsequent vitreous and
aqueous seeding, as well as CNS and lymph node metastases
(MacPherson et al., 2007). Other developed GEMMs include concurrent
inactivation of Rb and p107 (Chen et al., 2004; Robanus-Maandag et al.,
1998), Rb, p107 and p130 (McEvoy et al., 2011), or Rb and p107
combined with Arf deletion, or amplifications of MDMX and MYCN
(Conkrite et al., 2012; McEvoy et al., 2011; Wu et al., 2017). Most of
them, however, have the disadvantage of incomplete penetrance and/
or long latency, making it difficult to interpret the efficacy of new
therapies, or do not reproduce the patient outcome to treatments as
compared to xenografts that replicate patient response closely (Brennan
et al., 2011).
Finally, various tumor and non-tumor bearing animal models have
been used to study the pharmacokinetic of different drugs depending on
the intraocular delivery model. Large animals such as primates, pigs
and rabbits are preferentially chosen because of their appropriate size,
their similar proportion between ocular compartments compared to
human eyes and the possibility they allow for repeated or continuous
sampling of the ocular fluids and the cannulation of the ophthalmic
arteries (Carcaboso et al., 2007, 2010; Daniels et al., 2018; Ditta et al.,
2012; Schaiquevich et al., 2012c; Vézina, 2013). Macaques and rabbits
have been successfully used to characterize the toxicity of intra-oph-
thalmic artery and intravitreal melphalan in the retina (Francis et al.,
Fig. 27. Choroidal occlusive vasculopathy. A.
Grade 1a: sectorial incomplete sparing the fovea.
Fundus showing nasal incomplete choroidal atrophy
and preserved temporal choroid. B. Grade 3a: diffuse
with< 50% complete choroidal atrophy. C. Grade
4b: mixed diffuse with 50% complete atrophy in-
volving the fovea and 50% incomplete choroidal
atrophy. D. Grade 5a: diffuse> 50% complete
choroidal atrophy, but with spared fovea.
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2014; Shimoda et al., 2008; Wilson et al., 2011).
8.2. Gene therapy
The well-defined genetic origin of retinoblastoma and its confine-
ment within a small, accessible and visible location nicely fit the con-
ditions for a gene therapy approach. Transduced genes may generate
therapeutic products to be released locally, or products that target
dysfunctional oncogenic pathways within the tumor cells.
The first gene therapy to achieve a phase I clinical trial in retino-
blastoma used a replication-deficient adenoviral vector (AdV-TK), car-
rying the herpes simplex thymidine kinase, a suicide gene activated by
ganciclovir. The trial included eight retinoblastoma patients facing
imminent enucleation due to active vitreous seeding (Chevez-Barrios
et al., 2005; Hurwitz et al., 1999). Repeated intravitreal injections of
AdV-TK and concomitant intravenous ganciclovir were proven feasible
and safe. Treatment-related vitreal inflammation was controlled with
corticosteroids. However, despite initial resolution of active vitreous
seeds, all eyes were finally enucleated secondary to retinal tumor pro-
gression, likely because adenovirus 5 vectors have limited ability to
penetrate, infect and transduce retinal tumors, or alternatively because
the expression of the genes transduced by adenoviruses is only short-
term. Subsequent studies on this vector found that a modified adeno-
virus 5 fiber gene achieved better cell infection and protein expression
(Mallam et al., 2004). Another gene therapy approach explored local
transduction of IFN1B, encoding interferon-β, an antineoplastic mole-
cule, with an adeno-associated virus, showing antitumor activity
against Y79 xenografts in vivo (Shih et al., 2009).
Other viral vectors for retinoblastoma gene therapy induce an on-
colytic effect, such as the adenoviruses H101 (Song et al., 2010) and
Ad-TERT p-E1 (Wang et al., 2013), which have been tested in pre-
clinical studies. Currently, the most advanced oncolytic adenovirus for
retinoblastoma is VCN-01, designed to replicate selectively in tumor
cells with high abundance of free E2F-1 transcription factor activity due
to the dysfunctional RB1 pathway (Pascual-Pasto et al., 2019). The
genome of VCN-01 contains one deletion in the E1A gene that precludes
viral replication in RB1-functional cells and one insertion of an E2F1
promoter under the E1A gene that favors replication in cells with free
E2F-1 (Rodriguez-Garcia et al., 2015). In mice, the intravitreous ad-
ministration of VCN-01 in orthotopic retinoblastoma xenografts in-
fected and killed tumor cells, improved ocular survival significantly
compared to standard of care chemotherapy, and reduced the frequency
of CNS metastases (Pascual-Pasto et al., 2019). In immunocompetent
rabbits, this treatment induced minor local inflammation and did not
replicate in retinas (Pascual-Pasto et al., 2019). Intravitreous VCN-01 is
currently undergoing a phase I clinical trial in children with refractory
retinoblastoma (NCT03284268) and preliminary results of the 2 first
patients treated have been published, showing the feasibility and safety
of the procedure and evidence of viral replication markers in tumor
cells (Pascual-Pasto et al., 2019).
8.3. Cell-of-origin targeted therapy
Two approaches that target intrinsic cell-of-origin features remain
possible: First, if the cell-of-origin signaling circuitry that drives tu-
morigenesis represents an embryonic developmental stage, it may be
possible to target this circuitry without affecting other cell types in
retinoblastoma patients. For example, we know that the cone precursor
proliferative response depends on intrinsically highly expressed pro-
teins including RXRγ, TRβ2, MYCN, and MDM2 (Xu et al., 2014).
Several preclinical agents are available to attack these troublemakers
and could be considered for translational development. Second, it has
been suggested that cancer pathways may be epigenetically deregulated
as a direct or indirect result of RB1 loss (Zhang et al., 2012). It might
thus be useful to target the cone precursors’ epigenetic responses to pRB
loss.
8.4. Personalized therapy and liquid biopsy
Unprecedented opportunity for customized therapy is emerging by
capitalization on individual liquid biopsy made possible since the in-
troduction of the safety-enhanced intravitreal chemotherapy. Now that
aqueous humor can be routinely and repeatedly sampled from one or
both eyes in retinoblastoma patients as a non-invasive surrogate of
tumor biopsy (Berry et al., 2017c), new insights into tumor biology can
be undertaken based on all aqueous humor content, including cell-free
DNA, exosomes and proteins.
The proof of principle of this approach has been recently established
in a retrospective study, significantly correlating somatic chromosomal
copy-number alterations (6p gain) in cell-free DNA (cf-DNA) from
aqueous humor and secondary enucleation (Berry et al., 2018b). If
clinically validated, this remarkable achievement may influence man-
agement, especially in terms of treatment monitoring and/or persona-
lized therapies based on specific tumor profiles and to distinguish
MYCN from non-MYCN retinoblastomas. In addition, this technology is
opening an avenue to study the chronology of mutations associated
with tumor progression.
Another seminal paper (Gerrish et al., 2019) now further expands
the applications of cf-DNA analysis in liquid biopsy of retinoblastoma
patients by demonstrating that i) somatic RB1 mutations can be suc-
cessfully detected (even at concentrations < 0.1 ng/μl), including
single-nucleotides and copy-number variants, ii) mutant RB1 allele
frequency in cf-DNA tightly reflects tumoral zygosity allowing the
distinction of loss of heterozygosity (LOH) vs non-LOH events, iii) >
90% of cf-DNA in the aqueous humor is of tumoral origin, and iv)
aqueous cf-DNA content appears to be proportional to the tumor
burden. This outstanding advance was obtained by sequential targeted
capture enrichment for the promoter and exonic regions of the RB1
gene, highly heterozygous single nucleotide polymorphisms and non-
polymorphic regions across chromosome 13, followed by massively
parallel sequencing. This breakthrough is expected to significantly im-
pact the current clinical management of retinoblastoma, characterized
by a dramatic reduction of enucleation rates even in advanced cases. In
apparent non-hereditary retinoblastoma patients, eye preservation
therapy is drying up the only existing source of tumor DNA for somatic
mutation detection prior to genomic confirmation and thus restraining
the identification of germline carriers (15%) in this population. Now
that cf-DNA from the conserved eye is available for somatic mutational
screening, accurate genetic counseling and clinical surveillance in the
family at large can be re-enforced. Furthermore, the identification of
compound heterozygote, homo- or hemizygote somatic hits in the
aqueous humor of unilateral retinoblastoma, as well as one or more
heterozygote somatic hits in germline patients with multifocal tumors,
may provide biological markers for personalized detection of minimally
disseminated disease in bone marrow biopsy and lumbar puncture.
8.5. New drugs or combinations of drugs
Among the increasing number of new potential targets against re-
tinoblastoma, different therapeutic strategies can be envisaged tar-
geting either the micro-environment (e.g. angiogenesis or glycolytic
inhibitors) (Houston et al., 2013) or specific retinoblastoma pathways
(e.g. inhibitors of SIK or MDM2/MDMX-p53 interaction) (Pritchard
et al., 2016). Alternatively, new molecules potentiating the anti-tumor
activity of known treatment modalities, including chemotherapy,
radiotherapy or hyperthermia, may also lead to improved clinical
outcome. For example, improvement of chemohyperthermia may result
from combined administration of carboplatin and inhibitors of heat
shock proteins, which are rapidly produced to buffer stress, including
but not restricted to heat damage, and enable recovery in virtue of their
anti-apoptotic properties. Interestingly, HSP70 and HSP90 have been
identified in retinoblastoma cells (Jiang et al., 2008), justifying further
investigations on the role of heat shock protein inhibitors as
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potentiating molecules of hyperthermia.
8.6. New galenic formulation of known drugs
One of the limitations of chemohypethermia is that less than 1% of
the intravenous carboplatin reaches the tumor, while the entire body is
exposed to toxic adverse effects. An alternative approach using small
chemotherapeutic molecules activated by heat only could therefore be
beneficial by reducing the dose without impacting efficacy (Fig. 28).
Small-molecule thermoresponsive anticancer drugs that synergize with
thermotherapy have been reported and validated in an adenocarci-
noma-bearing murine model (Clavel et al., 2015).
8.7. Conclusion
Over the last decade, the advent of new techniques of chemotherapy
delivery directly into the eye (namely intra-arterial, intravitreal and
more recently intracameral injections) radically transformed the con-
servative treatment of retinoblastoma, allowing not only salvage of the
majority of eyes, even those with advanced disease, but also eradicating
external beam radiotherapy, as well as significantly reducing the rate of
primary and secondary enucleations and the indications for systemic
chemotherapy. These major advancements were obtained while main-
taining a very low rate of metastatic disease, but our ability to detect
minimally disseminated disease, as well as to treat CNS disease, still
needs improvement to achieve zero-tolerance regarding metastatic
death. Finally, in order to promote a better quality of life from diagnosis
throughout the active therapeutic period and over the patients’ whole
lifetime, further efforts should aspire to shorten the time to success,
contain adverse side effects, improve visual outcome, reduce the in-
cidence of second primary neoplasms, and better support the needs of
the survivors and their families.
Funding
The authors have no financial interest in any aspect of this article.
No conflicting relationship exists for any author.
Co-authors'contributions
FLM: Design and redaction of the manuscript, iconography selection
of and sketch conception; MBP: 3.6, 7.2; GC: 3.3, 3.7, 7.2; DC: 4; TK: 2,
3.5, 3.6; DL: 5; PM: 3.2.4; ACM: 3.8, 7.4; AMC: 8.1, 8.2; AM: 6.1, 6.2,
6.3; PS: 7.1; CB: data analysis; PD: 8.5, 8.6; SH: data management -
editing; FP: 7.2.2; YV: 3.5; MCG: 3.2, 7.3.1, 7.3.2; CS: Redaction and
harmonization of the whole manuscript.
Acknowledgements
My gratitude goes to Professor Claude Gailloud who founded and Dr
Aubin Balmer who further developped the Retinoblastoma Clinic in
Lausanne. The iconography illustrating this paper was obtained thanks
to the collaboration of Marc Curchod (eye pictures), Yann Leuba
(montage) and Isabel de Dioz (drawings) from the Centre d’Imagerie
Oculaire at Jules-Gonin Eye Hospital. Our gratitude extends to Laurent
Gouban and Cédric Blanchard, librarian and assistant-librarian at Jules-
Gonin Eye Hospital respectively, for their help in obtaining retino-
blastoma papers reviewed for the purpose of this manuscript.
References
Abouzeid, H., Balmer, A., Moulin, A.P., Mataftsi, A., Zografos, L., Munier, F.L., 2012.
Phenotypic variability of retinocytomas: preregression and postregression growth
patterns. Br. J. Ophthalmol. 96, 884–889.
Abouzeid, H., Moeckli, R., Gaillard, M.C., Beck-Popovic, M., Pica, A., Zografos, L., Balmer,
A., Pampallona, S., Munier, F.L., 2008. (106)Ruthenium brachytherapy for retino-
blastoma. Int. J. Radiat. Oncol. Biol. Phys. 71, 821–828.
Abouzeid, H., Schorderet, D.F., Balmer, A., Munier, F.L., 2009. Germline mutations in
retinoma patients: relevance to low-penetrance and low-expressivity molecular basis.
Mol. Vis. 15, 771–777.
Abramson, D.H., Beaverson, K., Sangani, P., Vora, R.A., Lee, T.C., Hochberg, H.M.,
Kirszrot, J., Ranjithan, M., 2003. Screening for retinoblastoma: presenting signs as
prognosticators of patient and ocular survival. Pediatrics 112, 1248–1255.
Abramson, D.H., Beaverson, K.L., Chang, S.T., Dunkel, I.J., McCormick, B., 2004.
Outcome following initial external beam radiotherapy in patients with Reese-
Ellsworth group Vb retinoblastoma. Arch. Ophthalmol. 122, 1316–1323.
Abramson, D.H., Catalanotti, F., Brodie, S.E., Kellick, M.G., Francis, J.H., 2018.
Intravitreal chemotherapy and laser for newly visible subretinal seeds in retino-
blastoma. Ophthalmic Genet. 39, 353–356.
Abramson, D.H., Daniels, A.B., Marr, B.P., Francis, J.H., Brodie, S.E., Dunkel, I.J., Gobin,
Y.P., 2016a. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group
D retinoblastoma. PLoS One 11, e0146582.
Abramson, D.H., Du, T.T., Beaverson, K.L., 2002. (Neonatal) retinoblastoma in the first
month of life. Arch. Ophthalmol. 120, 738–742.
Abramson, D.H., Dunkel, I.J., Brodie, S.E., Kim, J.W., Gobin, Y.P., 2008. A phase I/II
study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for
intraocular retinoblastoma initial results. Ophthalmology 115, 1398–1404 1404
e1391.
Abramson, D.H., Dunkel, I.J., Brodie, S.E., Marr, B., Gobin, Y.P., 2010. Bilateral super-
selective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem
therapy. Arch. Ophthalmol. 128, 370–372.
Abramson, D.H., Fabius, A.W., Francis, J.H., Marr, B.P., Dunkel, I.J., Brodie, S.E.,
Escuder, A., Gobin, Y.P., 2017a. Ophthalmic artery chemosurgery for eyes with ad-
vanced retinoblastoma. Ophthalmic Genet. 38, 16–21.
Abramson, D.H., Fabius, A.W., Issa, R., Francis, J.H., Marr, B.P., Dunkel, I.J., Gobin, Y.P.,
2015a. Advanced unilateral retinoblastoma: the impact of ophthalmic artery che-
mosurgery on enucleation rate and patient survival at MSKCC. PLoS One 10,
e0145436.
Abramson, D.H., Frank, C.M., 1998. Second nonocular tumors in survivors of bilateral
retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105,
573–579 discussion 579-580.
Abramson, D.H., Frank, C.M., Chantada, G.L., de Totah, A.B., de Pifano, I.T., Ramirez,
G.T., Gomez, R.T., Fandino, A.T., Tran, H.T., Madden, T.J., Dunkel, I.J., 1999a.
Intraocular carboplatin concentrations following intravenous administration for
human intraocular retinoblastoma. Ophthalmic Genet. 20, 31–36.
Abramson, D.H., Frank, C.M., Dunkel, I.J., 1999b. A phase I/II study of subconjunctival
carboplatin for intraocular retinoblastoma. Ophthalmology 106, 1947–1950.
Abramson, D.H., Frank, C.M., Susman, M., Whalen, M.P., Dunkel, I.J., Boyd 3rd, N.W.,
1998. Presenting signs of retinoblastoma. J. Pediatr. 132, 505–508.
Abramson, D.H., Gombos, D.S., 1996. The topography of bilateral retinoblastoma lesions.
Retina 16, 232–239.
Abramson, D.H., Ji, X., Francis, J.H., Catalanotti, F., Brodie, S.E., Habib, L., 2019.
Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal
seeds. Br. J. Ophthalmol. 103, 488–493.
Abramson, D.H., Marr, B.P., Brodie, S.E., Dunkel, I., Palioura, S., Gobin, Y.P., 2012a.
Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five
year review. PLoS One 7, e34120.
Abramson, D.H., Marr, B.P., Brodie, S.E., Dunkel, I.J., Lin, A., Folberg, R., Gobin, Y.P.,
2012b. Intraocular hemorrhage after intra-arterial chemotherapy for retinoblastoma
in sickle cell trait. Open Ophthalmol. J. 6, 1–3.
Abramson, D.H., Marr, B.P., Dunkel, I.J., Brodie, S., Zabor, E.C., Driscoll, S.J., Gobin, Y.P.,
2012c. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or
subretinal seeding: 2-year results. Br. J. Ophthalmol. 96, 499–502.
Abramson, D.H., Marr, B.P., Francis, J.H., Dunkel, I.J., Fabius, A.W., Brodie, S.E.,
Mondesire-Crump, I., Gobin, Y.P., 2016b. Simultaneous bilateral ophthalmic artery
chemosurgery for bilateral retinoblastoma (tandem therapy). PLoS One 11,
e0156806.
Abramson, D.H., Melson, M.R., Dunkel, I.J., Frank, C.M., 2001. Third (fourth and fifth)
Fig. 28. Example of a heat-activated derivative of melphalan that only becomes
bioavailable at higher temperatures, allowing the thermoresponsive chain to be
cut at the ester bond to release the drug.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
56
nonocular tumors in survivors of retinoblastoma. Ophthalmology 108, 1868–1876.
Abramson, D.H., Ronner, H.J., Ellsworth, R.M., 1979. Second tumors in nonirradiated
bilateral retinoblastoma. Am. J. Ophthalmol. 87, 624–627.
Abramson, D.H., Schefler, A.C., 2004a. Transpupillary thermotherapy as initial treatment
for small intraocular retinoblastoma: technique and predictors of success.
Ophthalmology 111, 984–991.
Abramson, D.H., Schefler, A.C., 2004b. Update on retinoblastoma. Retina 24, 828–848.
Abramson, D.H., Shields, C.L., Jabbour, P., Teixeira, L.F., Fonseca, J.R.F., Marques,
M.C.P., Munier, F.L., Puccinelli, F., Hadjistilianou, T., Bracco, S., Chantada, G.,
Ceciliano, A., Gobin, Y.P., 2017b. Metastatic deaths in retinoblastoma patients
treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) world-
wide. Int J Retina Vitreous 3, 40.
Abramson, D.H., Shields, C.L., Munier, F.L., Chantada, G.L., 2015b. Treatment of re-
tinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol 133,
1341–1347.
Ahnelt, P.K., 1998. The photoreceptor mosaic. Eye 12 (Pt 3b), 531–540.
Ajioka, I., Dyer, M.A., 2008. A new model of tumor susceptibility following tumor sup-
pressor gene inactivation. Cell Cycle 7, 735–740.
Akolekar, R., Beta, J., Picciarelli, G., Ogilvie, C., D'Antonio, F., 2015. Procedure-related
risk of miscarriage following amniocentesis and chorionic villus sampling: a sys-
tematic review and meta-analysis. Ultrasound Obstet. Gynecol. 45, 16–26.
Akyuz, C., Kiratli, H., Sen, H., Aydin, B., Tarlan, B., Varan, A., 2015. Intra-arterial che-
motherapy for retinoblastoma: a single-center experience. Ophthalmologica 234,
227–232.
Albert, D.M., 1987. Historic review of retinoblastoma. Ophthalmology 94, 654–662.
Amram, A.L., Rico, G., Kim, J.W., Chintagumpala, M., Herzog, C.E., Gombos, D.S.,
Chevez-Barrios, P., 2017. Vitreous seeds in retinoblastoma: clinicopathologic classi-
fication and correlation. Ophthalmology 124, 1540–1547.
Anagnoste, S.R., Scott, I.U., Murray, T.G., Kramer, D., Toledano, S., 2000.
Rhegmatogenous retinal detachment in retinoblastoma patients undergoing che-
moreduction and cryotherapy. Am. J. Ophthalmol. 129, 817–819.
Ancona-Lezama, D., Dalvin, L.A., Lucio-Alvarez, J.A., Jabbour, P., Shields, C.L., 2018.
OPHTHALMIC VASCULAR EVENTS after INTRA-ARTERIAL CHEMOTHERAPY for
RETINOBLASTOMA: Real-World Comparison between Primary and Secondary
Treatments. Retina.
Andreoli, M.T., Chau, F.Y., Shapiro, M.J., Leiderman, Y.I., 2017. Epidemiological trends
in 1452 cases of retinoblastoma from the surveillance, Epidemiology, and end results
(SEER) registry. Can. J. Ophthalmol. 52, 592–598.
Antoneli, C.B., Ribeiro, K.C., Steinhorst, F., Novaes, P.E., Chojniak, M.M., Malogolowkin,
M., 2006. Treatment of retinoblastoma patients with chemoreduction plus local
therapy: experience of the AC Camargo Hospital, Brazil. J. Pediatr. Hematol. Oncol.
28, 342–345.
Antoneli, C.B., Steinhorst, F., de Cassia Braga Ribeiro, K., Novaes, P.E., Chojniak, M.M.,
Arias, V., de Camargo, B., 2003. Extraocular retinoblastoma: a 13-year experience.
Cancer 98, 1292–1298.
Archer, D.B., Amoaku, W.M., Kelly, G., 1993. Choroidoretinal neovascularisation fol-
lowing radon seed treatment of retinoblastoma in two patients. Br. J. Ophthalmol. 77,
95–99.
Azar, D., Donaldson, C., Dalla-Pozza, L., 2003. Questioning the need for routine bone
marrow aspiration and lumbar puncture in patients with retinoblastoma. Clin. Exp.
Ophthalmol. 31, 57–60.
Azar, D., Donaldson, C., Kalapesi, F., Cumming, R., 2006. Retinoblastoma in New South
Wales 1975 to 2001. J. Pediatr. Hematol. Oncol. 28, 642–646.
Azary, S., Ganguly, A., Bunin, G.R., Lombardi, C., Park, A.S., Ritz, B., Heck, J.E., 2016.
Sporadic retinoblastoma and parental smoking and alcohol consumption before and
after conception: a report from the children's oncology group. PLoS One 11,
e0151728.
Aziz, H.A., Kim, J.W., Munier, F.L., Berry, J.L., 2017. Acute hemorrhagic retinopathy
following intravitreal melphalan injection for retinoblastoma: a report of two cases
and technical modifications to enhance the prevention of retinal toxicity. Ocul Oncol
Pathol 3, 34–40.
Bader, J.L., Meadows, A.T., Zimmerman, L.E., Rorke, L.B., Voute, P.A., Champion, L.A.,
Miller, R.W., 1982. Bilateral retinoblastoma with ectopic intracranial retinoblastoma:
trilateral retinoblastoma. Cancer Genet. Cytogenet. 5, 203–213.
Baker, M.S., McConnell, L.K., Kleinberg, T.T., Shriver, E.M., Bilyk, J.R., Allen, R.C., 2016.
Orbital sarcomas in retinoblastoma patients: recommendations for screening and
treatment guidelines. Curr. Opin. Ophthalmol. 27, 443–448.
Bakhshi, S., Meel, R., Kashyap, S., Sharma, S., 2011. Bone marrow aspirations and lumbar
punctures in retinoblastoma at diagnosis: correlation with IRSS staging. J. Pediatr.
Hematol. Oncol. 33, e182–185.
Balaguer, J., Wilson, M.W., Billups, C.A., Mancini, J., Haik, B.G., Qaddoumi, I., Khoury,
J.D., Rodriguez-Galindo, C., 2009. Predictive factors of invasion in eyes with re-
tinoblastoma enucleated after eye salvage treatments. Pediatr. Blood Canc. 52,
351–356.
Balmer, A., Munier, F., 2007. Differential diagnosis of leukocoria and strabismus, first
presenting signs of retinoblastoma. Clin. Ophthalmol. 1, 431–439.
Balmer, A., Munier, F., Gailloud, C., 1991. Retinoma. Case studies. Ophthalmic Paediatr.
Genet. 12, 131–137.
Barai, S., Bandopadhayaya, G.P., Raj, P., Julka, P.K., Kumar, R., Malhotra, A., Dhanpathi,
H., Nainiwal, S., Haloi, A.K., 2004. Role of skeletal scintigraphy in advanced re-
tinoblastomas. Acta Radiol. 45, 313–316.
Barboriak, D.P., Lee, L., Provenzale, J.M., 2001. Lu-Serial MR imaging of pineal cysts:
implications for natural history and follow-up. AJR Am. J. Roentgenol. 176, 737–743.
Baroni, L.V., Sampor, C., Fandino, A., Solernou, V., Demirdjian, G., de Davila, M.T.,
Chantada, G.L., 2014. Anterior segment invasion in retinoblastoma: is it a risk factor
for extraocular relapse? J. Pediatr. Hematol. Oncol. 36, e509–512.
Bartuma, K., Pal, N., Kosek, S., Holm, S., All-Ericsson, C., 2014. A 10-year experience of
outcome in chemotherapy-treated hereditary retinoblastoma. Acta Ophthalmol. 92,
404–411.
Batra, A., Kain, R., Kumari, M., Paul, R., Dhawan, D., Bakhshi, S., 2016a. Parents' per-
spective of quality of life of retinoblastoma survivors. Pediatr. Blood Canc. 63,
1287–1289.
Batra, A., Kumari, M., Paul, R., Patekar, M., Dhawan, D., Bakhshi, S., 2016b. Quality of
life assessment in retinoblastoma: a cross-sectional study of 122 survivors from India.
Pediatr. Blood Canc. 63, 313–317.
Baud, O., Cormier-Daire, V., Lyonnet, S., Desjardins, L., Turleau, C., Doz, F., 1999.
Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients
with constitutional cytogenetic 13q deletion. Clin. Genet. 55, 478–482.
Baumal, C.R., Shields, C.L., Shields, J.A., Tasman, W.S., 1998. Surgical repair of rheg-
matogenous retinal detachment after treatment for retinoblastoma. Ophthalmology
105, 2134–2139.
Beck, M.N., Balmer, A., Dessing, C., Pica, A., Munier, F., 2000. First-line chemotherapy
with local treatment can prevent external-beam irradiation and enucleation in low-
stage intraocular retinoblastoma. J. Clin. Oncol. 18, 2881–2887.
Beck Popovic, M., Balmer, A., Maeder, P., Braganca, T., Munier, F.L., 2006. Benign pineal
cysts in children with bilateral retinoblastoma: a new variant of trilateral retino-
blastoma? Pediatr. Blood Canc. 46, 755–761.
Bellaton, E., Bertozzi, A.I., Behar, C., Chastagner, P., Brisse, H., Sainte-Rose, C., Doz, F.,
Desjardins, L., 2003. Neoadjuvant chemotherapy for extensive unilateral retino-
blastoma. Br. J. Ophthalmol. 87, 327–329.
Benavente, C.A., Dyer, M.A., 2015. Genetically engineered mouse and orthotopic human
tumor xenograft models of retinoblastoma. In: Eferl, R., Casanova, E. (Eds.), Mouse
Models of Cancer: Methods and Protocols. Springer New York, New York, NY, pp.
307–317.
Berry, J.L., Bechtold, M., Shah, S., Zolfaghari, E., Reid, M., Jubran, R., Kim, J.W., 2017a.
Not all seeds are created equal: seed classification is predictive of outcomes in re-
tinoblastoma. Ophthalmology 124, 1817–1825.
Berry, J.L., Cobrinik, D., Kim, J.W., 2016a. Detection and intraretinal localization of an
'invisible' retinoblastoma using optical coherence tomography. Ocul Oncol Pathol 2,
148–152.
Berry, J.L., Jubran, R., Kim, J.W., Wong, K., Bababeygy, S.R., Almarzouki, H., Lee, T.C.,
Murphree, A.L., 2013. Long-term outcomes of Group D eyes in bilateral retino-
blastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr.
Blood Canc. 60, 688–693.
Berry, J.L., Jubran, R., Lee, T.C., Murphree, A.L., Lee, D., Kim, J.W., 2015. Low-dose
chemoreduction for infants diagnosed with retinoblastoma before 6 Months of age.
Ocul Oncol Pathol 1, 103–110.
Berry, J.L., Kogachi, K., Aziz, H.A., McGovern, K., Zolfaghari, E., Murphree, A.L., Jubran,
R., Kim, J.W., 2017b. Risk of metastasis and orbital recurrence in advanced retino-
blastoma eyes treated with systemic chemoreduction versus primary enucleation.
Pediatr. Blood Canc. 64.
Berry, J.L., Kogachi, K., Jubran, R., Kim, J.W., 2018a. Loss of fundus view as an indication
for secondary enucleation in retinoblastoma. Pediatr. Blood Canc. 65.
Berry, J.L., Shih, G., Moysidis, S.N., Jubran, R., Wong, K., Lee, T.C., Murphree, A.L., Kim,
J.W., 2016b. Patterns of subretinal fluid resolution in group D eyes treated with
chemoreduction: experience from the children's hospital Los angeles/University of
southern California. Ophthalmic Genet. 37, 400–403.
Berry, J.L., Xu, L., Kooi, I., Murphree, A.L., Prabakar, R.K., Reid, M., Stachelek, K., Le,
B.H.A., Welter, L., Reiser, B.J., Chevez-Barrios, P., Jubran, R., Lee, T.C., Kim, J.W.,
Kuhn, P., Cobrinik, D., Hicks, J., 2018b. Genomic cfDNA analysis of aqueous humor
in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retino-
blastoma. Mol. Cancer Res. 16, 1701–1712.
Berry, J.L., Xu, L., Murphree, A.L., Krishnan, S., Stachelek, K., Zolfaghari, E., McGovern,
K., Lee, T.C., Carlsson, A., Kuhn, P., Kim, J.W., Cobrinik, D., Hicks, J., 2017c.
Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. JAMA
Ophthalmol 135, 1221–1230.
Bhatnagar, R., Vine, A.K., 1991. Diffuse infiltrating retinoblastoma. Ophthalmology 98,
1657–1661.
Bianciotto, C., Shields, C.L., Iturralde, J.C., Sarici, A., Jabbour, P., Shields, J.A., 2012.
Fluorescein angiographic findings after intra-arterial chemotherapy for retino-
blastoma. Ophthalmology 119, 843–849.
Blach, L.E., McCormick, B., Abramson, D.H., 1996. External beam radiation therapy and
retinoblastoma: long-term results in the comparison of two techniques. Int. J. Radiat.
Oncol. Biol. Phys. 35, 45–51.
Blach, L.E., McCormick, B., Abramson, D.H., Ellsworth, R.M., 1994. Trilateral retino-
blastoma–incidence and outcome: a decade of experience. Int. J. Radiat. Oncol. Biol.
Phys. 29, 729–733.
Bogenmann, E., Lochrie, M.A., Simon, M.I., 1988. Cone cell-specific genes expressed in
retinoblastoma. Science 240, 76–78.
Bojinova, R.I., Schorderet, D.F., Addor, M.C., Gaide, A.C., Thonney, F., Pescia, G.,
Nenadov-Beck, M., Balmer, A., Munier, F.L., 2001. Further delineation of the facial
13q14 deletion syndrome in 13 retinoblastoma patients. Ophthalmic Genet. 22,
11–18.
Bohm, K.J., Gobin, Y.P., Francis, J.H., McInerney, G., Dabo-Trubelja, A., Dalecki, P.H.,
Marr, B.P., Abramson, D.H., 2018. Choroidal infarction following ophthalmic artery
chemotherapy. Int J Retina Vitreous 4, 16.
Bond, W.S., Akinfenwa, P.Y., Perlaky, L., Hurwitz, M.Y., Hurwitz, R.L., Chevez-Barrios, P.,
2013. Tumorspheres but not adherent cells derived from retinoblastoma tumors are
of malignant origin. PLoS One 8, e63519.
Bovey, E.H., Fernandez-Ragaz, A., Heon, E., Balmer, A., Munier, F.L., 1999.
Rhegmatogenous retinal detachment after treatment of retinoblastoma. Ophthalmic
Genet. 20, 141–151.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
57
Bowman, R.J., Mafwiri, M., Luthert, P., Luande, J., Wood, M., 2008. Outcome of re-
tinoblastoma in east Africa. Pediatr. Blood Canc. 50, 160–162.
Bracco, S., Leonini, S., De Francesco, S., Cioni, S., Gennari, P., Vallone, I.M., Piu, P.,
Galimberti, D., Romano, D.G., Caini, M., De Luca, M., Toti, P., Galluzzi, P.,
Hadjistilianou, T., Cerase, A., 2013. Intra-arterial chemotherapy with melphalan for
intraocular retinoblastoma. Br. J. Ophthalmol. 97, 1219–1221.
Brennan, R.C., Federico, S., Bradley, C., Zhang, J., Flores-Otero, J., Wilson, M., Stewart,
C., Zhu, F., Guy, K., Dyer, M.A., 2011. Targeting the p53 pathway in retinoblastoma
with subconjunctival Nutlin-3a. Cancer Res. 71, 4205–4213.
Brennan, R.C., Qaddoumi, I., Billups, C.A., Free, T.L., Haik, B.G., Rodriguez-Galindo, C.,
Wilson, M.W., 2015. Comparison of high-risk histopathological features in eyes with
primary or secondary enucleation for retinoblastoma. Br. J. Ophthalmol. 99,
1366–1371.
Brennan, R.C., Qaddoumi, I., Mao, S., Wu, J., Billups, C.A., Stewart, C.F., Hoehn, M.E.,
Rodriguez-Galindo, C., Wilson, M.W., 2017. Ocular salvage and vision preservation
using a topotecan-based regimen for advanced intraocular retinoblastoma. J. Clin.
Oncol. 35, 72–77.
Brichard, B., De Bruycker, J.J., De Potter, P., Neven, B., Vermylen, C., Cornu, G., 2002.
Combined chemotherapy and local treatment in the management of intraocular re-
tinoblastoma. Med. Pediatr. Oncol. 38, 411–415.
Brinkmann, R., Koinzer, S., Schlott, K., Ptaszynski, L., Bever, M., Baade, A., Luft, S.,
Miura, Y., Roider, J., Birngruber, R., 2012. Real-time temperature determination
during retinal photocoagulation on patients. J. Biomed. Opt. 17, 061219.
Brisse, H.J., de Graaf, P., Galluzzi, P., Cosker, K., Maeder, P., Goricke, S., Rodjan, F., de
Jong, M.C., Savignoni, A., Aerts, I., Desjardins, L., Moll, A.C., Hadjistilianou, T., Toti,
P., van der Valk, P., Castelijns, J.A., Sastre-Garau, X., European Retinoblastoma
Imaging, C., 2015. Assessment of early-stage optic nerve invasion in retinoblastoma
using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective
accuracy study with histopathological correlation. Eur. Radiol. 25, 1443–1452.
Broaddus, E., Topham, A., Singh, A.D., 2009. Incidence of retinoblastoma in the USA:
1975-2004. Br. J. Ophthalmol. 93, 21–23.
Brooks Jr., H.L., Meyer, D., Shields, J.A., Balas, A.G., Nelson, L.B., Fontanesi, J., 1990.
Removal of radiation-induced cataracts in patients treated for retinoblastoma. Arch.
Ophthalmol. 108, 1701–1708.
Buerk, B.M., Lai, W.W., Sharma, M.C., Shapiro, M.J., 2006. Minimally invasive method
for repair of rhegmatogenous retinal detachment following treatment for retino-
blastoma. Ophthalmic Surg. Laser. Imag. 37, 82–85.
Buitrago, E., Del Sole, M.J., Torbidoni, A., Fandino, A., Asprea, M., Croxatto, J.O.,
Chantada, G.L., Bramuglia, G.F., Schaiquevich, P., 2013. Ocular and systemic toxicity
of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Exp.
Eye Res. 108, 103–109.
Buitrago, E., Hocht, C., Chantada, G., Fandino, A., Navo, E., Abramson, D.H.,
Schaiquevich, P., Bramuglia, G.F., 2010. Pharmacokinetic analysis of topotecan after
intra-vitreal injection. Implications for retinoblastoma treatment. Exp. Eye Res. 91,
9–14.
Buitrago, E., Winter, U., Williams, G., Asprea, M., Chantada, G., Schaiquevich, P., 2016.
Pharmacokinetics of melphalan after intravitreal injection in a rabbit model. J. Ocul.
Pharmacol. Ther. 32, 230–235.
Byrne, J., Fears, T.R., Whitney, C., Parry, D.M., 1995. Survival after retinoblastoma: long-
term consequences and family history of cancer. Med. Pediatr. Oncol. 24, 160–165.
Canturk, S., Qaddoumi, I., Khetan, V., Ma, Z., Furmanchuk, A., Antoneli, C.B., Sultan, I.,
Kebudi, R., Sharma, T., Rodriguez-Galindo, C., Abramson, D.H., Chantada, G.L.,
2010. Survival of retinoblastoma in less-developed countries impact of socio-
economic and health-related indicators. Br. J. Ophthalmol. 94, 1432–1436.
Cao, L., Peng, B., Yao, L., Zhang, X., Sun, K., Yang, X., Yu, L., 2010. The ancient function
of RB-E2F pathway: insights from its evolutionary history. Biol. Direct 5, 55.
Carcaboso, A.M., Bramuglia, G.F., Chantada, G.L., Fandino, A.C., Chiappetta, D.A., de
Davila, M.T., Rubio, M.C., Abramson, D.H., 2007. Topotecan vitreous levels after
periocular or intravenous delivery in rabbits: an alternative for retinoblastoma che-
motherapy. Investig. Ophthalmol. Vis. Sci. 48, 3761–3767.
Carcaboso, A.M., Chiappetta, D.A., Opezzo, J.A., Hocht, C., Fandino, A.C., Croxatto, J.O.,
Rubio, M.C., Sosnik, A., Abramson, D.H., Bramuglia, G.F., Chantada, G.L., 2010.
Episcleral implants for topotecan delivery to the posterior segment of the eye.
Investig. Ophthalmol. Vis. Sci. 51, 2126–2134.
Cassoux, N., Aerts, I., Lumbroso-Le Rouic, L., Freneaux, P., Desjardins, L., 2017. Eye
salvage with combination of intravitreal and intracameral melphalan injection for
recurrent retinoblastoma with anterior chamber involvement: report of a case. Ocul
Oncol Pathol 3, 129–132.
Castera, L., Sabbagh, A., Dehainault, C., Michaux, D., Mansuet-Lupo, A., Patillon, B.,
Lamar, E., Aerts, I., Lumbroso-Le Rouic, L., Couturier, J., Stoppa-Lyonnet, D.,
Gauthier-Villars, M., Houdayer, C., 2010. MDM2 as a modifier gene in retino-
blastoma. J. Natl. Cancer Inst. 102, 1805–1808.
Cavenee, W.K., Dryja, T.P., Phillips, R.A., Benedict, W.F., Godbout, R., Gallie, B.L.,
Murphree, A.L., Strong, L.C., White, R.L., 1983. Expression of recessive alleles by
chromosomal mechanisms in retinoblastoma. Nature 305, 779–784.
Cebulla, C.M., Alegret, A., Ehlies, F.J., Davis 2nd, R.P., Hess, D.J., Murray, T.G.,
Echography Study, G., 2009. Echographic localization of periocular Carboplatin for
treatment of advanced retinoblastoma. Retin. Cases Brief Rep. 3, 4–7.
Chan, M.P., Hungerford, J.L., Kingston, J.E., Plowman, P.N., 2009. Salvage external beam
radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of
eye and vision preservation. Br. J. Ophthalmol. 93, 891–894.
Chantada, G., Doz, F., Antoneli, C.B., Grundy, R., Clare Stannard, F.F., Dunkel, I.J.,
Grabowski, E., Leal-Leal, C., Rodriguez-Galindo, C., Schvartzman, E., Popovic, M.B.,
Kremens, B., Meadows, A.T., Zucker, J.M., 2006a. A proposal for an international
retinoblastoma staging system. Pediatr. Blood Canc. 47, 801–805.
Chantada, G., Fandino, A., Davila, M.T., Manzitti, J., Raslawski, E., Casak, S.,
Schvartzman, E., 2004. Results of a prospective study for the treatment of retino-
blastoma. Cancer 100, 834–842.
Chantada, G., Luna-Fineman, S., Sitorus, R.S., Kruger, M., Israels, T., Leal-Leal, C.,
Bakhshi, S., Qaddoumi, I., Abramson, D.H., Doz, F., Committee, S.-P.G.-I.R.G.W,
2013. SIOP-PODC recommendations for graduated-intensity treatment of retino-
blastoma in developing countries. Pediatr. Blood Canc. 60, 719–727.
Chantada, G.L., Dunkel, I.J., Antoneli, C.B., de Davila, M.T., Arias, V., Beaverson, K.,
Fandino, A.C., Chojniak, M., Abramson, D.H., 2007. Risk factors for extraocular re-
lapse following enucleation after failure of chemoreduction in retinoblastoma.
Pediatr. Blood Canc. 49, 256–260.
Chantada, G.L., Fandino, A.C., Carcaboso, A.M., Lagomarsino, E., de Davila, M.T., Guitter,
M.R., Rose, A.B., Manzitti, J., Bramuglia, G.F., Abramson, D.H., 2009. A phase I study
of periocular topotecan in children with intraocular retinoblastoma. Investig.
Ophthalmol. Vis. Sci. 50, 1492–1496.
Chantada, G.L., Fandino, A.C., Guitter, M.R., Raslawski, E.C., Dominguez, J.L., Manzitti,
J., de Davila, M.T., Zubizarreta, P., Scopinaro, M., 2010. Results of a prospective
study for the treatment of unilateral retinoblastoma. Pediatr. Blood Canc. 55, 60–66.
Chantada, G.L., Fandino, A.C., Raslawski, E.C., Manzitti, J., de Davila, M.T., Casak, S.J.,
Scopinaro, M.J., Schvartzman, E., 2005. Experience with chemoreduction and focal
therapy for intraocular retinoblastoma in a developing country. Pediatr. Blood Canc.
44, 455–460.
Chantada, G.L., Fandino, A.C., Schvartzman, E., Raslawski, E., Schaiquevich, P., Manzitti,
J., 2014. Impact of chemoreduction for conservative therapy for retinoblastoma in
Argentina. Pediatr. Blood Canc. 61, 821–826.
Chantada, G.L., Qaddoumi, I., Canturk, S., Khetan, V., Ma, Z., Kimani, K., Yeniad, B.,
Sultan, I., Sitorus, R.S., Tacyildiz, N., Abramson, D.H., 2011. Strategies to manage
retinoblastoma in developing countries. Pediatr. Blood Canc. 56, 341–348.
Chantada, G.L., Rossi, J., Casco, F., Fandino, A., Scopinaro, M., de Davila, M.T.,
Abramson, D.H., 2006b. An aggressive bone marrow evaluation including im-
munocytology with GD2 for advanced retinoblastoma. J. Pediatr. Hematol. Oncol.
28, 369–373.
Chaudhry, S., Onadim, Z., Sagoo, M.S., Reddy, M.A., 2018. THE RECOGNITION OF
CAVITARY RETINOBLASTOMA TUMORS: implications for management and genetic
analysis. Retina 38, 782–787.
Chaussade, A., Millot, G., Wells, C., Brisse, H., Lae, M., Savignoni, A., Desjardins, L.,
Dendale, R., Doz, F., Aerts, I., Jimenez, I., Cassoux, N., Stoppa Lyonnet, D., Gauthier
Villars, M., Houdayer, C., 2019. Correlation between RB1germline mutations and
second primary malignancies in hereditary retinoblastoma patients treated with ex-
ternal beam radiotherapy. Eur. J. Med. Genet. 62, 217–223.
Chawla, B., Hasan, F., Azad, R., Seth, R., Upadhyay, A.D., Pathy, S., Pandey, R.M., 2016.
Clinical presentation and survival of retinoblastoma in Indian children. Br. J.
Ophthalmol. 100, 172–178.
Chen, D., Livne-bar, I., Vanderluit, J.L., Slack, R.S., Agochiya, M., Bremner, R., 2004. Cell-
specific effects of RB or RB/p107 loss on retinal development implicate an in-
trinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5, 539–551.
Chen, M., Jiang, H., Zhang, J., Shen, G., Jiang, Y., Li, H., Liu, Z., 2017. Outcome of intra-
arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective
study. Acta Ophthalmol. 95, 613–618.
Chevez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C.,
Hurwitz, M.Y., Hurwitz, R.L., 2005. Response of retinoblastoma with vitreous tumor
seeding to adenovirus-mediated delivery of thymidine kinase followed by ganci-
clovir. J. Clin. Oncol. 23, 7927–7935.
Chevez-Barrios, P., Hurwitz, M.Y., Louie, K., Marcus, K.T., Holcombe, V.N., Schafer, P.,
Aguilar-Cordova, C.E., Hurwitz, R.L., 2000. Metastatic and nonmetastatic models of
retinoblastoma. Am. J. Pathol. 157, 1405–1412.
Chhablani, J., Romanzo, A., Balmer, A., Pica, A., Gaillard, M.C., Cozza, R., Moeckli, R.,
Munier, F.L., 2010. (106)Ruthenium brachytherapy for ciliary recurrence with su-
praciliary effusion in retinoblastoma. Ophthalmic Genet. 31, 190–192.
Chiang, B., Jung, J.H., Prausnitz, M.R., 2018. The suprachoroidal space as a route of
administration to the posterior segment of the eye. Adv. Drug Deliv. Rev. 126, 58–66.
Chung, J., Turaka, K., Shields, C.L., 2010. Retinocytoma shows lack of response to che-
moreduction. J. Pediatr. Ophthalmol. Strabismus 47 Online, e1–3.
Chung, S.E., Sa, H.S., Koo, H.H., Yoo, K.H., Sung, K.W., Ham, D.I., 2008. Clinical mani-
festations and treatment of retinoblastoma in Korea. Br. J. Ophthalmol. 92,
1180–1184.
Clarke, A.R., Maandag, E.R., van Roon, M., van der Lugt, N.M., van der Valk, M., Hooper,
M.L., Berns, A., te Riele, H., 1992. Requirement for a functional Rb-1 gene in murine
development. Nature 359, 328–330.
Clavel, C.M., Nowak-Sliwinska, P., Păunescu, E., Dyson, P.J., 2015. Thermoresponsive
fluorinated small-molecule drugs: a new concept for efficient localized che-
motherapy. MedChemComm 6, 2054–2062.
Cobrinik, D., 2013. Learning about retinoblastoma from mouse models that missed. In:
Martinez-Murillo, R., Martinez, A. (Eds.), Animal Models of Brain Tumors. Springer,
New York, pp. 141–152.
Cobrinik, D., 2015. Retinoblastoma progression. EBioMedicine 2, 623–624.
Cohen, V.M., Shields, C.L., Furuta, M., Shields, J.A., 2008. Vitreous seeding from retinal
astrocytoma in three cases. Retina 28, 884–888.
Conkrite, K., Sundby, M., Mu, D., Mukai, S., MacPherson, D., 2012. Cooperation between
Rb and Arf in suppressing mouse retinoblastoma. J. Clin. Investig. 122, 1726–1733.
Cornish, E.E., Xiao, M., Yang, Z., Provis, J.M., Hendrickson, A.E., 2004. The role of opsin
expression and apoptosis in determination of cone types in human retina. Exp. Eye
Res. 78, 1143–1154.
Corson, T.W., Gallie, B.L., 2007. One hit, two hits, three hits, more? Genomic changes in
the development of retinoblastoma. Genes Chromosomes Cancer 46, 617–634.
Cozza, R., De Ioris, M.A., Ilari, I., Devito, R., Fidani, P., De Sio, L., Demelas, F., Romanzo,
A., Donfrancesco, A., 2009. Metastatic retinoblastoma: single institution experience
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
58
over two decades. Br. J. Ophthalmol. 93, 1163–1166.
Curcio, C.A., Sloan, K.R., Kalina, R.E., Hendrickson, A.E., 1990. Human photoreceptor
topography. J. Comp. Neurol. 292, 497–523.
Daicker, B., 1972. Anatomie und Pathologie der menschlichen retino-ziliaren
Fundusperipherie, Anatomie und Pathologie der menschlichen retino-ziliaren
Fundusperipherie. Karger Publishers, pp. I–VIII.
Dalvin, L.A., Ancona-Lezama, D., Lucio-Alvarez, J.A., Masoomian, B., Jabbour, P.,
Shields, C.L., 2018. Ophthalmic vascular events after primary unilateral intra-arterial
chemotherapy for retinoblastoma in early and recent eras. Ophthalmology 125,
1803–1811.
Daniels, A.B., Froehler, M.T., Nunnally, A.H., Pierce, J.M., Bozic, I., Stone, C.A.,
Santapuram, P.R., Tao, Y.K., Boyd, K.L., Himmel, L.E., Chen, S.C., Du, L., Friedman,
D.L., Richmond, A., 2019. Rabbit model of intra-arterial chemotherapy toxicity de-
monstrates retinopathy and vasculopathy related to drug and dose, not procedure or
approach. Investig. Ophthalmol. Vis. Sci. 60, 954–964.
Daniels, A.B., Froehler, M.T., Pierce, J.M., Nunnally, A.H., Calcutt, M.W., Bridges, T.M.,
LaNeve, D.C., Williams, P.E., Boyd, K.L., Reyzer, M.L., Lindsley, C.W., Friedman, D.L.,
Richmond, A., 2018. Pharmacokinetics, tissue localization, toxicity, and treatment
efficacy in the first small animal (rabbit) model of intra-arterial chemotherapy for
retinoblastoma. Investig. Ophthalmol. Vis. Sci. 59, 446–454.
Daruich, A.L., Moulin, A.P., Tran, H.V., Matet, A., Munier, F.L., 2017. SUBFOVEAL
NODULE IN COATS' DISEASE: toward an updated classification predicting visual
prognosis. Retina 37, 1591–1598.
De Francesco, S., Pichi, F., Lembo, A., Mastrangelo, D., Paradiso, A., De Luca, M., Toti, P.,
Nucci, P., Hadjistilianou, T., 2014. Massive anterior chamber involvement after intra-
arterial chemotherapy for retinoblastoma: ultrasound biomicroscopy and histo-
pathology. Int. Ophthalmol. 34, 967–970.
de Graaf, P., Goricke, S., Rodjan, F., Galluzzi, P., Maeder, P., Castelijns, J.A., Brisse, H.J.,
2012. Guidelines for imaging retinoblastoma: imaging principles and MRI standar-
dization. Pediatr. Radiol. 42, 2–14.
De Ioris, M.A., Valente, P., Randisi, F., Buzzonetti, L., Carai, A., Cozza, R., Del Bufalo, F.,
Romanzo, A., Angioni, A., Cacchione, A., Bernardi, B., Mastronuzzi, A., 2014.
Baseline central nervous system magnetic resonance imaging in early detection of
trilateral retinoblastoma: pitfalls in the diagnosis of pineal gland lesions. Anticancer
Res. 34, 7449–7454.
de Jong, M.C., de Graaf, P., Brisse, H.J., Galluzzi, P., Goricke, S.L., Moll, A.C., Munier,
F.L., Popovic, M.B., Moulin, A.P., Binaghi, S., Castelijns, J.A., Maeder, P., European
Retinoblastoma Imaging, C., 2015a. The potential of 3T high-resolution magnetic
resonance imaging for diagnosis, staging, and follow-up of retinoblastoma. Surv.
Ophthalmol. 60, 346–355.
de Jong, M.C., Kors, W.A., de Graaf, P., Castelijns, J.A., Kivela, T., Moll, A.C., 2014a.
Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 15,
1157–1167.
de Jong, M.C., Kors, W.A., de Graaf, P., Castelijns, J.A., Moll, A.C., Kivela, T., 2015b. The
incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am. J.
Ophthalmol. 160, 1116–1126 e1115.
de Jong, M.C., Moll, A.C., Goricke, S., van der Valk, P., Kors, W.A., Castelijns, J.A., de
Graaf, P., 2014b. Lu-from a suspicious cystic pineal gland to pineoblastoma in a
patient with familial unilateral retinoblastoma. Ophthalmic Genet. 1–3.
De la Huerta, I., Seider, M.I., Hetts, S.W., Damato, B.E., 2016. Delayed cerebral infarction
following intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol 134,
712–714.
Del Amo, E.M., Rimpela, A.K., Heikkinen, E., Kari, O.K., Ramsay, E., Lajunen, T., Schmitt,
M., Pelkonen, L., Bhattacharya, M., Richardson, D., Subrizi, A., Turunen, T.,
Reinisalo, M., Itkonen, J., Toropainen, E., Casteleijn, M., Kidron, H., Antopolsky, M.,
Vellonen, K.S., Ruponen, M., Urtti, A., 2017. Pharmacokinetic aspects of retinal drug
delivery. Prog. Retin. Eye Res. 57, 134–185.
Demirci, H., Shields, C.L., Meadows, A.T., Shields, J.A., 2005. Long-term visual outcome
following chemoreduction for retinoblastoma. Arch. Ophthalmol. 123, 1525–1530.
Dimaras, H., Corson, T.W., Cobrinik, D., White, A., Zhao, J., Munier, F.L., Abramson,
D.H., Shields, C.L., Chantada, G.L., Njuguna, F., Gallie, B.L., 2015. Retinoblastoma.
Nat. Rev. Dis. Primers 1, 15021.
Dimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N.L., Piovesan, B., Marrano, P.,
Corson, T.W., Eagle Jr., R.C., Squire, J.A., Gallie, B.L., 2008. Loss of RB1 induces non-
proliferative retinoma; increasing genomic instability correlates with progression to
retinoblastoma. Hum. Mol. Genet. 17, 1363–1372.
Ditta, L.C., Choudhri, A.F., Tse, B.C., Landers, M.M., Haik, B.G., Steinle, J.J., Williams,
J.S., Wilson, M.W., 2012. Validating a nonhuman primate model of super-selective
intraophthalmic artery chemotherapy: comparing ophthalmic artery diameters.
Investig. Ophthalmol. Vis. Sci. 53, 7791–7794.
Dommering, C.J., Marees, T., van der Hout, A.H., Imhof, S.M., Meijers-Heijboer, H.,
Ringens, P.J., van Leeuwen, F.E., Moll, A.C., 2012. RB1 mutations and second pri-
mary malignancies after hereditary retinoblastoma. Fam. Cancer 11, 225–233.
Doz, F., Neuenschwander, S., Plantaz, D., Courbon, B., Gentet, J.C., Bouffet, E., Mosseri,
V., Vannier, J.P., Mechinaud, F., Desjardins, L., et al., 1995. Etoposide and carbo-
platin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie
Pediatrique. J. Clin. Oncol. 13, 902–909.
Draper, G.J., Sanders, B.M., Brownbill, P.A., Hawkins, M.M., 1992. Patterns of risk of
hereditary retinoblastoma and applications to genetic counselling. Br. J. Canc. 66,
211–219.
Dryja, T.P., Rapaport, J., McGee, T.L., Nork, T.M., Schwartz, T.L., 1993. Molecular
etiology of low-penetrance retinoblastoma in two pedigrees. Am. J. Hum. Genet. 52,
1122–1128.
Dunkel, I.J., Chan, H.S., Jubran, R., Chantada, G.L., Goldman, S., Chintagumpala, M.,
Khakoo, Y., Abramson, D.H., 2010a. High-dose chemotherapy with autologous he-
matopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr. Blood Canc. 55,
149–152.
Dunkel, I.J., Jubran, R.F., Gururangan, S., Chantada, G.L., Finlay, J.L., Goldman, S.,
Khakoo, Y., O'Brien, J.M., Orjuela, M., Rodriguez-Galindo, C., Souweidane, M.M.,
Abramson, D.H., 2010b. Trilateral retinoblastoma: potentially curable with intensive
chemotherapy. Pediatr. Blood Canc. 54, 384–387.
Dunkel, I.J., Khakoo, Y., Kernan, N.A., Gershon, T., Gilheeney, S., Lyden, D.C., Wolden,
S.L., Orjuela, M., Gardner, S.L., Abramson, D.H., 2010c. Intensive multimodality
therapy for patients with stage 4a metastatic retinoblastoma. Pediatr. Blood Canc. 55,
55–59.
Dunkel, I.J., Krailo, M.D., Chantada, G.L., Banerjee, A., Abouelnaga, S., Buchsbaum, J.,
Merchant, T.E., Granger, M., Jubran, R.F., Kellick, M., Weinstein, J., Abramson, D.H.,
Rodriguez-Galindo, C., Chintagumpala, M.M., 2017. Intensive multi-modality
therapy for extra-ocular retinoblastoma (RB): a Children's Oncology Group (COG)
trial (ARET0321). J. Clin. Oncol. 35 10506–10506.
Dunkel, I.J., Shi, W., Salvaggio, K., Marr, B.P., Brodie, S.E., Gobin, Y.P., Abramson, D.H.,
2014. Risk factors for severe neutropenia following intra-arterial chemotherapy for
intra-ocular retinoblastoma. PLoS One 9, e108692.
Eagle Jr., R.C., 2009. High-risk features and tumor differentiation in retinoblastoma: a
retrospective histopathologic study. Arch. Pathol. Lab Med. 133, 1203–1209.
Eagle Jr., R.C., Shields, C.L., Bianciotto, C., Jabbour, P., Shields, J.A., 2011.
Histopathologic observations after intra-arterial chemotherapy for retinoblastoma.
Arch. Ophthalmol. 129, 1416–1421.
Eagle Jr., R.C., Shields, J.A., Donoso, L., Milner, R.S., 1989. Malignant transformation of
spontaneously regressed retinoblastoma, retinoma/retinocytoma variant.
Ophthalmology 96, 1389–1395.
Edelhauser, H.F., Rowe-Rendleman, C.L., Robinson, M.R., Dawson, D.G., Chader, G.J.,
Grossniklaus, H.E., Rittenhouse, K.D., Wilson, C.G., Weber, D.A., Kuppermann, B.D.,
Csaky, K.G., Olsen, T.W., Kompella, U.B., Holers, V.M., Hageman, G.S., Gilger, B.C.,
Campochiaro, P.A., Whitcup, S.M., Wong, W.T., 2010. Ophthalmic drug delivery
systems for the treatment of retinal diseases: basic research to clinical applications.
Investig. Ophthalmol. Vis. Sci. 51, 5403–5420.
Eisner, G., 1973. Biomicroscopy of the Peripheral Fundus: an Atlas and Textbook.
Springer.
Ellsworth, R.M., 1969. The practical management of retinoblastoma. Trans. Am.
Ophthalmol. Soc. 67, 462–534.
Eloy, P., Dehainault, C., Sefta, M., Aerts, I., Doz, F., Cassoux, N., Lumbroso le Rouic, L.,
Stoppa-Lyonnet, D., Radvanyi, F., Millot, G.A., Gauthier-Villars, M., Houdayer, C.,
2016. A parent-of-origin effect impacts the phenotype in low penetrance retino-
blastoma families segregating the c.1981C>T/p.Arg661Trp mutation of RB1. PLoS
Genet. 12, e1005888.
Eng, C., Li, F.P., Abramson, D.H., Ellsworth, R.M., Wong, F.L., Goldman, M.B., Seddon, J.,
Tarbell, N., Boice Jr., J.D., 1993. Mortality from second tumors among long-term
survivors of retinoblastoma. J. Natl. Cancer Inst. 85, 1121–1128.
Epstein, J.A., Shields, C.L., Shields, J.A., 2003. Trends in the management of retino-
blastoma: evaluation of 1,196 consecutive eyes during 1974 to 2001. J. Pediatr.
Ophthalmol. Strabismus 40, 196–203 quiz 217-198.
Ericson, L.A., Rosengren, B.H., 1961. Present therapeutic resources in retinoblastoma.
Acta Ophthalmol. 39, 569–576.
Fabian, I.D., Naeem, Z., Stacey, A.W., Chowdhury, T., Duncan, C., Reddy, M.A., Sagoo,
M.S., 2017a. Long-term visual acuity, strabismus, and nystagmus outcomes following
multimodality treatment in group D retinoblastoma eyes. Am. J. Ophthalmol. 179,
137–144.
Fabian, I.D., Puccinelli, F., Gaillard, M.C., Beck-Popovic, M., Munier, F.L., 2017b.
Diagnosis and management of secondary epipapillary retinoblastoma. Br. J.
Ophthalmol. 101, 1412–1418.
Fabian, I.D., Stacey, A.W., Chowdhury, T., Duncan, C., Karaa, E.K., Scheimberg, I., Reddy,
M.A., Sagoo, M.S., 2017c. High-risk histopathology features in primary and sec-
ondary enucleated international intraocular retinoblastoma classification group D
eyes. Ophthalmology 124, 851–858.
Fabian, I.D., Stacey, A.W., Naeem, Z., Onadim, Z., Chowdhury, T., Duncan, C., Sagoo,
M.S., Reddy, M.A., 2018. Strabismus in retinoblastoma survivors with long-term
follow-up. J AAPOS 22, 276 e271–276 e277.
Fernandes, A.G., Pollock, B.D., Rabito, F.A., 2018. Retinoblastoma in the United States: a
40-year incidence and survival analysis. J. Pediatr. Ophthalmol. Strabismus 55,
182–188.
Fernandez, M.P., Al-Holou, S.N., Fischer, O., Murray, T., Harbour, J.W., Dubovy, S.R.,
Berrocal, A.M., 2017. Fluorescein angiography findings in diffuse retinoblastoma:
two case reports with clinicopathologic correlation. J AAPOS 21, 337–339 e332.
Fischer, C., Petriccione, M., Vitolano, S., Guarini, E., Davis, M.E., Dunkel, I.J., 2017. The
effect of ophthalmic artery chemosurgery on immune function in retinoblastoma
patients: a single institution retrospective analysis. J. Pediatr. Hematol. Oncol. 39,
555–559.
Fledelius, H.C., Christensen, A.C., 1996. Reappraisal of the human ocular growth curve in
fetal life, infancy, and early childhood. Br. J. Ophthalmol. 80, 918–921.
Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., Peto, J., 2004. Lifetime risks of
common cancers among retinoblastoma survivors. J. Natl. Cancer Inst. 96, 357–363.
Flexner, S., 1891. A peculiar glioma (neuroepithelioma?) of the retina. Bull. Johns
Hopkins Hosp. 2, 115–119.
Fluhs, D., Anastassiou, G., Wening, J., Sauerwein, W., Bornfeld, N., 2004. The design and
the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med. Phys. 31,
1481–1488.
Fontanesi, J., Pratt, C.B., Kun, L.E., Hustu, H.O., Coffey, D., Meyer, D., 1996. Treatment
outcome and dose-response relationship in infants younger than 1 year treated for
retinoblastoma with primary irradiation. Med. Pediatr. Oncol. 26, 297–304.
Foos, R.Y., 1972. Vitreoretinal juncture; topographical variations. Investig. Ophthalmol.
11, 801–808.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
59
Foster, B.S., Mukai, S., 1996. Intraocular retinoblastoma presenting as ocular and orbital
inflammation. Int. Ophthalmol. Clin. 36, 153–160.
Francis, J.H., Abramson, D.H., Brodie, S.E., Marr, B.P., 2013a. Indocyanine green en-
hanced transpupillary thermotherapy in combination with ophthalmic artery che-
mosurgery for retinoblastoma. Br. J. Ophthalmol. 97, 164–168.
Francis, J.H., Abramson, D.H., Gaillard, M.C., Marr, B.P., Beck-Popovic, M., Munier, F.L.,
2015a. The classification of vitreous seeds in retinoblastoma and response to in-
travitreal melphalan. Ophthalmology 122, 1173–1179.
Francis, J.H., Abramson, D.H., Gobin, Y.P., Marr, B.P., Tendler, I., Brodie, S.E., Dunkel,
I.J., 2015b. Efficacy and toxicity of second-course ophthalmic artery chemosurgery
for retinoblastoma. Ophthalmology 122, 1016–1022.
Francis, J.H., Abramson, D.H., Ji, X., Shields, C.L., Teixeira, L.F., Schefler, A.C., Cassoux,
N., Hadjistilianou, D., Berry, J.L., Frenkel, S., Munier, F.L., 2017a. Risk of extraocular
extension in eyes with retinoblastoma receiving intravitreous chemotherapy. JAMA
Ophthalmol 135, 1426–1429.
Francis, J.H., Barker, C.A., Wolden, S.L., McCormick, B., Segal, K., Cohen, G., Gobin, Y.P.,
Marr, B.P., Brodie, S.E., Dunkel, I.J., Abramson, D.H., 2013b. Salvage/adjuvant
brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma.
Int. J. Radiat. Oncol. Biol. Phys. 87, 517–523.
Francis, J.H., Brodie, S.E., Marr, B., Zabor, E.C., Mondesire-Crump, I., Abramson, D.H.,
2017b. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-
year experience. Ophthalmology 124, 488–495.
Francis, J.H., Gobin, Y.P., Nagiel, A., Dunkel, I.J., Kucine, N., Marr, B.P., Brodie, S.E.,
Abramson, D.H., 2012. Thrombophilia in patients with retinoblastoma receiving
ophthalmic artery chemosurgery. Arch. Ophthalmol. 130, 1605–1608.
Francis, J.H., Iyer, S., Gobin, Y.P., Brodie, S.E., Abramson, D.H., 2017c. Retinoblastoma
vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery
chemosurgery with or without intravitreous and periocular chemotherapy.
Ophthalmology 124, 1548–1555.
Francis, J.H., Levin, A.M., Zabor, E.C., Gobin, Y.P., Abramson, D.H., 2018a. Ten-year
experience with ophthalmic artery chemosurgery: ocular and recurrence-free sur-
vival. PLoS One 13, e0197081.
Francis, J.H., Marr, B.P., Abramson, D.H., 2016. Classification of vitreous seeds in re-
tinoblastoma: correlations with patient, tumor, and treatment characteristics.
Ophthalmology 123, 1601–1605.
Francis, J.H., Marr, B.P., Brodie, S.E., Abramson, D.H., 2015c. Anterior ocular toxicity of
intravitreous melphalan for retinoblastoma. JAMA Ophthalmol 133, 1459–1463.
Francis, J.H., Roosipu, N., Levin, A.M., Brodie, S.E., Dunkel, I.J., Gobin, Y.P., Abramson,
D.H., 2018b. Current treatment of bilateral retinoblastoma: the impact of in-
traarterial and intravitreous chemotherapy. Neoplasia 20, 757–763.
Francis, J.H., Schaiquevich, P., Buitrago, E., Del Sole, M.J., Zapata, G., Croxatto, J.O.,
Marr, B.P., Brodie, S.E., Berra, A., Chantada, G.L., Abramson, D.H., 2014. Local and
systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a
preclinical and clinical study. Ophthalmology 121, 1810–1817.
Friedman, D.N., Lis, E., Sklar, C.A., Oeffinger, K.C., Reppucci, M., Fleischut, M.H., Francis,
J.H., Marr, B., Abramson, D.H., Dunkel, I.J., 2014. Whole-body magnetic resonance
imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of her-
editary retinoblastoma: a pilot study. Pediatr. Blood Canc. 61, 1440–1444.
Friedrich, P., Itriago, E., Rodriguez-Galindo, C., Ribeiro, K., 2017. Racial and ethnic
disparities in the incidence of pediatric Extracranial embryonal tumors. J. Natl.
Cancer Inst. 109.
Friend, S.H., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, D.M., Dryja,
T.P., 1986. A human DNA segment with properties of the gene that predisposes to
retinoblastoma and osteosarcoma. Nature 323, 643–646.
Fugaro, M.N., Kiupel, M., Montiani-Ferreira, F., Hawkins, J.F., Janovitz, E.B., 2005.
Retinoblastoma in the eye of a llama (Llama glama). Vet. Ophthalmol. 8, 287–290.
Funes, S., Sampor, C., Villasante, F., Fandino, A., Manzitti, J., Sgroi, M., Neira, P., Peralta,
L., Lagomarsino, E., Schaiquevich, P., Ceciliano, A., Chantada, G.L., 2018. Feasibility
and results of an intraarterial chemotherapy program for the conservative treatment
of retinoblastoma in Argentina. Pediatr. Blood Canc. 65, e27086.
Fung, Y.K., Murphree, A.L., T'Ang, A., Qian, J., Hinrichs, S.H., Benedict, W.F., 1987.
Structural evidence for the authenticity of the human retinoblastoma gene. Science
236, 1657–1661.
Gaillard, M.C., Houghton, S., Stathopoulos, C., Munier, F.L., 2018. OCT-guided man-
agement of subclinical recurrent retinoblastoma. Ophthalmic Genet. 39, 338–343.
Gaillard, M.C., Mataftsi, A., Balmer, A., Houghton, S., Munier, F.L., 2014. Ranibizumab in
the management of advanced Coats disease Stages 3B and 4: long-term outcomes.
Retina 34, 2275–2281.
Gallie, B.L., Budning, A., DeBoer, G., Thiessen, J.J., Koren, G., Verjee, Z., Ling, V., Chan,
H.S., 1996. Chemotherapy with focal therapy can cure intraocular retinoblastoma
without radiotherapy. Arch. Ophthalmol. 114, 1321–1328.
Gallie, B.L., Campbell, C., Devlin, H., Duckett, A., Squire, J.A., 1999. Developmental basis
of retinal-specific induction of cancer by RB mutation. Cancer Res. 59, 1731s–1735s.
Gallie, B.L., Phillips, R.A., Ellsworth, R.M., Abramson, D.H., 1982. Significance of re-
tinoma and phthisis bulbi for retinoblastoma. Ophthalmology 89, 1393–1399.
Gatta, G., Ferrari, A., Stiller, C.A., Pastore, G., Bisogno, G., Trama, A., Capocaccia, R.,
Group, R.W., 2012. Embryonal cancers in Europe. Eur. J. Cancer 48, 1425–1433.
Gerrish, A., Stone, E., Clokie, S., Ainsworth, J.R., Jenkinson, H., McCalla, M., Hitchcott,
C., Colmenero, I., Allen, S., Parulekar, M., Cole, T., 2019. Non-invasive diagnosis of
retinoblastoma using cell-free DNA from aqueous humour. Br. J. Ophthalmol.
https://doi.org/10.1136/bjophthalmol-2018-313005. (Epub ahead of print).
Ghassemi, F., Amoli, F.A., 2014. Pathological findings in enucleated eyes after intravitreal
melphalan injection. Int. Ophthalmol. 34, 533–540.
Ghassemi, F., Rahmanikhah, E., Roohipoor, R., Karkhaneh, R., Faegh, A., 2013.
Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant
therapy. Pediatr. Blood Canc. 60, 599–604.
Ghassemi, F., Shields, C.L., 2012. Intravitreal melphalan for refractory or recurrent
vitreous seeding from retinoblastoma. Arch. Ophthalmol. 130, 1268–1271.
Ghassemi, F., Shields, C.L., Ghadimi, H., Khodabandeh, A., Roohipoor, R., 2014.
Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous
seeding from retinoblastoma. JAMA Ophthalmol 132, 936–941.
Gobin, Y.P., Dunkel, I.J., Marr, B.P., Brodie, S.E., Abramson, D.H., 2011. Intra-arterial
chemotherapy for the management of retinoblastoma: four-year experience. Arch.
Ophthalmol. 129, 732–737.
Gobin, Y.P., Dunkel, I.J., Marr, B.P., Francis, J.H., Brodie, S.E., Abramson, D.H., 2012.
Combined, sequential intravenous and intra-arterial chemotherapy (bridge che-
motherapy) for young infants with retinoblastoma. PLoS One 7, e44322.
Goddard, A.G., Kingston, J.E., Hungerford, J.L., 1999. Delay in diagnosis of retino-
blastoma: risk factors and treatment outcome. Br. J. Ophthalmol. 83, 1320–1323.
Golabchi, K., Soleimani-Jelodar, R., Aghadoost, N., Momeni, F., Moridikia, A., Nahand,
J.S., Masoudifar, A., Razmjoo, H., Mirzaei, H., 2018. MicroRNAs in retinoblastoma:
potential diagnostic and therapeutic biomarkers. J. Cell. Physiol. 233, 3016–3023.
Gombos, D.S., 2012. Retinoblastoma in the perinatal and neonatal child. Semin. Fetal
Neonatal Med. 17, 239–242.
Gombos, D.S., Cauchi, P.A., Hungerford, J.L., Addison, P., Coen, P.G., Kingston, J.E.,
2006. Vitreous relapse following primary chemotherapy for retinoblastoma: is ad-
juvant diode laser a risk factor? Br. J. Ophthalmol. 90, 1168–1172.
Gombos, D.S., Hungerford, J., Abramson, D.H., Kingston, J., Chantada, G., Dunkel, I.J.,
Antoneli, C.B., Greenwald, M., Haik, B.G., Leal, C.A., Medina-Sanson, A., Schefler,
A.C., Veerakul, G., Wieland, R., Bornfeld, N., Wilson, M.W., Yu, C.B., 2007.
Secondary acute myelogenous leukemia in patients with retinoblastoma: is che-
motherapy a factor? Ophthalmology 114, 1378–1383.
Gombos, D.S., Kelly, A., Coen, P.G., Kingston, J.E., Hungerford, J.L., 2002.
Retinoblastoma treated with primary chemotherapy alone: the significance of tumour
size, location, and age. Br. J. Ophthalmol. 86, 80–83.
Gratias, S., Rieder, H., Ullmann, R., Klein-Hitpass, L., Schneider, S., Boloni, R., Kappler,
M., Lohmann, D.R., 2007. Allelic loss in a minimal region on chromosome 16q24 is
associated with vitreous seeding of retinoblastoma. Cancer Res. 67, 408–416.
Greenwald, M.J., Strauss, L.C., 1996. Treatment of intraocular retinoblastoma with car-
boplatin and etoposide chemotherapy. Ophthalmology 103, 1989–1997.
Greger, V., Debus, N., Lohmann, D., Hopping, W., Passarge, E., Horsthemke, B., 1994.
Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma.
Hum. Genet. 94, 491–496.
Gregersen, P.A., Urbak, S.F., Funding, M., Overgaard, J., Jensen, U.B., Alsner, J., 2016.
Danish retinoblastoma patients 1943-2013 - genetic testing and clinical implications.
Acta Oncol. 55, 412–417.
Grobner, S.N., Worst, B.C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva,
V.A., Johann, P.D., Balasubramanian, G.P., Segura-Wang, M., Brabetz, S., Bender, S.,
Hutter, B., Sturm, D., Pfaff, E., Hubschmann, D., Zipprich, G., Heinold, M., Eils, J.,
Lawerenz, C., Erkek, S., Lambo, S., Waszak, S., Blattmann, C., Borkhardt, A., Kuhlen,
M., Eggert, A., Fulda, S., Gessler, M., Wegert, J., Kappler, R., Baumhoer, D., Burdach,
S., Kirschner-Schwabe, R., Kontny, U., Kulozik, A.E., Lohmann, D., Hettmer, S.,
Eckert, C., Bielack, S., Nathrath, M., Niemeyer, C., Richter, G.H., Schulte, J., Siebert,
R., Westermann, F., Molenaar, J.J., Vassal, G., Witt, H., Project, I.P.-S., Project, I.M.-
S., Burkhardt, B., Kratz, C.P., Witt, O., van Tilburg, C.M., Kramm, C.M., Fleischhack,
G., Dirksen, U., Rutkowski, S., Fruhwald, M., von Hoff, K., Wolf, S., Klingebiel, T.,
Koscielniak, E., Landgraf, P., Koster, J., Resnick, A.C., Zhang, J., Liu, Y., Zhou, X.,
Waanders, A.J., Zwijnenburg, D.A., Raman, P., Brors, B., Weber, U.D., Northcott,
P.A., Pajtler, K.W., Kool, M., Piro, R.M., Korbel, J.O., Schlesner, M., Eils, R., Jones,
D.T.W., Lichter, P., Chavez, L., Zapatka, M., Pfister, S.M., 2018. The landscape of
genomic alterations across childhood cancers. Nature 555, 321–327.
Grossniklaus, H.E., Dhaliwal, R.S., Martin, D.F., 1998. Diffuse anterior retinoblastoma.
Retina 18, 238–241.
Group, A.W., Ccm, Group, A.W., 2013. Italian cancer figures, report 2012: cancer in
children and adolescents. Epidemiol. Prev. 37, 1–225.
Gunduz, K., Gunalp, I., Yalcindag, N., Unal, E., Tacyildiz, N., Erden, E., Geyik, P.O., 2004.
Causes of chemoreduction failure in retinoblastoma and analysis of associated factors
leading to eventual treatment with external beam radiotherapy and enucleation.
Ophthalmology 111, 1917–1924.
Habib, L.A., Francis, J.H., Fabius, A.W., Gobin, P.Y., Dunkel, I.J., Abramson, D.H., 2018.
Second primary malignancies in retinoblastoma patients treated with intra-arterial
chemotherapy: the first 10 years. Br. J. Ophthalmol. 102, 272–275.
Hadjistilianou, T., De Francesco, S., Martone, G., Malandrini, A., 2006. Retinocytoma
associated with calcified vitreous deposits. Eur. J. Ophthalmol. 16, 349–351.
Hagstrom, S.A., Dryja, T.P., 1999. Mitotic recombination map of 13cen-13q14 derived
from an investigation of loss of heterozygosity in retinoblastomas. Proc. Natl. Acad.
Sci. U. S. A. 96, 2952–2957.
Haider, S., Qureshi, W., Ali, A., 2008. Leukocoria in children. J. Pediatr. Ophthalmol.
Strabismus 45, 179–180.
Haik, B.G., Dunleavy, S.A., Cooke, C., Ellsworth, R.M., Abramson, D.H., Smith, M.E.,
Karcioglu, Z.A., 1987. Retinoblastoma with anterior chamber extension.
Ophthalmology 94, 367–370.
Hall, L.S., Ceisler, E., Abramson, D.H., 1999. Visual outcomes in children with bilateral
retinoblastoma. J AAPOS 3, 138–142.
Halperin, E.C., 2000. Neonatal neoplasms. Int. J. Radiat. Oncol. Biol. Phys. 47, 171–178.
Hamama-Raz, Y., Rot, I., Buchbinder, E., 2012. The coping experience of parents of a
child with retinoblastoma-malignant eye cancer. J. Psychosoc. Oncol. 30, 21–40.
Hamel, P., Heon, E., Gallie, B.L., Budning, A.S., 2000. Focal therapy in the management of
retinoblastoma: when to start and when to stop. J AAPOS 4, 334–337.
Hartman, R.R., Kompella, U.B., 2018. Intravitreal, subretinal, and suprachoroidal injec-
tions: evolution of microneedles for drug delivery. J. Ocul. Pharmacol. Ther. 34,
141–153.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
60
Hasanreisoglu, M., Dolz-Marco, R., Ferenczy, S.R., Shields, J.A., Shields, C.L., 2015.
Spectral domain optical coherence tomography reveals hidden fovea beneath ex-
tensive vitreous seeding from retinoblastoma. Retina 35, 1486–1487.
Hayden, B., Jockovich, M.E., Murray, T.G., Kralinger, M.T., Voigt, M., Hernandez, E.,
Feuer, W., Parel, J.M., 2006. Iontophoretic delivery of carboplatin in a murine model
of retinoblastoma. Investig. Ophthalmol. Vis. Sci. 47, 3717–3721.
Hayden, B.C., Jockovich, M.E., Murray, T.G., Voigt, M., Milne, P., Kralinger, M., Feuer,
W.J., Hernandez, E., Parel, J.M., 2004. Pharmacokinetics of systemic versus focal
Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of
retinoblastoma. Investig. Ophthalmol. Vis. Sci. 45, 3644–3649.
Heck, J.E., Lombardi, C.A., Meyers, T.J., Cockburn, M., Wilhelm, M., Ritz, B., 2012.
Perinatal characteristics and retinoblastoma. Cancer Causes Control 23, 1567–1575.
Herzog, S., Lohmann, D.R., Buiting, K., Schuler, A., Horsthemke, B., Rehder, H., Rieder,
H., 2001. Marked differences in unilateral isolated retinoblastomas from young and
older children studied by comparative genomic hybridization. Hum. Genet. 108,
98–104.
Hildanus, F., 1682. Observationum centuria VI, observation I. In: Opera observationem et
curationum medico-chiruricarum. Francofurti : J.L. Dufour., pp. 497–499.
Hilgartner, H., 1903. Report of case of double glioma treated with x-ray. 1903. Texas Med
J, pp. 322.
Honavar, S.G., Shields, C.L., Shields, J.A., Demirci, H., Naduvilath, T.J., 2001. Intraocular
surgery after treatment of retinoblastoma. Arch. Ophthalmol. 119, 1613–1621.
Hosoya, K., Kyoko, H., Toyooka, N., Kato, A., Orihashi, M., Tomi, M., Tachikawa, M.,
2008. Evaluation of amino acid-mustard transport as L-type amino acid transporter 1
(LAT1)-mediated alkylating agents. Biol. Pharm. Bull. 31, 2126–2130.
Houston, S.K., Lampidis, T.J., Murray, T.G., 2013. Models and discovery strategies for
new therapies of retinoblastoma. Expert Opin. Drug Discov. 8, 383–394.
Hudson, L.E., Mendoza, P., Hudson, W.H., Ziesel, A., Hubbard 3rd, G.B., Wells, J.,
Dwivedi, B., Kowalski, J., Seby, S., Patel, V., Geisert, E., Specht, C., Grossniklaus,
H.E., 2018. Distinct gene expression profiles define anaplastic grade in retino-
blastoma. Am. J. Pathol. 188, 2328–2338.
Hurwitz, M.Y., Marcus, K.T., Chevez-Barrios, P., Louie, K., Aguilar-Cordova, E., Hurwitz,
R.L., 1999. Suicide gene therapy for treatment of retinoblastoma in a murine model.
Hum. Gene Ther. 10, 441–448.
Hurwitz, R.L., Bogenmann, E., Font, R.L., Holcombe, V., Clark, D., 1990. Expression of the
functional cone phototransduction cascade in retinoblastoma. J. Clin. Investig. 85,
1872–1878.
Hwang, C.S., Mendoza, P.R., Wells, J.R., Grossniklaus, H.E., Hubbard 3rd, G.B., 2017.
Proliferative vitreoretinopathy in treated retinoblastoma. Ophthalmol Retina 1,
165–172.
Imhof, S.M., Moll, A.C., Schouten-van Meeteren, A.Y., 2006. Stage of presentation and
visual outcome of patients screened for familial retinoblastoma: nationwide regis-
tration in The Netherlands. Br. J. Ophthalmol. 90, 875–878.
Inomata, M., Kaneko, A., 1987. Chemosensitivity profiles of primary and cultured human
retinoblastoma cells in a human tumor clonogenic assay. Jpn. J. Cancer Res. 78,
858–868.
Ishida, Y., Qiu, D., Maeda, M., Fujimoto, J., Kigasawa, H., Kobayashi, R., Sato, M.,
Okamura, J., Yoshinaga, S., Rikiishi, T., Shichino, H., Kiyotani, C., Kudo, K., Asami,
K., Hori, H., Kawaguchi, H., Inada, H., Adachi, S., Manabe, A., Kuroda, T., 2016.
Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based
retrospective cohort study in Japan. Int. J. Clin. Oncol. 21, 506–516.
Jacks, T., Fazeli, A., Schmitt, E.M., Bronson, R.T., Goodell, M.A., Weinberg, R.A., 1992.
Effects of an Rb mutation in the mouse. Nature 359, 295–300.
Jakobiec, F.A., Tso, M.O., Zimmerman, L.E., Danis, P., 1977. Retinoblastoma and in-
tracranial malignancy. Cancer 39, 2048–2058.
Jaradat, I., Yousef, Y.A., Mehyar, M., Sultan, I., Khurma, S., Al-Rawashded, K., Wilson,
M., Qaddoumi, I., Salem, A., Alnawaiseh, I., 2011. Retinoblastoma in Jordan: an
epidemiological study (2006-2010). Hematol Oncol Stem Cell Ther 4, 126–131.
Jehanne, M., Lumbroso-Le Rouic, L., Savignoni, A., Aerts, I., Mercier, G., Bours, D.,
Desjardins, L., Doz, F., 2009. Analysis of ototoxicity in young children receiving
carboplatin in the context of conservative management of unilateral or bilateral re-
tinoblastoma. Pediatr. Blood Canc. 52, 637–643.
Jenkinson, H., 2015. Retinoblastoma: diagnosis and management–the UK perspective.
Arch. Dis. Child. 100, 1070–1075.
Ji, X., Hua, P., Li, J., Li, J., Zhao, J., Zhao, P., 2016. Intravitreal melphalan for vitreous
seeds: initial experience in China. J. Ophthalmol. 2016, 4387286.
Jiang, L.B., Liu, X.Q., Li, B., He, X.J., Jin, Y.L., Li, L.Q., Gao, F., Wang, N.L., 2008. Heat
shock proteins and survivin: relationship and effects on proliferation index of re-
tinoblastoma cells. Histol. Histopathol. 23, 827–831.
Jijelava, K.P., Grossniklaus, H.E., 2013. Diffuse anterior retinoblastoma: a review. Saudi
J. Ophthalmol. 27, 135–139.
Jubran, R.F., Erdreich-Epstein, A., Butturini, A., Murphree, A.L., Villablanca, J.G., 2004.
Approaches to treatment for extraocular retinoblastoma: children's Hospital Los
Angeles experience. J. Pediatr. Hematol. Oncol. 26, 31–34.
Kaliki, S., Patel, A., Iram, S., Palkonda, V.A.R., 2017. Clinical presentation and outcomes
of stage III or stage IV retinoblastoma in 80 asian Indian patients. J. Pediatr.
Ophthalmol. Strabismus 54, 177–184.
Kaliki, S., Patel, A., Iram, S., Ramappa, G., Mohamed, A., Palkonda, V.A.R., 2019.
RETINOBLASTOMA IN India: clinical presentation and outcome in 1,457 patients
(2,074 eyes). Retina 39, 379–391.
Kaliki, S., Shields, C.L., Eagle Jr., R.C., Vemuganti, G.K., Almeida, A., Manjandavida, F.P.,
Mulay, K., Honavar, S.G., Shields, J.A., 2013a. Ciliary body medulloepithelioma:
analysis of 41 cases. Ophthalmology 120, 2552–2559.
Kaliki, S., Shields, C.L., Gupta, A., Mishra, D.K., Das, C., Say, E.A., Shields, J.A., 2015a.
Newly diagnosed active retinoblastoma in adults. Retina 35, 2483–2488.
Kaliki, S., Shields, C.L., Rojanaporn, D., Al-Dahmash, S., McLaughlin, J.P., Shields, J.A.,
Eagle Jr., R.C., 2013b. High-risk retinoblastoma based on international classification
of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120, 997–1003.
Kaliki, S., Srinivasan, V., Gupta, A., Mishra, D.K., Naik, M.N., 2015b. Clinical features
predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control
study. Ophthalmology 122, 1165–1172.
Kaliki, S., Taneja, S., Palkonda, V.A.R., 2018. INADVERTENT INTRAOCULAR SURGERY
IN CHILDREN with UNSUSPECTED RETINOBLASTOMA: A Study of 14 Cases. Retina.
Kalita, D., Shome, D., Jain, V.G., Chadha, K., Bellare, J.R., 2014. In vivo intraocular
distribution and safety of periocular nanoparticle carboplatin for treatment of ad-
vanced retinoblastoma in humans. Am. J. Ophthalmol. 157, 1109–1115.
Kanber, D., Berulava, T., Ammerpohl, O., Mitter, D., Richter, J., Siebert, R., Horsthemke,
B., Lohmann, D., Buiting, K., 2009. The human retinoblastoma gene is imprinted.
PLoS Genet. 5, e1000790.
Kaneko, A., Suzuki, S., 2003. Eye-preservation treatment of retinoblastoma with vitreous
seeding. Jpn. J. Clin. Oncol. 33, 601–607.
Kaneko, A., Takayama, J., et al., 1990. Chemo-thermotherapy was successful in two cases
of recurrence of intraocular retinoblastoma after irradiation. Rinsho Ganka 44,
289–292.
Kao, L.Y., 2000. Diffuse infiltrating retinoblastoma: an inherited case. Retina 20,
217–219.
Kapatai, G., Brundler, M.A., Jenkinson, H., Kearns, P., Parulekar, M., Peet, A.C.,
McConville, C.M., 2013. Gene expression profiling identifies different sub-types of
retinoblastoma. Br. J. Canc. 109, 512–525.
Karatza, E.C., Shields, C.L., Flanders, A.E., Gonzalez, M.E., Shields, J.A., 2006. Pineal cyst
simulating pinealoblastoma in 11 children with retinoblastoma. Arch. Ophthalmol.
124, 595–597.
Karcioglu, Z.A., al-Mesfer, S.A., Abboud, E., Jabak, M.H., Mullaney, P.B., 1997. Workup
for metastatic retinoblastoma. A review of 261 patients. Ophthalmology 104,
307–312.
Karcioglu, Z.A., 2002. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina
22, 707–710.
Kase, S., Parikh, J.G., Rao, N.A., 2008. Peripapillary subretinal neovascularization in
retinoblastoma. Graefes Arch. Clin. Exp. Ophthalmol. 246, 931–934.
Kaufmann, S.H., Peereboom, D., Buckwalter, C.A., Svingen, P.A., Grochow, L.B.,
Donehower, R.C., Rowinsky, E.K., 1996. Cytotoxic effects of topotecan combined
with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 88,
734–741.
Kelly, A., Kaufman, S.C., Ali, R., Grajewski, A., Anderson, J., 2016. Rare anterior segment
retinoblastoma masquerading as corneal endotheliitis. Eye Contact Lens 42, e1–3.
Khandekar, R., Ganesh, A., Al Lawati, J., 2004. A 12-year epidemiological review of re-
tinoblastoma in Omani children. Ophthalmic Epidemiol. 11, 151–159.
Kim, H., Lee, J.W., Kang, H.J., Park, H.J., Kim, Y.Y., Shin, H.Y., Yu, Y.S., Kim, I.H., Ahn,
H.S., 2008. Clinical results of chemotherapy based treatment in retinoblastoma pa-
tients: a single center experience. Cancer Res Treat 40, 164–171.
Kim, J.M., Kim, J.H., Kim, S.J., Park, K.D., Shin, H.Y., Ahn, H.S., Yu, Y.S., 2010a. Visual
prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy
plus local treatments. Korean J. Ophthalmol. 24, 347–352.
Kim, J.W., Ngai, L.K., Sadda, S., Murakami, Y., Lee, D.K., Murphree, A.L., 2014. Retcam
fluorescein angiography findings in eyes with advanced retinoblastoma. Br. J.
Ophthalmol. 98, 1666–1671.
Kim, J.W., Yau, J.W., Moshfeghi, D., Fishman, M., 2010b. Orbital fibrosis and intraocular
recurrence of retinoblastoma following periocular carboplatin. J. Pediatr.
Ophthalmol. Strabismus 47, e1–4 Online.
King, B.A., Parra, C., Li, Y., Helton, K.J., Qaddoumi, I., Wilson, M.W., Ogg, R.J., 2015.
Spatiotemporal patterns of tumor occurrence in children with intraocular retino-
blastoma. PLoS One 10, e0132932.
Kingston, J.E., Hungerford, J.L., Madreperla, S.A., Plowman, P.N., 1996. Results of
combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.
Arch. Ophthalmol. 114, 1339–1343.
Kiratli, H., Koc, I., Varan, A., Akyuz, C., 2017. Intravitreal chemotherapy in the man-
agement of vitreous disease in retinoblastoma. Eur. J. Ophthalmol. 27, 423–427.
Kivela, T., Polkunen, M.L., 2003. Pieter Pauw's tumor oculorum: reappraisal of the pre-
sumed first description of retinoblastoma in 1597. Arch. Ophthalmol. 121, 881–886.
Kivela, T., 1999. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma
associated with primary ectopic intracranial retinoblastoma. J. Clin. Oncol. 17,
1829–1837.
Kivela, T., 2009. The epidemiological challenge of the most frequent eye cancer: re-
tinoblastoma, an issue of birth and death. Br. J. Ophthalmol. 93, 1129–1131.
Kivela, T.T., Hadjistilianou, T., 2017. Neonatal retinoblastoma. Asia Pac J. Oncol. Nurs. 4,
197–204.
Kleinerman, R.A., Tucker, M.A., Tarone, R.E., Abramson, D.H., Seddon, J.M., Stovall, M.,
Li, F.P., Fraumeni Jr., J.F., 2005. Risk of new cancers after radiotherapy in long-term
survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272–2279.
Kleinerman, R.A., Yu, C.L., Little, M.P., Li, Y., Abramson, D., Seddon, J., Tucker, M.A.,
2012. Variation of second cancer risk by family history of retinoblastoma among
long-term survivors. J. Clin. Oncol. 30, 950–957.
Klufas, M.A., Gobin, Y.P., Marr, B., Brodie, S.E., Dunkel, I.J., Abramson, D.H., 2012. Intra-
arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to
direct ophthalmic artery catheterization. AJNR Am. J. Neuroradiol. 33, 1608–1614.
Klutz, M., Brockmann, D., Lohmann, D.R., 2002. A parent-of-origin effect in two families
with retinoblastoma is associated with a distinct splice mutation in the RB1 gene. Am.
J. Hum. Genet. 71, 174–179.
Knudson Jr., A.G., 1971. Mutation and cancer: statistical study of retinoblastoma. Proc.
Natl. Acad. Sci. U. S. A. 68, 820–823.
Koelbing, M.H., 1954. Fabricius Hildanus' understanding and treatment of intra-ocular
tumors. Ophthalmologica 127, 288–293.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
61
Kohe, S., Brundler, M.A., Jenkinson, H., Parulekar, M., Wilson, M., Peet, A.C., McConville,
C.M., Children's, C., Leukaemia, G., 2015. Metabolite profiling in retinoblastoma
identifies novel clinicopathological subgroups. Br. J. Canc. 113, 1216–1224.
Kooi, I.E., Mol, B.M., Massink, M.P., Ameziane, N., Meijers-Heijboer, H., Dommering,
C.J., van Mil, S.E., de Vries, Y., van der Hout, A.H., Kaspers, G.J., Moll, A.C., Te Riele,
H., Cloos, J., Dorsman, J.C., 2016a. Somatic genomic alterations in retinoblastoma
beyond RB1 are rare and limited to copy number changes. Sci. Rep. 6, 25264.
Kooi, I.E., Mol, B.M., Massink, M.P., de Jong, M.C., de Graaf, P., van der Valk, P., Meijers-
Heijboer, H., Kaspers, G.J., Moll, A.C., Te Riele, H., Cloos, J., Dorsman, J.C., 2016b. A
meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes
involved in tumor progression. PLoS One 11, e0153323.
Kooi, I.E., Mol, B.M., Moll, A.C., van der Valk, P., de Jong, M.C., de Graaf, P., van Mil,
S.E., Schouten-van Meeteren, A.Y., Meijers-Heijboer, H., Kaspers, G.L., Te Riele, H.,
Cloos, J., Dorsman, J.C., 2015. Loss of photoreceptorness and gain of genomic al-
terations in retinoblastoma reveal tumor progression. EBioMedicine 2, 660–670.
Kramer, K., Kushner, B.H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P.,
Humm, J.L., Xu, H., Wolden, S.L., Souweidane, M.M., Larson, S.M., Cheung, N.K.,
2010. Compartmental intrathecal radioimmunotherapy: results for treatment for
metastatic CNS neuroblastoma. J. Neuro Oncol. 97, 409–418.
Kroll, M.E., Carpenter, L.M., Murphy, M.F., Stiller, C.A., 2012. Effects of changes in di-
agnosis and registration on time trends in recorded childhood cancer incidence in
Great Britain. Br. J. Canc. 107, 1159–1162.
Kunkele, A., Jurklies, C., Wieland, R., Lohmann, D., Bornfeld, N., Eggert, A., Schulte, J.H.,
2013. Chemoreduction improves eye retention in patients with retinoblastoma: a
report from the German Retinoblastoma Reference Centre. Br. J. Ophthalmol. 97,
1277–1283.
Kunkele, A., Wilm, J., Holdt, M., Lohmann, D., Bornfeld, N., Eggert, A., Temming, P.,
Schulte, J.H., 2015. Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a
report from the German Retinoblastoma Referral Centre. Br. J. Ophthalmol. 99,
949–953.
Laurent, V.E., Torbidoni, A.V., Sampor, C., Ottaviani, D., Vazquez, V., Gabri, M.R., Garcia
de Davila, M.T., Ramirez-Ortiz, M.A., Alonso, C.N., Rossi, J., Alonso, D.F., Chantada,
G.L., 2016. Minimal disseminated disease in nonmetastatic retinoblastoma with high-
risk pathologic features and association with disease-free survival. JAMA Ophthalmol
134, 1374–1379.
Laurent, V.E., Sampor, C., Solernou, V., Rossi, J., Gabri, M., Eandi-Eberle, S., de Davila,
M.T., Alonso, D.F., Chantada, G.L., 2013. Detection of minimally disseminated dis-
ease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse
transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur. J. Cancer 49,
2892–2899.
Laurie, N.A., Gray, J.K., Zhang, J., Leggas, M., Relling, M., Egorin, M., Stewart, C., Dyer,
M.A., 2005. Topotecan combination chemotherapy in two new rodent models of
retinoblastoma. Clin. Cancer Res. 11, 7569–7578.
Le Goff, M.M., Bishop, P.N., 2008. Adult vitreous structure and postnatal changes. Eye 22,
1214–1222.
Leal-Leal, C.A., Rivera-Luna, R., Flores-Rojo, M., Juarez-Echenique, J.C., Ordaz, J.C.,
Amador-Zarco, J., 2006. Survival in extra-orbital metastatic retinoblastoma:treat-
ment results. Clin. Transl. Oncol. 8, 39–44.
Leander, C., Fu, L.C., Pena, A., Howard, S.C., Rodriguez-Galindo, C., Wilimas, J.A.,
Ribeiro, R.C., Haik, B., 2007. Impact of an education program on late diagnosis of
retinoblastoma in Honduras. Pediatr. Blood Canc. 49, 817–819.
Lee, E.Y., Bookstein, R., Young, L.J., Lin, C.J., Rosenfeld, M.G., Lee, W.H., 1988.
Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line
Y79. Proc. Natl. Acad. Sci. U. S. A. 85, 6017–6021.
Lee, E.Y., Chang, C.Y., Hu, N., Wang, Y.C., Lai, C.C., Herrup, K., Lee, W.H., Bradley, A.,
1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and
haematopoiesis. Nature 359, 288–294.
Lee, T.C., Almeida, D., Claros, N., Abramson, D.H., Cobrinik, D., 2006. Cell cycle-specific
and cell type-specific expression of Rb in the developing human retina. Investig.
Ophthalmol. Vis. Sci. 47, 5590–5598.
Lee, W.H., Bookstein, R., Hong, F., Young, L.J., Shew, J.Y., Lee, E.Y., 1987. Human re-
tinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235,
1394–1399.
Li, S.Y., Chen, S.C., Tsai, C.F., Sheu, S.M., Yeh, J.J., Tsai, C.B., 2016. Incidence and
survival of retinoblastoma in Taiwan: a nationwide population-based study 1998-
2011. Br. J. Ophthalmol. 100, 839–842.
Lim, T.H., Robertson, D.M., 2000. Presumed rhegmatogenous retinal detachment in pa-
tients with retinoblastoma. Retina 20, 22–27.
Lima, N.N., do Nascimento, V.B., de Carvalho, S.M., Neto, M.L., Moreira, M.M., Brasil,
A.Q., Junior, F.T., de Oliveira, G.F., Reis, A.O., 2013. Spirituality in childhood cancer
care. Neuropsychiatric Dis. Treat. 9, 1539–1544.
Linn Murphree, A., 2005. Intraocular retinoblastoma: the case for a new group classifi-
cation. Ophthalmol. Clin. North Am. 18, 41–53 (viii).
Lohmann, D.R., Gallie, B.L., 2004. Retinoblastoma: revisiting the model prototype of
inherited cancer. Am. J. Med. Genet. C Semin Med. Genet. 129C, 23–28.
Lu, J.E., Francis, J.H., Dunkel, I.J., Shields, C.L., Yu, M.D., Berry, J.L., Kogachi, K., Skalet,
A.H., Miller, A.K., Santapuram, P.R., Daniels, A.B., Abramson, D.H., 2018. Metastases
and death rates after primary enucleation of unilateral retinoblastoma in the USA
2007-2017. Br. J. Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-312915.
(Epub ahead of print).
Lueder, G.T., Heon, E., Gallie, B.L., 1995. Retinoma associated with vitreous seeding. Am.
J. Ophthalmol. 119, 522–523.
Lumbroso-Le Rouic, L., Aerts, I., Levy-Gabriel, C., Dendale, R., Sastre, X., Esteve, M.,
Asselain, B., Bours, D., Doz, F., Desjardins, L., 2008. Conservative treatments of in-
traocular retinoblastoma. Ophthalmology 115, 1405–1410 1410 e1401-1402.
Lumbroso, L., Doz, F., Urbieta, M., Levy, C., Bours, D., Asselain, B., Vedrenne, J., Zucker,
J.M., Desjardins, L., 2002. Chemothermotherapy in the management of retino-
blastoma. Ophthalmology 109, 1130–1136.
Luna-Fineman, S., Chantada, G., Fuentes-Alabi, S., Alejos, A., Amador, G., Barnoya, M.,
Benavides, R., Castellanos, M.E., Gamboa, J., Giron, V., Goenz, M.A., Fu, L.,
Maldonado, C., Mendez, G., Morales, R.A., Ortiz, R., Sanchez, G., Rodriguez-Galindo,
C., 2019. Delayed enucleation with neoadjuvant chemotherapy in advanced in-
traocular unilateral retinoblastoma: AHOPCA-II, a prospective, multi-institutional
protocol in Central America. J. Clin. Oncol in press.
Ma, B., Lei, X., Guan, Y., Mou, L.S., Yuan, Y.F., Yue, H., Lu, Y., Xu, G.T., Qian, J., 2011.
Maintenance of retinal cancer stem cell-like properties through long-term serum-free
culture from human retinoblastoma. Oncol. Rep. 26, 135–143.
Maat-Kievit, J.A., Oepkes, D., Hartwig, N.G., Vermeij-Keers, C., van Kamp, I.L., van de
Kamp, J.J., 1993. A large retinoblastoma detected in a fetus at 21 weeks of gestation.
Prenat. Diagn. 13, 377–384.
MacCarthy, A., Birch, J.M., Draper, G.J., Hungerford, J.L., Kingston, J.E., Kroll, M.E.,
Onadim, Z., Stiller, C.A., Vincent, T.J., Murphy, M.F., 2009. Retinoblastoma in great
britain 1963-2002. Br. J. Ophthalmol. 93, 33–37.
MacCarthy, A., Draper, G.J., Steliarova-Foucher, E., Kingston, J.E., 2006. Retinoblastoma
incidence and survival in European children (1978-1997). Report from the auto-
mated childhood cancer information system project. Eur. J. Cancer 42, 2092–2102.
MacCarthy, A., Bayne, A.M., Brownbill, P.A., Bunch, K.J., Diggens, N.L., Draper, G.J.,
Hawkins, M.M., Jenkinson, H.C., Kingston, J.E., Stiller, C.A., Vincent, T.J., Murphy,
M.F., 2013. Second and subsequent tumours among 1927 retinoblastoma patients
diagnosed in Britain 1951-2004. Br. J. Cancer 108, 2455–2463.
MacKay, C.J., Abramson, D.H., Ellsworth, R.M., 1984. Metastatic patterns of retino-
blastoma. Arch. Ophthalmol. 102, 391–396.
Macpherson, D., 2008. Insights from mouse models into human retinoblastoma. Cell Div.
3, 9.
MacPherson, D., Conkrite, K., Tam, M., Mukai, S., Mu, D., Jacks, T., 2007. Murine bi-
lateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene
amplification. EMBO J. 26, 784–794.
Madreperla, S.A., Hungerford, J.L., Cooling, R.J., Sullivan, P., Gregor, Z., 2000. Repair of
late retinal detachment after successful treatment of retinoblastoma. Retina 20,
28–32.
Maidana, D.E., Pellegrini, M., Shields, J.A., Shields, C.L., 2014. Choroidal thickness after
intraarterial chemotherapy for retinoblastoma. Retina 34, 2103–2109.
Mallam, J.N., Hurwitz, M.Y., Mahoney, T., Chevez-Barrios, P., Hurwitz, R.L., 2004.
Efficient gene transfer into retinal cells using adenoviral vectors: dependence on
receptor expression. Investig. Ophthalmol. Vis. Sci. 45, 1680–1687.
Mallipatna, A., Gallie, B., Chévez-Barrios, P., Lumbroso-Le Rouic, L., Chantada, G., Doz,
F., Brisse, H., Munier, F., Albert, D., Catala-Mora, J., 2017. Retinoblastoma. AJCC
cancer staging manual 8, 819–831.
Mallipatna, A.C., Dimaras, H., Chan, H.S., Heon, E., Gallie, B.L., 2011. Periocular topo-
tecan for intraocular retinoblastoma. Arch. Ophthalmol. 129, 738–745.
Manjandavida, F.P., Honavar, S.G., Reddy, V.A., Khanna, R., 2014. Management and
outcome of retinoblastoma with vitreous seeds. Ophthalmology 121, 517–524.
Marees, T., Moll, A.C., Imhof, S.M., de Boer, M.R., Ringens, P.J., van Leeuwen, F.E., 2008.
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of
follow-up. J. Natl. Cancer Inst. 100, 1771–1779.
Marees, T., van Leeuwen, F.E., de Boer, M.R., Imhof, S.M., Ringens, P.J., Moll, A.C., 2009.
Cancer mortality in long-term survivors of retinoblastoma. Eur. J. Cancer 45,
3245–3253.
Marees, T., van Leeuwen, F.E., Schaapveld, M., Imhof, S.M., de Boer, M.R., Kors, W.A.,
Ringens, P.J., Moll, A.C., 2010. Risk of third malignancies and death after a second
malignancy in retinoblastoma survivors. Eur. J. Cancer 46, 2052–2058.
Margo, C., Hidayat, A., Kopelman, J., Zimmerman, L.E., 1983. Retinocytoma. A benign
variant of retinoblastoma. Arch. Ophthalmol. 101, 1519–1531.
Marr, B.P., Dunkel, I.J., Linker, A., Abramson, D.H., 2012. Periocular carboplatin for
retinoblastoma: long-term report (12 years) on efficacy and toxicity. Br. J.
Ophthalmol. 96, 881–883.
Mataftsi, A., Zografos, L., Balmer, A., Uffer, S., Stupp, R., Janzer, R.C., Pica, A.,
Schorderet, D.F., Munier, F.L., 2012. Chiasmatic infiltration secondary to late ma-
lignant transformation of retinoma. Ophthalmic Genet. 33, 155–158.
McEvoy, J., Flores-Otero, J., Zhang, J., Nemeth, K., Brennan, R., Bradley, C., Krafcik, F.,
Rodriguez-Galindo, C., Wilson, M., Xiong, S., Lozano, G., Sage, J., Fu, L., Louhibi, L.,
Trimarchi, J., Pani, A., Smeyne, R., Johnson, D., Dyer, M.A., 2011. Coexpression of
normally incompatible developmental pathways in retinoblastoma genesis. Cancer
Cell 20, 260–275.
McEvoy, J., Nagahawatte, P., Finkelstein, D., Richards-Yutz, J., Valentine, M., Ma, J.,
Mullighan, C., Song, G., Chen, X., Wilson, M., Brennan, R., Pounds, S., Becksfort, J.,
Huether, R., Lu, C., Fulton, R.S., Fulton, L.L., Hong, X., Dooling, D.J., Ochoa, K.,
Mardis, E.R., Wilson, R.K., Easton, J., Zhang, J., Downing, J.R., Ganguly, A., Dyer,
M.A., 2014. RB1 gene inactivation by chromothripsis in human retinoblastoma.
Oncotarget 5, 438–450.
McFall, R.C., Sery, T.W., Makadon, M., 1977. Characterization of a new continuous cell
line derived from a human retinoblastoma. Cancer Res. 37, 1003–1010.
Meier, P., Sterker, I., Tegetmeyer, H., 2006. [Leucocoria in childhood]. Klin Monbl
Augenheilkd 223, 521–527.
Mendelsohn, M.E., Abramson, D.H., Madden, T., Tong, W., Tran, H.T., Dunkel, I.J., 1998.
Intraocular concentrations of chemotherapeutic agents after systemic or local ad-
ministration. Arch. Ophthalmol. 116, 1209–1212.
Mendoza, P.R., Specht, C.S., Hubbard, G.B., Wells, J.R., Lynn, M.J., Zhang, Q., Kong, J.,
Grossniklaus, H.E., 2015. Histopathologic grading of anaplasia in retinoblastoma.
Am. J. Ophthalmol. 159, 764–776.
Metz, C.H., Bornfeld, N., Metz, K.A., Gok, M., 2016. Suspected vitreous seeding of uveal
melanoma: relevance of diagnostic vitrectomy. Br. J. Ophthalmol. 100, 660–664.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
62
Meyer, C.H., Michels, S., Rodrigues, E.B., Hager, A., Mennel, S., Schmidt, J.C., Helb, H.M.,
Farah, M.E., 2011. Incidence of rhegmatogenous retinal detachments after in-
travitreal antivascular endothelial factor injections. Acta Ophthalmol. 89, 70–75.
Miller, D.M., Murray, T.G., Cicciarelli, N.L., Capo, H., Markoe, A.M., 2005. Pars plana
lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts
in retinoblastoma. Ophthalmology 112, 1620–1624.
Mitter, D., Ullmann, R., Muradyan, A., Klein-Hitpass, L., Kanber, D., Ounap, K., Kaulisch,
M., Lohmann, D., 2011. Genotype-phenotype correlations in patients with retino-
blastoma and interstitial 13q deletions. Eur. J. Hum. Genet. 19, 947–958.
Mohney, B.G., Elner, V.M., Smith, A.B., Harbour, J.W., Smith, B.D., Musch, D.C., Smith,
S.J., 2017. Preclinical acute ocular safety study of combined intravitreal carboplatin
and etoposide phosphate for retinoblastoma. Ophthalmic Surg Lasers Imaging Retina
48, 151–159.
Moll, A.C., Dijk, J.v., Bosscha, M.I., Dommering, C.J., Graaf, P.d., Kors, W.A., Leeuwen,
F.E.v., 2013. Second malignancies and other long-term effects in retinoblastoma
survivors. In: Retinoblastoma: Clinical Advances and Emerging Treatment Strategies,
pp. 110–124.
Moll, A.C., Dommering, C.J., Bosscha, M.I., de Graaf, P., Kors, W.A., van Leeuwen, F.E.,
2012. Risk factors for the incidence of second cancers in survivors of retinoblastoma
with a family history. J. Clin. Oncol. 30, 3028 author reply 3028-3029.
Moll, A.C., Imhof, S.M., Bouter, L.M., Tan, K.E., 1997. Second primary tumors in patients
with retinoblastoma. A review of the literature. Ophthalmic Genet. 18, 27–34.
Moll, A.C., Imhof, S.M., Kuik, D.J., Bouter, L.M., Den Otter, W., Bezemer, P.D., Koten,
J.W., Tan, K.E., 1996. High parental age is associated with sporadic hereditary re-
tinoblastoma: the Dutch retinoblastoma register 1862-1994. Hum. Genet. 98,
109–112.
Moll, A.C., Imhof, S.M., Schouten-Van Meeteren, A.Y., Boers, M., 2002. Screening for
pineoblastoma in patients with retinoblastoma. Arch. Ophthalmol. 120, 1774 author
reply 1774.
Moll, A.C., Imhof, S.M., Schouten-Van Meeteren, A.Y., Kuik, D.J., Hofman, P., Boers, M.,
2001. Second primary tumors in hereditary retinoblastoma: a register-based study,
1945-1997: is there an age effect on radiation-related risk? Ophthalmology 108,
1109–1114.
Moreno, F., Sinaki, B., Fandino, A., Dussel, V., Orellana, L., Chantada, G., 2014. A po-
pulation-based study of retinoblastoma incidence and survival in Argentine children.
Pediatr. Blood Canc. 61, 1610–1615.
Moscinski, L.C., Pendergrass, T.W., Weiss, A., Hvizdala, E., Buckley, K.S., Kalina, R.E.,
1996. Recommendations for the use of routine bone marrow aspiration and lumbar
punctures in the follow-up of patients with retinoblastoma. J. Pediatr. Hematol.
Oncol. 18, 130–134.
Motegi, T., Kaga, M., Yanagawa, Y., Kadowaki, H., Watanabe, K., Inoue, A., Komatsu, M.,
Minoda, K., 1983. A recognizable pattern of the midface of retinoblastoma patients
with interstitial deletion of 13q. Hum. Genet. 64, 160–162.
Moulin, A.P., Gaillard, M.C., Balmer, A., Munier, F.L., 2012. Ultrasound biomicroscopy
evaluation of anterior extension in retinoblastoma: a clinicopathological study. Br. J.
Ophthalmol. 96, 337–340.
Muen, W.J., Kingston, J.E., Robertson, F., Brew, S., Sagoo, M.S., Reddy, M.A., 2012.
Efficacy and complications of super-selective intra-ophthalmic artery melphalan for
the treatment of refractory retinoblastoma. Ophthalmology 119, 611–616.
Mullaney, P.B., Abboud, E.B., Al-Mesfer, S.A., 1997. Retinal detachment associated with
type III retinoblastoma regression after cryotherapy and external-beam radiotherapy.
Am. J. Ophthalmol. 123, 140–142.
Mulvihill, A., Budning, A., Jay, V., Vandenhoven, C., Heon, E., Gallie, B.L., Chan, H.S.,
2003. Ocular motility changes after subtenon carboplatin chemotherapy for retino-
blastoma. Arch. Ophthalmol. 121, 1120–1124.
Munier, F., Pescia, G., Jotterand-Bellomo, M., Balmer, A., Gailloud, C., Thonney, F., 1989.
Constitutional karyotype in retinoblastoma. Case report and review of literature.
Ophthalmic Paediatr. Genet. 10, 129–150.
Munier, F.L., 2014. Classification and management of seeds in retinoblastoma. Ellsworth
lecture ghent August 24th 2013. Ophthalmic Genet. 35, 193–207.
Munier, F.L., Balmer, A., van Melle, G., Gailloud, C., 1994. Radial asymmetry in the to-
pography of retinoblastoma. Clues to the cell of origin. Ophthalmic Genet. 15,
101–106.
Munier, F.L., Beck-Popovic, M., Balmer, A., Gaillard, M.C., Bovey, E., Binaghi, S., 2011.
Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar em-
bolization after superselective ophthalmic artery chemotherapy for advanced in-
traocular retinoblastoma. Retina 31, 566–573.
Munier, F.L., Gaillard, M.-C., Decembrini, S., Beck-Popovic, M., 2015. Aqueous seeding:
fall of the ultimate intraocular retinoblastoma sanctuary by a new in situ che-
motherapy technique. Investig. Ophthalmol. Vis. Sci. 56 1663–1663.
Munier, F.L., Gaillard, M.C., Balmer, A., Soliman, S., Podilsky, G., Moulin, A.P., Beck-
Popovic, M., 2012a. Intravitreal chemotherapy for vitreous disease in retinoblastoma
revisited: from prohibition to conditional indications. Br. J. Ophthalmol. 96,
1078–1083.
Munier, F.L., Gaillard, M.C., Decembrini, S., Bongiovanni, M., Beck-Popovic, M., 2017a.
Intracameral chemotherapy (melphalan) for aqueous seeding in retinoblastoma: bi-
cameral injection technique and related toxicity in a pilot case study. Ocul Oncol
Pathol 3, 149–155.
Munier, F.L., Mosimann, P., Puccinelli, F., Gaillard, M.C., Stathopoulos, C., Houghton, S.,
Bergin, C., Beck-Popovic, M., 2017b. First-line intra-arterial versus intravenous
chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better vi-
sual outcomes, ocular survival and shorter time to success with intra-arterial delivery
from retrospective review of 20 years of treatment. Br. J. Ophthalmol. 101,
1086–1093.
Munier, F.L., Moulin, A., Gaillard, M.C., Bongiovanni, M., Decembrini, S., Houghton, S.,
Beck-Popovic, M., Stathopoulos, C., 2018. Intracameral chemotherapy for globe
salvage in retinoblastoma with secondary anterior chamber invasion. Ophthalmology
125, 615–617.
Munier, F.L., Soliman, S., Moulin, A.P., Gaillard, M.C., Balmer, A., Beck-Popovic, M.,
2012b. Profiling safety of intravitreal injections for retinoblastoma using an anti-
reflux procedure and sterilisation of the needle track. Br. J. Ophthalmol. 96,
1084–1087.
Munier, F.L., Verwey, J., Pica, A., Balmer, A., Zografos, L., Abouzeid, H., Timmerman, B.,
Goitein, G., Moeckli, R., 2008. New developments in external beam radiotherapy for
retinoblastoma: from lens to normal tissue-sparing techniques. Clin. Exp.
Ophthalmol. 36, 78–89.
Munier, F.L., Wang, M.X., Spence, M.A., Thonney, F., Balmer, A., Pescia, G., Donoso, L.A.,
Murphree, A.L., 1993. Pseudo low penetrance in retinoblastoma. Fortuitous familial
aggregation of sporadic cases caused by independently derived mutations in two
large pedigrees. Arch. Ophthalmol. 111, 1507–1511.
Murakami, N., Suzuki, S., Ito, Y., Yoshimura, R., Inaba, K., Kuroda, Y., Morota, M.,
Mayahara, H., Sakudo, M., Wakita, A., Okamoto, H., Sumi, M., Kagami, Y.,
Nakagawa, K., Ohtomo, K., Itami, J., 2012. (1)(0)(6)Ruthenium plaque therapy (RPT)
for retinoblastoma. Int. J. Radiat. Oncol. Biol. Phys. 84, 59–65.
Murphree, A.L., Villablanca, J.G., Deegan 3rd, W.F., Sato, J.K., Malogolowkin, M., Fisher,
A., Parker, R., Reed, E., Gomer, C.J., 1996. Chemotherapy plus local treatment in the
management of intraocular retinoblastoma. Arch. Ophthalmol. 114, 1348–1356.
Narang, S., Mashayekhi, A., Rudich, D., Shields, C.L., 2012. Predictors of long-term visual
outcome after chemoreduction for management of intraocular retinoblastoma. Clin.
Exp. Ophthalmol. 40, 736–742.
Naru, J., Aggarwal, R., Mohanty, A.K., Singh, U., Bansal, D., Kakkar, N., Agnihotri, N.,
2017. Identification of differentially expressed proteins in retinoblastoma tumors
using mass spectrometry-based comparative proteomic approach. J. Proteomics 159,
77–91.
Nawaiseh, I., Al-Hussaini, M., Alhamwi, A., Meyar, M., Sultan, I., Alrawashdeh, K.,
Jaradat, I., Yousef, Y.A., 2015. The impact of growth patterns of retinoblastoma
(endophytic, exophytic, and mixed patterns). Turk Patoloji Derg 31, 45–50.
Nemeth, K.M., Federico, S., Carcaboso, A.M., Shen, Y., Schaiquevich, P., Zhang, J.,
Egorin, M., Stewart, C., Dyer, M.A., 2011. Subconjunctival carboplatin and systemic
topotecan treatment in preclinical models of retinoblastoma. Cancer 117, 421–434.
Ohnishi, Y., Yamana, Y., Minei, M., Ibayashi, H., 1982. Application of fluorescein an-
giography in retinoblastoma. Am. J. Ophthalmol. 93, 578–588.
Ong, S.J., Chao, A.N., Wong, H.F., Liou, K.L., Kao, L.Y., 2015. Selective ophthalmic ar-
terial injection of melphalan for intraocular retinoblastoma: a 4-year review. Jpn. J.
Ophthalmol. 59, 109–117.
Osman, I.M., Abouzeid, H., Balmer, A., Gaillard, M.C., Othenin-Girard, P., Pica, A.,
Moeckli, R., Schorderet, D.F., Munier, F.L., 2011. Modern cataract surgery for ra-
diation-induced cataracts in retinoblastoma. Br. J. Ophthalmol. 95, 227–230.
Paez-Escamilla, M., Bagheri, N., Teira, L.E., Corrales-Medina, F.F., Harbour, W., 2017.
Intracameral topotecan hydrochloride for anterior chamber seeding of retino-
blastoma. JAMA Ophthalmol 135, 1453–1454.
Palamar, M., Pirondini, C., Shields, C.L., Shields, J.A., 2008. Cavitary retinoblastoma:
ultrasonographic and fluorescein angiographic findings in 3 cases. Arch. Ophthalmol.
126, 1598–1600.
Palazzi, M., Abramson, D.H., Ellsworth, R.M., 1990. Endophytic vs exophytic unilateral
retinoblastoma: is there any real difference? J. Pediatr. Ophthalmol. Strabismus 27,
255–258.
Palioura, S., Gobin, Y.P., Brodie, S.E., Marr, B.P., Dunkel, I.J., Abramson, D.H., 2012.
Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with
extensive (> 50%) retinal detachment. Pediatr. Blood Canc. 59, 859–864.
Palma, J., Sasso, D.F., Dufort, G., Koop, K., Sampor, C., Diez, B., Richard, L., Castillo, L.,
Chantada, G.L., 2012. Successful treatment of metastatic retinoblastoma with high-
dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow
Transplant. 47, 522–527.
Pant, G., Verma, N., Kumar, A., Pooniya, V., Gupta, S.K., 2017. Outcome of extraocular
retinoblastoma in a resource limited center from low middle income country. Pediatr.
Hematol. Oncol. 34, 419–424.
Paquette, L.B., Miller, D., Jackson, H.A., Lee, T., Randolph, L., Murphree, A.L., Panigrahy,
A., 2012. In utero detection of retinoblastoma with fetal magnetic resonance and
ultrasound: initial experience. AJP reports 2, 55.
Park, S.J., Woo, S.J., Park, K.H., 2014. Incidence of retinoblastoma and survival rate of
retinoblastoma patients in Korea using the Korean National Cancer Registry database
(1993-2010). Investig. Ophthalmol. Vis. Sci. 55, 2816–2821.
Parness-Yossifon, R., Bryar, P.J., Weinstein, J.L., Srikumaran, D., Mets, M.B., 2009.
Sudden dispersion of retinoblastoma shortly after initial chemotherapy treatment.
Am. J. Ophthalmol. 147, 903–906.
Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N.G., Restrepo-Perdomo, C.A., Mato-
Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., Cuadrado-
Vilanova, M., Castillo-Ecija, H., Botteri, G., Garcia-Gerique, L., Moreno-Gilabert, H.,
Gimenez-Alejandre, M., Alonso-Lopez, P., Farrera-Sal, M., Torres-Manjon, S., Ramos-
Lozano, D., Moreno, R., Aerts, I., Doz, F., Cassoux, N., Chapeaublanc, E., Torrebadell,
M., Roldan, M., Konig, A., Sunol, M., Claverol, J., Lavarino, C., Carmen de, T., Fu, L.,
Radvanyi, F., Munier, F.L., Catala-Mora, J., Mora, J., Alemany, R., Cascallo, M.,
Chantada, G.L., Carcaboso, A.M., 2019. Therapeutic targeting of the RB1 pathway in
retinoblastoma with the oncolytic adenovirus VCN-01. Sci. Transl. Med. 11https://
doi.org/10.1126/scitranslmed.aat9321. pii:eaat9321.
Pascual-Pasto, G., Olaciregui, N.G., Vila-Ubach, M., Paco, S., Monterrubio, C., Rodriguez,
E., Winter, U., Batalla-Vilacis, M., Catala, J., Salvador, H., Parareda, A., Schaiquevich,
P., Sunol, M., Mora, J., Lavarino, C., de Torres, C., Chantada, G.L., Carcaboso, A.M.,
2016. Preclinical platform of retinoblastoma xenografts recapitulating human disease
and molecular markers of dissemination. Cancer Lett. 380, 10–19.
Patel, S.R., Lin, A.S., Edelhauser, H.F., Prausnitz, M.R., 2011. Suprachoroidal drug
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
63
delivery to the back of the eye using hollow microneedles. Pharm. Res. (N. Y.) 28,
166–176.
Paulino, A.C., 1999. Trilateral retinoblastoma: is the location of the intracranial tumor
important? Cancer 86, 135–141.
Pavlidou, E., Burris, C., Thaung, C., Scheimberg, I., Kingston, J., Hungerford, J.L., Reddy,
M.A., Sagoo, M.S., 2015. Anterior segment seeding in eyes with retinoblastoma
failing to respond to intraophthalmic artery chemotherapy. JAMA Ophthalmol 133,
1455–1458.
Pawius, P., 1657. Observatio XXIII. Tumor Oculorum. Observations Anatomicae
Selectoires. Appendedto: Bartholinus T. Historiarum Anatomicarum Rariorum,
Centuria III & IV. Petrus Morsing, Copenhagen, Denmark, pp. 38–39.
Pham, T.T., Siebert, E., Asbach, P., Willerding, G., Erb-Eigner, K., 2015. Magnetic re-
sonance imaging based morphologic evaluation of the pineal gland for suspected
pineoblastoma in retinoblastoma patients and age-matched controls. J. Neurol. Sci.
359, 185–192.
Phillips, T.J., McGuirk, S.P., Chahal, H.K., Kingston, J., Robertson, F., Brew, S., Roebuck,
D., Hungerford, J.L., Herod, J., 2013. Autonomic cardio-respiratory reflex reactions
and superselective ophthalmic arterial chemotherapy for retinoblastoma. Paediatr.
Anaesth. 23, 940–945.
Pica, A., Moeckli, R., Balmer, A., Beck-Popovic, M., Chollet-Rivier, M., Do, H.P., Weber,
D.C., Munier, F.L., 2011. Preliminary experience in treatment of papillary and ma-
cular retinoblastoma: evaluation of local control and local complications after
treatment with linear accelerator-based stereotactic radiotherapy with micro-
multileaf collimator as second-line or salvage treatment after chemotherapy. Int. J.
Radiat. Oncol. Biol. Phys. 81, 1380–1386.
Pontes de Carvalho, R.A., Krausse, M.L., Murphree, A.L., Schmitt, E.E., Campochiaro,
P.A., Maumenee, I.H., 2006. Delivery from episcleral exoplants. Investig.
Ophthalmol. Vis. Sci. 47, 4532–4539.
Popovic, M.B., Diezi, M., Kuchler, H., Abouzeid, H., Maeder, P., Balmer, A., Munier, F.L.,
2007. Trilateral retinoblastoma with suprasellar tumor and associated pineal cyst. J.
Pediatr. Hematol. Oncol. 29, 53–56.
Pratt, C.B., Crom, D.B., Howarth, C., 1985. The use of chemotherapy for extraocular re-
tinoblastoma. Med. Pediatr. Oncol. 13, 330–333.
Pratt, C.B., Meyer, D., Chenaille, P., Crom, D.B., 1989. The use of bone marrow aspira-
tions and lumbar punctures at the time of diagnosis of retinoblastoma. J. Clin. Oncol.
7, 140–143.
Pritchard, E.M., Dyer, M.A., Guy, R.K., 2016. Progress in small molecule therapeutics for
the treatment of retinoblastoma. Mini Rev. Med. Chem. 16, 430–454.
Qaddoumi, I., Bass, J.K., Wu, J., Billups, C.A., Wozniak, A.W., Merchant, T.E., Haik, B.G.,
Wilson, M.W., Rodriguez-Galindo, C., 2012. Carboplatin-associated ototoxicity in
children with retinoblastoma. J. Clin. Oncol. 30, 1034–1041.
Qi, D.L., Cobrinik, D., 2017. MDM2 but not MDM4 promotes retinoblastoma cell pro-
liferation through p53-independant regulation of MYCN translation. Oncogene 36,
1760–1769.
Racher, H., Soliman, S., Argiropoulos, B., Chan, H.S., Gallie, B.L., Perrier, R., Matevski, D.,
Rushlow, D., Piovesan, B., Shaikh, F., MacDonald, H., Corson, T.W., 2016. Molecular
analysis distinguishes metastatic disease from second cancers in patients with re-
tinoblastoma. Cancer Genet 209, 359–363.
Ramasubramanian, A., Kytasty, C., Meadows, A.T., Shields, J.A., Leahey, A., Shields, C.L.,
2013. Incidence of pineal gland cyst and pineoblastoma in children with retino-
blastoma during the chemoreduction era. Am. J. Ophthalmol. 156, 825–829.
Rangamani, S., SathishKumar, K., Manoharan, N., Julka, P.K., Rath, G.K., Shanta, V.,
Swaminathan, R., Rama, R., Datta, K., Mandal, S., Koyande, S., Deshmane, V.,
Ganesh, B., Banavali, S.D., Badwe, R.A., Ramesh, C., Appaji, L., Nandakumar, A.,
2015. Paediatric retinoblastoma in India: evidence from the national cancer registry
programme. Asian Pac. J. Cancer Prev. APJCP 16, 4193–4198.
Rao, R., Honavar, S.G., Mulay, K., Reddy, V.A.P., 2018a. Eye salvage in diffuse anterior
retinoblastoma using systemic chemotherapy with periocular and intravitreal topo-
tecan. J AAPOS 22, 235–237 e232.
Rao, R., Honavar, S.G., Sharma, V., Reddy, V.A.P., 2018b. Intravitreal topotecan in the
management of refractory and recurrent vitreous seeds in retinoblastoma. Br. J.
Ophthalmol. 102, 490–495.
Reddy, M.A., Naeem, Z., Duncan, C., Robertson, F., Herod, J., Rennie, A., Liasis, A.,
Thompson, D.A., Sagoo, M., 2017. Reduction of severe visual loss and complications
following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Br. J.
Ophthalmol. 101, 1704–1708.
Reese, A.B., Ellsworth, R.M., 1963. The evaluation and current concept of retinoblastoma
therapy. Trans. Am. Acad. Ophthalmol. Otolaryngol. 67, 164–172.
Regan, D.P., Dubielzig, R.R., Zeiss, C.J., Charles, B., Hoy, S.S., Ehrhart, E.J., 2013.
Primary primitive neuroectodermal tumors of the retina and ciliary body in dogs. Vet.
Ophthalmol. 16 (Suppl. 1), 87–93.
Reid, T.W., Albert, D.M., Rabson, A.S., Russell, P., Craft, J., Chu, E.W., Tralka, T.S.,
Wilcox, J.L., 1974. Characteristics of an established cell line of retinoblastoma. J.
Natl. Cancer Inst. 53, 347–360.
Rimpela, A.K., Reinisalo, M., Hellinen, L., Grazhdankin, E., Kidron, H., Urtti, A., Del Amo,
E.M., 2018. Implications of melanin binding in ocular drug delivery. Adv. Drug Deliv.
Rev. 126, 23–43.
Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.L., Jeanny, J.C.,
Dannenberg, J.H., Berns, A., te Riele, H., 1998. p107 is a suppressor of retino-
blastoma development in pRb-deficient mice. Genes Dev. 12, 1599–1609.
Rodjan, F., de Graaf, P., Brisse, H.J., Goricke, S., Maeder, P., Galluzzi, P., Aerts, I.,
Alapetite, C., Desjardins, L., Wieland, R., Popovic, M.B., Diezi, M., Munier, F.L.,
Hadjistilianou, T., Knol, D.L., Moll, A.C., Castelijns, J.A., 2012. Trilateral retino-
blastoma: neuroimaging characteristics and value of routine brain screening on ad-
mission. J. Neuro Oncol. 109, 535–544.
Rodjan, F., de Graaf, P., van der Valk, P., Hadjistilianou, T., Cerase, A., Toti, P., de Jong,
M.C., Moll, A.C., Castelijns, J.A., Galluzzi, P., European Retinoblastoma Imaging, C.,
2015. Detection of calcifications in retinoblastoma using gradient-echo MR imaging
sequences: comparative study between in vivo MR imaging and ex vivo high-re-
solution CT. AJNR Am. J. Neuroradiol. 36, 355–360.
Rodrigues, M.M., Rajagopalan, S., Lee, L., Nair, C.N., Advani, S.H., Donoso, L., Chader,
G.J., Wiggert, B., 1992. Retinoblastoma: messenger RNA for interphotoreceptor re-
tinoid binding protein. Curr. Eye Res. 11, 425–433.
Rodriguez-Galindo, C., Wilson, M.W., Haik, B.G., Merchant, T.E., Billups, C.A., Shah, N.,
Cain, A., Langston, J., Lipson, M., Kun, L.E., Pratt, C.B., 2003. Treatment of in-
traocular retinoblastoma with vincristine and carboplatin. J. Clin. Oncol. 21,
2019–2025.
Rodriguez-Garcia, A., Gimenez-Alejandre, M., Rojas, J.J., Moreno, R., Bazan-Peregrino,
M., Cascallo, M., Alemany, R., 2015. Safety and efficacy of VCN-01, an oncolytic
adenovirus combining fiber HSG-binding domain replacement with RGD and hya-
luronidase expression. Clin. Cancer Res. 21, 1406–1418.
Rojanaporn, D., Kaliki, S., Bianciotto, C.G., Iturralde, J.C., Say, E.A., Shields, C.L., 2012.
Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retino-
blastoma: long-term results. Arch. Ophthalmol. 130, 585–590.
Rootman, D.B., Gonzalez, E., Mallipatna, A., Vandenhoven, C., Hampton, L., Dimaras, H.,
Chan, H.S., Gallie, B.L., Heon, E., 2013. Hand-held high-resolution spectral domain
optical coherence tomography in retinoblastoma: clinical and morphologic con-
siderations. Br. J. Ophthalmol. 97, 59–65.
Ross, G., Lipper, E.G., Abramson, D., Preiser, L., 2001. The development of young chil-
dren with retinoblastoma. Arch. Pediatr. Adolesc. Med. 155, 80–83.
Rowlands, M.A., Mondesire-Crump, I., Levin, A., Mauguen, A., Francis, J.H., Dunkel, I.J.,
Brodie, S.E., Gobin, Y.P., Abramson, D.H., 2018. Total retinal detachments due to
retinoblastoma: outcomes following intra-arterial chemotherapy/ophthalmic artery
chemosurgery. PLoS One 13, e0195395.
Ruiz Del Rio, N., Abelairas Gomez, J.M., Alonso Garcia de la Rosa, F.J., Peralta Calvo,
J.M., de Las Heras Martin, A., 2014. [Trilateral retinoblastoma. Correlation between
the genetic anomalies of the RB1 gene and the presence of pineal gland cysts]. Arch.
Soc. Esp. Oftalmol. 89, 4–9.
Rushlow, D.E., Mol, B.M., Kennett, J.Y., Yee, S., Pajovic, S., Theriault, B.L., Prigoda-Lee,
N.L., Spencer, C., Dimaras, H., Corson, T.W., Pang, R., Massey, C., Godbout, R., Jiang,
Z., Zacksenhaus, E., Paton, K., Moll, A.C., Houdayer, C., Raizis, A., Halliday, W., Lam,
W.L., Boutros, P.C., Lohmann, D., Dorsman, J.C., Gallie, B.L., 2013. Characterisation
of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical
studies. Lancet Oncol. 14, 327–334.
Sahgal, A., Millar, B.A., Michaels, H., Jaywant, S., Chan, H.S., Heon, E., Gallie, B.,
Laperriere, N., 2006. Focal stereotactic external beam radiotherapy as a vision-
sparing method for the treatment of peripapillary and perimacular retinoblastoma:
preliminary results. Clin. Oncol. 18, 628–634.
Saktanasate, J., Vongkulsiri, S., Khoo, C.T., 2015. Invisible retinoblastoma. JAMA
Ophthalmol 133, e151123.
Saleh, R.A., Gross, S., Cassano, W., Gee, A., 1988. Metastatic retinoblastoma successfully
treated with immunomagnetic purged autologous bone marrow transplantation.
Cancer 62, 2301–2303.
Salim, A., Wiknjosastro, G.H., Danukusumo, D., Barnas, B., Zalud, I., 1998. Fetal re-
tinoblastoma. J. Ultrasound Med. 17, 717–720.
Sampieri, K., Amenduni, M., Papa, F.T., Katzaki, E., Mencarelli, M.A., Marozza, A.,
Epistolato, M.C., Toti, P., Lazzi, S., Bruttini, M., De Filippis, R., De Francesco, S.,
Longo, I., Meloni, I., Mari, F., Acquaviva, A., Hadjistilianou, T., Renieri, A., Ariani, F.,
2009. Array comparative genomic hybridization in retinoma and retinoblastoma
tissues. Cancer Sci. 100, 465–471.
Saremi, L., Imani, S., Rostaminia, M., Nadeali, Z., 2014. Parental age-related risk of re-
tinoblastoma in Iranian children. Asian Pac. J. Cancer Prev. APJCP 15, 2847–2850.
Sastre, X., Chantada, G.L., Doz, F., Wilson, M.W., de Davila, M.T., Rodriguez-Galindo, C.,
Chintagumpala, M., Chevez-Barrios, P., International Retinoblastoma Staging
Working, G., 2009. Proceedings of the consensus meetings from the International
Retinoblastoma Staging Working Group on the pathology guidelines for the ex-
amination of enucleated eyes and evaluation of prognostic risk factors in retino-
blastoma. Arch. Pathol. Lab Med. 133, 1199–1202.
Scelfo, C., Francis, J.H., Khetan, V., Jenkins, T., Marr, B., Abramson, D.H., Shields, C.L.,
Pe'er, J., Munier, F., Berry, J., Harbour, J.W., Yarovoy, A., Lucena, E., Murray, T.G.,
Bhagia, P., Paysse, E., Tuncer, S., Chantada, G.L., Moll, A.C., Ushakova, T., Plager,
D.A., Ziyovuddin, I., Leal, C.A., Materin, M.A., Ji, X.D., Cursino, J.W., Polania, R.,
Kiratli, H., All-Ericsson, C., Kebudi, R., Honavar, S.G., Vishnevskia-Dai, V., Epelman,
S., Daniels, A.B., Ling, J.D., Traore, F., Ramirez-Ortiz, M.A., 2017. An international
survey of classification and treatment choices for group D retinoblastoma. Int. J.
Ophthalmol. 10, 961–967.
Schaiquevich, P., Buitrago, E., Ceciliano, A., Fandino, A.C., Asprea, M., Sierre, S.,
Abramson, D.H., Bramuglia, G.F., Chantada, G.L., 2012a. Pharmacokinetic analysis of
topotecan after superselective ophthalmic artery infusion and periocular adminis-
tration in a porcine model. Retina 32, 387–395.
Schaiquevich, P., Buitrago, E., Taich, P., Torbidoni, A., Ceciliano, A., Fandino, A., Asprea,
M., Requejo, F., Abramson, D.H., Bramuglia, G.F., 2012b. Pharmacokinetic analysis
of melphalan after superselective ophthalmic artery infusion in preclinical models
and retinoblastoma patients. Investig. Ophthalmol. Vis. Sci. 53, 4205–4212.
Schaiquevich, P., Buitrago, E., Taich, P., Torbidoni, A., Ceciliano, A., Fandino, A., Asprea,
M., Requejo, F., Abramson, D.H., Bramuglia, G.F., Chantada, G.L., 2012c.
Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infu-
sion in preclinical models and retinoblastoma patients. Investig. Ophthalmol. Vis. Sci.
53, 4205–4212.
Schaiquevich, P., Carcaboso, A.M., Buitrago, E., Taich, P., Opezzo, J., Bramuglia, G.,
Chantada, G.L., 2014. Ocular pharmocology of topotecan and its activity in retino-
blastoma. Retina 34, 1719–1727.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
64
Schaiquevich, P., Ceciliano, A., Millan, N., Taich, P., Villasante, F., Fandino, A.C.,
Dominguez, J., Chantada, G.L., 2013. Intra-arterial chemotherapy is more effective
than sequential periocular and intravenous chemotherapy as salvage treatment for
relapsed retinoblastoma. Pediatr. Blood Canc. 60, 766–770.
Schaiquevich, P., Fabius, A.W., Francis, J.H., Chantada, G.L., Abramson, D.H., 2017.
Ocular pharmacology of chemotherapy for retinoblastoma. Retina 37, 1–10.
Schedler, K.J., Traine, P.G., Lohmann, D.R., Haritoglou, C., Metz, K.A., Rodrigues, E.B.,
2016. Hereditary diffuse infiltrating retinoblastoma. Ophthalmic Genet. 37, 95–97.
Schefler, A.C., Cicciarelli, N., Feuer, W., Toledano, S., Murray, T.G., 2007. Macular re-
tinoblastoma: evaluation of tumor control, local complications, and visual outcomes
for eyes treated with chemotherapy and repetitive foveal laser ablation.
Ophthalmology 114, 162–169.
Schiavetti, A., Hadjistilianou, T., Clerico, A., Bonci, E., Ragni, G., Castello, M.A., 2005.
Conservative therapy in intraocular retinoblastoma: response/recurrence rate. J.
Pediatr. Hematol. Oncol. 27, 3–6.
Schmack, I., Hubbard, G.B., Kang, S.J., Aaberg Jr., T.M., Grossniklaus, H.E., 2006.
Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injec-
tion for intraocular retinoblastoma. Am. J. Ophthalmol. 142, 310–315.
Schueler, A.O., Fluhs, D., Anastassiou, G., Jurklies, C., Neuhauser, M., Schilling, H.,
Bornfeld, N., Sauerwein, W., 2006. Beta-ray brachytherapy with 106Ru plaques for
retinoblastoma. Int. J. Radiat. Oncol. Biol. Phys. 65, 1212–1221.
Schuler, A., Weber, S., Neuhauser, M., Jurklies, C., Lehnert, T., Heimann, H., Rudolph, G.,
Jockel, K.H., Bornfeld, N., Lohmann, D.R., 2005. Age at diagnosis of isolated uni-
lateral retinoblastoma does not distinguish patients with and without a constitutional
RB1 gene mutation but is influenced by a parent-of-origin effect. Eur. J. Cancer 41,
735–740.
Scott, I.U., Murray, T.G., Feuer, W.J., Van Quill, K., Markoe, A.M., Ling, S., Roth, D.B.,
O'Brien, J.M., 1999. External beam radiotherapy in retinoblastoma: tumor control
and comparison of 2 techniques. Arch. Ophthalmol. 117, 766–770.
Seider, M.I., Grewal, D.S., Mruthyunjaya, P., 2016. Portable optical coherence tomo-
graphy detection or confirmation of ophthalmoscopically invisible or indeterminate
active retinoblastoma. Ophthalmic Surg Lasers Imaging Retina 47, 965–968.
Seigel, G.M., Hackam, A.S., Ganguly, A., Mandell, L.M., Gonzalez-Fernandez, F., 2007.
Human embryonic and neuronal stem cell markers in retinoblastoma. Mol. Vis. 13,
823–832.
Semb, C., Erikson, H., Refsum, H.E., 1961. Ten years experience with tank respirators in
the treatment of post-operative respiratory failure. Acta Chir Scand Suppl. Suppl.
283, 39–44.
Semo, M., Vugler, A.A., Jeffery, G., 2007. Paradoxical opsin expressing cells in the inner
retina that are augmented following retinal degeneration. Eur. J. Neurosci. 25,
2296–2306.
Sengupta, S., Pan, U., Khetan, V., 2016. Adult onset retinoblastoma. Indian J.
Ophthalmol. 64, 485–491.
Seregard, S., Kock, E., af Trampe, E., 1995. Intravitreal chemotherapy for recurrent re-
tinoblastoma in an only eye. Br. J. Ophthalmol. 79, 194–195.
Seregard, S., Lundell, G., Svedberg, H., Kivelä, T., 2004. Incidence of retinoblastoma from
1958 to 1998 in Northern Europe: advantages of birth cohort analysis.
Ophthalmology 111, 1228–1232.
Sethi, R.V., Shih, H.A., Yeap, B.Y., Mouw, K.W., Petersen, R., Kim, D.Y., Munzenrider,
J.E., Grabowski, E., Rodriguez-Galindo, C., Yock, T.I., Tarbell, N.J., Marcus, K.J.,
Mukai, S., MacDonald, S.M., 2014. Second nonocular tumors among survivors of
retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer
120, 126–133.
Shah, P.K., Narendran, V., Kalpana, N., 2010. In vivo growth of retinoblastoma in a
newborn infant. Indian J. Ophthalmol. 58, 421–423.
Shah, P.K., Narendran, V., Manayath, G.J., Chowdhary, S., 2011. Atypical retinocytoma
with diffuse vitreous seeds: an insight. Oman J. Ophthalmol. 4, 81–83.
Sheen, V., Tucker, M.A., Abramson, D.H., Seddon, J.M., Kleinerman, R.A., 2008. Cancer
screening practices of adult survivors of retinoblastoma at risk of second cancers.
Cancer 113, 434–441.
Shen, H., Tang, Y., Xu, X., Tang, H., 2013. Detection of the GD2+/CD56+/CD45- im-
munophenotype by flow cytometry in cerebrospinal fluids from a patient with re-
tinoblastoma. Pediatr. Hematol. Oncol. 30, 30–32.
Sheppard, L., Eiser, C., Kingston, J., 2005. Mothers' perceptions of children's quality of life
following early diagnosis and treatment for retinoblastoma (Rb). Child Care Health
Dev. 31, 137–142.
Sherr, C.J., McCormick, F., 2002. The RB and p53 pathways in cancer. Cancer Cell 2,
103–112.
Shields, C.L., Alset, A.E., Say, E.A., Caywood, E., Jabbour, P., Shields, J.A., 2016a.
Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before
and during the intravitreal chemotherapy era. J. Pediatr. Ophthalmol. Strabismus 53,
275–284.
Shields, C.L., Bianciotto, C.G., Jabbour, P., Ramasubramanian, A., Lally, S.E., Griffin,
G.C., Rosenwasser, R., Shields, J.A., 2011. Intra-arterial chemotherapy for retino-
blastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.
Arch. Ophthalmol. 129, 1399–1406.
Shields, C.L., De Potter, P., Himelstein, B.P., Shields, J.A., Meadows, A.T., Maris, J.M.,
1996. Chemoreduction in the initial management of intraocular retinoblastoma.
Arch. Ophthalmol. 114, 1330–1338.
Shields, C.L., Douglass, A.M., Beggache, M., Say, E.A., Shields, J.A., 2016b.
INTRAVITREOUS chemotherapy for active vitreous seeding from retinoblastoma:
outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture. Retina
36, 1184–1190.
Shields, C.L., Ghassemi, F., Tuncer, S., Thangappan, A., Shields, J.A., 2008. Clinical
spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes.
Ophthalmology 115, 2253–2258.
Shields, C.L., Gorry, T., Shields, J.A., 2004a. Outcome of eyes with unilateral sporadic
retinoblastoma based on the initial external findings by the family and the pedia-
trician. J. Pediatr. Ophthalmol. Strabismus 41, 143–149 quiz 172-143.
Shields, C.L., Honavar, S., Shields, J.A., Demirci, H., Meadows, A.T., 2000. Vitrectomy in
eyes with unsuspected retinoblastoma. Ophthalmology 107, 2250–2255.
Shields, C.L., Honavar, S.G., Meadows, A.T., Shields, J.A., Demirci, H., Singh, A.,
Friedman, D.L., Naduvilath, T.J., 2002. Chemoreduction plus focal therapy for re-
tinoblastoma: factors predictive of need for treatment with external beam radio-
therapy or enucleation. Am. J. Ophthalmol. 133, 657–664.
Shields, C.L., Kaliki, S., Shah, S.U., Bianciotto, C.G., Jabbour, P., Shields, J.A., 2012.
Effect of intraarterial chemotherapy on retinoblastoma-induced retinal detachment.
Retina 32, 799–804.
Shields, C.L., Lally, S.E., Manjandavida, F.P., Leahey, A.M., Shields, J.A., 2016c. Diffuse
anterior retinoblastoma with globe salvage and visual preservation in 3 consecutive
cases. Ophthalmology 123, 378–384.
Shields, C.L., Manjandavida, F.P., Lally, S.E., Pieretti, G., Arepalli, S.A., Caywood, E.H.,
Jabbour, P., Shields, J.A., 2014. Intra-arterial chemotherapy for retinoblastoma in 70
eyes: outcomes based on the international classification of retinoblastoma.
Ophthalmology 121, 1453–1460.
Shields, C.L., Mashayekhi, A., Au, A.K., Czyz, C., Leahey, A., Meadows, A.T., Shields, J.A.,
2006a. The International Classification of Retinoblastoma predicts chemoreduction
success. Ophthalmology 113, 2276–2280.
Shields, C.L., Mashayekhi, A., Cater, J., Shelil, A., Meadows, A.T., Shields, J.A., 2004b.
Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recur-
rence in 457 tumors. Am. J. Ophthalmol. 138, 329–337.
Shields, C.L., Mashayekhi, A., Sun, H., Uysal, Y., Friere, J., Komarnicky, L., Shields, J.A.,
2006b. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma re-
currence after chemoreduction in 84 tumors. Ophthalmology 113, 2087–2092.
Shields, C.L., Meadows, A.T., Shields, J.A., Carvalho, C., Smith, A.F., 2001.
Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malig-
nancy (trilateral retinoblastoma). Arch. Ophthalmol. 119, 1269–1272.
Shields, C.L., Ramasubramanian, A., Thangappan, A., Hartzell, K., Leahey, A., Meadows,
A.T., Shields, J.A., 2009. Chemoreduction for group E retinoblastoma: comparison of
chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in
76 eyes. Ophthalmology 116, 544–551 e541.
Shields, C.L., Santos, M.C., Diniz, W., Gunduz, K., Mercado, G., Cater, J.R., Shields, J.A.,
1999. Thermotherapy for retinoblastoma. Arch. Ophthalmol. 117, 885–893.
Shields, C.L., Say, E.A., Pointdujour-Lim, R., Cao, C., Jabbour, P.M., Shields, J.A., 2015.
Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial
intra-arterial chemotherapy. J. Fr. Ophtalmol. 38, 542–549.
Shields, C.L., Say, E.A.T., Pefkianaki, M., Regillo, C.D., Caywood, E.H., Jabbour, P.M.,
Shields, J.A., 2017. Rhegmatogenous retinal detachment after intraarterial che-
motherapy for retinoblastoma: the 2016 founders award lecture. Retina 37,
1441–1450.
Shields, C.L., Schoenberg, E., Kocher, K., Shukla, S.Y., Kaliki, S., Shields, J.A., 2013.
Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases: results based
on age at presentation. Ophthalmology 120, 311–316.
Shields, C.L., Shields, J.A., Baez, K.A., Cater, J., De Potter, P.V., 1993a. Choroidal inva-
sion of retinoblastoma: metastatic potential and clinical risk factors. Br. J.
Ophthalmol. 77, 544–548.
Shields, C.L., Shields, J.A., Needle, M., de Potter, P., Kheterpal, S., Hamada, A., Meadows,
A.T., 1997. Combined chemoreduction and adjuvant treatment for intraocular re-
tinoblastoma. Ophthalmology 104, 2101–2111.
Shields, J.A., Demirci, H., Mashayekhi, A., Eagle Jr., R.C., Shields, C.L., 2006c.
Melanocytoma of the optic disk: a review. Surv. Ophthalmol. 51, 93–104.
Shields, J.A., Sanborn, G.E., Augsburger, J.J., Orlock, D., Donoso, L.A., 1982. Fluorescein
angiography of retinoblastoma. Trans. Am. Ophthalmol. Soc. 80, 98–112.
Shields, J.A., Shields, C.L., De Potter, P., 1993b. Cryotherapy for retinoblastoma. Int.
Ophthalmol. Clin. 33, 101–105.
Shih, C.S., Laurie, N., Holzmacher, J., Spence, Y., Nathwani, A.C., Davidoff, A.M., Dyer,
M.A., 2009. AAV-mediated local delivery of interferon-beta for the treatment of re-
tinoblastoma in preclinical models. NeuroMolecular Med. 11, 43–52.
Shimoda, Y., Hamano, R., Ishihara, K., Shimoda, N., Hagimura, N., Akiyama, H., Kishi, S.,
Kaneko, A., 2008. Effects of intraocular irrigation with melphalan on rabbit retinas
during vitrectomy. Graefes Arch. Clin. Exp. Ophthalmol. 246, 501–508.
Shin, J.Y., Kim, J.H., Yu, Y.S., Khwarg, S.I., Choung, H.K., Shin, H.Y., Ahn, H.S., 2010.
Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or
combined with local therapy. Korean J. Ophthalmol. 24, 219–224.
Simpson, A.E., Gilbert, J.A., Rudnick, D.E., Geroski, D.H., Aaberg Jr., T.M., Edelhauser,
H.F., 2002. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch.
Ophthalmol. 120, 1069–1074.
Singh, A.D., Santos, C.M., Shields, C.L., Shields, J.A., Eagle Jr., R.C., 2000. Observations
on 17 patients with retinocytoma. Arch. Ophthalmol. 118, 199–205.
Singh, H., Koos, D., Fernandez, E., Thornton, M.E., Grubbs, B.H., Moats, R., Fraser, S.,
Cobrinik, D., 2018a. Precursor proliferation and inward migration in intact cultured
retina. Investig. Ophthalmol. Vis. Sci. 59 4961–4961.
Singh, H.P., Wang, S., Cobrinik, D., 2016. Human cone precursor program underlying a
proliferative response to pRB loss. Investig. Ophthalmol. Vis. Sci. 57, 556.
Singh, H.P., Wang, S., Stachelek, K., Lee, S., Reid, M.W., Thornton, M.E., Craft, C.M.,
Grubbs, B.H., Cobrinik, D., 2018b. Developmental stage-specific proliferation and
retinoblastoma genesis in RB-deficient human but not mouse cone precursors. Proc.
Natl. Acad. Sci. U. S. A. 115, E9391–E9400.
Singh, P.H., Thornton, M., Grubbs, B., Cobrinik, D., 2019. MYCN overexpression induces
cone precursor proliferation and tumorigenesis in explanted retinae. Investig.
Ophthalmol. Vis. Sci. 60 ARVO E-Abstract 1320.
Sippel, K.C., Fraioli, R.E., Smith, G.D., Schalkoff, M.E., Sutherland, J., Gallie, B.L., Dryja,
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
65
T.P., 1998. Frequency of somatic and germ-line mosaicism in retinoblastoma: im-
plications for genetic counseling. Am. J. Hum. Genet. 62, 610–619.
Sirin, S., de Jong, M.C., Galluzzi, P., Maeder, P., Brisse, H.J., Castelijns, J.A., de Graaf, P.,
Goericke, S.L., European Retinoblastoma Imaging, C., 2016. MRI-based assessment of
the pineal gland in a large population of children aged 0-5 years and comparison with
pineoblastoma: part II, the cystic gland. Neuroradiology 58, 713–721.
Smith, S.J., Smith, B.D., 2013. Evaluating the risk of extraocular tumour spread following
intravitreal injection therapy for retinoblastoma: a systematic review. Br. J.
Ophthalmol. 97, 1231–1236.
Smith, S.J., Smith, B.D., Mohney, B.G., 2014. Ocular side effects following intravitreal
injection therapy for retinoblastoma: a systematic review. Br. J. Ophthalmol. 98,
292–297.
Soliman, S.E., D'Silva, C.N., Dimaras, H., Dzneladze, I., Chan, H., Gallie, B.L., 2018.
Clinical and genetic associations for carboplatin-related ototoxicity in children
treated for retinoblastoma: a retrospective noncomparative single-institute experi-
ence. Pediatr. Blood Canc. 65, e26931.
Soliman, S.E., Dimaras, H., Khetan, V., Gardiner, J.A., Chan, H.S., Heon, E., Gallie, B.L.,
2016. Prenatal versus postnatal screening for familial retinoblastoma.
Ophthalmology 123, 2610–2617.
Soliman, S.E., VandenHoven, C., MacKeen, L.D., Heon, E., Gallie, B.L., 2017. Optical
coherence tomography-guided decisions in retinoblastoma management.
Ophthalmology 124, 859–872.
Song, X., Zhou, Y., Jia, R., Xu, X., Wang, H., Hu, J., Ge, S., Fan, X., 2010. Inhibition of
retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adeno-
virus H101. Investig. Ophthalmol. Vis. Sci. 51, 2626–2635.
Spaulding, A.G., Fuhs, J.C., 1968. Retinoblastoma and retinal detachment. Surv.
Ophthalmol. 13, 152–156.
Spencer, C., Pajovic, S., Devlin, H., Dinh, Q.D., Corson, T.W., Gallie, B.L., 2005. Distinct
patterns of expression of the RB gene family in mouse and human retina. Gene Expr.
Patterns 5, 687–694.
Sreelakshmi, K.V., Chandra, A., Krishnakumar, S., Natarajan, V., Khetan, V., 2017.
Anterior chamber invasion in retinoblastoma: not an indication for adjuvant che-
motherapy. Investig. Ophthalmol. Vis. Sci. 58, 4654–4661.
Stacey, A.W., Clarke, B., Moraitis, C., Fabian, I.D., Smith, V., Sagoo, M.S., Reddy, M.A.,
2019. The incidence of binocular visual impairment and blindness in children with
bilateral retinoblastoma. Ocul Oncol Pathol 5, 1–7.
Staffieri, S.E., McGillivray, G., Elder, J.E., Bristowe, A., Cole, S., McKenzie, J.D., Fink,
A.M., 2015. Managing fetuses at high risk of retinoblastoma: lesion detection on
screening MRI. Prenat. Diagn. 35, 174–178.
Stathopoulos, C., Gaillard, M.C., Moulin, A., Puccinelli, F., Beck-Popovic, M., Munier,
F.L., 2018a. Intravitreal Anti-Vascular Endothelial Growth Factor For The
Management Of Neovascularization In Retinoblastoma After Intravenous And/Or
Intraarterial Chemotherapy: Long-Term Outcomes in a Series of 35 Eyes. Retina.
https://doi.org/10.1097/IAE.0000000000002339. (Epub ahead of print).
Stathopoulos, C., Gaillard, M.C., Puccinelli, F., Maeder, P., Hadjistilianou, D., Beck-
Popovic, M., Munier, F.L., 2018b. Successful conservative treatment of massive
choroidal relapse in 2 retinoblastoma patients monitored by ultrasound biomicro-
scopy and/or spectral domain optic coherence tomography. Ophthalmic Genet. 39,
242–246.
Stathopoulos, C., Moulin, A., Gaillard, M.C., Beck-Popovic, M., Puccinelli, F., Munier,
F.L., 2019. Conservative treatment of diffuse infiltrating retinoblastoma: optical co-
herence tomography-assisted diagnosis and follow-up in three consecutive cases. Br.
J. Ophthalmol. 103, 826–830.
Stathopoulos, C., Say, E.A.T., Shields, C.L., 2018c. Prenatal ultrasonographic detection
and prenatal (prior to birth) management of hereditary retinoblastoma. Graefes Arch.
Clin. Exp. Ophthalmol. 256, 861–862.
Steinle, J.J., Zhang, Q., Thompson, K.E., Toutounchian, J., Yates, C.R., Soderland, C.,
Wang, F., Stewart, C.F., Haik, B.G., Williams, J.S., Jackson, J.S., Mandrell, T.D.,
Johnson, D., Wilson, M.W., 2012. Intra-ophthalmic artery chemotherapy triggers
vascular toxicity through endothelial cell inflammation and leukostasis. Investig.
Ophthalmol. Vis. Sci. 53, 2439–2445.
Steliarova-Foucher, E., Colombet, M., Ries, L.A.G., Moreno, F., Dolya, A., Bray, F.,
Hesseling, P., Shin, H.Y., Stiller, C.A., contributors, I.-., 2017. International incidence
of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 18,
719–731.
Suryawanshi, P., Ramadwar, M., Dikshit, R., Kane, S.V., Kurkure, P., Banavali, S.,
Viswanathan, S., 2011. A study of pathologic risk factors in postchemoreduced, en-
ucleated specimens of advanced retinoblastomas in a developing country. Arch.
Pathol. Lab Med. 135, 1017–1023.
Süsskind, D., Hagemann, U., Schrader, M., Januschowski, K., Schnichels, S., Aisenbrey, S.,
2016. Toxic effects of melphalan, topotecan and carboplatin on retinal pigment
epithelial cells. Acta Ophthalmol. 94, 471–478.
Suzuki, S., Aihara, Y., Fujiwara, M., Sano, S., Kaneko, A., 2015. Intravitreal injection of
melphalan for intraocular retinoblastoma. Jpn. J. Ophthalmol. 59, 164–172.
Suzuki, S., Yamane, T., Mohri, M., Kaneko, A., 2011. Selective ophthalmic arterial in-
jection therapy for intraocular retinoblastoma: the long-term prognosis.
Ophthalmology 118, 2081–2087.
Syed, N.A., Nork, T.M., Poulsen, G.L., Riis, R.C., George, C., Albert, D.M., 1997.
Retinoblastoma in a dog. Arch. Ophthalmol. 115, 758–763.
Taich, P., Ceciliano, A., Buitrago, E., Sampor, C., Fandino, A., Villasante, F., Lucena, E.,
Romero, L., Chantada, G.L., Schaiquevich, P., 2014. Clinical pharmacokinetics of
intra-arterial melphalan and topotecan combination in patients with retinoblastoma.
Ophthalmology 121, 889–897.
Taich, P., Requejo, F., Asprea, M., Sgroi, M., Gobin, P., Abramson, D.H., Chantada, G.,
Schaiquevich, P., 2016. Topotecan delivery to the optic nerve after ophthalmic artery
chemosurgery. PLoS One 11, e0151343.
Tawansy, K.A., Samuel, M.A., Shammas, M., Murphree, A.L., 2006. Vitreoretinal com-
plications of retinoblastoma treatment. Retina 26, S47–S52.
Teichmann, K.D., 2002. Intravitreal injections: does globe size matter? J. Cataract
Refract. Surg. 28, 1886–1889.
Temming, P., Arendt, M., Viehmann, A., Eisele, L., Le Guin, C.H., Schundeln, M.M.,
Biewald, E., Astrahantseff, K., Wieland, R., Bornfeld, N., Sauerwein, W., Eggert, A.,
Jockel, K.H., Lohmann, D.R., 2017. Incidence of second cancers after radiotherapy
and systemic chemotherapy in heritable retinoblastoma survivors: a report from the
German reference center. Pediatr. Blood Canc. 64, 71–80.
Temming, P., Viehmann, A., Arendt, M., Eisele, L., Spix, C., Bornfeld, N., Sauerwein, W.,
Jockel, K.H., Lohmann, D.R., 2015. Pediatric second primary malignancies after re-
tinoblastoma treatment. Pediatr. Blood Canc. 62, 1799–1804.
Thampi, S., Hetts, S.W., Cooke, D.L., Stewart, P.J., Robbins, E., Banerjee, A., Dubois, S.G.,
Char, D., Halbach, V., Matthay, K., 2013. Superselective intra-arterial melphalan
therapy for newly diagnosed and refractory retinoblastoma: results from a single
institution. Clin. Ophthalmol. 7, 981–989.
Toi, A., Sutherland, J., Gallie, B., Gardiner, J., Sermer, M., 2003. Evaluation of the fetus at
risk for retinoblastoma: what is the role of prenatal ultrasound? Ultrasound Med.
Biol. 29, S137.
Torbidoni, A.V., Laurent, V.E., Sampor, C., Ottaviani, D., Vazquez, V., Gabri, M.R., Rossi,
J., de Davila, M.T., Alonso, C., Alonso, D.F., Chantada, G.L., 2015. Association of
cone-rod homeobox transcription factor messenger RNA with pediatric metastatic
retinoblastoma. JAMA Ophthalmol 133, 805–812.
Torbidoni, A.V., Sampor, C., Laurent, V.E., Aschero, R., Iyer, S., Rossi, J., Alderete, D.,
Alonso, D.F., Szijan, I., Chantada, G.L., 2018. Minimal disseminated disease evalua-
tion and outcome in trilateral retinoblastoma. Br. J. Ophthalmol. 102, 1597–1601.
Traine, P.G., Schedler, K.J., Rodrigues, E.B., 2016. Clinical presentation and genetic
paradigm of diffuse infiltrating retinoblastoma: a review. Ocul Oncol Pathol 2,
128–132.
Tran, H.V., Schorderet, D.F., Gaillard, M.C., Balmer, A., Munier, F.L., 2012. Risk assess-
ment of recurrence in sporadic retinoblastoma using a molecular-based algorithm.
Ophthalmic Genet. 33, 6–11.
Tse, B.C., Steinle, J.J., Johnson, D., Haik, B.G., Wilson, M.W., 2013. Superselective in-
traophthalmic artery chemotherapy in a nonhuman primate model: histopathologic
findings. JAMA Ophthalmol 131, 903–911.
Tsimpida, M., Thompson, D.A., Liasis, A., Smith, V., Kingston, J.E., Sagoo, M.S., Reddy,
M.A., 2013. Visual outcomes following intraophthalmic artery melphalan for patients
with refractory retinoblastoma and age appropriate vision. Br. J. Ophthalmol. 97,
1464–1470.
Tuncer, S., Sencer, S., Kebudi, R., Tanyildiz, B., Cebeci, Z., Aydin, K., 2016. Superselective
intra-arterial chemotherapy in the primary management of advanced intra-ocular
retinoblastoma: first 4-year experience from a single institution in Turkey. Acta
Ophthalmol. 94, e644–e651.
Turaka, K., Shields, C.L., Meadows, A.T., Leahey, A., 2012. Second malignant neoplasms
following chemoreduction with carboplatin, etoposide, and vincristine in 245 pa-
tients with intraocular retinoblastoma. Pediatr. Blood Canc. 59, 121–125.
Ueda, M., Tanabe, J., Inomata, M., Kaneko, A., Kimura, T., 1995. [Study on conservative
treatment of retinoblastoma–effect of intravitreal injection of melphalan on the rabbit
retina]. Nippon. Ganka Gakkai Zasshi 99, 1230–1235.
United Nations, Department of Economic and Social Affairs, Population Division, 2017.
World Population Prospects: the 2017 Revision.
Usmanov, R.H., Kivela, T., 2014. Predicted trends in the incidence of retinoblastoma in
the asia-pacific region. Asia Pac J. Ophthalmol. (Phila) 3, 151–157.
Uusitalo, M.S., Van Quill, K.R., Scott, I.U., Matthay, K.K., Murray, T.G., O'Brien, J.M.,
2001. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma
with high-risk features on histopathologic examination. Arch. Ophthalmol. 119,
41–48.
Valverde, J.R., Alonso, J., Palacios, I., Pestana, A., 2005. RB1 gene mutation up-date, a
meta-analysis based on 932 reported mutations available in a searchable database.
BMC Genet. 6, 53.
van Dijk, J., Grootenhuis, M.A., Imhof, S.M., Cohen-Kettenis, P.T., Moll, A.C., Huisman,
J., 2009. Coping strategies of retinoblastoma survivors in relation to behavioural
problems. Psycho Oncol. 18, 1281–1289.
van Dijk, J., Huisman, J., Moll, A.C., Schouten-van Meeteren, A.Y., Bezemer, P.D.,
Ringens, P.J., Cohen-Kettenis, P.T., Imhof, S.M., 2007a. Health-related quality of life
of child and adolescent retinoblastoma survivors in The Netherlands. Health Qual.
Life Outcomes 5, 65.
van Dijk, J., Imhof, S.M., Moll, A.C., Ringens, P.J., Cohen-Kettenis, P.T., Rijmen, F.,
Huisman, J., 2007b. Quality of life of adult retinoblastoma survivors in The
Netherlands. Health Qual. Life Outcomes 5, 30.
van Dijk, J., Oostrom, K.J., Huisman, J., Moll, A.C., Cohen-Kettenis, P.T., Ringens, P.J.,
Imhof, S.M., 2010. Restrictions in daily life after retinoblastoma from the perspective
of the survivors. Pediatr. Blood Canc. 54, 110–115.
Vasilatou-Kosmidis, H., 2003. Cancer in neonates and infants. Med. Pediatr. Oncol.
41, 7–9.
Vasquez, L.M., Giuliari, G.P., Halliday, W., Pavlin, C.J., Gallie, B.L., Heon, E., 2011.
Ultrasound biomicroscopy in the management of retinoblastoma. Eye 25, 141–147.
Venturi, C., Bracco, S., Cerase, A., Cioni, S., Galluzzi, P., Gennari, P., Vallone, I.M.,
Tinturini, R., Vittori, C., De Francesco, S., Caini, M., D'Ambrosio, A., Toti, P., Renieri,
A., Hadjistilianou, T., 2013. Superselective ophthalmic artery infusion of melphalan
for intraocular retinoblastoma: preliminary results from 140 treatments. Acta
Ophthalmol. 91, 335–342.
Verhoeff, F.H., Jackson, E., 1926. Minutes of the Proceedings, 62nd Annual Meeting. pp.
38–43.
Vézina, M., 2013. Comparative ocular anatomy in commonly used laboratory animals. In:
Weir, B.A., Collins, M. (Eds.), Assessing Ocular Toxicology in Laboratory Animals.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
66
Humana Press, Totowa, NJ, pp. 1–21.
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M.,
Nakamura, Y., White, R., Smits, A.M., Bos, J.L., 1988. Genetic alterations during
colorectal-tumor development. N. Engl. J. Med. 319, 525–532.
Waddell, K.M., Kagame, K., Ndamira, A., Twinamasiko, A., Picton, S.V., Simmons, I.G.,
Johnston, W.T., Newton, R., 2015. Clinical features and survival among children with
retinoblastoma in Uganda. Br. J. Ophthalmol. 99, 387–390.
Wallach, M., Balmer, A., Munier, F., Houghton, S., Pampallona, S., von der Weid, N.,
Beck-Popovic, M., Swiss Pediatric Oncology, G., Swiss Childhood Cancer, R., 2006.
Shorter time to diagnosis and improved stage at presentation in Swiss patients with
retinoblastoma treated from 1963 to 2004. Pediatrics 118, e1493–1498.
Wang, H., Wei, F., Li, H., Ji, X., Li, S., Chen, X., 2013. Combination of oncolytic adeno-
virus and endostatin inhibits human retinoblastoma in an in vivo mouse model. Int. J.
Mol. Med. 31, 377–385.
Warden, S.M., Mukai, S., 2006. Pars plana vitrectomy in eyes treated for retinoblastoma.
Retina 26, S53–S56.
Watts, P., Westall, C., Colpa, L., MacKeen, L., Abdolell, M., Gallie, B., Heon, E., 2002.
Visual results in children treated for macular retinoblastoma. Eye 16, 75–80.
Weintraub, N., Rot, I., Shoshani, N., Pe'er, J., Weintraub, M., 2011. Participation in daily
activities and quality of life in survivors of retinoblastoma. Pediatr. Blood Canc. 56,
590–594.
Weiss, A.H., Karr, D.J., Kalina, R.E., Lindsley, K.L., Pendergrass, T.W., 1994. Visual
outcomes of macular retinoblastoma after external beam radiation therapy.
Ophthalmology 101, 1244–1249.
Whitehead, M.T., Oh, C.C., Choudhri, A.F., 2013. Incidental pineal cysts in children who
undergo 3-T MRI. Pediatr. Radiol. 43, 1577–1583.
Williams, R.W., 1991. The human retina has a cone-enriched rim. Vis. Neurosci. 6,
403–406.
Wilson, M.W., Haik, B.G., Liu, T., Merchant, T.E., Rodriguez-Galindo, C., 2005. Effect on
ocular survival of adding early intensive focal treatments to a two-drug che-
motherapy regimen in patients with retinoblastoma. Am. J. Ophthalmol. 140,
397–406.
Wilson, M.W., Jackson, J.S., Phillips, B.X., Buchanan, J., Frase, S., Wang, F., Steinle, J.J.,
Stewart, C.F., Mandrell, T.D., Haik, B.G., Williams, J.S., 2011. Real-time ophthal-
moscopic findings of superselective intraophthalmic artery chemotherapy in a non-
human primate model. Arch. Ophthalmol. 129, 1458–1465.
Wilson, M.W., Rodriguez-Galindo, C., Haik, B.G., Moshfeghi, D.M., Merchant, T.E., Pratt,
C.B., 2001. Multiagent chemotherapy as neoadjuvant treatment for multifocal in-
traocular retinoblastoma. Ophthalmology 108, 2106–2114 discussion 2114-2105.
Wilson, T.W., Chan, H.S., Moselhy, G.M., Heydt Jr., D.D., Frey, C.M., Gallie, B.L., 1996.
Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclos-
porine in rabbits. Arch. Ophthalmol. 114, 1390–1395.
Winter, U., Nicolas, M., Sgroi, M., Sampor, C., Torbidoni, A., Fandino, A., Chantada, G.L.,
Munier, F.L., Schaiquevich, P., 2018. Assessment of retinoblastoma RNA reflux after
intravitreal injection of melphalan. Br. J. Ophthalmol. 102, 415–418.
Winter, U., Mena, H.A., Negrotto, S., Arana, E., Pascual-Pasto, G., Laurent, V., Suñol, M.,
Chantada, G.L., Carcaboso, A.M., Schaiquevich, P., 2016. Schedule-dependent anti-
angiogenic and cytotoxic effects of chemotherapy on vascular endothelial and re-
tinoblastoma cells. PLoS One 11, e0160094. https://doi.org/10.1371/jounral.pone.
0160094.
Wintersteiner, H., 1897. Das neuroëpithelioma Retinae; eine anatomische und klinische
Studie. Deuticke.
Wong, F.L., Boice Jr., J.D., Abramson, D.H., Tarone, R.E., Kleinerman, R.A., Stovall, M.,
Goldman, M.B., Seddon, J.M., Tarbell, N., Fraumeni Jr., J.F., Li, F.P., 1997. Cancer
incidence after retinoblastoma. Radiation dose and sarcoma risk. J. Am. Med. Assoc.
278, 1262–1267.
Woo, K.I., Harbour, J.W., 2010. Review of 676 second primary tumors in patients with
retinoblastoma: association between age at onset and tumor type. Arch. Ophthalmol.
128, 865–870.
Wu, N., Jia, D., Bates, B., Basom, R., Eberhart, C.G., MacPherson, D., 2017. A mouse
model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemer-
gence. J. Clin. Investig. 127, 888–898.
Wyse, E., Handa, J.T., Friedman, A.D., Pearl, M.S., 2016. A review of the literature for
intra-arterial chemotherapy used to treat retinoblastoma. Pediatr. Radiol. 46,
1223–1233.
Xu, X.L., Fang, Y., Lee, T.C., Forrest, D., Gregory-Evans, C., Almeida, D., Liu, A., Jhanwar,
S.C., Abramson, D.H., Cobrinik, D., 2009. Retinoblastoma has properties of a cone
precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137,
1018–1031.
Xu, X.L., Lee, T.C., Offor, N., Cheng, C., Liu, A., Fang, Y., Jhanwar, S.C., Abramson, D.H.,
Cobrinik, D., 2010. Tumor-associated retinal astrocytes promote retinoblastoma cell
proliferation through production of IGFBP-5. Am. J. Pathol. 177, 424–435.
Xu, X.L., Singh, H.P., Wang, L., Qi, D.L., Poulos, B.K., Abramson, D.H., Jhanwar, S.C.,
Cobrinik, D., 2014. Rb suppresses human cone-precursor-derived retinoblastoma
tumours. Nature 514, 385–388.
Yamane, T., Kaneko, A., Mohri, M., 2004. The technique of ophthalmic arterial infusion
therapy for patients with intraocular retinoblastoma. Int. J. Clin. Oncol. 9, 69–73.
Yannuzzi, N.A., Francis, J.H., Marr, B.P., Belinsky, I., Dunkel, I.J., Gobin, Y.P., Abramson,
D.H., 2015. Enucleation vs ophthalmic artery chemosurgery for advanced intraocular
retinoblastoma: a retrospective analysis. JAMA Ophthalmol 133, 1062–1066.
Yarovoy, A.A., Ushakova, T.L., Gorshkov, I.M., Polyakov, V.G., Golubeva, O.V.,
Gorovtsova, O.V., Krivovyaz, O.S., 2015. Intraocular surgery with melphalan irriga-
tion for vitreous hemorrhage in an only eye with retinoblastoma. Eur. J. Ophthalmol.
26, e17–19.
Yip, B.H., Pawitan, Y., Czene, K., 2006. Parental age and risk of childhood cancers: a
population-based cohort study from Sweden. Int. J. Epidemiol. 35, 1495–1503.
Yousef, Y.A., Soliman, S.E., Astudillo, P.P., Durairaj, P., Dimaras, H., Chan, H.S., Heon, E.,
Gallie, B.L., Shaikh, F., 2016. Intra-arterial chemotherapy for retinoblastoma: a sys-
tematic review. JAMA Ophthalmol. 134, 584–591.
Yu, C.L., Tucker, M.A., Abramson, D.H., Furukawa, K., Seddon, J.M., Stovall, M.,
Fraumeni Jr., J.F., Kleinerman, R.A., 2009. Cause-specific mortality in long-term
survivors of retinoblastoma. J. Natl. Cancer Inst. 101, 581–591.
Zhang, J., Benavente, C.A., McEvoy, J., Flores-Otero, J., Ding, L., Chen, X., Ulyanov, A.,
Wu, G., Wilson, M., Wang, J., Brennan, R., Rusch, M., Manning, A.L., Ma, J., Easton,
J., Shurtleff, S., Mullighan, C., Pounds, S., Mukatira, S., Gupta, P., Neale, G., Zhao, D.,
Lu, C., Fulton, R.S., Fulton, L.L., Hong, X., Dooling, D.J., Ochoa, K., Naeve, C., Dyson,
N.J., Mardis, E.R., Bahrami, A., Ellison, D., Wilson, R.K., Downing, J.R., Dyer, M.A.,
2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature
481, 329–334.
Zhao, J., Dimaras, H., Massey, C., Xu, X., Huang, D., Li, B., Chan, H.S., Gallie, B.L., 2011.
Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks
risk of tumor extension and increases death from metastasis. J. Clin. Oncol. 29,
845–851.
Zhu, X., Dunn, J.M., Goddard, A.D., Squire, J.A., Becker, A., Phillips, R.A., Gallie, B.L.,
1992. Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenet. Cell Genet.
59, 248–252.
Zhu, D., Berry, J.L., Ediriwickrema, L., Wong, K., Lee, T.C., Murphree, A.L., Kim, J.W.,
Jubran, R., 2015. Long-term outcomes of group B eyes in patients with retino-
blastoma treated with short-course chemoreduction: experience from children's
hospital Los Angeles/University of southern California. Ocul Oncol Pathol 2,
105–111.
Zhu, X.P., Dunn, J.M., Phillips, R.A., Goddard, A.D., Paton, K.E., Becker, A., Gallie, B.L.,
1989. Preferential germline mutation of the paternal allele in retinoblastoma. Nature
340, 312–313.
Web references
United Nations, Department of Economic and Social Affairs, Population Division, 2017.
World Population Prospects: the 2017 Revision. https://esa.un.org/unpd/wpp/.
Children’s Oncology Group, 2011. Newly Diagnosed with Retinoblastoma. Children’s
Oncology Group [online]. http://www.childrensoncologygroup.org/index.php/
newlydiagnosedwithretinoblastoma.
http://grantome.com/grant/NIH/RC3-CA150730-01.
F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764
67
